WO2024018403A1 - Substituted imidazoamide compounds, and methods using same - Google Patents

Substituted imidazoamide compounds, and methods using same Download PDF

Info

Publication number
WO2024018403A1
WO2024018403A1 PCT/IB2023/057373 IB2023057373W WO2024018403A1 WO 2024018403 A1 WO2024018403 A1 WO 2024018403A1 IB 2023057373 W IB2023057373 W IB 2023057373W WO 2024018403 A1 WO2024018403 A1 WO 2024018403A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
chloro
phenyl
tetrahydro
imidazo
Prior art date
Application number
PCT/IB2023/057373
Other languages
French (fr)
Inventor
Andrew G. Cole
Yi Fan
Gavin D. Heffernan
Duyan Nguyen
Seyma OZTURK
Jorge G. Quintero
Satish SAKILAM
Michael J. Sofia
Original Assignee
Arbutus Biopharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corporation filed Critical Arbutus Biopharma Corporation
Publication of WO2024018403A1 publication Critical patent/WO2024018403A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

The present disclosure includes substituted imidazoamide compounds of Formula (I), analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and/or prevent cancer in a patient.

Description

TITLE Substituted Imidazoamide Compounds, and Methods Using Same CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No.63/390,989, filed July 21, 2022, which is incorporated herein by reference in its entirety. BACKGROUND Hepatitis B virus (HBV) is a noncytopathic, liver tropic DNA virus belonging to Hepadnaviridae family. HBV infection is one of the world's most prevalent diseases, being listed by National Institute of Allergy and Infectious Diseases (NIAID) as a High Priority Area of Interest. Although most individuals resolve the infection following acute symptoms, approximately 30% of cases become chronic.350-400 million people worldwide are estimated to have chronic hepatitis B, leading to 0.5-1 million deaths per year, due largely to the development of hepatocellular carcinoma, cirrhosis and/or other complications. A limited number of drugs are currently approved for the management of chronic hepatitis B, including two formulations of alpha-interferon (standard and pegylated) and five nucleoside/nucleotide analogues (lamivudine, adefovir, entecavir, telbivudine, and tenofovir) that inhibit HBV DNA polymerase. At present, the first-line treatment choices are entecavir, tenofovir and/or peg-interferon alfa-2a. However, peg-interferon alfa-2a achieves desirable serological milestones in only one third of treated patients, and is frequently associated with severe side effects. Entecavir and tenofovir are potent HBV inhibitors, but require long-term or possibly lifetime administration to continuously suppress HBV replication, and may eventually fail due to emergence of drug-resistant viruses. There is thus a pressing need for the introduction of novel, safe and effective therapies for chronic hepatitis B. Hepatitis D virus (HDV) is a small circular enveloped RNA virus that can propagate only in the presence of HBV. In particular, HDV requires the HBV surface antigen protein to propagate itself. Infection with both HBV and HDV results in more severe complications compared to infection with HBV alone. These complications include a greater likelihood of experiencing liver failure in acute infections and a rapid progression to liver cirrhosis, with an increased chance of developing liver cancer in chronic infections. In combination with hepatitis B virus, hepatitis D has the highest mortality rate of all the hepatitis infections. The routes of transmission of HDV are similar to those for HBV. Infection is largely restricted to persons at high risk of HBV infection, particularly injecting drug users and persons receiving clotting factor concentrates. Currently, there is no effective antiviral therapy available for the treatment of acute or chronic type D hepatitis. Interferon-alfa, given weekly for 12 to 18 months, is the only licensed treatment for hepatitis D. Response to this therapy is limited-in only about one- quarter of patients is serum HDV RNA undetectable 6 months post therapy. There is a need in the art for the identification of novel compounds that can be used to treat, ameliorate, and/or prevent HBV infection in a subject. In certain embodiments, the novel compounds can be used in patients that are HBV infected, patients who are at risk of becoming HBV infected, and/or patients that are infected with drug-resistant HBV. In other embodiments, the HBV-infected subject is further HDV-infected. The present invention addresses this need. BRIEF SUMMARY The present disclosure provides certain compounds of formula (I), or a salt, solvate, geometric isomer, isotopologue, stereoisomer, and/or tautomer thereof, wherein the substituents in (I) are defined elsewhere herein: The present disclosure further provides pharmaceutical compositions comprising at least one compound of the present disclosure and at least one pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises at least one additional agent that treats, ameliorates, and/or prevents hepatitis virus infection. The present disclosure further provides methods of treating, ameliorating, and/or preventing hepatitis virus infection in a subject. In certain embodiments, the method comprises administering to the subject in need thereof a therapeutically effective amount of at least one compound of the present disclosure and/or at least one pharmaceutical composition of the present disclosure. In certain embodiments, the subject is infected with hepatitis B virus (HBV). In certain embodiments, the subject is infected with hepatitis D virus (HDV). In certain embodiments, the subject is infected with HBV and HDV. The present disclosure further provides methods of treating, ameliorating, and/or preventing cancer in a subject. In certain embodiments, the method comprises administering to the subject in need thereof a therapeutically effective amount of at least one compound of the present disclosure and/or at least one pharmaceutically acceptable composition of the present disclosure. In certain embodiments, the cancer is amenable to treatment by inhibiting PD-1, PD-L1, or the PD-1/PD-L1 interaction. In certain embodiments, the cancer is at least one of pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer, or colon cancer. In certain embodiments, the cancer is at least one of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL). DETAILED DESCRIPTION OF THE DISCLOSURE The present disclosure relates, in certain aspects, to the discovery of certain substituted imidazoamide compounds. In one aspect, the compounds of the present disclosure are useful to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection and related conditions in a subject. In certain embodiments, these compounds are administered along with at least one additional agent useful for treating, ameliorating, and/or preventing the viral infection. In other embodiments, the subject is infected with HBV. In yet other embodiments, the subject is infected with HDV. In yet other embodiments, the HBV-infected subject is further infected with HDV. In another aspect, the compounds of the disclosure are useful to treat, ameliorate and/or prevent cancer and related conditions in a subject. Definitions As used herein, each of the following terms has the meaning associated with it in this section. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Generally, the nomenclature used herein and the laboratory procedures in animal pharmacology, pharmaceutical science, separation science and organic chemistry are those well-known and commonly employed in the art. It should be understood that the order of steps or order for performing certain actions is immaterial, so long as the present teachings remain operable. Moreover, two or more steps or actions can be conducted simultaneously or not. As used herein, the articles "a" and "an" refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element. As used herein, the term "alkenyl," employed alone or in combination with other terms, means, unless otherwise stated, a stable monounsaturated or diunsaturated straight chain or branched chain hydrocarbon group having the stated number of carbon atoms. Examples include vinyl, propenyl (or allyl), crotyl, isopentenyl, butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and the higher homologs and isomers. A functional group representing an alkene is exemplified by -CH2-CH=CH2. As used herein, the term "alkoxy" employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined elsewhere herein, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy (or isopropoxy) and the higher homologs and isomers. A specific example is (C1-C3)alkoxy, such as, but not limited to, ethoxy and methoxy. As used herein, the term "alkyl" by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atoms designated (i.e., C1-C10 means one to ten carbon atoms) and includes straight, branched chain, or cyclic substituent groups. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, and cyclopropylmethyl. A specific embodiment is (C1-C6) alkyl, such as, but not limited to, ethyl, methyl, isopropyl, isobutyl, n-pentyl, n-hexyl and cyclopropylmethyl. As used herein, the term "alkynyl" employed alone or in combination with other terms means, unless otherwise stated, a stable straight chain or branched chain hydrocarbon group with a triple carbon-carbon bond, having the stated number of carbon atoms. Non-limiting examples include ethynyl and propynyl, and the higher homologs and isomers. The term "propargylic" refers to a group exemplified by -CH2-C≡CH. The term "homopropargylic" refers to a group exemplified by -CH2CH2-C≡CH. As used herein, the term "aromatic" refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e., having (4n+2) delocalized π (pi) electrons, where 'n' is an integer. As used herein, the term "aryl" employed alone or in combination with other terms means, unless otherwise stated, a carbocyclic aromatic system containing one or more rings (typically one, two or three rings) wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene. Examples include phenyl, anthracyl and naphthyl. Aryl groups also include, for example, phenyl or naphthyl rings fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa-1,3,5- trienyl, or indanyl), which can be substituted at one or more carbon atoms of the aromatic and/or saturated or partially saturated rings. As used herein, the term "aryl-(C1-C6)alkyl" refers to a functional group wherein a one to six carbon alkylene chain is attached to an aryl group, e.g., -CH2CH2-phenyl or -CH2- phenyl (or benzyl). Specific examples are aryl-CH2- and aryl-CH(CH3)-. The term "substituted aryl-(C1-C6)alkyl" refers to an aryl-(C1-C6)alkyl functional group in which the aryl group is substituted. A specific example is substituted aryl(CH2)-. Similarly, the term "heteroaryl-(C1-C6)alkyl" refers to a functional group wherein a one to three carbon alkylene chain is attached to a heteroaryl group, e.g., -CH2CH2-pyridyl. A specific example is heteroaryl-(CH2)-. The term "substituted heteroaryl-(C1-C6)alkyl" refers to a heteroaryl-(C1- C6)alkyl functional group in which the heteroaryl group is substituted. A specific example is substituted heteroaryl-(CH2)-. In one aspect, the terms "co-administered" and "co-administration" as relating to a subject refer to administering to the subject a compound and/or composition of the disclosure along with a compound and/or composition that may also treat or prevent a disease or disorder contemplated herein. In certain embodiments, the co-administered compounds and/or compositions are administered separately, or in any kind of combination as part of a single therapeutic approach. The co-administered compound and/or composition may be formulated in any kind of combinations as mixtures of solids and liquids under a variety of solid, gel, and liquid formulations, and as a solution. As used herein, the term "cycloalkyl" by itself or as part of another substituent refers to, unless otherwise stated, a cyclic chain hydrocarbon having the number of carbon atoms designated (i.e., C3-C6 refers to a cyclic group comprising a ring group consisting of three to six carbon atoms) and includes straight, branched chain or cyclic substituent groups. Examples of (C3-C6)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cycloalkyl rings can be optionally substituted. Non-limiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5- dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl; bicyclo[6.2.0]decanyl, decahydronaphthalenyl, and dodecahydro-1H- fluorenyl. The term "cycloalkyl" also includes bicyclic hydrocarbon rings, non-limiting examples of which include, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1] heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl. As used herein, the term "DCM" refers to dichloromethane. As used herein, a "disease" is a state of health of a subject wherein the subject cannot maintain homeostasis, and wherein if the disease is not ameliorated then the subject's health continues to deteriorate. As used herein, a "disorder" in a subject is a state of health in which the subject is able to maintain homeostasis, but in which the subject's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the subject's state of health. As used herein, the term "halide" refers to a halogen atom bearing a negative charge. The halide anions are fluoride (F−), chloride (Cl−), bromide (Br−), and iodide (I−). As used herein, the term "halo" or "halogen" alone or as part of another substituent refers to, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. As used herein, the term "Hepatitis B virus" (or HBV) refers to a virus species of the genus Orthohepadnavirus, which is a part of the Hepadnaviridae family of viruses, and that is capable of causing liver inflammation in humans. As used herein, the term "Hepatitis D virus" (or HDV) refers to a virus species of the genus Deltaviridae, which is capable of causing liver inflammation in humans. The HDV particle comprises an envelope, which is provided by HBV and surrounds the RNA genome and the HDV antigen. The HDV genome is a single, negative stranded, circular RNA molecule nearly 1.7 kb in length. The genome contains several sense and antisense open reading frames (ORFs), only one of which is functional and conserved. The RNA genome is replicated through an RNA intermediate, the antigenome. The genomic RNA and its complement, the antigenome, can function as ribozymes to carry out self-cleavage and self- ligation reactions. A third RNA present in the infected cell, also complementary to the genome, but 800 bp long and polyadenylated, is the mRNA for the synthesis of the delta antigen (HDAg). As used herein, the term "heteroalkenyl" by itself or in combination with another term refers to, unless otherwise stated, a stable straight or branched chain monounsaturated or diunsaturated hydrocarbon group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. Up to two heteroatoms may be placed consecutively. Examples include - CH=CH-O-CH3, -CH=CH-CH2-OH, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, and -CH2- CH=CH-CH2-SH. As used herein, the term "heteroalkyl" by itself or in combination with another term refers to, unless otherwise stated, a stable straight or branched chain alkyl group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatom(s) may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the fragment to which it is attached, as well as attached to the most distal carbon atom in the heteroalkyl group. Examples include: -OCH2CH2CH3, - CH2CH2CH2OH, -CH2CH2NHCH3, -CH2SCH2CH3, and -CH2CH2S(=O)CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2NH-OCH3, or -CH2CH2SSCH3. As used herein, the term "heteroaryl" or "heteroaromatic" refers to a heterocycle having aromatic character. A polycyclic heteroaryl may include one or more rings that are partially saturated. Examples include tetrahydroquinoline and 2,3-dihydrobenzofuryl. As used herein, the term "heterocycle" or "heterocyclyl" or "heterocyclic" by itself or as part of another substituent refers to, unless otherwise stated, an unsubstituted or substituted, stable, mono- or multi-cyclic heterocyclic ring system that comprises carbon atoms and at least one heteroatom selected from the group consisting of N, O, and S, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic system may be attached, unless otherwise stated, at any heteroatom or carbon atom that affords a stable structure. A heterocycle may be aromatic or non-aromatic in nature. In certain embodiments, the heterocycle is a heteroaryl. Examples of non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazoline, pyrazolidine, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydropyridine, 1,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dioxane, 1,3- dioxane, homopiperazine, homopiperidine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin and hexamethyleneoxide. Examples of heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl (such as, but not limited to, 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl. Examples of polycyclic heterocycles include indolyl (such as, but not limited to, 3-, 4- , 5-, 6- and 7-indolyl), indolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (such as, but not limited to, 1- and 5-isoquinolyl), 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (such as, but not limited to, 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1,8-naphthyridinyl, 1,4-benzodioxanyl, coumarin, dihydrocoumarin, 1,5-naphthyridinyl, benzofuryl (such as, but not limited to, 3-, 4-, 5-, 6- and 7-benzofuryl), 2,3-dihydrobenzofuryl, 1,2-benzisoxazolyl, benzothienyl (such as, but not limited to, 3-, 4-, 5-, 6-, and 7-benzothienyl), benzoxazolyl, benzothiazolyl (such as, but not limited to, 2-benzothiazolyl and 5-benzothiazolyl), purinyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl, and quinolizidinyl. The aforementioned listing of heterocyclyl and heteroaryl moieties is intended to be representative and not limiting. As described herein, the term "PD-L1 inhibitor" includes any compound that is capable of reducing, minimizing, and/or inhibiting the expression and/or function of the protein Programmed Death-Ligand 1 (PD-L1) either directly or indirectly (e.g., by binding to PD-L1 and stabilizing and/or promoting dimerization of PD-L1, thereby precluding association of PD-1). PD-L1, also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is a type 1 transmembrane protein that plays a major role in suppressing the adaptive arm of immune system during pregnancy, tissue allograft transplants, autoimmune disease, cancer, and hepatitis. PD-L1 binds to its receptor, the inhibitory checkpoint molecule PD-1 (which is found on activated T cells, B cells, and myeloid cells) so as to modulate activation or inhibition of the adaptive arm of immune system. In certain embodiments, the PD-L1 inhibitor inhibits the expression and/or function of PD-L1 by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. As used herein, the term "pharmaceutical composition" or "composition" refers to a mixture of at least one compound useful within the disclosure with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a subject. As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound useful within the disclosure, and is relatively non-toxic, i.e., the material may be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained. As used herein, the term "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the disclosure within or to the subject such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the disclosure, and not injurious to the subject. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the disclosure, and are physiologically acceptable to the subject. Supplementary active compounds may also be incorporated into the compositions. The "pharmaceutically acceptable carrier" may further include a pharmaceutically acceptable salt of the compound useful within the disclosure. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the disclosure are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference. As used herein, the language "pharmaceutically acceptable salt" refers to a salt of the administered compound prepared from pharmaceutically acceptable non-toxic acids and/or bases, including inorganic acids, inorganic bases, organic acids, inorganic bases, solvates (including hydrates) and clathrates thereof. As used herein, a "pharmaceutically effective amount," "therapeutically effective amount," or "effective amount" of a compound is that amount of compound that is sufficient to provide a beneficial effect to the subject to which the compound is administered. The term "prevent," "preventing," or "prevention" as used herein means avoiding or delaying the onset of symptoms associated with a disease or condition in a subject that has not developed such symptoms at the time the administering of an agent or compound commences. Disease, condition and disorder are used interchangeably herein. By the term "specifically bind" or "specifically binds" as used herein is meant that a first molecule preferentially binds to a second molecule (e.g., a particular receptor or enzyme), but does not necessarily bind only to that second molecule. As used herein, the terms "subject" and "individual" and "patient" can be used interchangeably and may refer to a human or non-human mammal or a bird. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. In certain embodiments, the subject is human. As used herein, the term "substituted" refers to that an atom or group of atoms has replaced hydrogen(s) as the substituent attached to another group. As used herein, the term "substituted alkyl," "substituted cycloalkyl," "substituted alkenyl," or "substituted alkynyl" refers to alkyl, cycloalkyl, alkenyl or alkynyl, as defined elsewhere herein, substituted by one, two or three substituents independently selected from the group consisting of halogen, -OH, alkoxy, tetrahydro-2-H-pyranyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, 1-methyl-imidazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, - C(=O)OH, -C(=O)O(C1-C6)alkyl, trifluoromethyl, -C≡N, -C(=O)NH2, -C(=O)NH(C1- C6)alkyl, -C(=O)N((C1-C6)alkyl)2, -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, - C(=NH)NH2, and -NO2, in certain embodiments containing one or two substituents independently selected from halogen, -OH, alkoxy, -NH2, trifluoromethyl, -N(CH3)2, and - C(=O)OH, in certain embodiments independently selected from halogen, alkoxy and -OH. Examples of substituted alkyls include, but are not limited to, 2,2-difluoropropyl, 2- carboxycyclopentyl and 3-chloropropyl. For aryl, aryl-(C1-C3)alkyl and heterocyclyl groups, the term "substituted" as applied to the rings of these groups refers to any level of substitution, namely mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. In certain embodiments, the substituents vary in number between one and four. In other embodiments, the substituents vary in number between one and three. In yet another embodiments, the substituents vary in number between one and two. In yet other embodiments, the substituents are independently selected from the group consisting of C1-C6 alkyl, -OH, C1-C6 alkoxy, halo, amino, acetamido and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight or cyclic. In certain embodiments, each occurrence of alkyl or cycloalkyl is independently optionally substituted with at least one substituent selected from the group consisting of C1- C6 alkyl, halo, -OR, phenyl (thus yielding, in non-limiting examples, optionally substituted phenyl-(C1-C3 alkyl), such as, but not limited to, benzyl or substituted benzyl) and -N(R)(R), wherein each occurrence of R is independently H, C1-C6 alkyl or C3-C8 cycloalkyl. In other embodiments, each occurrence of aryl or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, halo, -CN, -OR, -N(R)(R), -NO2, -S(=O)2N(R)(R), acyl, and C1- C6 alkoxycarbonyl, wherein each occurrence of R is independently H, C1-C6 alkyl or C3-C8 cycloalkyl. In yet other embodiments, each occurrence of aryl or heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of C1- C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, halo, -CN, -OR, -N(R)(R), and C1-C6 alkoxycarbonyl, wherein each occurrence of R is independently H, C1-C6 alkyl or C3-C8 cycloalkyl. Unless otherwise noted, when two substituents are taken together to form a ring having a specified number of ring atoms (e.g., R2 and R3 taken together with the nitrogen to which they are attached to form a ring having from 3 to 7 ring members), the ring can have carbon atoms and optionally one or more (e.g., 1 to 3) additional heteroatoms independently selected from nitrogen, oxygen, or sulfur. The ring can be saturated or partially saturated, and can be optionally substituted. Whenever a term or either of their prefix roots appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given elsewhere herein for "alkyl" and "aryl" respectively. In certain embodiments, substituents of compounds are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges. For example, the term "C1-6 alkyl" is specifically intended to individually disclose C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl. The terms "treat," "treating," and "treatment," as used herein, means reducing the frequency or severity with which symptoms of a disease or condition are experienced by a subject by virtue of administering an agent or compound to the subject. Ranges: throughout this disclosure, various aspects of the disclosure can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual and partial numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range. Compounds Programmed death-ligand 1 (PD-L1), which is also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is a human transmembrane protein that plays a major role in suppressing the immune system as needed. Generally, the presence of a foreign antigen in the body triggers proliferation of antigen-specific CD8+ T cells in the lymph nodes. However, binding of PD-L1 to the receptor programmed cell death protein 1 (PD-1) or B7.1 membrane protein (both of which are found on activated T cells, B cells, and myeloid cells), transmits an inhibitory signal, which reduces proliferation of the CD8+ T cells in the lymph nodes. Such interaction effectively suppresses the immune response and avoids detection and destruction of the antigens. In certain embodiments, small-molecule immunomodulators targeting the PD-1/PD- L1 signaling pathway are used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infection and related conditions in a subject. In other embodiments, inhibition of PDL-1 enhances the immune response to at least one HBV antigen. The disclosure include a compound of formula (I), or a salt, solvate, prodrug, stereoisomer (such as, in a non-limiting example, an enantiomer or diastereoisomer, and any mixtures thereof, such as, in a non-limiting example, mixtures in any proportion of enantiomers and/or diastereoisomers thereof), tautomer, and/or geometric isomer, and any mixtures thereof. It should be noted that the absolute stereochemistry of the chiral center(s) represented in any structure depicted herein and/or compound named herein is merely illustrative and non-limiting. The present disclosure provides a compound of formula (I), or a salt, solvate, geometric isomer, isotopologue, stereoisomer, or tautomer thereof: (I), wherein: X1 is selected from the group consisting of CR2a and N; X2 is selected from the group consisting of CR2b and N; X3 is selected from the group consisting of CR2c and N; X4 is selected from the group consisting of CR2d and N; X5 is selected from the group consisting of CR2e and N; X6 is selected from the group consisting of CR2f and N; wherein one to four selected from the group consisting of X1, X2, X3, X4, X5, and X6 are N; R1a and R1b are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R1c is ; R1d is ; R2a, R2b, R2c, R2d, R2e, and R2f, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R3a, R3b, R3c, and R3d, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R4a and R4b are each independently selected from the group consisting of H and optionally substituted C1-C6 alkyl, wherein one of R4a and R4b may combine with one of R3b or R3c to form a optionally substituted C5-C8 cycloalkyl, optionally substituted C4-C8 heterocyclyl, or optionally substituted C6-C10 aryl; R5 is selected from the group consisting of H and optionally substituted C1-C6 alkyl, wherein R5 may combine with one of R3b or R3c to form an optionally substituted C4-C8 heterocycloalkyl; R6 is selected from the group consisting of H, -(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -(CH2)0-3(optionally substituted C3-C8 cycloalkyl), optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C1-C6 hydroxyalkyl, wherein R5 and R6 may optionally combine with the nitrogen atom to which they are bound to form an optionally substituted C2-C8 heterocyclyl, wherein each optional substituent in R6, or the C2-C8 heterocyclyl of R5 and R6, is independently selected from the group consisting of halogen, benzyl, phenyl, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O), C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2, and wherein two optional substituents in R6, or in the C2-C8 heterocyclyl of R5 and R6, may combine with the atoms to which they are bound to form a C3-C8 cycloalkyl or C2-C8 heterocycloalkyl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, C(=O), and C(=O)Ra; R7 is selected from the group consisting of H and optionally substituted C1-C6 alkyl; R8 is selected from the group consisting of , , , , , , , and ; R9a, R9b, R9c, R9d, R9e, and R9f, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R10 is selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted benzyl, and optionally substituted phenyl; R11 is selected from the group consisting of H, -(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -C(=O)(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -(CH2)0-3(optionally substituted C3-C8 cycloalkyl), -C(=O)(CH2)0-3(optionally substituted C3-C8 cycloalkyl), optionally substituted C1-C6 alkyl, C(=O)(optionally substituted C1-C6 alkyl), optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C1-C6 hydroxyalkyl, and -(CH2)0-3(optionally substituted phenyl), wherein each optional substituent in R11 is independently selected from the group consisting of halogen, benzyl, phenyl, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O), C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2, and wherein two optional substituents in R11 may combine with the atoms to which they are bound to form a C3-C8 cycloalkyl or C2-C8 heterocycloalkyl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, C(=O), and C(=O)Ra; L is selected from the group consisting of a bond and optionally substituted C1-C2 alkylenyl; T1 is selected from the group consisting of CR3a and N; Y is selected from the group consisting of NR10, O, and S; and Ra, Rb, and Rc are each independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted benzyl, and optionally substituted phenyl, wherein each optional substituent in Ra, Rb, and Rc is independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy, OH, CN, and NO2. In certain embodiments, each occurrence of optionally substituted alkyl, optionally substituted alkylenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aminoalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted phenyl, and optionally substituted benzyl is independently optionally substituted with at least one substituent selected from the group consisting of halogen, benzyl, phenyl, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2. In certain embodiments, the compound of formula (I) is a compound of formula (Ia): (Ia). In certain embodiments, the compound of formula (I) is a compound of formula (Ib): (Ib). In certain embodiments, the compound of formula (I) is a compound of formula (Ic): (Ic). In certain embodiments, the compound of formula (I) is a compound of formula (Id): (Id). In certain embodiments, the compound of formula (I) is a compound of formula (Ie): (Ie). In certain embodiments, the compound of formula (I) is a compound of formula (If): (If). In certain embodiments, the compound of formula (I) is a compound of formula (Ig): (Ig). In certain embodiments, the compound of formula (I) is a compound of formula (Ih): (Ih). In certain embodiments, each of R2b, R2c, R2d, R2e, and R2f are H. In certain embodiments, each of R2a, R2c, R2d, R2e, and R2f are H. In certain embodiments, each of R2a, R2b, R2d, R2e, and R2f are H. In certain embodiments, each of R2a, R2b, R2c, R2e, and R2f are H. In certain embodiments, each of R2a, R2b, R2c, R2d, and R2f are H. In certain embodiments, each of R2a, R2b, R2c, R2d, and R2e are H. In certain embodiments, R1a is Cl. In certain embodiments, R1a is Me. In certain embodiments, R1b is Cl. In certain embodiments, R1b is Me. In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R3a is H. In certain embodiments, R3a is OMe. In certain embodiments, R3a is OCF2H. In certain embodiments, R3a is F. In certain embodiments, R3a is Cl. In certain embodiments, R3b is H. In certain embodiments, R3b is OMe. In certain embodiments, R3b is OCF2H. In certain embodiments, R3b is F. In certain embodiments, R3b is Cl. In certain embodiments, R3c is H. In certain embodiments, R3c is OMe. In certain embodiments, R3c is OCF2H. In certain embodiments, R3c is Cl. In certain embodiments, R3c is F. In certain embodiments, R3d is H. In certain embodiments, R3d is OMe. In certain embodiments, R3d is OCF2H. In certain embodiments, R3d is F. In certain embodiments, R4a is H. In certain embodiments, R4b is H. In certain embodiments, R5 is H. In certain embodiments, R5 is Me. In certain embodiments, R6 is (CH2)1-3CH2F. In certain embodiments, R6 is (CH2)1- 3OH. In certain embodiments, R6 is (CH2)1-3OCH3. In certain embodiments, R6 is (CH2)0- 2CH(OH)(CH2)0-2CH3. In certain embodiments, R6 is (CH2)1-3C(CH3)2OH. In certain embodiments, R6 is (CH2)1-3C(=O)OH. In certain embodiments, R6 is (CH2)0- 2CH(OH)(CH2)0-2C(=O)OH. In certain embodiments, R6 is (CH2)0-2CH(CH3)(CH2)0- 2C(=O)OH. In certain embodiments, R6 is (CH2)0-2(optionally substituted cyclopropylenyl). In certain embodiments, R6 is (CH2)0-2(optionally substituted bicyclo[1.1.1]pentanyl). In certain embodiments, R6 is (CH2)0-2(optionally substituted pentanyl). In certain embodiments, R6 is (CH2)0-2(optionally substituted 4-piperidinyl). In certain embodiments, R6 is (CH2)0-3(optionally substituted 5-oxopyrrolidin-2-yl). In certain embodiments, R6 is (CH2)0-3(optionally substituted tetrahydropyran-4-yl). In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R6 is . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R5 and R6 combine with the nitrogen atom to which they are bound to form . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is N R3b H N O N . In certain embodiments, R1c is R3c R12 . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is and . In certain embodiments, R12 is H. In certain embodiments, R12 is C(=O)(C1-C6 alkyl). In certain embodiments, R12 is C1-C6 alkyl. In certain embodiments, R12 is C1-C6 haloalkyl. In certain embodiments, R12 is benzyl. In certain embodiments, R12 is phenyl. In certain embodiments, R12 is H. In certain embodiments, R12 is methyl. In certain embodiments, R12 is C(=O)Me. In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is In certain embodiments, R1c is
Figure imgf000025_0001
. In certain embodiments, R1c is . In certain embodiments, R1c i
Figure imgf000026_0001
. In certain embodiments, R1c is . In certain embodiments, R1c is
Figure imgf000026_0002
certain embodiments, R1c is . In certain embodiments, R1c is
Figure imgf000026_0003
. In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R1c is . In certain embodiments, R7 is H. In certain embodiments, L is a bond. In certain embodiments, T1 is N. In certain embodiments, T1 is CH. In certain embodiments, Y is NMe. In certain embodiments, Y is NH. In certain embodiments, at least one selected from R9a, R9b, R9c, R9d, R9e, and R9f is H. In certain embodiments, at least two selected from R9a, R9b, R9c, R9d, R9e, and R9f are H. In certain embodiments, at least three selected from R9a, R9b, R9c, R9d, R9e, and R9f are H. In certain embodiments, at least four selected from R9a, R9b, R9c, R9d, R9e, and R9f are H. In certain embodiments, at least five selected from R9a, R9b, R9c, R9d, R9e, and R9f are H. In certain embodiments, each of R9a, R9b, R9c, R9d, R9e, and R9f are H. In certain embodiments, R10 is H. In certain embodiments, R10 is Me. In certain embodiments, R11 is H. In certain embodiments, R11 is (CH2)0-2(optionally substituted 5-oxopyrrolidin-2-yl). In certain embodiments, R11 is (CH2)0-3(optionally substituted piperidinyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted cyclopropyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted cyclohexyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted bicyclo[2.2.1]heptanyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted oxetanyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted bicyclo[1.1.1]pentanyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted thiazolyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted oxazolyl). In certain embodiments, R11 is (CH2)0- 3(optionally substituted imidazolyl). In certain embodiments, R11 is (CH2)0-3(optionally substituted 7,8-dihydroimidazo[1,2-a]pyrimidinyl). In certain embodiments, R11 is (CH2)0- 3(optionally substituted imidazo[1,2-a]pyrimidinyl). In certain embodiments, R11 is (CH2)0- 3(optionally substituted benzo[d]isoxazolyl). In certain embodiments, R11 is (CH2)0- 3(optionally substituted tetrahydro-2H-pyranyl). In certain embodiments, R11 is (CH2)0- 3(optionally substituted phenyl). In certain embodiments, R11 is (CH2)1-2CH(OH)CF3. In certain embodiments, R11 is (CH2)0-5CH2F, (CH2)0-5CF3. In certain embodiments, R11 is (CH2)1-5CH2OH. In certain embodiments, R11 is (CH2)1-5CH2O(C1-C6 alkyl). In certain embodiments, R11 is (CH2)1-5CH2O(C3-C6 cycloalkyl). In certain embodiments, R11 is H. In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R11 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodimen 8
Figure imgf000040_0001
ts, R is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R8 is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is In
Figure imgf000041_0001
certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is In ce 1d
Figure imgf000046_0001
rtain embodiments, R is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, R1d is . In certain embodiments, the compound of formula (I) is selected from the group consisting of: N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-(difluoromethoxy)phenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3-methoxyphenyl)pyridin- 4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)- 3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((R)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((R)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-6-methoxy-5-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-[2,4’- bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-6-methoxy-5-(((2-methoxyethyl)amino)methyl)-[2,4’- bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3’-chloro-4-fluoro-6-methoxy-[2,4’- bipyridin]-2’-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((2- methoxyethyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)(methyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2-hydroxy-2- methylpropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3-hydroxypyrrolidin- 1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; ((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)glycine; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)propanoic acid; 4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (S)-4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (R)-4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 2-(1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)propanoic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; (S)-3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; (R)-3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)bicyclo[1.1.1]pentane-1-carboxylic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; 1-(2-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)ethyl)cyclopropane-1-carboxylic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-4-carboxylic acid; 4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; 5-(1-acetylpiperidin-4-yl)-N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (S)-4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (R)-4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)glycine; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)propanoic acid; 1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (S)-1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (R)-1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; 2-(1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid; 4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (S)-4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (R)-4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; methyl 2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; methyl (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; methyl (R)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; 2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; (R)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylprolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3-hydroxypyrrolidin-1-yl)acetyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((S)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((S)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-prolyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(L-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(D-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(L-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((D)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(R-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((D)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; methyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; methyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; 5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(pyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; methyl (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; methyl (R)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; 4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; (R)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(pyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol- 1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol- 1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; isopropyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; isopropyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; isopropyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; 5-(1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4-carbonyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2-hydroxypropyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)propanoyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2-a]pyrimidin-2-yl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-3-carbonyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpyrrolidine-3-carbonyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2-ylmethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methylprolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol-4-yl)ethyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylprolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3-oxopropyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((oxetan-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((oxetan-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 3-(((4-(4-(3-(5-((3-carboxybicyclo[1.1.1]pentan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2- yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 3-(((4-(4-(3-(5-((4-carboxybicyclo[2.2.1]heptan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2- yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (S)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (R)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3-yl)methyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1s,4s)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1s,4s)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3'-chloro-5-(((3-hydroxycyclopentyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-((((1R,3R)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-((((1R,3R)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-((((1S,3S)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-((((1S,3S)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-((3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl 3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; and methyl (R)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; or a salt, solvate, geometric isomer, isotopologue, or tautomer thereof. Table 1.
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
The compounds of the disclosure may possess one or more stereocenters, and each stereocenter may exist independently in either the (R) or (S) configuration. In certain embodiments, compounds described herein are present in optically active or racemic forms. The compounds described herein encompass racemic, optically active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein. Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. A compound illustrated herein by the racemic formula further represents either of the two enantiomers or mixtures thereof, or in the case where two or more chiral center are present, all diastereomers or mixtures thereof. In certain embodiments, the compounds of the disclosure exist as tautomers. All tautomers are included within the scope of the compounds recited herein. Compounds described herein also include isotopically labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds described herein include and are not limited to 2H, 3H, 11C, 13C, 14C, 36Cl, 18F, 123I, 125I, 13N, 15N, 15O, 17O, 18O, 32P, and 35S. In certain embodiments, substitution with heavier isotopes such as deuterium affords greater chemical stability. Isotopically labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically labeled reagent in place of the non-labeled reagent otherwise employed. In certain embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels. In all of the embodiments provided herein, examples of suitable optional substituents are not intended to limit the scope of the claimed disclosure. The compounds of the disclosure may contain any of the substituents, or combinations of substituents, provided herein. Salts The compounds described herein may form salts with acids or bases, and such salts are included in the present disclosure. The term "salts" embraces addition salts of free acids or bases that are useful within the methods of the disclosure. The term "pharmaceutically acceptable salt" refers to salts that possess toxicity profiles within a range that affords utility in pharmaceutical applications. In certain embodiments, the salts are pharmaceutically acceptable salts. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which have utility in the practice of the present disclosure, such as for example utility in process of synthesis, purification or formulation of compounds useful within the methods of the disclosure. Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids (including hydrogen phosphate and dihydrogen phosphate). Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (or pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, sulfanilic, 2-hydroxyethanesulfonic, trifluoromethanesulfonic, p-toluenesulfonic, cyclohexylaminosulfonic, stearic, alginic, β-hydroxybutyric, salicylic, galactaric, galacturonic acid, glycerophosphonic acids and saccharin (e.g., saccharinate, saccharate). Salts may be comprised of a fraction of one, one or more than one molar equivalent of acid or base with respect to any compound of the disclosure. Suitable pharmaceutically acceptable base addition salts of compounds of the disclosure include, for example, ammonium salts and metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N'-dibenzylethylene- diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (or N- methylglucamine) and procaine. All of these salts may be prepared from the corresponding compound by reacting, for example, the appropriate acid or base with the compound. Combination Therapies In one aspect, the compounds of the disclosure are useful within the methods of the disclosure in combination with one or more additional agents useful for treating HBV and/or HDV infections. These additional agents may comprise compounds or compositions identified herein, or compounds (e.g., commercially available compounds) known to treat, prevent, or reduce the symptoms of HBV and/or HDV infections. Non-limiting examples of one or more additional agents useful for treating HBV and/or HDV infections include: (a) reverse transcriptase inhibitors; (b) capsid inhibitors; (c) cccDNA formation inhibitors; (d) RNA destabilizers; (e) oligomeric nucleotides targeted against the HBV genome; (f) immunostimulators, such as checkpoint inhibitors (e.g., PD-L1 inhibitors); (g) GalNAc-siRNA conjugates targeted against an HBV gene transcript; and (h) therapeutic vaccines. (a) Reverse Transcriptase Inhibitors In certain embodiments, the reverse transcriptase inhibitor is a reverse-transcriptase inhibitor (NARTI or NRTI). In other embodiments, the reverse transcriptase inhibitor is a nucleotide analog reverse-transcriptase inhibitor (NtARTI or NtRTI). Reported reverse transcriptase inhibitors include, but are not limited to, entecavir, clevudine, telbivudine, lamivudine, adefovir, and tenofovir, tenofovir disoproxil, tenofovir alafenamide, adefovir dipovoxil, (1R,2R,3R,5R)-3-(6-amino-9H-9-purinyl)-2-fluoro-5- (hydroxymethyl)-4-methylenecyclopentan-1-ol (described in U.S. Patent No.8,816,074, incorporated herein in its entirety by reference), emtricitabine, abacavir, elvucitabine, ganciclovir, lobucavir, famciclovir, penciclovir, and amdoxovir. Reported reverse transcriptase inhibitors further include, but are not limited to, entecavir, lamivudine, and (1R,2R,3R,5R)-3-(6-amino-9H-9-purinyl)-2-fluoro-5- (hydroxymethyl)-4-methylenecyclopentan-1-ol. Reported reverse transcriptase inhibitors further include, but are not limited to, a covalently bound phosphoramidate or phosphonamidate moiety of the above-mentioned reverse transcriptase inhibitors, or as described in for example U.S. Patent No.8,816,074, US Patent Application Publications No. US 2011/0245484 A1, and US 2008/0286230A1, all of which incorporated herein in their entireties by reference. Reported reverse transcriptase inhibitors further include, but are not limited to, nucleotide analogs that comprise a phosphoramidate moiety, such as, for example, methyl ((((1R,3R,4R,5R)-3-(6-amino-9H-purin-9-yl)-4-fluoro-5-hydroxy-2-methylenecyclopentyl) methoxy)(phenoxy) phosphoryl)-(D or L)-alaninate and methyl ((((1R,2R,3R,4R)-3-fluoro-2- hydroxy-5-methylene-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)cyclopentyl)methoxy)(phenoxy) phosphoryl)-(D or L)-alaninate. Also included are the individual diastereomers thereof, which include, for example, methyl ((R)-(((1R,3R,4R,5R)-3-(6-amino-9H-purin-9-yl)-4-fluoro-5- hydroxy-2-methylenecyclopentyl)methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate and methyl ((S)-(((1R,3R,4R,5R)-3-(6-amino-9H-purin-9-yl)-4-fluoro-5-hydroxy-2- methylenecyclopentyl) methoxy)(phenoxy)phosphoryl)-(D or L)-alaninate. Reported reverse transcriptase inhibitors further include, but are not limited to, compounds comprising a phosphonamidate moiety, such as, for example, tenofovir alafenamide, as well as those described in U.S. Patent Application Publication No. US 2008/0286230 A1, incorporated herein in its entirety by reference. Methods for preparing stereoselective phosphoramidate or phosphonamidate containing actives are described in, for example, U.S. Patent No.8,816,074, as well as U.S. Patent Application Publications No. US 2011/0245484 A1 and US 2008/0286230 A1, all of which incorporated herein in their entireties by reference. (b) Capsid Inhibitors As described herein, the term "capsid inhibitor" includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly. For example, a capsid inhibitor may include, but is not limited to, any compound that inhibits capsid assembly, induces formation of non-capsid polymers, promotes excess capsid assembly or misdirected capsid assembly, affects capsid stabilization, and/or inhibits encapsidation of RNA (pgRNA). Capsid inhibitors also include any compound that inhibits capsid function in a downstream event(s) within the replication process (e.g., viral DNA synthesis, transport of relaxed circular DNA (rcDNA) into the nucleus, covalently closed circular DNA (cccDNA) formation, virus maturation, budding and/or release, and the like). For example, in certain embodiments, the inhibitor detectably inhibits the expression level or biological activity of the capsid protein as measured, e.g., using an assay described herein. In certain embodiments, the inhibitor inhibits the level of rcDNA and downstream products of viral life cycle by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. Reported capsid inhibitors include, but are not limited to, compounds described in International Patent Applications Publication Nos WO 2013006394, WO 2014106019, and WO2014089296, all of which incorporated herein in their entireties by reference. Reported capsid inhibitors also include, but are not limited to, the following compounds and pharmaceutically acceptable salts and/or solvates thereof: Bay-41-4109 (see Int’l Patent Application Publication No. WO 2013144129), AT-61 (see Int’l Patent Application Publication No. WO 1998033501; and King, et al., 1998, Antimicrob. Agents Chemother.42(12):3179–3186), DVR-01 and DVR-23 (see Int’l Patent Application Publication No. WO 2013006394; and Campagna, et al., 2013, J. Virol.87(12):6931, all of which incorporated herein in their entireties by reference. In addition, reported capsid inhibitors include, but are not limited to, those generally and specifically described in U.S. Patent Application Publication Nos. US 2015/0225355, US 2015/0132258, US 2016/0083383, US 2016/0052921, US 2019/0225593, and Int’l Patent Application Publication Nos. WO 2013096744, WO 2014165128, WO 2014033170, WO 2014033167, WO 2014033176, WO 2014131847, WO 2014161888, WO 2014184350, WO 2014184365, WO 2015059212, WO 2015011281, WO 2015118057, WO 2015109130, WO 2015073774, WO 2015180631, WO 2015138895, WO 2016089990, WO 2017015451, WO 2016183266, WO 2017011552, WO 2017048950, WO2017048954, WO 2017048962, WO 2017064156, WO 2018052967, WO 2018172852, WO 2020023710, WO2020123674, and are incorporated herein in their entirety by reference. (c) cccDNA Formation Inhibitors Covalently closed circular DNA (cccDNA) is generated in the cell nucleus from viral rcDNA and serves as the transcription template for viral mRNAs. As described herein, the term "cccDNA formation inhibitor" includes compounds that are capable of inhibiting the formation and/or stability of cccDNA either directly or indirectly. For example, a cccDNA formation inhibitor may include, but is not limited to, any compound that inhibits capsid disassembly, rcDNA entry into the nucleus, and/or the conversion of rcDNA into cccDNA. For example, in certain embodiments, the inhibitor detectably inhibits the formation and/or stability of the cccDNA as measured, e.g., using an assay described herein. In certain embodiments, the inhibitor inhibits the formation and/or stability of cccDNA by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. Reported cccDNA formation inhibitors include, but are not limited to, compounds described in Int’l Patent Application Publication No. WO 2013130703, and are incorporated herein in their entirety by reference. In addition, reported cccDNA formation inhibitors include, but are not limited to, those generally and specifically described in U.S. Patent Application Publication No. US 2015/0038515 A1, and are incorporated herein in their entirety by reference. (d) RNA Destabilizer As used herein, the term "RNA destabilizer" refers to a molecule, or a salt or solvate thereof, that reduces the total amount of HBV RNA in mammalian cell culture or in a live human subject. In a non-limiting example, an RNA destabilizer reduces the amount of the RNA transcript(s) encoding one or more of the following HBV proteins: surface antigen, core protein, RNA polymerase, and e antigen. In certain embodiments, the RNA destabilizer reduces the total amount of HBV RNA in mammalian cell culture or in a live human subject by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. Reported RNA destabilizers include compounds described in U.S. Patent No. 8,921,381, as well as compounds described in U.S. Patent Application Publication Nos. US 2015/0087659 and US 2013/0303552, all of which are incorporated herein in their entireties by reference. In addition, reported RNA destabilizers include, but are not limited to, those generally and specifically described in Int’l Patent Application Publication Nos. WO 2015113990, WO 2015173164, US 2016/0122344, WO 2016107832, WO 2016023877, WO 2016128335, WO 2016177655, WO 2016071215, WO 2017013046, WO 2017016921, WO 2017016960, WO 2017017042, WO 2017017043, WO 2017102648, WO 2017108630, WO 2017114812, WO 2017140821, WO 2018085619, and are incorporated herein in their entirety by reference. (e) Oligomeric Nucleotides Targeted Against the HBV Genome Reported oligomeric nucleotides targeted against the HBV genome include, but are not limited to, Arrowhead-ARC-520 (see U.S. Patent No.8,809,293; and Wooddell et al., 2013, Molecular Therapy 21(5):973–985, all of which incorporated herein in their entireties by reference). In certain embodiments, the oligomeric nucleotides can be designed to target one or more genes and/or transcripts of the HBV genome. Oligomeric nucleotide targeted to the HBV genome also include, but are not limited to, isolated, double stranded, siRNA molecules, that each include a sense strand and an antisense strand that is hybridized to the sense strand. In certain embodiments, the siRNA target one or more genes and/or transcripts of the HBV genome. (f) Immunostimulators Checkpoint Inhibitors As described herein, the term "checkpoint inhibitor" includes any compound that is capable of inhibiting immune checkpoint molecules that are regulators of the immune system (e.g., stimulate or inhibit immune system activity). For example, some checkpoint inhibitors block inhibitory checkpoint molecules, thereby stimulating immune system function, such as stimulation of T cell activity against cancer cells. A non-limiting example of a checkpoint inhibitor is a PD-L1 inhibitor. As described herein, the term "PD-L1 inhibitor" includes any compound that is capable of reducing, minimizing, and/or inhibiting the expression and/or function of the protein Programmed Death-Ligand 1 (PD-L1) either directly or indirectly (e.g., by binding to PD-L1 and stabilizing and/or promoting dimerization of PD-L1, thereby precluding association of PD-1). PD-L1, also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is a type 1 transmembrane protein that plays a major role in suppressing the adaptive arm of immune system during pregnancy, tissue allograft transplants, autoimmune disease, cancer, and hepatitis. PD-L1 binds to its receptor, the inhibitory checkpoint molecule PD-1 (which is found on activated T cells, B cells, and myeloid cells) so as to modulate activation or inhibition of the adaptive arm of immune system. In certain embodiments, the PD-L1 inhibitor inhibits the expression and/or function of PD-L1 by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. PD-L1 is a type 1 transmembrane protein that plays a major role in suppressing the adaptive arm of immune system during pregnancy, tissue allograft transplants, autoimmune disease, cancer, and hepatitis. PD-L1 expressed by tumor cells plays a critical role in the induction of inhibitory signals through the interaction with programmed cell death-1 (PD-1), which is expressed on the surface of T cells. This PD-1/PD-L1 interaction results in suppression of tumor-specific T cell responses functioning as a tumor immune evasion mechanism. Immune checkpoint inhibitors targeting the PD-1/PD-L1 interaction have become a successful immunotherapy in treating many advanced cancers and are based on a mechanism of monoclonal antibody binding to and directly disrupting the PD-1/PD-L1 interaction. Three of such antibodies have been approved by the FDA (i.e., atezolizumab, durvalumab, and avelumab). Thus, PD-1/PD-L1 binding has the net effect of inhibiting T cell receptor signaling, and the disruption and/or inhibition of this interaction represents a validated target for the treatment of many advanced cancers. Reported PD-L1 inhibitors include, but are not limited to, compounds recited in one of the following patent application publications: US 2018/0057455; US 2018/0057486; WO 2017/106634; WO 2018/026971; WO 2018/045142; WO 2018/118848; WO 2018/119221; WO 2018/119236; WO 2018/119266; WO 2018/119286; WO 2018/121560; WO 2019/076343; WO 2019/087214; and are incorporated herein in their entirety by reference. (g) GalNAc-siRNA Conjugates Targeted Against an HBV Gene Transcript "GalNAc" is the abbreviation for N-acetylgalactosamine, and "siRNA" is the abbreviation for small interfering RNA. An siRNA that targets an HBV gene transcript is covalently bonded to GalNAc in a GalNAc-siRNA conjugate useful in the practice of the present disclosure. While not wishing to be bound by theory, it is believed that GalNAc binds to asialoglycoprotein receptors on hepatocytes thereby facilitating the targeting of the siRNA to the hepatocytes that are infected with HBV. The siRNA enter the infected hepatocytes and stimulate destruction of HBV gene transcripts by the phenomenon of RNA interference. Examples of GalNAc-siRNA conjugates useful in the practice of this aspect of the present disclosure are set forth in published international application PCT/CA2017/050447 (PCT Application Publication number WO/2017/177326, published on October 19, 2017) which is hereby incorporated by reference in its entirety. (h) Therapeutic Vaccines In certain embodiments, administration of a therapeutic vaccine is useful in the practice of the present disclosure for the treatment of a viral disease in a subject. In certain embodiments, the viral disease is a hepatitis virus. In certain embodiments, the hepatitis virus is at least one selected from the group consisting of hepatitis B virus (HBV) and hepatitis D virus (HDV). In certain embodiments, the subject is a human. A synergistic effect may be calculated, for example, using suitable methods such as, for example, the Sigmoid-Emax equation (Holford & Scheiner, 1981, Clin. Pharmacokinet. 6:429-453), the equation of Loewe additivity (Loewe & Muischnek, 1926, Arch. Exp. Pathol Pharmacol.114: 313-326) and the median-effect equation (Chou & Talalay, 1984, Adv. Enzyme Regul.22:27-55). Each equation referred to elsewhere herein may be applied to experimental data to generate a corresponding graph to aid in assessing the effects of the drug combination. The corresponding graphs associated with the equations referred to elsewhere herein are the concentration-effect curve, isobologram curve and combination index curve, respectively. Synthesis The present disclosure further provides methods of preparing the compounds of the present disclosure. Compounds of the present teachings can be prepared in accordance with the procedures outlined herein, from commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field. It is appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, and so forth) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions can vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented can be varied for the purpose of optimizing the formation of the compounds described herein. The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatography such as high pressure liquid chromatograpy (HPLC), gas chromatography (GC), gel-permeation chromatography (GPC), or thin layer chromatography (TLC). Preparation of the compounds can involve protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed. (Wiley & Sons, 1991), the entire disclosure of which is incorporated by reference herein for all purposes. The reactions or the processes described herein can be carried out in suitable solvents that can be readily selected by one skilled in the art of organic synthesis. Suitable solvents typically are substantially nonreactive with the reactants, intermediates, and/or products at the temperatures at which the reactions are carried out, i.e., temperatures that can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected. A compound of formula (I) can be prepared, for example, according to the synthetic methods outlined in Schemes 1-11. In Schemes 1-11, T1, X1, X2, X3, X4, X5, X6, R1a, R1b, R5, R6, R10, and R11 are as defined elsewhere herein; Hal is halide; Boc is tert-butylcarboxy; each occurrence of R is independently selected from the group consisting of H and C1-C6 alkyl; and each occurrence of M is independently selected from the group consisting of B(OH)2 and Bpin. Further, in Schemes 1-11: R3 is selected from the group consisting of R3a, R3b, R3c, and R3d, as defined elsewhere herein; R4 is selected from the group consisting of R4a and R4b, as defined elsewhere herein; R9 is selected from the group consisting of R9a, R9b, R9c, R9d, R9e, and R9f, as defined elsewhere herein; m is an integer selected from selected from the group consisting of 0, 1, 2, 3, 4, 5, and 6; n is an integer selected from the group consisting of 0, 1, 2, and 3; Y1 is selected from the group consisting of CR10, NR10, O, and S; each of Z1 and Z2 are independently selected from the group consisting of C and N, wherein Y1, Z1, and Z2 are selected such that the heterocycle comprising Y1, Z1, and Z2 is a neutral heteroaromatic in which each constituent atom possesses a satisfied valency; and R13 is any substituent of R11 except -C(=O)(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -C(=O)(CH2)0-3(optionally substituted C3-C8 cycloalkyl), and C(=O)(optionally substituted C1-C6 alkyl).
Scheme 1. In Scheme 1, boronic acid or boronic ester 1-1 is coupled with aromatic halide 1-2 under standard metal-catalyzed coupling conditions, non-limiting examples including using a palladium catalyst and a suitable base, to provide compound 1-3. N-acylation of aromatic amine 1-3 with carboxylic acid or ester 1-4 provides amide compound 1-5. In non-limiting embodiments, when compound 1-4 is a carboxylic acid, a suitable coupling agent, including but not limited to HATU, may be employed in the presence of a tertiary amine base. In further non-limiting embodiments, when compound 1-4 is an ester, aromatic amine 1-3 can be pretreated with a suitable base, including but not limited to lithium bis(trimethylsilyl)amide or sodium hydride. Removal of the Boc protecting group in compound 1-5 under standard conditions, including but not limited to acidic conditions with hydrochloric acid or trifluoroacetic acid, provides compound 1-6. Reductive alkylation of compound 1-6 with a suitable aldehyde or ketone, or N-alkylation of compound 1-6 with a suitable electrophile, non-limiting examples including an alkyl halide or alkyl tosylate, provides compound 1-7. Coupling of compound 1-7 with boronic acid or boronic ester 1-8 under standard metal-catalyzed coupling conditions, non-limiting examples including using a palladium catalyst and a suitable base, provides compound 1-9. Reaction of compound 1-9 with amine 1-10 under reductive amination conditions provides compound 1-11. Scheme 2. An alternative method for preparing compounds of formula (I) is shown in Scheme 2. Aromatic halide 2-1 can be coupled with boronic acid or boronic ester 2-2 under standard metal-catalyzed coupling conditions, non-limiting examples including using a palladium catalyst and a suitable base, to provide compound 2-3. Reductive amination of compound 2-3 with amine 2-4 provides compound 2-5. The Boc protecting group of compound 2-5 can be removed under standard conditions, non-limiting examples including acidic conditions with hydrochloric acid or trifluoroacetic acid, to provide compound 2-6. Compound 2-7 can be prepared by reductive alkylation of compound 2-6 with a suitable aldehyde or ketone, or N- alkylation of compound 2-6 with a suitable alkyl electrophile, non-limiting examples including an alkyl halide and alkyl tosylate.
Scheme 3. Compounds of formula (I) can also be prepared as shown in Scheme 3. Reductive alkylation of amine 3-1 with a suitable aldehyde or ketone, or N-alkylation of amine 3-1 with a suitable electrophile, non-limiting examples including an alkyl halide or alkyl tosylate, provides compound 3-2. N-acylation of the aryl amine 3-3 with 3-2 provides amide 3-4. In non-limiting embodiments, when compound 3-2 is a carboxylic acid a suitable coupling agent, such as HATU, may be employed in the presence of a suitable tertiary amine base. In other non-limiting embodiments, when compound 3-2 is an ester, aromatic amine compound 3-3 can be pretreated with a suitable base, such as lithium bis(trimethylsilyl)amide or sodium hydride. Compound 3-6 can be prepared by coupling compound 3-4 with boronic acid or boronic ester compound 3-5 under standard metal-catalyzed coupling conditions, non- limiting examples including a using palladium catalyst and a suitable base. Reductive amination of compound 3-6 with an amine 3-7 provides compound 3-8.
Scheme 4. Compounds of formula (I) can also be prepared as shown in Scheme 4. Aromatic halide 4-1 can be coupled with boronic acid or boronic ester 4-2 under standard metal- catalyzed coupling conditions, non-limiting examples including using a palladium catalyst and a suitable base, to provide compound 4-3. N-acylation of aromatic amine 4-4 with carboxylic acid or ester 4-5 provides amide 4-6. In non-limiting embodiments, when compound 4-5 is a carboxylic acid, a suitable coupling agent, such as HATU, can be employed in the presence of a tertiary amine base. In other non-limiting embodiments, when compound 4-5 is a carboxylic ester, aromatic amine 4-4 can be pretreated with a suitable base, including but not limited to lithium bis(trimethylsilyl)amide or sodium hydride. Compound 4-7 can be prepared by borylation of compound 4-6 (e.g., under Miyaura borylation conditions using a suitable palladium catalyst, a suitable borylating agent, including but not limited to bis(pinacolato)diboron, and a suitable base, including but not limited to potassium acetate). Compound 4-7 can be coupled with aromatic halide 4-3 under standard metal-catalyzed coupling conditions, non-limiting examples including using a palladium catalyst and a suitable base, to provide compound 4-8. Reductive amination of compound 4-8 with amine 4-9 provides compound 4-10.
Scheme 5. An alternative procedure for the preparation of compounds of formula (I) is shown in Scheme 5. N-acylation of aromatic amine 5-1 with carboxylic acid or ester 5-2 provides amide 5-3. In non-limiting embodiments, when compound 5-2 is a carboxylic acid, a suitable coupling agent, such as HATU, may be employed in the presence of a suitable tertiary amine base. In other non-limiting embodiments, when compound 5-2 is an ester, aromatic amine 5-1 can be pretreated with a suitable base, including but not limited to lithium bis(trimethylsilyl)amide or sodium hydride. Compound 5-3 can be borylated (e.g. under Miyaura borylation conditions using a suitable palladium catalyst, a suitable borylating agent, including but not limited to bis(pinacolato)diboron and a suitable base, including but not limited to potassium acetate) to provide compound 5-4. Compound 5-6 can be prepared by coupling compound 5-4 with aromatic halide 5-5 under standard metal-catalyzed coupling conditions, non-limiting examples including using a palladium catalyst and a suitable base. Reductive amination of compound 5-6 with amine 5-7 provides compound 5-8. Removal of the Boc protecting group in compound 5-8 under standard conditions, non-limiting examples including acidic conditions with hydrochloric acid or trifluoroacetic acid, followed by reductive alkylation with a suitable aldehyde or ketone, or N-alkylation with a suitable electrophile, non-limiting examples including an alkyl halide or alkyl tosylate, provides compound 5-9. Scheme 6. Compounds of formula (I) can also be prepared as shown in Scheme 6. Reductive amination of compound 6-1 with amine 6-2 provides amine 6-3. In non-limiting embodiments, amine 6-3 can optionally be protected with a suitable protecting group, including but not limited to a Boc protecting group. Compound 6-5 can be prepared by coupling amine 6-3 with boronic acid or boronic ester 6-4 under standard metal-catalyzed coupling conditions, non-limiting examples including using a suitable palladium catalyst and a suitable base, optionally followed by removal of any protecting group employed in compound 6-3, under suitable deprotection conditions, to give compound 6-5.
Scheme 7. An alternative procedure for the preparation of compounds of formula (I) is shown in Scheme 7. Reduction of the aldehyde or ketone present in compound 7-1 gives an alcohol compound 7-2. Suitable reducing agents, including but not limited to sodium or lithium borohydride or diisobutylaluminum hydride in an inert solvent, may be employed. Removal of the Boc protecting group in compound 7-2 under standard conditions, including but not limited to acidic conditions with hydrochloric acid or trifluoroacetic acid, followed by reductive alkylation with an aldehyde or ketone or N-alkylation with a suitable electrophile, non-limiting examples include an alkyl halide or alkyl mesylate, provides compound 7-3. Non-limiting examples of reductive alkylation conditions include using a suitable reducing agent, including but not limited to sodium cyanoborohydride or sodium triacetoxyborohydride in the presence of sodium acetate or acetic acid. The alcohol present in compound 7-3 can then be oxidized to give an aldehyde or ketone compound 7-4. Suitable oxidizing agents, including but not limited to Dess–Martin periodinane, pyridinium dichromate or manganese dioxide, may be employed. Reaction of compound 7-4 with an amine compound 7-5 under reductive amination conditions, non-limiting examples include using a suitable reducing agent, including but not limited to sodium cyanoborohydride or sodium triacetoxyborohydride in the presence of sodium acetate or acetic acid, then provides compound 7-6.
Scheme 8. Compounds of formula (I) can also be prepared as shown in Scheme 8. N-acylation of the amine compound 8-1 with a carboxylic acid, carboxylic acid anhydride or acid chloride gives an amide compound 8-2. In non-limiting embodiments, when the acylating agent is a carboxylic acid, a suitable coupling agent, including but not limited to HATU, may be employed in the presence a tertiary amine base. In further non-limiting embodiments, when the acylating agent is a carboxylic acid anhydride or acid chloride a suitable tertiary amine base may be employed. Compound 8-2 is then coupled with a boronic acid or boronic ester compound 8-3 under standard metal-catalyzed coupling conditions, non-limiting examples include using a suitable palladium catalyst and a suitable base, to give compound 8-4. Reaction of compound 8-4 with amine compound 8-5 under reductive amination conditions, non-limiting examples include using a suitable reducing agent, including but not limited to sodium cyanoborohydride or sodium triacetoxyborohydride in the presence of sodium acetate or acetic acid, then gives compound 8-6.
Scheme 9. An alternative procedure for the preparation of compounds of formula (I) is shown in Scheme 9. Reaction of aldehyde or ketone compound 9-1 with an amine compound 9-2 under reductive amination conditions, non-limiting examples include using a suitable reducing agent, including but not limited to sodium cyanoborohydride or sodium triacetoxyborohydride, in the presence of sodium acetate or acetic acid, gives amine compound 9-3. In non-limiting embodiments, amine compound 9-3 can optionally be protected with a suitable protecting group, including but not limited to a Boc protecting group. Amine compound 9-3 is then coupled with a boronic acid or boronic ester compound 9-4 under standard metal-catalyzed coupling conditions, non-limiting examples include using a suitable palladium catalyst and a suitable base, gives compound 9-5. N-acylation of aromatic amine 9-5 with carboxylic acid or ester 9-6 provides amide compound 9-7. In non- limiting embodiments, when compound 9-6 is a carboxylic acid, a suitable coupling agent, including but not limited to HATU, may be employed in the presence of a tertiary amine base. In further non-limiting embodiments, when compound 9-6 is an ester, aromatic amine 9-5 can be pretreated with a suitable base, including but not limited to lithium bis(trimethylsilyl)amide or sodium hydride. Optionally N-acylation is followed by removal of any protecting group employed in compound 9-3, under suitable deprotection conditions, to provide compound 9-7. Scheme 10. Compounds of formula (I) can also be prepared as shown in Scheme 10. N-acylation of the amine compound 10-1 with a carboxylic acid, carboxylic acid anhydride or acid chloride gives an amide compound 10-2. In non-limiting embodiments, when the acylating agent is a carboxylic acid, a suitable coupling agent, including but not limited to HATU, may be employed in the presence a tertiary amine base. In further non-limiting embodiments, when acylating agent is a carboxylic acid anhydride or acid chloride a suitable tertiary amine base may be employed. N-acylation of the aromatic amine 10-3 with ester compound 10-2 then provides amide compound 10-4. In non-limiting embodiments, aromatic amine 10-3 can be pretreated with a suitable base, including but not limited to lithium bis (trimethylsilyl)amide or sodium hydride. Compound 10-5 can be prepared by borylation of compound 10-4 (e.g., under Miyaura borylation conditions using a suitable palladium catalyst, a suitable borylating agent, including but not limited to bis(pinacolato)diboron, and a suitable base, including but not limited to potassium acetate). Compound 10-5 is then coupled with a halide compound 10-6 under standard metal-catalyzed coupling conditions, non- limiting examples include using a suitable palladium catalyst and a suitable base, to give compound 10-7. Reaction of aldehyde or ketone compound 10-7 with an amine compound 10-8 under reductive amination conditions, non-limiting examples include using a suitable reducing agent, including but not limited to sodium cyanoborohydride or sodium triacetoxyborohydride, in the presence of sodium acetate or acetic acid, provides compound 10-9. Scheme 11. An alternative procedure for the preparation of compounds of formula (I) is shown in Scheme 11. Reaction of aldehyde or ketone compound 11-1 with an amine compound 11-2 under reductive amination conditions, non-limiting examples include using a suitable reducing agent, including but not limited to sodium cyanoborohydride or sodium triacetoxyborohydride, in the presence of sodium acetate or acetic acid, gives amine compound 11-3. In non-limiting embodiments, amine compound 11-3 can optionally be protected with a suitable protecting group, including but not limited to a Boc protecting group. Compound 11-4 can be prepared by borylation of compound 11-3 (e.g., under Miyaura borylation conditions using a suitable palladium catalyst, a suitable borylating agent, including but not limited to bis(pinacolato)diboron, and a suitable base, including but not limited to potassium acetate). Compound 11-4 is then coupled with a halide compound 11-5 under standard metal-catalyzed coupling conditions, non-limiting examples include using a suitable palladium catalyst and a suitable base, to give compound 11-6. N-acylation of aromatic amine 11-6 with carboxylic acid or ester 11-7 provides amide compound 11-8. In non-limiting embodiments, when compound 11-7 is a carboxylic acid, a suitable coupling agent, including but not limited to HATU, may be employed in the presence of a tertiary amine base. In further non-limiting embodiments, when compound 11-7 is an ester, aromatic amine 11-6 can be pretreated with a suitable base, including but not limited to lithium bis(trimethylsilyl)amide or sodium hydride. Optionally N-acylation is followed by removal of any protecting group employed in compound 11-3, under suitable deprotection conditions, to provide compound 11-8. Methods The disclosure provides a method of treating, ameliorating, and/or preventing hepatitis virus infection in a subject. In certain embodiments, the infection comprises hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infection. In other embodiments, the infection comprises hepatitis B virus (HBV) infection. In yet other embodiments, the infection comprises hepatitis D virus (HDV) infection. In yet other embodiments, the method comprises administering to the subject in need thereof a therapeutically effective amount of at least one compound of the disclosure. In yet other embodiments, the compound of the disclosure is the only antiviral agent administered to the subject. In yet other embodiments, the at least one compound is administered to the subject in a pharmaceutically acceptable composition. In yet other embodiments, the subject is further administered at least one additional agent useful for treating the hepatitis virus infection. In yet other embodiments, the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitors; capsid inhibitors; cccDNA formation inhibitors; RNA destabilizers; oligomeric nucleotides targeted against the HBV genome; immunostimulators; GalNAc-siRNA conjugates targeted against an HBV gene transcript; and therapeutic vaccines. In yet other embodiments, the subject is co-administered the at least one compound and the at least one additional agent. In yet other embodiments, the at least one compound and the at least one additional agent are coformulated. The disclosure further provides a method of treating, ameliorating, and/or preventing cancer in a subject. In certain embodiments, the method comprises administering to the subject in need thereof a therapeutically effective amount of at least one compound of the disclosure. In other embodiments, the compound of the disclosure is the only anticancer agent administered to the subject. In yet other embodiments, the at least one compound is administered to the subject in a pharmaceutically acceptable composition. In yet other embodiments, the subject is further administered at least one additional agent or therapy useful for treating, ameliorating, or preventing the cancer. In yet other embodiments, the additional anticancer agent or therapy comprises nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, and/or resection therapy. In yet other embodiments, the additional anticancer agent or therapy comprises rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and/or ipilimumab. In certain embodiments, the cancer is amenable to treatment by inhibiting PD-1, PD- L1 or the PD-1/PD-L1 interaction. In other embodiments, the cancer is at least one of pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer, or colon cancer. In yet other embodiments, the cancer is at least one of lymphoma, multiple myeloma, or leukemia. In yet other embodiments, the cancer is at least one of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL). In certain embodiments, the subject is a mammal. In other embodiments, the mammal is a human. Pharmaceutical Compositions and Formulations The disclosure provides pharmaceutical compositions comprising at least one compound of the disclosure or a salt or solvate thereof, which are useful to practice methods of the disclosure. Such a pharmaceutical composition may consist of at least one compound of the disclosure or a salt or solvate thereof, in a form suitable for administration to a subject, or the pharmaceutical composition may comprise at least one compound of the disclosure or a salt or solvate thereof, and one or more pharmaceutically acceptable carriers, one or more additional ingredients, or some combination of these. At least one compound of the disclosure may be present in the pharmaceutical composition in the form of a physiologically acceptable salt, such as in combination with a physiologically acceptable cation or anion, as is well known in the art. In certain embodiments, the pharmaceutical composition of the present disclosure is useful for the treatment, amelioration, and/or prevention of hepatitis virus infection in a subject. In certain embodiments, the pharmaceutical compositions useful for practicing the method of the disclosure may be administered to deliver a dose of between 1 ng/kg/day and 100 mg/kg/day. In other embodiments, the pharmaceutical compositions useful for practicing the disclosure may be administered to deliver a dose of between 1 ng/kg/day and 1,000 mg/kg/day. The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the disclosure will vary, depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient. Pharmaceutical compositions that are useful in the methods of the disclosure may be suitably developed for nasal, inhalational, oral, rectal, vaginal, pleural, peritoneal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, epidural, intrathecal, intravenous or another route of administration. A composition useful within the methods of the disclosure may be directly administered to the brain, the brainstem, or any other part of the central nervous system of a mammal or bird. Other contemplated formulations include projected nanoparticles, microspheres, liposomal preparations, coated particles, polymer conjugates, resealed erythrocytes containing the active ingredient, and immunologically- based formulations. In certain embodiments, the compositions of the disclosure are part of a pharmaceutical matrix, which allows for manipulation of insoluble materials and improvement of the bioavailability thereof, development of controlled or sustained release products, and generation of homogeneous compositions. By way of example, a pharmaceutical matrix may be prepared using hot melt extrusion, solid solutions, solid dispersions, size reduction technologies, molecular complexes (e.g., cyclodextrins, and others), microparticulate, and particle and formulation coating processes. Amorphous or crystalline phases may be used in such processes. The route(s) of administration will be readily apparent to the skilled artisan and will depend upon any number of factors including the type and severity of the disease being treated, the type and age of the veterinary or human patient being treated, and the like. The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology and pharmaceutics. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single-dose or multi-dose unit. As used herein, a "unit dose" is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one- third of such a dosage. The unit dosage form may be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose. Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the disclosure is contemplated include, but are not limited to, humans and other primates, mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs. In certain embodiments, the compositions of the disclosure are formulated using one or more pharmaceutically acceptable excipients or carriers. In certain embodiments, the pharmaceutical compositions of the disclosure comprise a therapeutically effective amount of at least one compound of the disclosure and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers, which are useful, include, but are not limited to, glycerol, water, saline, ethanol, recombinant human albumin (e.g., RECOMBUMIN®), solubilized gelatins (e.g., GELOFUSINE®), and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey). The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), recombinant human albumin, solubilized gelatins, suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, are included in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate or gelatin. Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, inhalational, intravenous, subcutaneous, transdermal enteral, or any other suitable mode of administration, known to the art. The pharmaceutical preparations may be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or fragrance-conferring substances and the like. They may also be combined where desired with other active agents, e.g., other analgesic, anxiolytics or hypnotic agents. As used herein, "additional ingredients" include, but are not limited to, one or more ingredients that may be used as a pharmaceutical carrier. The composition of the disclosure may comprise a preservative from about 0.005% to 2.0% by total weight of the composition. The preservative is used to prevent spoilage in the case of exposure to contaminants in the environment. Examples of preservatives useful in accordance with the disclosure include but are not limited to those selected from the group consisting of benzyl alcohol, sorbic acid, parabens, imidurea and combinations thereof. One such preservative is a combination of about 0.5% to 2.0% benzyl alcohol and 0.05% to 0.5% sorbic acid. The composition may include an antioxidant and a chelating agent which inhibit the degradation of the compound. Antioxidants for some compounds are BHT, BHA, alpha- tocopherol and ascorbic acid in the exemplary range of about 0.01% to 0.3%, or BHT in the range of 0.03% to 0.1% by weight by total weight of the composition. The chelating agent may be present in an amount of from 0.01% to 0.5% by weight by total weight of the composition. Exemplary chelating agents include edetate salts (e.g. disodium edetate) and citric acid in the weight range of about 0.01% to 0.20%, or in the range of 0.02% to 0.10% by weight by total weight of the composition. The chelating agent is useful for chelating metal ions in the composition that may be detrimental to the shelf life of the formulation. While BHT and disodium edetate are exemplary antioxidant and chelating agent, respectively, for some compounds, other suitable and equivalent antioxidants and chelating agents may be substituted therefore as would be known to those skilled in the art. Liquid suspensions may be prepared using conventional methods to achieve suspension of the active ingredient in an aqueous or oily vehicle. Aqueous vehicles include, for example, water, and isotonic saline. Oily vehicles include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Liquid suspensions may further comprise one or more additional ingredients including, but not limited to, suspending agents, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffers, salts, flavorings, coloring agents, and sweetening agents. Oily suspensions may further comprise a thickening agent. Known suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl cellulose. Known dispersing or wetting agents include, but are not limited to, naturally-occurring phosphatides such as lecithin, condensation products of an alkylene oxide with a fatty acid, with a long chain aliphatic alcohol, with a partial ester derived from a fatty acid and a hexitol, or with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene stearate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyoxyethylene sorbitan monooleate, respectively). Known emulsifying agents include, but are not limited to, lecithin, acacia, and ionic or non ionic surfactants. Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl para-hydroxybenzoates, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin. Liquid solutions of the active ingredient in aqueous or oily solvents may be prepared in substantially the same manner as liquid suspensions, the primary difference being that the active ingredient is dissolved, rather than suspended in the solvent. As used herein, an "oily" liquid is one which comprises a carbon-containing liquid molecule and which exhibits a less polar character than water. Liquid solutions of the pharmaceutical composition of the disclosure may comprise each of the components described with regard to liquid suspensions, it being understood that suspending agents will not necessarily aid dissolution of the active ingredient in the solvent. Aqueous solvents include, for example, water, and isotonic saline. Oily solvents include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Powdered and granular formulations of a pharmaceutical preparation of the disclosure may be prepared using known methods. Such formulations may be administered directly to a subject, used, for example, to form tablets, to fill capsules, or to prepare an aqueous or oily suspension or solution by addition of an aqueous or oily vehicle thereto. Each of these formulations may further comprise one or more of dispersing or wetting agent, a suspending agent, ionic and non-ionic surfactants, and a preservative. Additional excipients, such as fillers and sweetening, flavoring, or coloring agents, may also be included in these formulations. A pharmaceutical composition of the disclosure may also be prepared, packaged, or sold in the form of oil-in-water emulsion or a water-in-oil emulsion. The oily phase may be a vegetable oil such as olive or arachis oil, a mineral oil such as liquid paraffin, or a combination of these. Such compositions may further comprise one or more emulsifying agents such as naturally occurring gums such as gum acacia or gum tragacanth, naturally- occurring phosphatides such as soybean or lecithin phosphatide, esters or partial esters derived from combinations of fatty acids and hexitol anhydrides such as sorbitan monooleate, and condensation products of such partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. These emulsions may also contain additional ingredients including, for example, sweetening or flavoring agents. Methods for impregnating or coating a material with a chemical composition are known in the art, and include, but are not limited to methods of depositing or binding a chemical composition onto a surface, methods of incorporating a chemical composition into the structure of a material during the synthesis of the material (i.e., such as with a physiologically degradable material), and methods of absorbing an aqueous or oily solution or suspension into an absorbent material, with or without subsequent drying. Methods for mixing components include physical milling, the use of pellets in solid and suspension formulations and mixing in a transdermal patch, as known to those skilled in the art. Administration/Dosing The regimen of administration may affect what constitutes an effective amount. The therapeutic formulations may be administered to the patient either prior to or after the onset of a disease or disorder. Further, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation. Administration of the compositions of the present disclosure to a patient, such as a mammal, such as a human, may be carried out using known procedures, at dosages and for periods of time effective to treat a disease or disorder contemplated herein. An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the activity of the particular compound employed; the time of administration; the rate of excretion of the compound; the duration of the treatment; other drugs, compounds or materials used in combination with the compound; the state of the disease or disorder, age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well-known in the medical arts. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A non-limiting example of an effective dose range for a therapeutic compound of the disclosure is from about 0.01 mg/kg to 100 mg/kg of body weight/per day. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation. The compound may be administered to an animal as frequently as several times daily, or it may be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every several months or even once a year or less. It is understood that the amount of compound dosed per day may be administered, in non-limiting examples, every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, with every other day administration, a 5 mg per day dose may be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on. The frequency of the dose is readily apparent to the skilled artisan and depends upon a number of factors, such as, but not limited to, type and severity of the disease being treated, and type and age of the animal. Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. A medical doctor, e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the disclosure employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The dosage unit forms of the disclosure are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding/formulating such a therapeutic compound for the treatment of a disease or disorder in a patient. In certain embodiments, the compositions of the disclosure are administered to the patient in dosages that range from one to five times per day or more. In other embodiments, the compositions of the disclosure are administered to the patient in range of dosages that include, but are not limited to, once every day, every two days, every three days to once a week, and once every two weeks. It will be readily apparent to one skilled in the art that the frequency of administration of the various combination compositions of the disclosure will vary from subject to subject depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors. Thus, the disclosure should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient will be determined by the attending physician taking all other factors about the patient into account. Compounds of the disclosure for administration may be in the range of from about 1 ^g to about 7,500 mg, about 20 ^g to about 7,000 mg, about 40 ^g to about 6,500 mg, about 80 ^g to about 6,000 mg, about 100 ^g to about 5,500 mg, about 200 ^g to about 5,000 mg, about 400 ^g to about 4,000 mg, about 800 ^g to about 3,000 mg, about 1 mg to about 2,500 mg, about 2 mg to about 2,000 mg, about 5 mg to about 1,000 mg, about 10 mg to about 750 mg, about 20 mg to about 600 mg, about 30 mg to about 500 mg, about 40 mg to about 400 mg, about 50 mg to about 300 mg, about 60 mg to about 250 mg, about 70 mg to about 200 mg, about 80 mg to about 150 mg, and any and all whole or partial increments there-in- between. In some embodiments, the dose of a compound of the disclosure is from about 0.5 ^g and about 5,000 mg. In some embodiments, a dose of a compound of the disclosure used in compositions described herein is less than about 5,000 mg, or less than about 4,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof. In certain embodiments, the present disclosure is directed to a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound of the disclosure, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of a disease or disorder in a patient. The term "container" includes any receptacle for holding the pharmaceutical composition or for managing stability or water uptake. For example, in certain embodiments, the container is the packaging that contains the pharmaceutical composition, such as liquid (solution and suspension), semisolid, lyophilized solid, solution and powder or lyophilized formulation present in dual chambers. In other embodiments, the container is not the packaging that contains the pharmaceutical composition, i.e., the container is a receptacle, such as a box or vial that contains the packaged pharmaceutical composition or unpackaged pharmaceutical composition and the instructions for use of the pharmaceutical composition. Moreover, packaging techniques are well known in the art. It should be understood that the instructions for use of the pharmaceutical composition may be contained on the packaging containing the pharmaceutical composition, and as such the instructions form an increased functional relationship to the packaged product. However, it should be understood that the instructions may contain information pertaining to the compound's ability to perform its intended function, e.g., treating, preventing, or reducing a disease or disorder in a patient. Administration Routes of administration of any of the compositions of the disclosure include inhalational, oral, nasal, rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal, and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, epidural, intrapleural, intraperitoneal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration. Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, emulsions, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions that would be useful in the present disclosure are not limited to the particular formulations and compositions that are described herein. Oral Administration For oral application, particularly suitable are tablets, dragees, liquids, drops, capsules, caplets and gelcaps. Other formulations suitable for oral administration include, but are not limited to, a powdered or granular formulation, an aqueous or oily suspension, an aqueous or oily solution, a paste, a gel, toothpaste, a mouthwash, a coating, an oral rinse, or an emulsion. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic, generally recognized as safe (GRAS) pharmaceutically excipients which are suitable for the manufacture of tablets. Such excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. Tablets may be non-coated or they may be coated using known methods to achieve delayed disintegration in the gastrointestinal tract of a subject, thereby providing sustained release and absorption of the active ingredient. By way of example, a material such as glyceryl monostearate or glyceryl distearate may be used to coat tablets. Further by way of example, tablets may be coated using methods described in U.S. Patents Nos.4,256,108; 4,160,452; and 4,265,874 to form osmotically controlled release tablets. Tablets may further comprise a sweetening agent, a flavoring agent, a coloring agent, a preservative, or some combination of these in order to provide for pharmaceutically elegant and palatable preparation. Hard capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin. The capsules comprise the active ingredient, and may further comprise additional ingredients including, for example, an inert solid diluent such as calcium carbonate, calcium phosphate, or kaolin. Hard capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin. Such hard capsules comprise the active ingredient, and may further comprise additional ingredients including, for example, an inert solid diluent such as calcium carbonate, calcium phosphate, or kaolin. Soft gelatin capsules comprising the active ingredient may be made using a physiologically degradable composition, such as gelatin from animal-derived collagen or from a hypromellose, a modified form of cellulose, and manufactured using optional mixtures of gelatin, water and plasticizers such as sorbitol or glycerol. Such soft capsules comprise the active ingredient, which may be mixed with water or an oil medium such as peanut oil, liquid paraffin, or olive oil. For oral administration, the compounds of the disclosure may be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents; fillers; lubricants; disintegrates; or wetting agents. If desired, the tablets may be coated using suitable methods and coating materials such as OPADRY® film coating systems available from Colorcon, West Point, Pa. (e.g., OPADRY® OY Type, OYC Type, Organic Enteric OY-P Type, Aqueous Enteric OY-A Type, OY-PM Type and OPADRY® White, 32K18400). It is understood that similar type of film coating or polymeric products from other companies may be used. A tablet comprising the active ingredient may, for example, be made by compressing or molding the active ingredient, optionally with one or more additional ingredients. Compressed tablets may be prepared by compressing, in a suitable device, the active ingredient in a free-flowing form such as a powder or granular preparation, optionally mixed with one or more of a binder, a lubricant, an excipient, a surface active agent, and a dispersing agent. Molded tablets may be made by molding, in a suitable device, a mixture of the active ingredient, a pharmaceutically acceptable carrier, and at least sufficient liquid to moisten the mixture. Pharmaceutically acceptable excipients used in the manufacture of tablets include, but are not limited to, inert diluents, granulating and disintegrating agents, binding agents, and lubricating agents. Known dispersing agents include, but are not limited to, potato starch and sodium starch glycolate. Known surface-active agents include, but are not limited to, sodium lauryl sulphate. Known diluents include, but are not limited to, calcium carbonate, sodium carbonate, lactose, microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and sodium phosphate. Known granulating and disintegrating agents include, but are not limited to, corn starch and alginic acid. Known binding agents include, but are not limited to, gelatin, acacia, pre-gelatinized maize starch, polyvinylpyrrolidone, and hydroxypropyl methylcellulose. Known lubricating agents include, but are not limited to, magnesium stearate, stearic acid, silica, and talc. Granulating techniques are well known in the pharmaceutical art for modifying starting powders or other particulate materials of an active ingredient. The powders are typically mixed with a binder material into larger permanent free-flowing agglomerates or granules referred to as a "granulation." For example, solvent-using "wet" granulation processes are generally characterized in that the powders are combined with a binder material and moistened with water or an organic solvent under conditions resulting in the formation of a wet granulated mass from which the solvent must then be evaporated. Melt granulation generally consists in the use of materials that are solid or semi-solid at room temperature (i.e., having a relatively low softening or melting point range) to promote granulation of powdered or other materials, essentially in the absence of added water or other liquid solvents. The low melting solids, when heated to a temperature in the melting point range, liquefy to act as a binder or granulating medium. The liquefied solid spreads itself over the surface of powdered materials with which it is contacted, and on cooling, forms a solid granulated mass in which the initial materials are bound together. The resulting melt granulation may then be provided to a tablet press or be encapsulated for preparing the oral dosage form. Melt granulation improves the dissolution rate and bioavailability of an active (i.e., drug) by forming a solid dispersion or solid solution. U.S. Patent No.5,169,645 discloses directly compressible wax-containing granules having improved flow properties. The granules are obtained when waxes are admixed in the melt with certain flow improving additives, followed by cooling and granulation of the admixture. In certain embodiments, only the wax itself melts in the melt combination of the wax(es) and additives(s), and in other cases both the wax(es) and the additives(s) will melt. The present disclosure also includes a multi-layer tablet comprising a layer providing for the delayed release of one or more compounds useful within the methods of the disclosure, and a further layer providing for the immediate release of one or more compounds useful within the methods of the disclosure. Using a wax/pH-sensitive polymer mix, a gastric insoluble composition may be obtained in which the active ingredient is entrapped, ensuring its delayed release. Liquid preparation for oral administration may be in the form of solutions, syrups or suspensions. The liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non- aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl para-hydroxy benzoates or sorbic acid). Liquid formulations of a pharmaceutical composition of the disclosure which are suitable for oral administration may be prepared, packaged, and sold either in liquid form or in the form of a dry product intended for reconstitution with water or another suitable vehicle prior to use. Parenteral Administration As used herein, "parenteral administration" of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrasternal injection, and kidney dialytic infusion techniques. Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multidose containers containing a preservative. Injectable formulations may also be prepared, packaged, or sold in devices such as patient-controlled analgesia (PCA) devices. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g., sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition. The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non- toxic parenterally acceptable diluent or solvent, such as water or 1,3-butanediol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form in a recombinant human albumin, a fluidized gelatin, in a liposomal preparation, or as a component of a biodegradable polymer system. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt. Topical Administration An obstacle for topical administration of pharmaceuticals is the stratum corneum layer of the epidermis. The stratum corneum is a highly resistant layer comprised of protein, cholesterol, sphingolipids, free fatty acids and various other lipids, and includes cornified and living cells. One of the factors that limit the penetration rate (flux) of a compound through the stratum corneum is the amount of the active substance that can be loaded or applied onto the skin surface. The greater the amount of active substance which is applied per unit of area of the skin, the greater the concentration gradient between the skin surface and the lower layers of the skin, and in turn the greater the diffusion force of the active substance through the skin. Therefore, a formulation containing a greater concentration of the active substance is more likely to result in penetration of the active substance through the skin, and more of it, and at a more consistent rate, than a formulation having a lesser concentration, all other things being equal. Formulations suitable for topical administration include, but are not limited to, liquid or semi-liquid preparations such as liniments, lotions, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes, and solutions or suspensions. Topically administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein. Enhancers of permeation may be used. These materials increase the rate of penetration of drugs across the skin. Typical enhancers in the art include ethanol, glycerol monolaurate, PGML (polyethylene glycol monolaurate), dimethylsulfoxide, and the like. Other enhancers include oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-methyl-2-pyrrolidone. One acceptable vehicle for topical delivery of some of the compositions of the disclosure may contain liposomes. The composition of the liposomes and their use are known in the art (i.e., U.S. Patent No.6,323,219). In alternative embodiments, the topically active pharmaceutical composition may be optionally combined with other ingredients such as adjuvants, anti-oxidants, chelating agents, surfactants, foaming agents, wetting agents, emulsifying agents, viscosifiers, buffering agents, preservatives, and the like. In other embodiments, a permeation or penetration enhancer is included in the composition and is effective in improving the percutaneous penetration of the active ingredient into and through the stratum corneum with respect to a composition lacking the permeation enhancer. Various permeation enhancers, including oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-methyl-2-pyrrolidone, are known to those of skill in the art. In another aspect, the composition may further comprise a hydrotropic agent, which functions to increase disorder in the structure of the stratum corneum, and thus allows increased transport across the stratum corneum. Various hydrotropic agents such as isopropyl alcohol, propylene glycol, or sodium xylene sulfonate, are known to those of skill in the art. The topically active pharmaceutical composition should be applied in an amount effective to affect desired changes. As used herein "amount effective" shall mean an amount sufficient to cover the region of skin surface where a change is desired. An active compound should be present in the amount of from about 0.0001% to about 15% by weight volume of the composition. For example, it should be present in an amount from about 0.0005% to about 5% of the composition; for example, it should be present in an amount of from about 0.001% to about 1% of the composition. Such compounds may be synthetically-or naturally derived. Buccal Administration A pharmaceutical composition of the disclosure may be prepared, packaged, or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) of the active ingredient, the balance comprising an orally dissolvable or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder or an aerosolized or atomized solution or suspension comprising the active ingredient. Such powdered, aerosolized, or aerosolized formulations, when dispersed, may have an average particle or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein. The examples of formulations described herein are not exhaustive and it is understood that the disclosure includes additional modifications of these and other formulations not described herein, but which are known to those of skill in the art. Rectal Administration A pharmaceutical composition of the disclosure may be prepared, packaged, or sold in a formulation suitable for rectal administration. Such a composition may be in the form of, for example, a suppository, a retention enema preparation, and a solution for rectal or colonic irrigation. Suppository formulations may be made by combining the active ingredient with a non-irritating pharmaceutically acceptable excipient which is solid at ordinary room temperature (i.e., about 20 ^C) and which is liquid at the rectal temperature of the subject (i.e., about 37 ^C in a healthy human). Suitable pharmaceutically acceptable excipients include, but are not limited to, cocoa butter, polyethylene glycols, and various glycerides. Suppository formulations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives. Retention enema preparations or solutions for rectal or colonic irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier. As is well known in the art, enema preparations may be administered using, and may be packaged within, a delivery device adapted to the rectal anatomy of the subject. Enema preparations may further comprise various additional ingredients including, but not limited to, antioxidants, and preservatives. Additional Administration Forms Additional dosage forms of this disclosure include dosage forms as described in U.S. Patents Nos.6,340,475, 6,488,962, 6,451,808, 5,972,389, 5,582,837, and 5,007,790. Additional dosage forms of this disclosure also include dosage forms as described in U.S. Patent Applications Nos.20030147952, 20030104062, 20030104053, 20030044466, 20030039688, and 20020051820. Additional dosage forms of this disclosure also include dosage forms as described in PCT Applications Nos. WO 03/35041, WO 03/35040, WO 03/35029, WO 03/35177, WO 03/35039, WO 02/96404, WO 02/32416, WO 01/97783, WO 01/56544, WO 01/32217, WO 98/55107, WO 98/11879, WO 97/47285, WO 93/18755, and WO 90/11757. Controlled Release Formulations and Drug Delivery Systems: In certain embodiments, the compositions and/or formulations of the present disclosure may be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations. The term sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a month or more and should be a release which is longer that the same amount of agent administered in bolus form. For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds. As such, the compounds for use the method of the disclosure may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation. In certain embodiments of the disclosure, the compounds useful within the disclosure are administered to a subject, alone or in combination with another pharmaceutical agent, using a sustained release formulation. The term delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug administration and that may, although not necessarily, include a delay of from about 10 minutes up to about 12 hours. The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration. The term immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately after drug administration. As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration. As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered to be within the scope of this disclosure and covered by the claims appended hereto. For example, it should be understood, that modifications in reaction conditions, including but not limited to reaction times, reaction size/volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing/oxidizing agents, with art- recognized alternatives and using no more than routine experimentation, are within the scope of the present application. It is to be understood that, wherever values and ranges are provided herein, the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, all values and ranges encompassed by these values and ranges are meant to be encompassed within the scope of the present disclosure. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application. The description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range and, when appropriate, partial integers of the numerical values within ranges. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range. The following examples further illustrate aspects of the present disclosure. However, they are in no way a limitation of the teachings or disclosure of the present disclosure as set forth herein. EXAMPLES The disclosure is now described with reference to the following Examples. These Examples are provided for the purpose of illustration only, and the disclosure is not limited to these Examples, but rather encompasses all variations that are evident as a result of the teachings provided herein. LCMS Methods LCMS Method A: Waters Acquity UPLC system employing a Waters Acquity UPLC BEH C18, 1.7 μm, 50 x 2.1 mm column with an aqueous acetonitrile based solvent gradient of 2-98% CH3CN/H2O (0.05 % TFA) over 9.5 mins. Flow rate = 0.8 mL/min. LCMS Method B: Waters Acquity UPLC system employing a Waters Acquity UPLC BEH C18, 1.7 μm, 50 x 2.1 mm column with an aqueous acetonitrile based solvent gradient of 2-98% CH3CN/H2O (0.05 % TFA) over 1.0 mins. Flow rate = 0.8 mL/min. LCMS Method C: Shimadzu UFLC system employing an ACE UltraCore Super PhenylHexyl, 2.5 μm, 50 x 2.1 mm column with an aqueous acetonitrile based solvent gradient of 5-100% CH3CN/H2O (0.05 % Formic acid) over 5.0 mins. Flow rate = 1.0 mL/min. LCMS Method D: Waters Acquity UPLC system employing a Waters Acquity UPLC BEH C18, 1.7 μm, 50 x 2.1 mm column with an aqueous acetonitrile based solvent gradient of 2-98% CH3CN/H2O (0.05 % TFA) over 5.0 mins. Flow rate = 0.8 mL/min. LCMS Method E: Shimadzu LC-20AD HPLC system employing a Xbridge Shield RP18 C18, 5 μm, 50 x 2.1 mm column with an aqueous acetonitrile based solvent gradient of 5-95% CH3CN/H2O (NH4HCO3) over 2.2 mins. Flow rate = 1.5 mL/min. Preparation of Dioxaborolanes 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde To a solution of 4-bromo-2-methoxybenzaldehyde (10 g, 46.5 mmol) and bis(pinacolato)diboron (23.6 g, 93.0 mmol) in 1,4-dioxane (100 mL) was added potassium acetate (13.7 g, 139 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1.90 g, 2.33 mmol) and the mixture stirred at 95 °C for 12 hr. The mixture was then filtered and the filtrate concentrated. The residue was purified by normal phase SiO2 chromatography (0-100% EtOAc/petroleum ether) to afford a yellow solid. The solid product was further purified by recrystallization from petroleum ether / ethyl acetate (6/1, 50 mL) at -30 oC twice to give 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde as a white solid (12 g, 98% yield).1H NMR (400 MHz, DMSO-d6): δ 10.40 (s, 1 H), 7.70 (d, 1 H), 7.37 (d, 2 H), 3.95 (s, 3 H), 1.32 (s, 12 H). 2-Fluoro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde A mixture of 4-bromo-2-fluoro-6-methoxybenzaldehyde (1 g, 4.29 mmol,), potassium acetate (842 mg, 8.58 mmol) and bis(pinacolato)diboron (2.18 g, 8.58 mmol) in 1,4-dioxane (10 mL) was degassed and purged with N2 three times. [1,1′- Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (350 mg, 0.429 mmol,) was then added and the mixture stirred at 85 °C for 12 h under N2. The mixture was then diluted with ethyl acetate (10 mL) and washed with water (2 x 15 mL) and saturated brine 20 mL (2 x 10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (4-16% Petroleum ether/Ethyl acetate) to afford 2-fluoro-6-methoxy-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (1 g, 99% yield) as a yellow solid.1H NMR (400 MHz, CDCl3): δ 10.47 (s, 1H), 7.17-7.14 (m, 2H), 3.98 (s, 3H), 1.36 (s, 12H). 2-(Difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde To a mixture of 4-bromo-2-(difluoromethoxy)benzaldehyde (300 mg, 1.20 mmol) and bis(pinacolato)diboron (394 mg, 1.55 mmol) in 1,4-dioxane (3 mL) was added potassium acetate (234 mg, 2.39 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (97.6 mg, 0.119 mmol) and the mixture stirred at 100 °C for 1 h under N2. Water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 10 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-15% EtOAc/petroleum ether) to afford 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (230 mg, crude) as a yellow oil.1H NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H), 7.92 (d, 1H), 7.75-7.35 (m, 1H), 7.68-7.32 (m, 2H), 1.34 (s, 12H). Example 1: 4-(2-(2-((3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)- 3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) Methyl 4-formylbicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-(hydroxymethyl)bicyclo[2.2.1]heptane-1-carboxylate (5 g, 27.1 mmol) in dichloromethane (120 mL) was added Dess-Martin periodinane (13.8 g, 32.6 mmol), then the mixture was stirred at room temperature for 12 h under N2. The mixture was added water (50 mL) and extracted with dichloromethane (2 x50 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-16% ethyl acetate/petroleum ether) to afford methyl 4-formylbicyclo[2.2.1]heptane-1-carboxylate (4.1 g, 83% yield) as a colorless oil.1H NMR (400 MHz, DMSO-d6): δ 9.76 (s, 1H), 3.63 (s, 3H), 1.99-1.95 (m, 4H), 1.77 (s, 2H), 1.67-1.62 (m, 2H), 1.48-1.45 (m, 2H). (b) Methyl (E)-4-(2-methoxyvinyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of (methoxymethyl)triphenylphosphonium chloride (3.76 g, 11.0 mmol) in THF (10 mL) was added 1.0 M potassium tert-butoxide solution in THF (11.0 mL, 11.0 mmol), then the mixture was stirred at room temperature for 1 h under N2. After that methyl 4-formylbicyclo[2.2.1]heptane-1-carboxylate (1 g, 5.49 mmol) was added to the mixture, then the mixture was stirred at room temperature for 6 h under N2. Water (30 mL) was added and the mixture extracted with ethyl acetate (2 x30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-15% ethyl acetate/petroleum ether) to afford methyl (E)-4-(2-methoxyvinyl)bicyclo[2.2.1]heptane-1-carboxylate (470 mg, 41% yield) as a colorless oil.1H NMR (400 MHz, DMSO-d6): δ 6.30 (d, 1H), 4.93 (d, 1H), 3.57 (s, 3H), 3.40 (s, 3H), 1.87-1.83 (m, 3H), 1.59-1.53 (m, 4H), 1.40-1.36 (m, 3H). (c) Methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl (E)-4-(2-methoxyvinyl)bicyclo[2.2.1]heptane-1-carboxylate (270 mg, 1.28 mmol) in THF (2.5 mL) was added aqueous hydrochloric acid (2.70 mL, 4 moL/L), then the mixture was stirred at room temperature for 1 h under N2. To the mixture was added saturated aqueous sodium bicarbonate solution (10 mL). Water (20 mL) was added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure to afford methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (260 mg, crude) as a colorless oil. The product was used in step (g) without further purification.1H NMR (400 MHz, DMSO- d6): δ 9.71 (t, 1H), 3.61 (s, 3H), 2.55 (d, 2H), 1.91-1.85 (m, 2H), 1.60-1.40 (m, 8H). (d) 2-Chloro-3-(2,3-dichloropyridin-4-yl)aniline To a mixture of 3-bromo-2-chloroaniline (10 g, 48.4 mmol) and 2,3-dichloro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (19.9 g, 72.6 mmol) in 1,4- dioxane/water (5:1, 300 mL) was added [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) (3.16 g, 4.84 mmol) and potassium phosphate (30.8 g, 145 mmol), then the mixture was stirred at 95 °C for 3 h under N2. Water (300 mL) was added and the mixture extracted with ethyl acetate (2 x 300 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-50% ethyl acetate/petroleum ether) to afford 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (8 g, 60% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 8.41 (d, 1H), 7.40 (d, 1H), 7.10 (t, 1H), 6.86 (dd, 1H), 6.46 (dd, 1H), 5.57 (s, 2H). (e) tert-Butyl 2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate To a mixture of 2-chloro-3-(2, 3-dichloropyridin-4-yl)aniline (1.8 g, 6.58 mmol) in THF (40 mL) was added 1.0 M lithium bis(trimethylsilyl)amide solution in THF (13.2 mL, 13.2 mmol) at 0 °C and the mixture was stirred at 0 °C for 0.5 h under N2. A solution of 5- (tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5- dicarboxylate (2.33 g, 7.90 mmol) in THF (40 mL) was then added at 0°C, and the mixture stirred at 0 °C for 0.5 h under N2. The mixture was combined with another two batches at 1.6 g scale. Water (100 mL) was added and the combined mixture extracted with ethyl acetate (2 x 100 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-40 % ethyl acetate/petroleum ether) to afford tert-butyl 2-((2-chloro-3- (2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-5-carboxylate (4 g, 60% yield) as a red solid.1H NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 8.53 (d, 1H), 8.34 (s, 1H), 7.57-7.53 (m, 2H), 7.24 (dd, 1H), 4.39 (s, 2H), 3.92 (s, 3H), 3.69 (t, 2H), 2.71 (t, 2H), 1.44 (s, 9H). (f) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (1 g, 1.86 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (4 mL), and then the mixture stirred at room temperature for 1 h under N2. The mixture was concentrated and saturated aqueous sodium bicarbonate (20 mL) solution added to the residue. Water (40 mL) was added and the mixture extracted with ethyl acetate (2 x40 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure to afford N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (860 mg, crude) as a white solid. MS: m/z found 436 [M+H]+. The product was used in the next step without further purification. (g) Methyl 4-(2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylate To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (380 mg, 0.87 mmol) and methyl 4-(2- oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (256 mg, 1.31 mmol) in dichloromethane/MeOH (1:1, 10 mL) was added sodium acetate (214 mg, 2.61 mmol), then the mixture was stirred at room temperature for 4 h under N2. Sodium cyanoborohydride (164 mg, 2.61 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was combined with three other batches (total 460 mg). Water (30 mL) was added and the combined mixture extracted with ethyl acetate (2 x30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-95% ethyl acetate/petroleum ether) to afford methyl 4-(2-(2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (700 mg, 59% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.89 (s, 1H), 8.49 (d, 1H), 8.35 (dd, 1H), 7.52-7.48 (m, 2H), 7.18 (d, 1H), 3.86 (s, 3H), 3.56 (s, 3H), 3.39 (s, 2H), 2.74-2.73 (m, 2H), 2.65-2.64 (m, 2H), 2.53- 2.51 (m, 2H), 1.96-1.83 (m, 2H), 1.70-1.68 (m, 2H), 1.55-1.48 (m, 4H), 1.44 (s, 2H), 1.37- 1.32 (m, 2H). (h) Methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate
Figure imgf000183_0001
To a mixture of methyl 4-(2-(2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (200 mg, 0.324 mmol) and 2-methoxy-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (110 mg, 0.421 mmol) in 1,4- dioxane/water (5:1, 6 mL) was added [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) (21 mg, 0.032 mmol) and potassium phosphate (206 mg, 0.972 mmol), and then the mixture was stirred at 130 °C for 2 h under N2. The mixture was concentrated and the residue was purified by prep-TLC (SiO2, ethyl acetate/MeOH =9/1) to afford methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (130 mg, 56% yield) as a yellow solid. MS: m/z found 716 [M+H]+. (i) Methyl 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (130 mg, 0.181 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt (97.2 mg, 0.544 mmol) in dichloromethane /methanol (5:1, 6 mL) was added sodium acetate (74.4 mg, 0.907 mmol) and the mixture stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (34.2 mg, 0.544 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by prep-TLC (SiO2, ethyl acetate/MeOH =1/1) to afford methyl 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylate (40 mg, 26% yield) as a yellow solid. MS: m/z found 842 [M+H]+. (j) 4-(2-(2-((3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
To a mixture of methyl 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (35 mg, 0.042 mmol) in THF/water (2:1, 7.5 mL) was added lithium hydroxide monohydrate (26 mg, 0.622 mmol) and the mixture stirred at room temperature for 12 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 4-(2-(2-((3-(2-(4-(((1- acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (19.2 mg, 54% yield) as a white solid. MS: m/z found 828 [M+H]+, retention time = 2.93 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.53-7.48 (m, 2H), 7.45 (d, 1H), 7.37-7.36 (m, 1H), 7.34-7.32 (m, 1H), 7.17 (dd, 1H), 4.60-4.57 (m, 1H), 4.13 (s, 2H), 4.04-3.98 (m, 7H), 3.60 (s, 2H), 3.22-3.13 (m, 2H), 2.96 (t, 2H), 2.82-2.79 (m, 2H), 2.73-2.69 (m, 3H), 2.18-2.10 (m, 5H), 2.01-1.95 (m, 2H), 1.89-1.84 (m, 2H), 1.68-1.41 (m, 10H). Example 2: 4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) Methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (from Example 1, step (i)) (240 mg, 0.335 mmol) and tetrahydro-2H-pyran-4-amine (67.7 mg, 0.669 mmol) in dichloromethane (7 mL) was added sodium acetate (82.4 mg, 1.0 mmol) and then the mixture stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (63 mg, 1.0 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by prep-TLC (SiO2, EtOAc/MeOH = 2/1) to afford methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (230 mg, 85% yield) as a yellow sold. MS: m/z found 801 [M+H]+. (b) 4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To the mixture of methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4- (((tetrahydro-2H-pyran-4-yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (220 mg, 0.274 mmol) in THF/water (2:1, 7.5 mL) was added lithium hydroxide monohydrate (172 mg, 4.1 mmol) and the mixture stirred at room temperature for 12 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (43.9 mg, 19% yield) as a white solid. MS: m/z found 787 [M+H]+, retention time = 3.02 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.53 (dd, 1H), 7.52-7.48 (m, 2H), 7.44 (d, 1H), 7.37 (s, 1H), 7.34 (dd, 1H), 7.16 (dd, 1H), 4.17 (s, 2H), 4.05-3.98 (m, 8H), 3.57 (s, 2H), 3.48-3.43 (m, 2H), 3.23-3.15 (m, 1H), 2.93-2.91 (m, 2H), 2.78-2.77 (m, 2H), 2.71-2.67 (m, 2H), 2.08-2.04 (m, 2H), 1.96-1.90 (m, 2H), 1.86-1.82 (m, 2H), 1.68-1.44 (m, 10H). Example 3: (S)-4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (S)-4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid was prepared in a similar fashion to Example 2, replacing tetrahydro-2H-pyran-4-amine with (S)- 5-(methoxymethyl)pyrrolidin-2-one hydrochloride salt in step (a). MS: m/z found 800 [M+H]+, retention time = 3.22 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.53 (d, 1H), 8.40 (dd, 1H), 7.39 (t, 1H), 7.32-7.31 (m, 2H), 7.19-7.16 (m, 2H), 7.06 (dd, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.82 (d, 2H), 3.78-3.73 (m, 1H), 3.49 (s, 2H), 2.86-2.83 (m, 2H), 2.70-2.67 (m, 2H), 2.66-2.58 (m, 4H), 2.25-2.19 (m, 3H), 1.87-1.77 (m, 2H), 1.76-1.73 (m, 3H), 1.53- 1.34 (m, 8H). Example 4: N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl 2-((2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate To a mixture of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, step (e)) (500 mg, 0.93 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde (244 mg, 0.93 mmol) in 1,4-dioxane / water (5:1, 12 mL) was added potassium carbonate (386 mg, 2.79 mmol) and [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) (76.1 mg, 0.09 mmol) and the mixture stirred at 130 °C for 4 h under N2. Water (10 mL) was added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-60 % EtOAc/petroleum ether) to afford tert-butyl 2-((2-chloro-3-(3- chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (320 mg, 54% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 10.48 (s, 1H), 10.02 (s, 1H), 8.83 (d, 1H), 8.39 (s, 1H), 7.88 (d, 1H), 7.62-7.57 (m, 3H), 7.46 (d, 1H), 7.32 (dd, 1H), 4.44 (s, 2H), 4.05 (s, 3H), 3.97 (s, 3H), 3.75-3.65 (m, 2H), 2.77-2.75 (m, 2H), 1.48 (s, 9H). (b) tert-Butyl 2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate To a mixture of tert-butyl 2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridine-5-carboxylate (300 mg, 0.47 mmol), 2,6-diazaspiro[3.4]octan-7-one trifluoroacetate salt (340 mg, 1.41 mmol) in methanol / dichloromethane (1:1, 6 mL) was added sodium acetate (232 mg, 2.83 mmol) and the mixture stirred at room temperature for 1.5 h under N2. After that sodium cyanoborohydride (88.8 mg, 1.41 mmol) was added to the mixture, then the mixture was stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue was purified by normal phase SiO2 chromatography (0-50 % MeOH/ EtOAc) to afford tert-butyl 2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (210 mg, 60% yield) as a white solid. MS: m/z found 746 [M+H]+. (c) N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a solution of tert-butyl 2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (200 mg, 0.27 mmol) in dichloromethane (6 mL) was added trifluoroacetic acid (2 mL, 27.0 mmol) and the mixture stirred at room temperature for 10 min under N2. The mixture was then concentrated to afford N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (170 mg, crude) as a white solid. MS: m/z found 646 [M+H]+. The crude product was used in the next step without further purification. (d) N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (160 mg, 0.25 mmol) and 2-hydroxyacetaldehyde (74.3 mg, 1.24 mmol) in dichloromethane / methanol (2:1, 9 mL) was added acetic acid (0.02 mL, 0.37 mmol) and the mixture stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (93.3 mg, 1.48 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (32.4 mg, 18% yield) as a white solid. MS: m/z found 690 [M+H]+, retention time = 3.39 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.53 (d, 1H), 8.41 (dd, 1H), 7.39 (t, 1H), 7.32-7.30 (m, 2H), 7.20- 7.18 (m, 2H), 7.05 (dd, 1H), 3.88 (s, 3H), 3.82 (s, 5H), 3.68 (t, 2H), 3.54-3.50 (m, 8H), 2.91- 2.88 (m, 2H), 2.72-2.68 (m, 4H), 2.50 (s, 2H). Example 5: 4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylic acid (a) Methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylate To a mixture of N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 4, step (c)) (130 mg, 0.201 mmol) and methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, step (c)) (78.9 mg, 0.402 mmol) in methanol/dichloromethane (1:1, 6 mL) was added sodium acetate (49.4 mg, 0.603 mmol) and the mixture stirred at room temperature for 4 h under N2. Sodium cyanoborohydride (37.9 mg, 0.603 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by prep-TLC (SiO2, EtOAc/MeOH = 1/1) to afford methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3- methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (150 mg, 90% yield) as a white solid. MS: m/z found 826 [M+H]+. (b) 4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan- 2-yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (145 mg, 0.175 mmol) in THF/water (2:1, 4.5 mL) was added lithium hydroxide monohydrate (110 mg, 2.6 mmol) and the mixture stirred at room temperature for 12 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford 4- (2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (17.6 mg, 11% yield) as a white solid. MS: m/z found 812 [M+H]+, retention time = 2.95 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.53-7.49 (m, 1H), 7.43 (d, 1H), 7.42-7.40 (m, 1H), 7.30-7.28 (m, 2H), 7.17 (dd, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 3.88 (s, 2H), 3.61-3.60 (m, 4H), 3.57-3.53 (m, 4H), 2.98-2.96 (m, 2H), 2.82-2.79 (m, 2H), 2.74-2.70 (m, 2H), 2.60 (s, 2H), 2.02-1.96 (m, 2H), 1.89-1.85 (m, 2H), 1.68-1.57 (m, 4H), 1.55 (s, 2H), 1.49-1.47 (m, 2H). Example 6: N-(3-(2-(4-((6-Acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl 2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate To a mixture of tert-butyl 2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridine-5-carboxylate (Example 4, step (a)) (400 mg, 0.63 mmol) and 1- (2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one trifluoroacetate salt (479 mg, 1.89 mmol) in methanol/dichloromethane (1:1, 10 mL) was added sodium acetate (258 mg, 3.14 mmol) and the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (118 mg, 1.89 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by prep-TLC (SiO2, EtOAc: MeOH = 2:1) to afford tert-butyl 2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2- yl)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (400 mg, 83% yield) as a white solid MS: m/z found 760 [M+H]+. (b) N-(3-(2-(4-((6-Acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)- 3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a solution of tert-butyl 2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2- yl)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (390 mg, 0.51 mmol) in dichloromethane (15 mL) was added trifluoroacetic acid (5 mL, 67.5 mmol) and the mixture stirred at room temperature for 10 min under N2. The mixture was then concentrated to afford N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamide (400 mg, crude) as a white solid. MS: m/z found 660 [M+H]+. The crude product was used in the next step without further purification. (c) N-(3-(2-(4-((6-Acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)- 3-chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (150 mg, 0.23 mmol) and 2-hydroxyacetaldehyde (68.2 mg, 1.14 mmol) in methanol / dichloromethane (1:3, 8 mL) was added acetic acid (0.02 mL, 0.34 mmol) and the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (143 mg, 2.27 mmol) was then added and the mixture was stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2- yl)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (30.2 mg, 18% yield) as a white solid. MS: m/z found 704 [M+H]+, retention time = 2.62 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.55 (d, 1H), 8.40 (dd, 1H), 7.39 (t, 1H), 7.37-7.32 (m, 2H), 7.25-7.21 (m, 2H), 7.05 (dd, 1H), 4.25 (s, 2H), 4.06 (s, 2H), 4.01 (s, 2H), 3.91 (s, 4H), 3.88 (s, 3H), 3.86 (s, 3H), 3.69 (t, 2H), 3.61 (s, 2H), 2.97-2.95 (m, 2H), 2.78-2.70 (m, 4H), 1.74 (s, 3H). Example 7: 4-(2-(2-((3-(2-(4-((2,6-Diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) Methyl 4-(2-(2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (Example 6, step (b)) (150 mg, 0.227 mmol) and methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, step (c)) (57.9 mg, 0.295 mmol) in dichloromethane / methanol (1:1, 4 mL) was added sodium acetate (55.8 mg, 0.681 mmol) and the mixture stirred at room temperature for 4 h under N2. Sodium cyanoborohydride (42.8 mg, 0.681 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by prep-TLC (SiO2, EtOAc/MeOH = 1/1) to afford methyl 4-(2-(2-((3-(2-(4-((6-acetyl-2,6- diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (90 mg, 47% yield) as a white solid. MS: m/z found 840 [M+H]+. (b) 4-(2-(2-((3-(2-(4-((2,6-Diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of methyl 4-(2-(2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2- yl)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (80 mg, 0.095 mmol) in THF/water (2:1, 6 mL) was added lithium hydroxide monohydrate (59.9 mg, 1.4 mmol) and the mixture was stirred at room temperature for 12 h under N2. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford 4-(2- (2-((3-(2-(4-((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (4.0 mg, 4% yield) as a yellow solid. MS: m/z found 784 [M+H]+, retention time = 3.02 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.51 (d, 1H), 7.50 (t, 1H), 7.43-7.41 (m, 1H), 7.37-7.35 (m, 1H), 7.28-7.26 (m, 2H), 7.17 (d, 1H), 3.99 (s, 3H), 3.91 (s, 3H), 3.71 (s, 2H), 3.67 (s, 3H), 3.57 (s, 2H), 3.47-3.43 (m, 5H), 2.94-2.92 (m, 1H), 2.81-2.67 (m, 3H), 1.98-1.91 (m, 2H), 1.87-1.83 (m, 2H), 1.66-1.57 (m, 4H), 1.51 (s, 2H), 1.46-1.40 (m, 2H), 1.33-1.31 (m, 2H). Example 8: 4-(2-(2-((3-(2-(4-((6-Acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) 4-(2-Oxoethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of methyl (E)-4-(2-methoxyvinyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, step (b)) (300 mg, 1.43 mmol) in THF/water (1:1, 8 mL) was added lithium hydroxide monohydrate (898 mg, 21.4 mmol) and the mixture stirred at 55 °C for 30 h under N2 to afford (E)-4-(2-methoxyvinyl)bicyclo[2.2.1]heptane-1-carboxylic acid (observed by TLC). To the above mixture was added 4 N aqueous HCl (12.0 mL) and the mixture stirred at room temperature for 1 h under N2. Saturated aqueous sodium bicarbonate solution (40 mL) and water (20 mL) were then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure to afford 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (140 mg, crude) as a white solid. The product was used for next step without purification.1H NMR (400 MHz, DMSO-d6): δ 12.07 (s, 1H), 9.72 (t, 1H), 2.59 (d, 2H), 1.57-1.48 (m, 10H). The product was used in the next step without further purification. (b) 4-(2-(2-((3-(2-(4-((6-Acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (Example 6, step (b)) (150 mg, 0.227 mmol) and 4- (2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (124 mg, 0.681 mmol) in dichloromethane / methanol (1:1, 4 mL) was added sodium acetate (55.9 mg, 0.681 mmol) and the mixture stirred at room temperature for 4 h under N2. Sodium cyanoborohydride (42.8 mg, 0.681 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 4-(2-(2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (4.3 mg, 2% yield) as a white solid. MS: m/z found 826 [M+H]+, retention time = 0.74 min (Method E).1H NMR (400 MHz, Methanol-d4): δ 8.54 (d, 1H), 8.41 (dd, 1H), 7.39 (t, 1H), 7.33-7.29 (m, 2H), 7.20-7.18 (m, 2H), 7.06 (dd, 1H), 4.21 (s, 2H), 3.97 (s, 2H), 3.88 (s, 3H), 3.83-3.81 (m, 5H), 3.62-3.59 (m, 4H), 3.51 (s, 2H), 2.89-2.86 (m, 2H), 2.71-2.69 (m, 2H), 2.64-2.60 (m, 2H), 1.88-1.85 (m, 2H), 1.78-1.74 (m, 4H), 1.56-1.36 (m, 9H). Example 9: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl (S)-(4-bromo-2-methoxybenzyl)((5-oxopyrrolidin-2- yl)methyl)carbamate To a mixture of 4-bromo-2-methoxybenzaldehyde (3 g, 14 mmol) and (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt (2.31 g, 15.4 mmol) in dichloromethane / methanol mixture (2:1, 60 mL) was added sodium acetate (3.43 g, 41.9 mmol) in one portion under N2 and the mixture stirred at room temperature for 1 hr. Sodium cyanoborohydride (2.63 g, 41.9 mmol) was then added and the mixture stirred at room temperature for 1 hr. Di- tert-butyl dicarbonate (3.2 mL, 14 mmol) and triethylamine (1.9 mL, 14.0 mmol) were then added in one portion under N2 and the mixture stirred at room temperature for 2 hr. The mixture was then concentrated, water (10 mL) and saturated aqueous brine solution (10 mL) added, and the mixture extracted with ethyl acetate (20 mL). The organic phase was dried with anhydrous sodium sulfate, filtered and concentrated. The residue was purified by normal phase SiO2 chromatography (16-90% ethyl acetate/petroleum ether) to afford 3.5 g of product. The product was further purified by reverse phase HPLC to afford tert-butyl (S)-(4- bromo-2-methoxybenzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate as a light yellow gum (2.2 g, 62% yield).1H NMR (400 MHz, CDCl3) δ 7.28 (s, 1H), 7.11-7.09 (m, 1H), 7.02 (s, 1H), 4.45-4.42 (m, 2H), 3.85-3.84 (m, 4H), 3.31-3.26 (m, 2H), 2.35-2.31 (m, 2H), 2.17-2.07 (m, 1H), 1.88-1.86 (m, 1H), 1.74-1.46 (m, 9H). (b) tert-Butyl (S)-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of tert-butyl (S)-(4-bromo-2-methoxybenzyl)((5-oxopyrrolidin-2- yl)methyl)carbamate (1.6 g, 3.87 mmol) and bis(pinacolato)diboron (2.46 g, 9.69 mmol) in 1,4-dioxane/THF mixture (4:1, 10 mL) was added potassium acetate (1.14 g, 11.6 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.47 g, 0.58 mmol) in one portion under N2 and the mixture stirred at 110 °C for 3 hr. The mixture was concentrated and the residue purified by normal phase SiO2 chromatography (25-90% ethyl acetate/petroleum ether) to afford tert-butyl (S)-(2-methoxy-4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (1.6 g, 63% yield) as a red solid. MS: m/z found 405 [MH-tBu]+. (c) tert-Butyl (S)-2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate To a mixture of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, step (e)) (120 mg, 0.224 mmol) and tert-butyl (S)-(2-methoxy-4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (257 mg, 0.559 mmol) in 1,4-dioxane / water (5:1, 3.6 mL) was added potassium carbonate (92.7 mg, 0.671 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (18.2 mg, 0.022 mmol) and the mixture stirred at 130 °C for 2 h under N2. Water (5 mL) was added and the mixture extracted with ethyl acetate (2 x 5 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, EtOAc: MeOH = 2:1) to afford tert-butyl (S)-2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate (150 mg, 80% yield) as a white solid. MS: m/z found 834 [M+H]+. (d) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide To a solution of tert-butyl (S)-2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate (140 mg, 0.17 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (2.8 mL, 37.8 mmol) and the mixture stirred at room temperature for 10 min under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford (S)- N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (23.2 mg, 21% yield) as a white solid. MS: m/z found 634 [M+H]+, retention time = 2.41 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.42 (m, 2H), 7.30-7.28 (m, 2H), 7.18 (dd, 1H), 4.00 (s, 3H), 3.95 (s, 3H), 3.91-3.87 (m, 5H), 3.21-3.16 (m, 2H), 2.78-2.68 (m, 4H), 2.37- 2.26 (m, 3H), 1.84-1.79 (m, 1H). Example 10: N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate trifluoroacetate salt To a solution of 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-2,5-dicarboxylate (2 g, 6.77 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (5 mL, 67.5 mmol) and then the mixture was stirred at room temperature for 1 h under N2. The mixture was concentrated to afford methyl 1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxylate trifluoroacetate salt (2 g, crude) as a yellow oil. MS: m/z found 196 [M+H]+. The crude product was used in the next step without further purification. (b) Methyl 5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate trifluoroacetate salt (2 g, 10.2 mmol), 1-bromo-3-fluoropropane (2.89 g, 20.5 mmol) in acetonitrile (20 mL) was added potassium carbonate (8.50 g, 61.5 mmol) and then the mixture stirred at 60 °C for 5 h under N2. The mixture was concentrated, water (30 mL) added to the residue and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-30 % MeOH / EtOAc) to afford methyl 5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate (1.5 g, 57% yield) as a yellow solid.1H NMR (400 MHz, DMSO- d6): δ 4.57 (t, 1H), 4.45 (t, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.38 (s, 2H), 2.77-2.74 (m, 2H), 2.67-2.59 (m, 4H), 1.94-1.86 (m, 2H). (c) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (Example 1, step (d)) (450 mg, 1.65 mmol) in THF (5 mL) was added 1.0 M lithium bis(trimethylsilyl)amide solution in THF (3.29 mL, 3.29 mmol) at 0°C, then the mixture was stirred at 0 °C for 0.5 h under N2. Methyl 5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxylate (504 mg, 1.97 mmol) in THF (5 mL) was then added and the mixture stirred at 0 °C for 1 h under N2. Water (20 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % EtOAc / petroleum ether) to afford N-(2-chloro-3-(2,3- dichloropyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (600 mg, 73% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.88 (s, 1H), 8.49 (d, 1H), 8.35 (d, 1H), 7.52-7.48 (m, 2H), 7.18 (d, 1H), 4.53 (t, 1H), 4.41 (t, 1H), 3.87 (s, 3H), 3.41 (s, 2H), 2.76-2.73 (m, 2H), 2.66-2.65 (m, 2H), 2.60-2.57 (m, 2H), 1.92-1.85 (m, 2H). (d) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5- (3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(3-fluoropropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (200 mg, 0.40 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (158 mg, 0.60 mmol) in 1,4-dioxane / water (5:1, 6 mL) was added potassium carbonate (167 mg, 1.21mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (32.9 mg, 0.04 mmol) and then the mixture stirred at 130 °C for 3 h under N2. Water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0- 100 % EtOAc / petroleum ether) to afford N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (120 mg, 50% yield). MS: m/z found 596 [M+H]+. (e) N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (110 mg, 0.184 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt (65.9 mg, 0.369 mmol) in dichloromethane / methanol (1:1, 10 mL) was added sodium acetate (45.4 mg, 0.553 mmol) and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (34.8 mg, 0.553 mmol) was then added and the mixture was stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (44.4 mg, 32% yield) as a white solid. MS: m/z found 722 [M+H]+, retention time = 2.84 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.44-7.42 (m, 2H), 7.30-7.27 (m, 2H), 7.17 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 2H), 3.99 (s, 3H), 3.95 (s, 3H), 3.92 (s, 3H), 3.58 (s, 2H), 3.17-3.14 (m, 1H), 2.95-2.92 (m, 2H), 2.81-2.67 (m, 6H), 2.11 (s, 3H), 2.08-1.98 (m, 4H), 1.41-1.28 (m, 2H). Example 11: N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan- 2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (Example 10, step (d)) (90 mg, 0.151 mmol) and 2,6-diazaspiro[3.4]octan-7- one trifluoroacetate salt (109 mg, 0.453 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (61.9 mg, 0.754 mmol) and then the mixture was stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (28.4 mg, 0.453 mmol) was then added and the mixture was stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford N-(2-chloro-3-(3- chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (29.9 mg, 27% yield) as a white solid. MS: m/z found 706 [M+H]+, retention time = 2.69 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.52 (dd, 1H), 7.50 (t, 1H), 7.42-7.38 (m, 2H), 7.29-7.27 (m, 2H), 7.17 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 3.99 (s, 3H), 3.92 (s, 3H), 3.77 (s, 2H), 3.58 (s, 4H), 3.41-3.40 (m, 4H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.57 (s, 2H), 2.06-1.96 (m, 2H). Example 12: N-(3-(2-(4-((6-Acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(3-(2-(4-((6-Acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 11, replacing 2,6-diazaspiro[3.4]octan-7-one trifluoroacetate salt with 1-(2,6- diazaspiro[3.3]heptan-2-yl)ethan-1-one trifluoroacetate salt in step (a). White solid, MS: m/z found 720 [M+H]+, retention time = 2.73 min (Method A).1H NMR (400 MHz, Methanol- d4): δ 8.64 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.42 (d, 1H), 7.37 (d, 1H), 7.28-7.27 (m, 2H), 7.17 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.30 (s, 2H), 4.05 (s, 2H), 3.99 (s, 3H), 3.92 (s, 3H), 3.74 (s, 2H), 3.58 (s, 2H), 3.53-3.48 (m, 4H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.06- 1.96 (m, 2H), 1.86 (s, 3H). Example 13: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 11, replacing 2,6-diazaspiro[3.4]octan-7-one trifluoroacetate salt with (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt in step (a). White solid, MS: m/z found 694 [M+H]+, retention time = 2.66 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.30-7.27 (m, 2H), 7.17 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 3.89-3.83 (m, 3H), 3.58 (s, 2H), 2.95- 2.92 (m, 2H), 2.81-2.68 (m, 6H), 2.37-2.28 (m, 3H), 2.06-1.98 (m, 2H), 1.82-1.81 (m, 1H). Example 14: 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 1, step (f)) (380 mg, 0.87 mmol) and 1-acetylpiperidin-4-one (368 mg, 2.61 mmol) in dichloromethane / methanol (1:1, 10 mL) was added titanium(IV) ethoxide (595 mg, 2.61 mmol) and then the mixture was stirred at room temperature for 12 h under N2. Sodium cyanoborohydride (164 mg, 2.61 mmol) was then added and the mixture stirred at room temperature for 1 h under N2. The mixture was concentrated and the residue was purified by normal phase SiO2 chromatography (0-40 % MeOH / EtOAc) to afford 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(2,3- dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (350 mg, 71% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 8.52 (d, 1H), 8.37 (d, 1H), 7.56-7.52 (m, 2H), 7.22-7.20 (m, 1H), 4.41-4.38 (m, 1H), 4.05-3.89 (m, 4H), 3.55 (s, 2H), 3.32-3.30 (m, 1H), 2.86-2.84 (m, 2H), 2.67-2.65 (m, 3H), 2.00-1.98 (m, 4H), 1.88-1.77 (m, 2H), 1.54-1.45 (m, 1H), 1.39-1.29 (m, 1H). (b) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (300 mg, 0.53 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (210 mg, 0.80 mmol) in 1,4-dioxane / water (5:1, 12 mL) was added potassium carbonate (221 mg, 1.60 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (43.6 mg, 0.05 mmol) and then the mixture stirred at 130 °C for 2 h under N2. Water (10 mL) was then added and the mixture extracted with dichloromethane (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-60 % MeOH / EtOAc) to afford 5-(1-acetylpiperidin-4-yl)-N- (2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (300 mg, 85% yield) as a yellow solid. MS: m/z found 661 [M+H]+. (c) 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (100 mg, 0.151 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt (54.0 mg, 0.302 mmol) in dichloromethane / methanol (1:1, 10 mL) was added sodium acetate (37.2 mg, 0.453 mmol) and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (28.5 mg, 0.453 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1-acetylpiperidin- 4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin- 4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (24.6 mg, 20% yield) as a white solid. MS: m/z found 787 [M+H]+, retention time = 2.70 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.53 (d, 1H), 8.41 (dd, 1H), 7.39 (t, 1H), 7.34-7.31 (m, 2H), 7.19-7.16 (m, 2H), 7.06 (dd, 1H), 4.53-4.49 (m, 1H), 4.40-4.37 (m, 1H), 3.93-3.83 (m, 10H), 3.59 (s, 2H), 3.05-3.02 (m, 2H), 2.92-2.89 (m, 2H), 2.67-2.52 (m, 6H), 2.01 (s, 3H), 2.00 (s, 3H), 1.91-1.88 (m, 4H), 1.55-1.17 (m, 4H). Example 15: (S)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) (S)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 14, step (b)) (70 mg, 0.106 mmol) and (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt (31.9 mg, 0.212 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (26.0 mg, 0.317 mmol) and then the mixture stirred at room temperature for 1 h under N2. Sodium cyanoborohydride (19.9 mg, 0.317 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (14.7 mg, 17% yield) as a white solid. MS: m/z found 759 [M+H]+, retention time = 2.56 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.53 (d, 1H), 8.41 (dd, 1H), 7.39 (t, 1H), 7.31-7.29 (m, 2H), 7.18-7.15 (m, 2H), 7.05 (dd, 1H), 4.51-4.49 (m, 1H), 3.93-3.89 (m, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.77 (d, 2H), 3.74-3.71 (m, 1H), 3.59 (s, 2H), 3.08-3.01 (m, 1H), 2.91-2.89 (m, 2H), 2.78-2.72 (m, 1H), 2.67-2.53 (m, 5H), 2.25-2.12 (m, 3H), 2.01 (s, 3H), 1.94-1.87 (m, 2H), 1.73-1.65 (m, 1H), 1.55-1.34 (m, 2H). Example 16: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-(((3- fluoropropyl)amino)methyl)-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-(((3- fluoropropyl)amino)methyl)-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 15, replacing (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt with 3- fluoropropan-1-amine hydrochloride salt in step (a). White solid, MS: m/z found 722 [M+H]+, retention time = 2.82 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.31-7.28 (m, 2H), 7.17 (dd, 1H), 4.60- 4.57 (m, 2H), 4.47 (t, 1H), 4.05-4.01 (m, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.91 (s, 2H), 3.71 (s, 2H), 3.17-3.15 (m, 1H), 3.04-3.01 (m, 2H), 2.82-2.76 (m, 5H), 2.68-2.67 (m, 1H), 2.13 (s, 3H), 2.06-1.91 (m, 4H), 1.64-1.31 (m, 2H). Example 17: (S)-N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)- 3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl (S)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate (Example 10, step (a)) (2 g, 10.2 mmol) and (S)-5-(bromomethyl)pyrrolidin-2- one (1.82 g, 10.2 mmol) in acetonitrile (30 mL) was added potassium carbonate (11.3 g, 82.0 mmol), and then the mixture stirred at 60 °C for 5 h under N2. Water (50 mL) was added and the mixture extracted with dichloromethane (2 x 50 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-40 % EtOAc / MeOH) to afford methyl (S)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate (1 g, 33% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 7.59 (s, 1H), 3.79-3.77 (m, 7H), 3.43 (s, 2H), 2.80-2.78 (m, 2H), 2.66-2.65 (m, 2H), 2.53- 2.51 (m, 2H), 2.12-2.09 (m, 3H), 1.72-1.69 (m, 1H). (b) (S)-N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-((5- oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a solution of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (Example 1, step (d)) (400 mg, 1.46 mmol) in THF (3 mL) was added 1.0 M lithium bis(trimethylsilyl)amide solution in THF (2.92 mL, 2.92 mmol) at 0 °C and the mixture was stirred at 0 °C for 0.5 h under N2. A solution of methyl (S)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (513 mg, 1.75 mmol) in THF (3 mL) was then added to the mixture at 0 °C, and the mixture stirred at 0 °C for 0.5 h under N2. The mixture was combined with another batch at the 0.1 g scale. The combined mixture was concentrated, water (10 mL) added to the residue and the mixture extracted with dichloromethane (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-37 % EtOAc / Petroleum ether) to afford (S)-N-(2-chloro-3- (2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (420 mg, 33% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 8.52 (d, 1H), 8.38 (d, 1H), 7.59 (s, 1H), 7.56- 7.52 (m, 2H), 7.23-7.21 (m, 1H), 3.90 (s, 3H), 3.78-3.77 (m, 1H), 3.50 (m, 2H), 2.82-2.69 (m, 2H), 2.56-2.54 (m, 2H), 2.53-2.51 (m, 2H), 2.10-2.00 (m, 3H), 1.75-1.72 (m, 1H). (c) (S)-N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)- 1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of (S)-N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-((5- oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (370 mg, 0.69 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde (182 mg, 0.69 mmol) in 1,4-dioxane / water (5:1, 12 mL) was added potassium phosphate (441 mg, 2.08 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) (45.2 mg, 0.07 mmol), and then the mixture stirred at 130 °C for 2 h under N2. The mixture was combined with another batch at the 50 mg scale. The combined mixture was concentrated and the residue was purified by normal phase SiO2 chromatography (0-37% MeOH / EtOAc) to afford (S)-N-(2-chloro-3-(3-chloro- 2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (370 mg, 80% yield) as a yellow solid. MS: m/z found 633 [M+H]+. (d) (S)-N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of (S)-N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (100 mg, 0.158 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt (42 mg, 0.237 mmol) in dichloromethane / methanol (1:1, 2 mL) was added sodium acetate (39 mg, 0.474 mmol), and then the mixture was stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (30 mg, 0.474 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was filtered and the filtrate concentrated. The residue was purified by reverse phase HPLC to afford (S)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (31.4 mg, 25% yield) as a yellow solid. MS: m/z found 759 [M+H]+, retention time = 2.63 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.45-7.42 (m, 2H), 7.30-7.28 (m, 2H), 7.17 (d, 1H), 4.51-4.48 (m, 1H), 4.03-3.99 (m, 10H), 3.69-3.65 (m, 1H), 3.58-3.55 (m, 1H), 3.17-3.14 (m, 1H), 3.01-2.92 (m, 1H), 2.80-2.79 (m, 1H), 2.73-2.70 (m, 3H), 2.68-2.67 (m, 3H), 2.42-2.32 (m, 3H), 2.12 (s, 3H), 2.07-1.99 (m, 2H), 1.86-1.83 (m, 1H), 1.32-1.28 (m, 2H). Example 18: (S)-N-(2-Chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) (S)-N-(2-Chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of (S)-N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 17, step (c)) (110 mg, 0.174 mmol) and 3-fluoropropan- 1-amine hydrochloride salt (59.1 mg, 0.521 mmol) in methanol / dichloromethane (1:1, 4 mL) was added sodium acetate (42.7 mg, 0.521 mmol) and the mixture stirred at room temperature for 2.5 h. Sodium cyanoborohydride (32.7 mg, 0.521 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(4-(((3- fluoropropyl)amino)methyl)-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5- oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (39.0 mg, 32% yield) as a white solid. MS: m/z found 694 [M+H]+, retention time = 2.76 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.44-7.41 (m, 2H), 7.31-7.28 (m, 2H), 7.17 (dd, 1H), 4.59 (t, 1H), 4.47 (t, 1H), 4.00-3.98 (m, 4H), 3.95 (s, 3H), 3.93-3.91 (m, 2H), 3.69-3.66 (m, 1H), 3.59-3.55 (m, 1H), 3.03-2.99 (m, 1H), 2.94-2.88 (m, 1H), 2.81-2.79 (m, 4H), 2.70-2.68 (m, 2H), 2.40-2.31 (m, 3H), 2.01-1.83 (m, 3H). Example 19: N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin- 2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 18, replacing 3-fluoropropan-1-amine hydrochloride salt with (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt in step (a). White solid, MS: m/z found 731 [M+H]+, retention time = 2.51 min (Method A).1H NMR (400 MHz, Methanol- d4): δ 8.65 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.30-7.27 (m, 2H), 7.17 (dd, 1H), 4.00-3.98 (m, 4H), 3.95 (s, 3H), 3.90-3.89 (m, 2H), 3.85-3.82 (m, 1H), 3.69-3.55 (m, 2H), 3.01-2.99 (m, 1H), 2.92-2.90 (m, 1H), 2.80-2.78 (m, 2H), 2.71-2.68 (m, 4H), 2.38- 2.28 (m, 6H), 1.85-1.80 (m, 2H). Example 20: N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate (Example 10, step (a)) (1 g, 5.12 mmol) and 2-hydroxyacetaldehyde (0.92 g, 15.4 mmol) in dichloromethane / methanol (3:1, 8 mL) was added acetic acid (0.44 mL, 7.68 mmol) and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (1.61 mg, 25.6 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated, water (10 mL) added to the residue and the mixture extracted with dichloromethane (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-50 % MeOH / EtOAc) to afford methyl 5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate (370 mg, 30% yield) as a white solid.1H NMR (400 MHz, DMSO- d6): δ 3.80 (s, 3H), 3.78 (s, 3H), 3.57 (t, 2H), 3.42 (s, 2H), 2.81-2.78 (m, 2H), 2.66-2.60 (m, 4H). (b) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide The 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (Example 1, step (d)) (230 mg, 0.84 mmol) in THF (3 mL) was added 1.0 M lithium bis(trimethylsilyl)amide solution in THF (1.68 mL, 1.68 mmol) at 0 °C, and then the mixture stirred at 0 °C for 0.5 h under N2. Methyl 5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (241 mg, 1.01 mmol) in THF (3 mL) was then added and the mixture stirred at room temperature for 12 h under N2. Water (10 mL) was added to the residue and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-40 % MeOH / EtOAc) to afford N-(2-chloro-3- (2,3-dichloropyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (120 mg, 30% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 8.52 (d, 1H), 8.38 (dd, 1H), 7.56-7.52 (m, 2H), 7.21 (dd, 1H), 4.46 (t, 1H), 3.90 (s, 3H), 3.58-3.55 (m, 2H), 3.48 (s, 2H), 2.83-2.80 (m, 2H), 2.69-2.61 (m, 4H). (c) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5- (2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(2-hydroxyethyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (100 mg, 0.208 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (110 mg, 0.416 mmol) in 1,4-dioxane / water (3:1, 4 mL) was added potassium carbonate (86.2 mg, 0.624 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (16.9 mg, 0.02 mmol), and then the mixture stirred at 130 °C for 1 h under N2. Water (5 mL) was added and the mixture extracted with ethyl acetate (2 x10 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, EtOAc: MeOH = 1:1) to afford N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(2- hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (45 mg, 41% yield) as a yellow solid. MS: m/z found 580 [M+H]+. (d) N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (40 mg, 0.0689 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt (24.6 mg, 0.138 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (17.0 mg, 0.207 mmol) and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (13.0 mg, 0.207 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-5-(2- hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (8.8 mg, 17% yield) as a white solid. MS: m/z found 706 [M+H]+, retention time = 2.64 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.45-7.42 (m, 2H), 7.31-7.28 (m, 2H), 7.17 (dd, 1H), 4.51-4.48 (m, 1H), 4.05-3.94 (m, 9H), 3.81-3.78 (m, 2H), 3.66-3.64 (m, 2H), 3.17-3.14 (m, 1H), 3.00-2.97 (m, 2H), 2.82-2.71 (m, 6H), 2.12 (s, 3H), 2.08-2.00 (m, 2H), 1.42-1.29 (m, 2H). Example 21: (S)-N-(2-Chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(2-Chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5-methoxyphenyl)pyridin-4- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(3-fluoropropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 10, step (c)) (400 mg, 0.81 mmol), 2-fluoro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde (338 mg, 1.21 mmol) in 1,4-dioxane / water (5:1, 9 mL) was added potassium carbonate (333 mg, 2.42 mmol), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (65.7 mg, 0.08 mmol), and then the mixture stirred at 130 °C for 3 h under N2. Water (10 mL) was added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-40 % MeOH / EtOAc) to afford N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5-methoxyphenyl)pyridin-4-yl)phenyl)- 5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (310 mg, 62% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H), 9.95 (s, 1H), 8.79 (d, 1H), 8.39 (d, 1H), 7.61-7.56 (m, 2H), 7.36 (s, 1H), 7.26-7.23 (m, 2H), 4.57 (t, 1H), 4.46 (t, 1H), 4.00 (s, 3H), 3.93 (s, 3H), 3.45 (s, 2H), 2.79-2.78 (m, 2H), 2.71-2.69 (m, 2H), 2.64-2.61 (m, 2H), 1.94-1.88 (m, 2H). (b) (S)-N-(2-Chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (90 mg, 0.146 mmol) and (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt (44.1 mg, 0.293 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (36.1 mg, 0.439 mmol), and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (27.6 mg, 0.439 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford (S)- N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (37.8 mg, 35% yield) as a white solid. MS: m/z found 712 [M+H]+, retention time = 2.83 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (d, 1H), 7.51 (t, 1H), 7.45 (d, 1H), 7.18-7.17 (m, 2H), 7.11 (d, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.00 (s, 3H), 3.97 (s, 3H), 3.95 (s, 2H), 3.87-3.81 (m, 1H), 3.58 (s, 2H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.70-2.67 (m, 2H), 2.36-2.27 (m, 3H), 2.06-1.96 (m, 2H), 1.81-1.80 (m, 1H). Example 22: (S)-N-(2-Chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(2-Chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-formylphenyl)pyridin-4- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(3-fluoropropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 10, step (c)) (400 mg, 0.81 mmol) and 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde (360 mg, 1.21 mmol) (338 mg, 1.21 mmol) in 1,4-dioxane / water (5:1, 9 mL) was added potassium carbonate (333 mg, 2.42 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (65.7 mg, 0.08 mmol), and then the mixture stirred at 130 °C for 3 h under N2. Water (10 mL) was added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-40 % MeOH / EtOAc) to afford N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-formylphenyl)pyridin-4-yl)phenyl)- 5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (310 mg, 61% yield) as a white solid. MS: m/z found 632 [M+H]+. (b) (S)-N-(2-Chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4- formylphenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (90 mg, 0.142 mmol) and (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt (42.9 mg, 0.285 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (36.1 mg, 0.439 mmol), and then the mixture was stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (27.6 mg, 0.439 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (24.7 mg, 23% yield) as a white solid. MS: m/z found 730 [M+H]+, retention time = 2.86 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (d, 1H), 7.65-7.60 (m, 2H), 7.53-7.49 (m, 2H), 7.44 (d, 1H), 7.18 (d, 1H), 6.97 (t, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.00 (s, 3H), 3.97 (s, 2H), 3.84-3.82 (m, 1H), 3.58 (s, 2H), 2.95-2.92 (m, 2H), 2.81-2.71 (m, 6H), 2.38-2.28 (m, 3H), 2.07-1.96 (m, 2H), 1.86-1.82 (m, 1H). Example 23: N-(2-Chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(2-Chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To the mixture of N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (Example 21, step (a)) (90 mg, 0.146 mmol) and 2,6- diazaspiro[3.4]octan-7-one (27.7 mg, 0.220 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (36.1 mg, 0.439 mmol), and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (27.6 mg, 0.439 mmol) was then added and the mixture was stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford N-(2-chloro-3-(3- chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (34.1 mg, 31% yield) as a white solid. MS: m/z found 724 [M+H]+, retention time = 2.69 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.45 (d, 1H), 7.18-7.16 (m, 2H), 7.11 (d, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.00 (s, 3H), 3.95 (s, 3H), 3.81 (s, 2H), 3.58 (s, 2H), 3.55 (s, 2H), 3.42 (s, 4H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.54 (s, 2H), 2.06-1.96 (m, 2H). Example 24: N-(2-Chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(2-Chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To the mixture of N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4- formylphenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (Example 22, step (a)) (90 mg, 0.142 mmol) and 2,6- diazaspiro[3.4]octan-7-one (26.9 mg, 0.213 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (35.0 mg, 0.427 mmol), and then the mixture was stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (26.8 mg, 0.427 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford N-(2-chloro-3-(3- chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (10.6 mg, 9% yield) as a white solid. MS: m/z found 742 [M+H]+, retention time = 2.85 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.52 (dd, 1H), 7.62-7.49 (m, 4H), 7.44 (d, 1H), 7.17 (dd, 1H), 6.95 (t, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 3.99 (s, 3H), 3.81 (s, 2H), 3.60-3.58 (m, 4H), 3.44-3.40 (m, 4H), 2.95- 2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.59 (s, 2H), 2.06-1.96 (m, 2H). Example 25: N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 23, replacing 2,6-diazaspiro[3.4]octan-7-one with 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt in step (a). White solid, MS: m/z found 740 [M+H]+, retention time = 2.84 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.45 (d, 1H), 7.18-7.16 (m, 2H), 7.12 (dd, 1H), 4.60 (t, 1H), 4.48 (m, 2H), 4.00 (s, 3H), 3.85-3.80 (m, 6H), 3.58 (s, 2H), 3.16-3.14 (m, 1H), 2.95-2.93 (m, 2H), 2.81-2.68 (m, 6H), 2.11 (s, 3H), 2.08-1.95 (m, 4H), 1.40-1.27 (m, 2H). Example 26: N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-(difluoromethoxy)phenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 24, replacing 2,6-diazaspiro[3.4]octan-7-one with 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt in step (a). White solid, MS: m/z found 758 [M+H]+, retention time = 2.93 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.65-7.62 (m, 2H), 7.53-7.49 (m, 2H), 7.44 (d, 1H), 7.19-7.17 (m, H), 6.99 (t, 1H), 4.60 (t, 1H), 4.48 (m, 2H), 4.00 (s, 3H), 3.98-3.92 (m, 3H), 3.58 (s, 2H), 3.17-3.16 (m, 1H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 6H), 2.12 (s, 3H), 2.08-1.99 (m, 4H), 1.43-1.31 (m, 2H). Example 27: 4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H- pyran-4-yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) Methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-(2-(2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, step (g)) (300 mg, 0.48 mmol) and 2-fluoro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (204 mg, 0.73 mmol) in 1,4-dioxane / water (5:1, 12 mL) was added [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) (31.7 mg, 0.05 mmol) and potassium phosphate (309 mg, 1.46 mmol), and then the mixture was stirred at 130 °C for 1 h under N2. Water (30 mL) was then added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-80% EtOAc/ Methanol) to afford methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (260 mg, 72 % yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H), 9.95 (s, 1H), 8.79 (d, 1H), 8.41-8.39 (m, 1H), 7.60-7.56 (m, 2H), 7.36 (s, 1H), 7.26-7.23 (m, 2H), 4.00 (s, 3H), 3.91 (s, 3H), 3.60 (s, 3H), 3.43 (s, 2H), 2.77-2.73 (m, 2H), 2.69-2.68 (m, 2H), 2.00-1.92 (m, 2H), 1.76-1.72 (m, 2H), 1.59-1.54 (m, 4H), 1.49 (s, 2H), 1.43-1.37 (m, 2H), 1.21-1.14 (m, 2H). (b) Methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H- pyran-4-yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (120 mg, 0.163 mmol) and tetrahydro-2H-pyran-4-amine (49.5 mg, 0.490 mmol) in dichloromethane / methanol (1:1, 8 mL) was added sodium acetate (40.2 mg, 0.490 mmol), and then the mixture stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (30.8 mg, 0.490 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. Water (20 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, EtOAc/MeOH =5/1) to afford methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (80 mg, 59% yield) as a yellow solid. MS: m/z found 819 [M+H]+. (c) 4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H-pyran- 4-yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of methyl 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4- (((tetrahydro-2H-pyran-4-yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (75 mg, 0.091 mmol) in THF / water (2:1, 3 mL) was added lithium hydroxide monohydrate (57.6 mg, 1.37 mmol), and then the mixture stirred at room temperature for 12 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 4-(2- (2-((2-Chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (29.4 mg, 38% yield) as a white solid. MS: m/z found 805 [M+H]+, retention time = 3.21 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.68 (d, 1H), 8.53 (d, 1H), 7.51 (t, 1H), 7.47 (d, 1H), 7.23 (s, 1H), 7.18-7.16 (m, 2H), 4.15 (s, 2H), 4.04-4.00 (m, 8H), 3.61 (s, 2H), 3.50-3.42 (m, 2H), 3.05-3.01 (m, 1H), 2.98-2.95 (m, 2H), 2.82-2.79 (m, 2H), 2.74-2.70 (m, 2H), 2.03-2.00 (m, 4H), 1.89-1.87 (m, 2H), 1.65-1.55 (m, 8H), 1.47-1.45 (m, 2H). Example 28: 4-(2-(2-((3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid 4-(2-(2-((3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid was prepared in a similar fashion to Example 27, replacing tetrahydro-2H-pyran-4-amine with 1- (4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt in step (b). White solid, MS: m/z found 846 [M+H]+, retention time = 3.09 min (Method A).1H NMR (400 MHz, Methanol- d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.46 (d, 1H), 7.21-7.13 (m, 3H), 4.54-4.51 (m, 1H), 4.07 (s, 2H), 4.04-3.96 (m, 7H), 3.61 (s, 2H), 3.22-3.15 (m, 1H), 2.98-2.95 (m, 3H), 2.82-2.79 (m, 2H), 2.74-2.70 (m, 3H), 2.12 (s, 3H), 2.07-1.98 (m, 4H), 1.89-1.85 (m, 2H), 1.65-1.55 (m, 6H), 1.49-1.37 (m, 4H). Example 29: 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 14, step (a)) (400 mg, 0.71 mmol) and 2-fluoro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde (299 mg, 1.07 mmol) in 1,4-dioxane / water (5:1, 6 mL) was added [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (46.4 mg, 0.07 mmol) and potassium phosphate (453 mg, 2.14 mmol), and then the mixture stirred at 130 °C for 2 h under N2. Water (20 mL) was added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0- 50% EtOAc/ MeOH) to afford 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3- fluoro-4-formyl-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (350 mg, 72% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H), 9.94 (s, 1H), 8.78 (d, 1H), 8.39 (d, 1H), 7.59-7.53 (m, 2H), 7.35 (s, 1H), 7.24-7.22 (m, 2H), 4.41-4.40 (m, 1H), 3.99 (s, 3H), 3.90 (s, 3H), 3.86-3.80 (m, 1H), 3.55 (s, 2H), 3.03 (t, 1H), 2.87-2.86 (m, 2H), 2.76-2.71 (m, 1H), 2.65 (s, 2H), 2.60-2.54 (m, 1H), 2.00 (s, 3H), 1.83-1.77 (m, 2H), 1.52-1.47 (m, 1H), 1.36-1.32 (m, 1H). (b) 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- fluoro-5-methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4- formyl-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (100 mg, 0.147 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt (52.5 mg, 0.294 mmol) in methanol / dichloromethane (1:1, 6 mL) was added sodium acetate (36.2 mg, 0.441 mmol), and then the mixture was stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (27.7 mg, 0.441 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1-acetylpiperidin- 4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamide (36.1 mg, 29% yield) as a white solid. MS: m/z found 805 [M+H]+, retention time = 3.57 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (d, 1H), 7.51 (t, 1H), 7.45 (d, 1H), 7.18-7.17 (m, 2H), 7.12 (d, 1H), 4.64-4.60 (m, 1H), 4.49-4.46 (m, 1H), 4.04-3.98 (m, 10H), 3.71 (s, 2H), 3.17-3.15 (m, 2H), 3.04-3.01 (m, 2H), 2.79-2.72 (m, 6H), 2.13 (s, 3H), 2.12 (s, 3H), 2.06-1.99 (m, 4H), 1.64-1.50 (m, 2H), 1.40-1.27 (m, 2H). Example 30: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy- 4-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7- oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4- formyl-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 29, step (a)) (100 mg, 0.147 mmol) and 2,6- diazaspiro[3.4]octan-7-one (27.8 mg, 0.220 mmol) in methanol / dichloromethane (1:1, 6 mL) was added sodium acetate (36.2 mg, 0.441 mmol), and then the mixture was stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (27.7 mg, 0.441 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford 5-(1- acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (40.8 mg, 30% yield) as a white solid. MS: m/z found 789 [M+H]+, retention time = 3.43 min (Method A).1H NMR (400 MHz, Methanol- d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.45 (d, 1H), 7.18-7.16 (m, 2H), 7.12 (d, 1H), 4.64-4.61 (m, 1H), 4.05-4.04 (m, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.82 (s, 2H), 3.71 (s, 2H), 3.55 (s, 2H), 3.46-3.41 (m, 4H), 3.21-3.11 (m, 1H), 3.02-3.01 (m, 2H), 2.90-2.82 (m, 1H), 2.79-2.76 (m, 2H), 2.71-2.64 (m, 1H), 2.54 (s, 2H), 2.13 (s, 3H), 2.07-2.00 (m, 2H), 1.66- 1.49 (m, 2H). Example 31: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo- 2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 14, step (b)) (170 mg, 0.257 mmol) and 2,6- diazaspiro[3.4]octan-7-one (48.6 mg, 0.385 mmol) in dichloromethane / methanol (1:1, 4 mL) was added sodium acetate (63.2 mg, 0.771 mmol), and then the mixture stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (48.4 mg, 0.771 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1-acetylpiperidin- 4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (47.3 mg, 23% yield) as a white solid. MS: m/z found 771 [M+H]+, retention time = 3.02 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.43-7.38 (m, 2H), 7.29-7.27 (m, 2H), 7.17 (dd, 1H), 4.64- 4.61 (m, 1H), 4.07-4.05 (m, 1H), 3.99 (s, 3H), 3.92 (s, 3H), 3.78 (s, 2H), 3.71 (s, 2H), 3.59 (s, 2H), 3.41-3.37 (m, 4H), 3.20-3.17 (m, 1H), 3.03-3.01 (m, 2H), 2.91-2.86 (m, 1H), 2.79-2.76 (m, 2H), 2.68-2.65 (m, 1H), 2.58 (s, 2H), 2.13 (s, 3H), 2.06-1.99 (m, 2H), 1.66-1.49 (m, 2H). Example 32: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 1-methyl-5-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate (Example 10, step (a)) (900 mg, 4.61 mmol) and 4-bromo-1,1,1-trifluoro-butane (1.76 g, 9.22 mmol) in acetonitrile (10 mL) was added potassium carbonate (3.82 g, 27.7 mmol), and then the mixture stirred at 60 °C for 5 h under N2. Water (30 mL) was added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-30 % MeOH / EtOAc) to afford methyl 1-methyl-5-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate (450 mg, 32% yield) as a yellow oil.1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 3H), 3.77 (s, 3H), 3.37 (s, 2H), 2.76-2.74 (m, 2H), 2.66-2.64 (m, 2H), 2.57 (t, 2H), 2.35-2.22 (m, 2H), 1.75-1.68 (m, 2H). (b) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(4,4,4- trifluorobutyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (Example 1, step (d)) (350 mg, 1.28 mmol) in THF (3 mL) was added 1.0M lithium bis(trimethylsilyl)amide solution in THF (2.56 mL, 2.56 mmol) at 0°C, and then the mixture stirred at 0 °C for 0.5 h under N2. A solution of methyl 1-methyl-5-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate (391 mg, 1.28 mmol) in THF (3 mL) was then added and the mixture stirred at 0 °C for 0.5 h under N2. Water (20 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % EtOAc / petroleum ether) to afford N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (450 mg, 64% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 8.52 (d, 1H), 8.38 (d, 1H), 7.55-7.53 (m, 2H), 7.21 (d, 1H), 3.90 (s, 3H), 3.44 (s, 2H), 2.78-2.76 (m, 2H), 2.69-2.67 (m, 2H), 2.60-2.57 (m, 2H), 2.35-2.23 (m, 2H), 1.77-1.71 (m, 2H). (c) N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1- methyl-5-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(4,4,4- trifluorobutyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (380 mg, 0.69 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (273.2 mg, 1.04 mmol, 1.5 eq) in 1,4-dioxane / water (5:1, 6 mL) was added potassium carbonate (288 mg, 2.08 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (56.8 mg, 0.07 mmol), and then the mixture stirred at 130 °C for 1 h under N2. Water (20 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % EtOAc / petroleum ether) to afford N-(2-chloro-3-(3-chloro-2-(4- formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (160 mg, 35% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 10.43 (s, 1H), 9.94 (s, 1H), 8.77 (d, 1H), 8.39 (dd, 1H), 7.82 (d, 1H), 7.57-7.52 (m, 3H), 7.41 (d, 1H), 7.25 (dd, 1H), 3.99 (s, 3H), 3.90 (s, 3H), 3.44 (s, 2H), 2.79-2.77 (m, 2H), 2.70-2.69 (m, 2H), 2.59 (t, 2H), 2.36-2.23 (m, 2H), 1.78-1.70 (m, 2H). (d) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (150 mg, 0.23 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (69.9 mg, 0.46 mmol) in dichloromethane / methanol (1:1, 6 mL) was added sodium acetate (57.1 mg, 0.70 mmol), and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (43.7 mg, 0.70 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy- 4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5- (4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (78.9 mg, 45% yield) as a white solid. MS: m/z found 744 [M+H]+, retention time = 3.02 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.30-7.27 (m, 2H), 7.17 (dd, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.90-3.83 (m, 3H), 3.57 (s, 2H), 2.93-2.91 (m, 2H), 2.80-2.78 (m, 2H), 2.72-2.69 (m, 4H), 2.35-2.24 (m, 5H), 1.89- 1.78 (m, 3H). Example 33: 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-(difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4- formylphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 14, step (a)) and 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde (159 mg, 0.53 mmol) in 1,4-dioxane / water (5:1, 12 mL) was added [1,1′- bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (23 mg, 0.03 mmol) and potassium phosphate (226 mg, 1.07 mmol), and then the mixture stirred at 130 °C for 2 h under N2. water (15 mL) was then added and the mixture extracted with ethyl acetate (2 x 15 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-50% EtOAc/ MeOH) to afford 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3- (3-chloro-2-(3-(difluoromethoxy)-4-formylphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (170 mg, 68% yield) as a white solid. MS: m/z found 697 [M+H]+. (b) 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3- (difluoromethoxy)-4-formylphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (80 mg, 0.114 mmol) and 1-(4-aminopiperidin-1- yl)ethan-1-one hydrochloride salt (40.9 mg, 0.229 mmol) in dichloromethane / methanol (1:1, 4 mL) was added sodium acetate (28.2 mg, 0.344 mmol), and then the mixture was stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (21.6 mg, 0.344 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford 5-(1- acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (20.3 mg, 21% yield) as a white solid. MS: m/z found 823 [M+H]+, retention time = 3.26 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.65-7.60 (m, 2H), 7.53-7.49 (m, 2H), 7.44 (d, 1H), 7.19-7.17 (m, 1H), 6.99 (t, 1H), 4.64-4.61 (m, 1H), 4.48-4.45 (m, 1H), 4.05-3.93 (m, 7H), 3.70 (s, 2H), 3.20-3.13 (m, 2H), 3.02-3.01 (m, 2H), 2.82-2.65 (m, 6H), 2.13 (s, 3H), 2.12 (s, 3H), 2.06-1.99 (m, 4H), 1.64-1.43 (m, 2H), 1.42-1.30 (m, 2H). Example 34: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)- 4-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7- oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3- (difluoromethoxy)-4-formylphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (Example 33, step (a)) (80 mg, 0.114 mmol) and 2,6- diazaspiro[3.4]octan-7-one (21.7 mg, 0.172 mmol) in dichloromethane / methanol (1:1, 4 mL) was added sodium acetate (28.2 mg, 0.344 mmol), and then the mixture stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (21.6 mg, 0.344 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1-acetylpiperidin- 4-yl)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (19.2 mg, 20% yield) as a white solid. MS: m/z found 807 [M+H]+, retention time = 3.16 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.53 (dd, 1H), 7.62-7.55 (m, 2H), 7.53-7.49 (m, 2H), 7.44 (d, 1H), 7.17 (dd, 1H), 6.95 (t, 1H), 4.64-4.61 (m, 1H), 4.05-4.01 (m, 1H), 3.99 (s, 3H), 3.81 (s, 2H), 3.71 (s, 2H), 3.60 (s, 2H), 3.45-3.40 (m, 4H), 3.21-3.13 (m, 1H), 3.02-3.01 (m, 2H), 2.92-2.83 (m, 1H), 2.79-2.76 (m, 2H), 2.72-2.68 (m, 1H), 2.59 (s, 2H), 2.13 (s, 3H), 2.06-1.98 (m, 2H), 1.69-1.49 (m, 2H). Example 35: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(3-Bromo-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution 3-bromo-2-chloroaniline (700 mg, 3.39 mmol) in THF (6 mL) at 0°C was added 1.0 M lithium bis(trimethylsilyl)amide solution in THF (6.78 mL, 6.78 mmol) and the mixture stirred at 0 °C for 0.5 h under N2. Methyl 5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (Example 10, step (b)) (1.04 g, 4.07 mmol) in THF (6 mL) was then added and the mixture stirred at 0 °C for 0.5 h under N2. Water (20 mL) was then added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % EtOAc / petroleum ether) to afford N-(3-bromo-2-chlorophenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (900 mg, 61% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.95 (s, 1H), 8.21 (dd, 1H), 7.59 (dd, 1H), 7.33 (t, 1H), 4.57 (t, 1H), 4.45 (t, 1H), 3.87 (s, 3H), 3.45 (s, 2H), 2.79-2.77 (m, 2H), 2.69- 2.61 (m, 4H), 1.96-1.88 (m, 2H). (b) N-(2-Chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-bromo-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (300 mg, 0.70 mmol) and bis(pinacolato)diboron in 1,4-dioxane (10 mL) was added potassium acetate (206 mg, 2.09 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (57.0 mg, 0.07 mmol), and then the mixture stirred at 130 °C for 5 h under N2. The mixture was concentrated and the residue purified by normal phase SiO2 chromatography (0-100 % EtOAc / petroleum ether) to afford N-(2-chloro-3-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (250 mg, 75% yield) as a yellow oil.1H NMR (400 MHz, DMSO-d6): δ 9.85 (s, 1H), 8.31 (dd, 1H), 7.42-7.37 (m, 2H), 4.57 (t, 1H), 4.46 (t, 1H), 3.88 (s, 3H), 3.45 (s, 2H), 2.80-2.77 (m, 2H), 2.69-2.61 (m, 4H), 1.97-1.84 (m, 2H), 1.33 (s, 12H). (c) 2',3'-Dichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde To a mixture of 6-chloro-2-methoxynicotinaldehyde (16.0 g, 93.2 mmol) and 2,3- dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (24.3 g, 88.6 mmol) in 1,4- dioxane / water (6:1, 350 mL) was added potassium carbonate (38.7 g, 280 mmol) and tetrakis(triphenylphosphine)palladium (5.39 g, 4.66 mmol) and the mixture stirred at 95 °C for 4 h under N2. The mixture was concentrated and the residue purified by normal phase SiO2 chromatography (0-21 % EtOAc / petroleum ether) to afford 2',3'-dichloro-6-methoxy- [2,4'-bipyridine]-5-carbaldehyde (14.6 g, 55% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H), 8.54 (d, 1H), 8.28 (d, 1H), 7.74 (d, 1H), 7.57 (d, 1H), 4.06 (s, 3H). (d) N-(2-Chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)-5- (3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2',3'-dichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (105 mg, 0.37 mmol) and N-(2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (230 mg, 0.48 mmol) in THF / water (5:1, 12 mL) was added chloro(2-dicyclohexylphosphino- 2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (29.2 mg, 0.04 mmol) and potassium phosphate (236 mg, 1.11 mmol), and then the mixture stirred at 80 °C for 12 h under N2. The mixture was combined with another batch at the 142 mg scale. Water (50 mL) was added and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-11 % MeOH / EtOAc) to afford N-(2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (380 mg, 73% yield). MS: m/z found 597 [M+H]+. (e) (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (260 mg, 0.44 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (131 mg, 0.87 mmol) in dichloromethane / methanol (1:1, 10 mL) was added sodium acetate (107 mg, 1.31 mmol), and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (82.0 mg, 1.31 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (54.9 mg, 17% yield) as a white solid. MS: m/z found 695 [M+H]+, retention time = 2.47 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.55 (dd, 1H), 7.83 (d, 1H), 7.79 (d, 1H), 7.52 (t, 1H), 7.44 (d, 1H), 7.24 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.06 (s, 3H), 4.03 (s, 3H), 3.91-3.83 (m, 3H), 3.58 (s, 2H), 2.95-2.92 (m, 2H), 2.79-2.71 (m, 6H), 2.38- 2.29 (m, 3H), 2.06-1.98 (m, 2H), 1.86-1.81 (m, 1H). Example 36: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (Example 35, step (d)) (100 mg, 0.167 mmol) and 2,6-diazaspiro[3.4]octan-7- one (31.7 mg, 0.251 mmol) in methanol / dichloromethane (1:1, 2 mL) was added sodium acetate (41.2 mg, 0.502 mmol) and the mixture stirred at room temperature for 2.5 h. Sodium cyanoborohydride (31.6 mg, 0.502 mmol) was then added and the mixture was stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (13.0 mg, 11% yield) as a white solid. MS: m/z found 707 [M+H]+, retention time = 2.55 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.56 (d, 1H), 7.93-7.76 (m, 2H), 7.52 (t, 1H), 7.43 (d, 1H), 7.24 (d, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.04 (s, 3H), 4.00 (s, 3H), 3.74 (s, 2H), 3.61- 3.58 (m, 4H), 3.43-3.37 (m, 4H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.60 (s, 2H), 2.06- 1.96 (m, 2H). Example 37: N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide N-(3-(5-(((1-Acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 36, replacing 2,6-diazaspiro[3.4]octan-7-one with 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt in step (a). White solid, MS: m/z found 723 [M+H]+, retention time = 3.35 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.56 (dd, 1H), 7.84 (d, 1H), 7.80 (d, 1H), 7.52 (t, 1H), 7.45 (d, 1H), 7.24 (dd, 1H), 4.59 (t, 1H), 4.49-4.46 (m, 2H), 4.06 (s, 3H), 4.00 (s, 3H), 3.97-3.93 (m, 1H), 3.90 (s, 2H), 3.58 (s, 2H), 3.15-3.13 (m, 1H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 6H), 2.12 (s, 3H), 2.08-1.98 (m, 4H), 1.44-1.29 (m, 2H). Example 38: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((tetrahydro-2H-pyran-4- yl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((tetrahydro-2H-pyran-4-yl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 36, replacing 2,6-diazaspiro[3.4]octan-7-one with tetrahydro-2H-pyran-4-amine in step (a). White solid, MS: m/z found 682 [M+H]+, retention time = 3.78 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.56 (dd, 1H), 7.83 (d, 1H), 7.80 (d, 1H), 7.52 (t, 1H), 7.44 (d, 1H), 7.24 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.06 (s, 3H), 4.00 (s, 3H), 3.98- 3.96 (m, 2H), 3.89 (s, 2H), 3.58 (s, 2H), 3.46-3.41 (m, 2H), 2.94 (t, 2H), 2.81-2.75 (m, 5H), 2.06-1.92 (m, 4H), 1.54-1.45 (m, 2H). Example 39: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((2-methoxyethyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((2-methoxyethyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide was prepared in a similar fashion to Example 36, replacing 2,6- diazaspiro[3.4]octan-7-one with tetrahydro-2H-pyran-4-amine in step (a). White solid, MS: m/z found 656 [M+H]+, retention time = 3.85 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.56 (dd, 1H), 7.82-7.79 (m, 2H), 7.52 (t, 1H), 7.44 (d, 1H), 7.24 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.07 (s, 3H), 4.00 (s, 3H), 3.87 (s, 2H), 3.58 (s, 2H), 3.55-3.54 (m, 2H), 3.37 (s, 3H), 2.95-2.94 (m, 2H), 2.84-2.75 (m, 6H), 2.09-1.96 (m, 2H). Example 40: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridine-5-carboxylate To a solution of 3-bromo-2-chloroaniline (500 mg, 2.42 mmol) in THF (5 mL) at 0 °C was added a 1.0 M lithium bis(trimethylsilyl)amide solution in THF (4.84 mL, 4.84 mmol) and the mixture was stirred at 0 °C for 0.5 h under N2. A solution of 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-dicarboxylate (858 mg, 2.91 mmol) in THF (5 mL) was then added and the mixture stirred at 0 °C for 0.5 h under N2. Water (15 mL) was added and the mixture extracted with ethyl acetate (2 x 15 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0- 16% EtOAc/petroleum ether) to afford tert-butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (900 mg, 79 % yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 10.05 (s, 1H), 8.22 (s, 1H), 7.64 (dd, 1H), 7.40 (t, 1H), 4.45 (s, 2H), 3.94 (s, 3H), 3.74 (t, 2H), 2.76 (t, 2H), 1.49 (s, 9H). (b) tert-Butyl 2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate To a mixture of tert-butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (1.50 g, 3.10 mmol) and bis(pinacolato)diboron (4.88 g, 19.2 mmol) in 1,4-dioxane (30 mL) was added potassium acetate (940 mg, 9.58 mmol), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (260 mg, 0.32 mmol), and then the mixture stirred at 130 °C for 12 h under N2. The mixture was concentrated and the residue purified by normal phase SiO2 chromatography (15-20% EtOAc/petroleum ether) to afford tert-butyl 2-((2-chloro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridine-5-carboxylate (650 mg, 40% yield) as a yellow solid. MS: m/z found 517 [M+H]+. (c) tert-Butyl 2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate To a mixture of tert-butyl 2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (301 mg, 0.58 mmol) and 2',3'-dichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (Example 35, step (c)) (110 mg, 0.39 mmol) in THF / water (5:1, 2.4 mL) was added potassium phosphate (247 mg, 1.17 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′- triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (30.6 mg, 0.04 mmol), and then the mixture was stirred at 80 °C for 4 h under N2. The mixture was then concentrated and the residue purified by normal phase SiO2 chromatography (0-55% EtOAc/petroleum ether) to afford tert-butyl 2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-5-carboxylate (150 mg, 60 % yield) as a yellow solid. MS: m/z found 637 [M+H]+. (d) tert-Butyl (S)-2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate To a mixture of tert-butyl 2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine- 5-carboxylate (166 mg, 0.26 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (78.5 mg, 0.52 mmol) in methanol / dichloromethane (1:1, 4 mL) was added sodium acetate (106 mg, 1.30 mmol), and then the mixture stirred at room temperature for 2 h under N2. Sodium cyanoborohydride (81.8 mg, 1.30 mmol) was then added and the mixture was stirred at room temperature for 0.5 h under N2. The mixture was concentrated and the residue purified by normal prep-TLC (SiO2, DCM: MeOH = 1:1) to afford tert-butyl (S)-2-((2- chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine- 5-carboxylate (90 mg, 46 % yield) as white solid. MS: m/z found 735 [M+H]+. (e) (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide To a mixture of tert-butyl (S)-2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (80 mg, 0.11 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (1 mL, 0.01 mmol), and then the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3'-chloro-6- methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (8.6 mg, 11 % yield) as white solid. MS: m/z found 635 [M+H]+, retention time = 2.37 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.61 (d, 1H), 8.52 (dd, 1H), 7.79 (d, 1H), 7.76 (d, 1H), 7.48 (t, 1H), 7.41 (d, 1H), 7.20 (dd, 1H), 4.02 (s, 3H), 3.96 (s, 3H), 3.87-3.78 (m, 5H), 3.14 (t, 2H), 2.73-2.65 (m, 4H), 2.34-2.25 (m, 3H), 1.82-1.77 (m, 1H). Example 41: (S)-N-(2-Chloro-3-(3',4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 2',3',4-Trichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde To a mixture of 4,6-dichloro-2-methoxynicotinaldehyde (0.5 g, 0.243 mmol) and 2,3- dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.63 g, 0.231 mmol) in 1,4-dioxane / water (5:1, 12 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.14 g, 0.121 mmol) and cesium carbonate (2.37 g, 0.728 mmol) and the mixture stirred at 95 °C for 3 h under N2. Water (30 mL) was then added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-23 % EtOAc/petroleum ether) to afford 2',3',4-trichloro-6-methoxy-[2,4'- bipyridine]-5-carbaldehyde (260 mg, 33% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H), 8.56 (d, 1H), 7.76 (d, 1H), 7.69 (s, 1H), 4.05 (s, 3H). (b) N-(2-Chloro-3-(3',4-dichloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)- 5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of 2',3',4-trichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (100 mg, 0.315 mmol) and N-(2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 35, step (b)) (195 mg, 0.409 mmol) in 1,4-dioxane / water (5:1, 12 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (25.7 mg, 0.032 mmol) and potassium carbonate (131 mg, 0.945 mmol) and the mixture stirred at 110 °C for 3 h under N2. Water (30 mL) was added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, EtOAc: MeOH = 5:1) to afford N-(2-chloro-3-(3',4-dichloro-5-formyl-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (100 mg, 50% yield) as a yellow solid. MS: m/z found 631 [M+H]+. (c) (S)-N-(2-Chloro-3-(3',4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3',4-dichloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (90 mg, 0.142 mol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (64.3 mg, 0.427 mmol) in methanol / dichloromethane (1:1, 4 mL) was added sodium acetate (46.7 mg, 0.570 mmol) and the mixture stirred at room temperature for 11.5 h. Sodium cyanoborohydride (26.8 mg, 0.427 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3',4-dichloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (16.3 mg, 15% yield) as a yellow solid. MS: m/z found 729 [M+H]+, retention time = 3.15 min (Method A) no peaks.1H NMR (400 MHz, Methanol-d4): δ 8.49-8.46 (m, 1H), 8.41 (d, 1H), 7.69 (d, 1H), 7.50 (t, 1H), 7.29 (s, 1H), 7.25-7.22 (m, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.12 (s, 3H), 3.99 (s, 3H), 3.86-3.81 (m, 1H), 3.60-3.50 (m, 4H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.51-2.46 (m, 2H), 2.29-2.25 (m, 2H), 2.16-2.06 (m, 1H), 2.04-1.98 (m, 2H), 1.70-1.67 (m, 1H). Example 42: (S)-N-(2-Chloro-3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 2',3'-Dichloro-4-fluoro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde To a mixture of 6-chloro-4-fluoro-2-methoxynicotinaldehyde (0.80 g, 4.22 mmol) and 2,3-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.73 g, 6.33 mmol) in THF/ water (5:1, 12 mL) was added potassium phosphate (2.69 g, 12.7 mmol) and [1,1′- bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (0.28 mg, 0.42 mmol), and then the mixture stirred at 80 °C for 2 h under N2. Water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-25 % EtOAc / petroleum ether) to afford 2',3'- dichloro-4-fluoro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (680 mg, 53% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 8.57 (d, 1H), 7.75 (d, 1H), 7.56 (d, 1H), 4.06 (s, 3H). (b) tert-Butyl (S)-((2',3'-dichloro-4-fluoro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of 2',3'-dichloro-4-fluoro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (400 mg, 1.33 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (400 mg, 2.66 mmol) in methanol / dichloromethane (1:1, 6 mL) was added sodium acetate (327 mg, 3.99 mmol), and then the mixture stirred at room temperature for 2.5 h under N2. Sodium cyanoborohydride (250 mg, 3.99 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2 to afford (S)-5-((((2',3'-dichloro-4-fluoro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)methyl)pyrrolidin-2-one (MS: m/z found 399 [M+H]+). Di- tert-butyl dicarbonate (956 mg, 4.38 mmol) and triethylamine (0.70 mL, 5.01 mmol) were then added and the mixture stirred at room temperature for 2 h under N2. Water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 10 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % EtOAc / petroleum ether) to afford tert-butyl (S)-((2',3'-dichloro-4-fluoro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (500 mg, 55% yield) as a yellow solid. MS: m/z found 499 [M+H]+. (c) tert-Butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-4-fluoro-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of tert-butyl (S)-((2',3'-dichloro-4-fluoro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (200 mg, 0.40 mmol) and N-(2-chloro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 35, step (b)) (248 mg, 0.52 mmol) in THF/ water (5:1, 6 mL) was added potassium phosphate (255 mg, 1.20 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′- biphenyl)]palladium(II) (31.51 mg, 0.04 mmol), and then the mixture stirred at 80 °C for 2 h under N2. Water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, EtOAc: MeOH = 3:1) to afford tert-butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-4-fluoro-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (200 mg, 61% yield) as a white solid. MS: m/z found 813 [M+H]+. (d) (S)-N-(2-Chloro-3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of tert-butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-4-fluoro-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (90 mg, 0.11 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2 mL, 27.0 mmol), and then the mixture was stirred at room temperature for 10 min under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3'- chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (13.6 mg, 17% yield) as a white solid. MS: m/z found 713 [M+H]+, retention time = 2.99 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.56 (dd, 1H), 7.80 (d, 1H), 7.52 (t, 1H), 7.33 (d, 1H), 7.24 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.09 (s, 3H), 4.00 (s, 3H), 3.92 (s, 2H), 3.85-3.82 (m, 1H), 3.59 (s, 2H), 2.96-2.93 (m, 2H), 2.81-2.67 (m, 6H), 2.37-2.29 (m, 3H), 2.07-1.98 (m, 2H), 1.84-1.81 (m, 1H). Example 43: N-(2-Chloro-3-(3'-chloro-4-fluoro-6-methoxy-5-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 2-((2',3'-Dichloro-4-fluoro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-2,6- diazaspiro[3.4]octan-7-one To a mixture of 2',3'-dichloro-4-fluoro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (Example 42, step (a)) (200 mg, 0.66 mmol) and 2,6-diazaspiro[3.4]octan-7-one (109 mg, 0.86 mmol) in dichloromethane / methanol (1:1, 10 mL) was added sodium acetate (163 mg, 1.99 mmol), and then the mixture was stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (125 mg, 1.99 mmol) was then added and the mixture was stirred at room temperature for 0.5 h under N2. Water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep- TLC (SiO2, EtOAc: MeOH = 4:1) to afford 2-((2',3'-dichloro-4-fluoro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)-2,6-diazaspiro[3.4]octan-7-one (200 mg, 73% yield) as a white solid. MS: m/z found 411 [M+H]+. (b) N-(2-Chloro-3-(3'-chloro-4-fluoro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan- 2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2-((2',3'-dichloro-4-fluoro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)- 2,6-diazaspiro[3.4]octan-7-one (180 mg, 0.44 mmol) and N-(2-chloro-3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (Example 35, step (b)) (271 mg, 0.57 mmol) in THF / water (5:1, 6 mL) was added potassium phosphate (279 mg, 1.31 mmol) and chloro(2- dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′- biphenyl)]palladium(II) (34.4 mg, 0.04 mmol), and then the mixture stirred at 80 °C for 1 h under N2. water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, EtOAc: MeOH = 1:1) to afford semi-purified product. The semi-purified product was further purified by reverse phase HPLC to afford N-(2-chloro-3-(3'-chloro-4-fluoro-6-methoxy-5-((7-oxo- 2,6-diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (16.1 mg, 5% yield) as a white solid. MS: m/z found 725 [M+H]+, retention time = 3.52 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.56 (dd, 1H), 7.79 (d, 1H), 7.52 (t, 1H), 7.32 (d, 1H), 7.24 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.07 (s, 3H), 4.00 (s, 3H), 3.77 (s, 2H), 3.58 (s, 2H), 3.57 (s, 2H), 3.44 (s, 4H), 2.95-2.92 (m, 2H), 2.81-2.75 (m, 4H), 2.56 (s, 2H), 2.06-1.98 (m, 2H). Example 44: N-(3-(5-(((1-Acetylpiperidin-4-yl)amino)methyl)-3'-chloro-4-fluoro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(3-(5-(((1-Acetylpiperidin-4-yl)amino)methyl)-3'-chloro-4-fluoro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 42, replacing (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt with 1-(4-aminopiperidin- 1-yl)ethan-1-one hydrochloride salt in step (b). White solid, MS: m/z found 741 [M+H]+, retention time = 2.91 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.68 (d, 1H), 8.56 (dd, 1H), 7.80 (d, 1H), 7.52 (t, 1H), 7.37 (d, 1H), 7.24 (dd, 1H), 4.60 (t, 1H), 4.83 (t, 1H), 4.11 (s, 3H), 4.05-3.95 (m, 6H), 3.61 (s, 2H), 3.19-3.15 (m, 1H), 2.98-2.95 (m, 3H), 2.81-2.72 (m, 5H), 2.13-1.97 (m, 7H), 1.47-1.30 (m, 3H). Example 45: (S)-N-(3-(3-Chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 3-(2,3-Dichloropyridin-4-yl)-2-methylaniline To a mixture of 2,3-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (4.98 g, 18.2 mmol) and 3-bromo-2-methylaniline (2.6 g, 13.9 mmol) in 1,4-dioxane / water (5:1, 36 mL) was added [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (910 mg, 1.4 mmol) and potassium phosphate (8.9 g, 41.9 mmol), and then the mixture stirred at 95 °C for 3 h under N2. Water (50 mL) was then added and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-30% EtOAc/Petroleum ether) to afford 3-(2,3-dichloropyridin-4-yl)-2- methylaniline (1.9 g, 53% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 8.41 (d, 1H), 7.36 (d, 1H), 6.99 (t, 1H), 6.73 (d, 1H), 6.34 (d, 1H), 5.08 (s, 2H), 1.77 (s, 3H). (b) N-(3-(2,3-Dichloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 3-(2,3-dichloropyridin-4-yl)-2-methylaniline (300 mg, 1.19 mmol) in THF (5 mL) was added 1.0 M lithium bis(trimethylsilyl)amide solution in THF (2.37 mL, 2.37 mmol) at 0°C, and the mixture stirred at 0 °C for 0.5 h under N2. A solution of methyl 5- (3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (Example 10, step (b)) (303 mg, 1.19 mmol) in THF (5 mL) was then added and the mixture stirred at 0 °C for 0.5 h under N2. Water (20 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % EtOAc / petroleum ether) to afford N-(3-(2,3- dichloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (200 mg, 35% yield) as a yellow oil.1H NMR (400 MHz, DMSO-d6): δ 9.82 (s, 1H), 8.56 (d, 1H), 7.74 (d, 1H), 7.43 (d, 1H), 7.34 (t, 1H), 7.05 (d, 1H), 4.57 (t, 1H), 4.45 (t, 1H), 3.87 (s, 3H), 3.44 (s, 2H), 2.80-2.77 (m, 2H), 2.68-2.61 (m, 4H), 1.98 (s, 3H), 1.78-1.76 (m, 2H). (c) N-(3-(3-Chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-5- (3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (160 mg, 0.34 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (132 mg, 0.50 mmol) in 1,4-dioxane / water (5:1, 6 mL) was added potassium carbonate (139 mg, 1.01 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (27.4 mg, 0.03 mmol), and then the mixture stirred at 130 °C for 1 h under N2. water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, EtOAc: MeOH = 4:1) to afford N-(3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (110 mg, 56% yield) as a yellow solid. MS: m/z found 576 [M+H]+. (d) (S)-N-(3-(3-Chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)-2- methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (100 mg, 0.17 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (52.3 mg, 0.35 mmol,) in dichloromethane / methanol (1:1, 10 mL) was added sodium acetate (42.7 mg, 0.52 mmol), and then the mixture stirred at room temperature for 0.5 h under N2. Sodium cyanoborohydride (32.7 mg, 0.52 mmol) was then added and the mixture stirred at room temperature for 0.5 h under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (25.3 mg, 21% yield) as a white solid. MS: m/z found 674 [M+H]+, retention time = 2.50 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.61 (d, 1H), 7.86 (d, 1H), 7.43-7.37 (m, 3H), 7.30-7.26 (m, 2H), 7.11 (d, 1H), 4.60 (t, 1H), 4.49 (t, 1H), 4.00 (s, 3H), 3.95 (s, 3H), 3.90-3.83 (m, 3H), 3.59 (s, 2H), 2.96-2.93 (m, 2H), 2.81-2.68 (m, 6H), 2.37-2.28 (m, 3H), 2.17 (s, 3H), 2.05-1.98 (m, 2H), 1.82-1.81(m, 1H). Example 46: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (Example 20, step (c)) (50 mg, 0.086 mmol) and (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt (25.9 mg, 0.172 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (21.2 mg, 0.258 mol) and then the mixture stirred at room temperature for 1.5 h under N2. Sodium cyanoborohydride (16.2 mg, 0.258 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (14.7 mg, 24% yield) as a white solid. MS: m/z found 678 [M+H]+, retention time = 2.53 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.30-7.27 (m, 2H), 7.17 (dd, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.90-3.89 (m, 2H), 3.87- 3.85 (m, 1H), 3.83-3.78 (m, 2H), 3.64 (s, 2H), 3.00-2.97 (m, 2H), 2.82-2.79 (m, 4H), 2.71- 2.68 (m, 2H), 2.37-2.26 (m, 3H), 1.84-1.79 (m, 1H). Example 47: 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl 2-((3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate To a mixture of 3-(2,3-dichloropyridin-4-yl)-2-methylaniline (Example 45, step (a)) (1.7 g, 6.72 mmol) in THF (20 mL) was added 1M Lithium bis(trimethylsilyl)amide in THF (13.4 mL, 13.4 mmol) at 0 °C and the mixture stirred for 0.5 h A solution of 5-(tert-butyl) 2- methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-dicarboxylate (2.4 g, 8.06 mmol) in THF (20 mL) was then added and the mixture stirred at room temperature for 1 hour under N2. Water (50 mL) was added and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by normal phase SiO2 chromatography (0-75% Ethyl acetate / Petroleum ether) to afford tert-butyl 2-((3-(2,3- dichloropyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridine-5-carboxylate (3.1 g, 85% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.91-9.88 (m, 1H), 8.47 (d, 1H), 7.69-7.68 (m, 1H), 7.43 (d, 1H), 7.35 (t, 1H), 7.07 (d, 1H), 4.39 (s, 2H), 3.88 (s, 3H), 3.69 (t, 2H), 2.69 (t, 2H), 1.98 (s, 3H), 1.40 (s, 9H). (b) N-(3-(2,3-Dichloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of tert-butyl 2-((3-(2,3-dichloropyridin-4-yl)-2- methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate (2.6 g, 5.03 mmol) in dichloromethane (30 mL) was added trifluoroacetic acid (12 mL, 12.0 mmol), then the mixture was stirred at room temperature for 1 hour under N2. Water (30 mL) was added and the mixture and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (2.3 g, crude) as a yellow solid. MS: m/z found 416 [M+H]+. The product was used for next step without further purification. (c) 5-(1-Acetylpiperidin-4-yl)-N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide and 1-acetylpiperidin-4-one (457 mg, 3.24 mmol) in methanol / dichloromethane (1:1 v/v, 10 mL) was added titanium(IV) ethoxide (739 mg, 3.24 mmol), then the mixture was stirred at room temperature for 11.5 hours under N2. Sodium cyanoborohydride (203 mg, 3.24 mmol), was then added and the mixture stirred at room temperature for 0.5 hours under N2. Water (30 mL) was added and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-30% methanol / ethyl acetate) to afford 5- (1-acetylpiperidin-4-yl)-N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (300 mg, 51% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 9.82 (s, 1H), 8.47 (d, 1H), 7.74 (d, 1H), 7.43 (d, 1H), 7.34 (t, 1H), 7.05 (d, 1H), 4.42-4.39 (m, 1H), 3.86 (s, 3H), 3.56 (s, 2H), 3.03 (t, 1H), 2.86 (t, 2H), 2.77-2.70 (m, 1H), 2.65-2.63 (m, 2H), 2.57-2.54 (m, 2H), 2.00 (s, 3H), 1.98 (s, 3H), 1.84- 1.78 (m, 2H), 1.54-1.35 (m, 2H). (d) 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin- 4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(2,3-dichloropyridin-4-yl)-2- methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (220 mg, 0.41 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (159 mg, 0.61 mmol) in 1,4-dioxane / water (5:1 v/v, 12 mL) was added potassium phosphate (258 mg, 1.22 mmol) and [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (26.5 mg, 0.04 mmol), then the mixture stirred at 130 °C for 2 hours under N2. Water (20 mL) was added and the mixture and extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-80% methanol / ethyl acetate) to afford 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (200 mg, 76% yield) as a white solid.1H NMR (400 MHz, DMSO- d6): δ 10.43 (s, 1H), 9.82 (s, 1H), 8.72 (d, 1H), 7.82 (d, 1H), 7.73 (d, 1H), 7.52 (s, 1H), 7.45 (d, 1H), 7.40 (d, 1H), 7.35 (t, 1H), 7.10 (d, 1H), 4.43-4.39 (m, 1H), 3.99 (s, 3H), 3.86 (s, 3H), 3.56 (s, 2H), 3.06-3.00 (m, 1H), 2.87-2.85 (m, 2H), 2.77-2.72 (m, 1H), 2.65-2.62 (m, 2H), 2.05 (s, 3H), 2.00 (s, 3H), 1.85-1.78 (m, 2H), 1.54-1.45 (m, 2H), 1.39-1.30 (m, 2H). (e) 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (70 mg, 0.11 mmol) and 2,6-diazaspiro[3.4]octan-7-one (20.6 mg, 0.16 mmol) in methanol / dichloromethane (1:1 v/v, 4 mL) was added sodium acetate (26.8 mg, 0.33 mmol), then the mixture was stirred at room temperature for 11.5 hours under N2. Sodium cyanoborohydride (20.5 mg, 0.33 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3- methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2- methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (17.1 mg, 20% yield) as a white solid. MS: m/z found 751 [M+H]+, retention time = 2.38 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.61 (d, 1H), 7.86 (d, 1H), 7.40-7.37 (m, 3H), 7.28-7.26 (m, 2H), 7.11 (d, 1H), 4.65-4.61 (m, 1H), 4.05-4.02 (m, 1H), 3.96 (s, 3H), 3.92 (s, 3H), 3.78 (s, 2H), 3.71 (s, 2H), 3.59 (s, 2H), 3.46-3.41 (m, 4H), 3.21-3.14 (m, 1H), 3.04-3.01 (m, 2H), 2.91-2.85 (m, 1H), 2.78-2.76 (m, 2H), 2.71-2.65 (m, 1H), 2.58 (s, 2H), 2.15 (s, 3H), 2.14 (s, 3H), 2.07-2.00 (m, 2H), 1.65-1.50 (m, 2H). Example 48: 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 47, step (d)) (80 mg, 0.13 mmol) and 1-(4- aminopiperidin-1-yl)ethan-1-one (44.6 mg, 0.31 mmol) in methanol / dichloromethane (1:1 v/v, 6 mL) was added sodium acetate (30 mg, 0.37 mmol), then the mixture was stirred at room temperature for 11.5 hours under N2. Sodium cyanoborohydride (23.5 mg, 0.37 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford 5-(1- acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)- 3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (50.8 mg, 50% yield) as a white solid. MS: m/z found 767 [M+H]+, retention time = 2.48 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.61 (d, 1H), 7.86 (d, 1H), 7.44-7.37 (m, 3H), 7.30-7.27 (m, 2H), 7.11 (dd, 1H), 4.65-4.61 (m, 1H), 4.51-4.47 (m, 1H), 4.06-4.01 (m, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.93 (s, 2H), 3.71 (s, 2H), 3.21-3.14 (m, 2H), 3.03 (t, 2H), 2.91-2.68 (m, 7H), 2.15 (s, 3H), 2.14 (s, 3H), 2.12 (s, 3H), 2.06-1.99 (m, 4H), 1.64-1.49 (m, 2H), 1.41-1.29 (m, 2H). Example 49: (S)-N-(3-(3'-Chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(3-Bromo-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 3-bromo-2-methyl-aniline (800 mg, 4.30 mmol) in THF (5 mL) was added 1M lithium bis(trimethylsilyl)amide in THF (8.60 mL, 8.60 mmol) at 0°C, then the mixture was stirred at 0 °C for 0.5 hours under N2. Methyl 5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (Example 10, step (b)) (1.10 g, 4.30 mmol) in THF (5 mL) was then added, and the mixture stirred at 0 °C for 0.5 hours under N2. Water (20 mL) was added, and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % ethyl acetate / petroleum ether) to afford N-(3-bromo-2- methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (1.2 g, 68% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 7.51 (d, 1H), 7.47 (d, 1H), 7.16 (t, 1H), 4.58 (t, 1H), 4.46 (t, 1H), 3.85 (s, 3H), 3.45 (s, 2H), 2.80-2.79 (m, 2H), 2.77-2.61 (m, 4H), 2.30 (s, 3H), 1.94-1.88 (m, 2H). (b) 5-(3-Fluoropropyl)-1-methyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-bromo-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (1.1 g, 2.69 mmol), bis(pinacolato)diboron (3.41 g, 13.4 mmol) in 1,4-dioxane (15 mL) was added potassium acetate (791 mg, 8.06 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (219 mg, 0.27 mmol), and then the mixture was stirred at 130 °C for 12 hours under N2. The mixture was concentrated and the residue purified by normal phase SiO2 chromatography (0- 100 % ethyl acetate / petroleum ether) to afford 5-(3-fluoropropyl)-1-methyl-N-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (1.1 g, 89% yield) as a yellow solid.1H NMR (400 MHz, DMSO- d6): δ 9.96 (s, 1H), 7.63 (d, 1H), 7.49 (d, 1H), 7.20 (t, 1H), 4.58 (t, 1H), 4.46 (t, 1H), 3.86 (s, 3H), 3.45 (s, 2H), 2.80-2.77 (m, 2H), 2.67-2.63 (m, 4H), 2.40 (s, 3H), 1.94-1.88 (m, 2H), 1.32 (s, 12H). (c) N-(3-(3'-Chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5- (3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2',3'-dichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (Example 35, step (c)) (180 mg, 0.64 mmol) and 5-(3-fluoropropyl)-1-methyl-N-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamide (348 mg, 0.76 mmol) in THF / water (5:1 v/v, 6 mL) was added chloro(2- dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′- biphenyl)]palladium(II) (50.0 mg, 0.06 mmol) and potassium phosphate (405 mg, 1.91 mmol), and the mixture stirred at 80 °C for 12 hours under N2. Water (10 mL) was then added, and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, ethyl acetate : methanol = 5:1 v/v) to afford N-(3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (150 mg, 41% yield) as a yellow solid. MS: m/z found 577 [M+H]+. (d) (S)-N-(3-(3'-Chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (140 mg, 0.243 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (73.1 mg, 0.485 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (59.7 mg, 0.728 mmol) and then the mixture stirred at room temperature for 0.5 hours under N2. Sodium cyanoborohydride (45.7 mg, 0.728 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (51.8 mg, 31 % yield) as a white solid. MS: m/z found 675 [M+H]+, retention time = 2.27 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 7.92 (d, 1H), 7.82 (d, 1H), 7.75 (d, 1H), 7.43 (d, 1H), 7.40 (t, 1H), 7.18 (d, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.06 (s, 3H), 3.97 (s, 3H), 3.87-3.83 (m, 3H), 3.59 (s, 2H), 2.96-2.93 (m, 2H), 2.80-2.69 (m, 6H), 2.38- 2.29 (m, 3H), 2.15 (s, 3H), 2.07-1.98 (m, 2H), 1.86-1.83 (m, 1H). Example 50: (S)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5- methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
A mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4- formyl-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 29, step (a)) (50 mg, 0.07 mmol), (S)-5- (aminomethyl)pyrrolidin-2-one (17 mg, 0.15 mmol) and acetic acid (4 uL, 4 mg, 0.07 mmol) in dichloromethane/methanol (1:1 v/v) was stirred for 1 hour at room temperature and sodium cyanoborohydride (9 mg, 0.15 mmol) was added. The mixture was stirred for an additional 10 min, quenched with water, and extracted with dichloromethane two times. The combined organic layers were dried over anhydrous magnesium sulfate, concentrated, and purified by preparative HPLC. The collected aqueous fractions were concentrated to ~2 mL, neutralized with aqueous sodium carbonate and the product was extracted into dichloromethane three times. The combined organic layers were dried over anhydrous magnesium sulfate and concentrated to give (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3- chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide as free base. White solid, MS: m/z found 777.3 [M+H]+, retention time = 2.66 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (dd, 1H), 8.52 (dd, 1H), 7.49 (dd, 1H), 7.43 (dd, 1H), 7.18 – 7.13 (m, 2H), 7.09 (dd, 1H), 4.61 (d, 1H), 4.02 (d, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.93 (s, 2H), 3.82 (p, 1H), 3.68 (s, 2H), 3.15 (t, 1H), 2.99 (d, 2H), 2.90 – 2.80 (m, 1H), 2.79 – 2.72 (m, 2H), 2.71 – 2.59 (m, 3H), 2.36 – 2.21 (m, 3H), 2.11 (s, 3H), 2.01 (t, 2H), 1.83 – 1.71 (m, 1H), 1.67 – 1.42 (m, 2H). Example 51: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with 2-aminoethanol. White solid, MS: m/z found 724.3 [M+H]+, retention time = 2.68 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.71 – 8.60 (m, 1H), 8.52 (dd, 1H), 7.49 (t, 1H), 7.45 – 7.40 (m, 1H), 7.20 – 7.12 (m, 2H), 7.10 (d, 1H), 4.61 (d, 1H), 4.02 (d, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.94 – 3.91 (m, 2H), 3.70 – 3.64 (m, 4H), 3.15 (t, 1H), 3.04 – 2.96 (m, 2H), 2.85 (t, 1H), 2.79 – 2.70 (m, 4H), 2.65 (t, 1H), 2.11 (s, 3H), 2.01 (t, 2H), 1.68 – 1.42 (m, 2H). Example 52: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy- 4-(((2-methoxyethyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((2- methoxyethyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with 2-methoxyethanamine. White solid, MS: m/z found 738.3 [M+H]+, retention time = 2.88 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.51 (dd, 1H), 7.49 (t, 1H), 7.43 (d, 1H), 7.18 – 7.13 (m, 2H), 7.09 (dd, 1H), 4.60 (d, 1H), 4.01 (d, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.93 – 3.89 (m, 2H), 3.68 (s, 2H), 3.50 (t, 2H), 3.31 (s, 3H), 3.14 (t, 1H), 2.99 (d, 2H), 2.90 – 2.79 (m, 1H), 2.79 – 2.72 (m, 4H), 2.65 (t, 1H), 2.11 (s, 3H), 2.00 (t, 2H), 1.67 – 1.40 (m, 2H). Example 53: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)(methyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)(methyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with 2- (methylamino)ethanol. White solid, MS: m/z found 738.3 [M+H]+, retention time = 2.66 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.69 – 8.60 (m, 1H), 8.51 (d, 1H), 7.49 (t, 1H), 7.43 (d, 1H), 7.15 (d, 2H), 7.09 (d, 1H), 4.60 (d, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 3.78 – 3.63 (m, 6H), 3.14 (t, 1H), 2.99 (d, 2H), 2.83 (d, 1H), 2.76 (d, 2H), 2.64 (d, 3H), 2.30 (s, 3H), 2.11 (s, 3H), 2.00 (t, 2H), 1.67 – 1.39 (m, 2H). Example 54: (S)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with (S)-1-aminopropan-2-ol. White solid, MS: m/z found 738.3 [M+H]+, retention time = 2.74 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (d, 1H), 7.49 (t, 1H), 7.43 (d, 1H), 7.16 (d, 2H), 7.10 (d, 1H), 4.61 (d, 1H), 4.06 – 3.97 (m, 1H), 3.97 (s, 3H), 3.95 (s, 4H), 3.91 – 3.83 (m, 2H), 3.69 (s, 2H), 3.15 (t, 1H), 3.04 – 2.96 (m, 2H), 2.85 (t, 1H), 2.79 – 2.73 (m, 2H), 2.70 – 2.46 (m, 3H), 2.12 (s, 3H), 2.01 (t, 2H), 1.69 – 1.43 (m, 2H), 1.15 (d, 3H). Example 55: (R)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (R)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with (R)-1-aminopropan-2-ol. White solid, MS: m/z found 738.3 [M+H]+, retention time = 2.74 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (dd, 1H), 8.52 (dd, 1H), 7.49 (t, 1H), 7.44 (dd, 1H), 7.20 – 7.13 (m, 2H), 7.13 – 7.04 (m, 1H), 4.61 (d, 1H), 4.02 (d, 1H), 3.97 (s, 3H), 3.95 (s, 4H), 3.91 – 3.81 (m, 2H), 3.69 (s, 2H), 3.15 (t, 1H), 3.00 (s, 2H), 2.90 – 2.80 (m, 1H), 2.79 – 2.72 (m, 2H), 2.69 – 2.45 (m, 3H), 2.11 (s, 3H), 2.01 (t, 2H), 1.67 – 1.41 (m, 2H), 1.15 (d, 3H). Example 56: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxy-2-methylpropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2-hydroxy-2- methylpropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with 1-amino-2-methyl-propan- 2-ol. White solid, MS: m/z found 752.3 [M+H]+, retention time = 2.82 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.68 – 8.61 (m, 1H), 8.52 (dd, 1H), 7.49 (dd, 1H), 7.46 – 7.38 (m, 1H), 7.21 – 7.13 (m, 2H), 7.10 (dd, 1H), 4.61 (d, 1H), 4.06 – 3.97 (m, 1H), 3.97 (s, 3H), 3.96 (s, 3H), 3.94 (s, 2H), 3.69 (s, 2H), 3.15 (t, 1H), 3.04 – 2.96 (m, 2H), 2.85 (t, 1H), 2.75 (t, 2H), 2.65 (t, 1H), 2.55 (s, 2H), 2.12 (s, 3H), 2.01 (t, 2H), 1.67 – 1.43 (m, 2H), 1.20 (s, 6H). Example 57: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 10, replacing 1-bromo-3-fluoropropane with 1-bromo-2-methoxyethane in step (b) and 1-(4-aminopiperidin-1-yl)ethan-1-one hydrochloride salt with (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt in step (e). MS: m/z found 692 [M+H]+, retention time = 2.70 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.51 (dd, 1H), 7.49 (t, 1H), 7.41-7.39 (m, 2H), 7.29-7.25 (m, 2H), 7.15 (dd, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.89-3.88 (m, 2H), 3.87-3.86 (m ,1H), 3.63-3.61 (m, 4H), 3.36 (s, 3H), 2.96- 2.94 (m, 2H), 2.85-2.82 (m, 2H), 2.78-2.67 (m, 4H), 2.33-2.28 (m, 3H), 1.80-1.76 (m, 1H). Example 58: (S)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with (S)-pyrrolidin-3-ol. White solid, MS: m/z found 750.3 [M+H]+, retention time = 2.70 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (d, 1H), 7.49 (t, 1H), 7.44 (d, 1H), 7.16 (t, 2H), 7.10 (d, 1H), 4.61 (d, 1H), 4.32 (s, 1H), 4.06 – 3.99 (m, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.86 (s, 2H), 3.69 (s, 2H), 3.15 (t, 1H), 3.03 – 2.91 (m, 3H), 2.89 – 2.71 (m, 4H), 2.70 – 2.59 (m, 2H), 2.53 (dd, 1H), 2.18 – 2.08 (m, 4H), 2.01 (t, 2H), 1.74 – 1.42 (m, 3H). Example 59: (R)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (R)-5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 50, replacing (S)-5-(aminomethyl)pyrrolidin-2-one with (R)-pyrrolidin-3-ol. White solid, MS: m/z found 750.3 [M+H]+, retention time = 2.70 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (d, 1H), 7.50 (t, 1H), 7.44 (d, 1H), 7.16 (s, 2H), 7.10 (d, 1H), 4.61 (d, 1H), 4.32 (s, 1H), 4.05 – 3.97 (m, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.86 (s, 2H), 3.69 (s, 2H), 3.15 (t, 1H), 3.03 – 2.91 (m, 3H), 2.88 – 2.72 (m, 4H), 2.71 – 2.59 (m, 2H), 2.54 (d, 1H), 2.19 – 2.08 (m, 4H), 2.01 (t, 2H), 1.72 – 1.41 (m, 3H). Example 60: 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-(difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 4-Bromo-2-(difluoromethoxy)benzaldehyde To a solution of 4-bromo-2-hydroxybenzaldehyde (4 g, 19.9 mmol) in dichloromethane / water (4:3 v/v, 40 mL) was added potassium hydroxide (6.70 g, 119 mmol) and (bromodifluoromethyl)trimethylsilane (6.06 g, 29.8 mmol) and then the mixture stirred at room temperature for 12 hours under N2. water (200 mL) was added, and the mixture extracted with ethyl acetate (2 x 200 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 4- bromo-2-(difluoromethoxy)benzaldehyde (2.1 g, 47 % yield) as a yellow solid. MS: m/z found 250 [M+H]+.1H NMR (400 MHz, DMSO-d6): δ10.00 (s, 1H), 7.55 (d, 1H), 7.46-7.41 (m, 2H), 7.22-7.04 (m, 1H). The product was used in the next step without further purification. (b) 2-(Difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde To a mixture of 4-bromo-2-(difluoromethoxy)benzaldehyde (500 mg, 1.99 mmol) and bis(pinacolato)diboron (758 mg, 2.99 mmol) in 1,4-dioxane (10 mL) was added potassium acetate (390 mg, 3.98 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (163 mg, 0.20 mmol), and then the mixture stirred at 100 °C for 12 hours under N2. The mixture was concentrated and the residue purified by normal phase SiO2 chromatography (0-5 % ethyl acetate / Petroleum ether) to afford 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde (200 mg, 33 % yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ10.33 (s, 1H), 7.87 (d, 1H), 7.71-7.56 (m, 1H), 7.49-7.27 (m, 2H), 1.34 (s, 12H). (c) 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4- formylphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(2,3-dichloropyridin-4-yl)-2- methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 47, step (c)) (200 mg, 0.37 mmol) and 2-(difluoromethoxy)-4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (132 mg, 0.44 mmol) in water / 1,4- dioxane(1:5 v/v, 12 mL) was added potassium phosphate (235 mg, 0.11 mmol) and [1,1′- bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (24.1 mg, 0.037 mmol), and then the mixture stirred at 130 °C for 2 h under N2. water (50 mL) was added, and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-50% methanol / ethyl acetate) to afford 5- (1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-formylphenyl)pyridin-4- yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide ( 110 mg) as a white solid. MS: m/z found 677 [M+H]+. (d) 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4- formylphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (50 mg, 0.074 mmol)and 1-(4-aminopiperidin-1-yl)ethan-1-one (21 mg, 0.147 mmol) in dichloromethane / methanol (1:1 v/v, 4 mL), was added sodium acetate (18.2 mg, 0.22 mmol), and then the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (13.9 mg, 0.22 mmol), was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1-acetylpiperidin-4-yl)-N-(3-(2- (4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-(difluoromethoxy)phenyl)-3-chloropyridin-4- yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (9 mg, 15% yield) as a white solid. MS: m/z found 803 [M+H]+, retention time = 2.66 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 7.86 (d, 1H), 7.65-7.59 (m,2H), 7.53 (s, 1H), 7.41-7.37 (m, 2H), 7.17-6.81 (m, 2H), 4.65-4.61 (m, 1H), 4.49-4.45 (m, 1H), 4.05-3.93 (m, 7H), 3.71 (s, 2H), 3.20-3.14 (m, 2H), 3.04-3.01 (m, 2H), 2.91-2.65 (m, 6H), 2.15 (s, 3H), 2.14 (s, 3H), 2.12 (s, 3H), 2.07-2.00 (m, 4H), 1.65-1.53 (m, 2H), 1.50-1.31 (m, 2H). Example 61: 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo- 2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(2,3-dichloropyridin-4-yl)-2- methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 47, step (c)) (500 mg, 0.92 mmol) and 2-fluoro-6-methoxy-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)benzaldehyde (388 mg, 1.39 mmol) in 1,4-dioxane / water (5:1 v/v, 12 mL) was added potassium phosphate (588 mg, 2.77 mmol) and [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) (60.2 mg, 0.92 mmol), and then the mixture stirred at 130 °C for 2 hours under N2. Water (50 mL) was then added and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-40 % methanol / ethyl acetate) to afford 5- (1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-4-formyl-5-methoxyphenyl)pyridin-4-yl)- 2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (400 mg, 67% yield) as a yellow solid. MS: m/z found 659 [M+H]+. (b) 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (100 mg, 0.15 mmol) and 2,6-diazaspiro[3.4]octan-7-one (38.3 mg, 0.30 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (37.3 mg, 0.46 mmol), and then the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (28.6 mg, 0.46 mmol) was then added and the mixture was stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro- 2-(3-fluoro-5-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)- 2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (15.5 mg, 12% yield) as a white solid. MS: m/z found 769 [M+H]+, retention time = 2.44 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 7.86 (d, 1H), 7.42-7.37 (m, 2H), 7.17 (s, 1H), 7.12-7.10 (m, 2H), 4.65-4.60 (m, 1H), 4.06-4.00 (m, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.82 (s, 2H), 3.71 (s, 2H), 3.51 (s, 2H), 3.43 (s, 4H), 3.17-3.14 (m, 1H), 3.04-3.02 (m, 2H), 2.89-2.86 (m, 1H), 2.77-2.75 (m, 2H), 2.68-2.64 (m, 1H), 2.54 (s, 2H), 2.15 (s, 3H), 2.14 (s, 3H), 2.06-2.00 (m, 2H) , 1.65-1.62 (m, 1H) , 1.54-1.50 (m, 1H). Example 62: 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 5-(1-Acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- fluoro-5-methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 61, step (a)) (100 mg, 0.15 mmol) and 1-(4- aminopiperidin-1-yl)ethan-1-one (43.1 mg, 0.30 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (37.3 mg, 0.46 mmol), and then the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (28.6 mg, 0.46 mmol), was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford 5-(1- acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (30 mg, 25% yield) as a white solid. MS: m/z found 785 [M+H]+, retention time = 2.58 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 7.86 (d, 1H), 7.42-7.37 (m, 2H), 7.18 (s, 1H), 7.13-7.10 (m, 2H), 4.65-4.61 (m, 1H), 4.50-4.47 (m, 1H), 4.03-3.96 (m, 10H), 3.71 (s, 2H), 3.18-3.15 (m, 2H), 3.04-3.01 (m, 2H), 2.91-2.85 (m, 1H), 2.79-2.65 (m, 5H), 2.15 (s, 3H), 2.14 (s, 3H), 2.12 (s, 3H), 2.06-1.98 (m, 4H), 1.65-1.53 (m, 2H), 1.51-1.31 (m, 2H). Example 63: N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(3-(3-Chloro-2-(3-fluoro-4-formyl-5-methoxyphenyl)pyridin-4-yl)-2- methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 45, step (b)) (300 mg, 0.63 mmol) and 2-fluoro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde (265 mg, 0.94 mmol) in 1,4-dioxane / water (5:1, 3.6 mL) was added [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (41.0 mg, 0.06 mmol) and potassium phosphate (401 mg, 1.89 mmol), and then the mixture stirred at 130 °C for 2.5 hours under N2. The mixture was concentrated and the residue purified prep-TLC (SiO2, ethyl acetate : methanol = 4:1 v/v) to afford N-(3-(3-chloro-2-(3-fluoro-4-formyl-5- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (250 mg, 66% yield) as a white solid. MS: m/z found 594 [M+H]+. (b) N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)- 3-chloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 1-(4-aminopiperidin-1-yl)ethan-1-one (75.2 mg, 0.42 mmol) and N- (3-(3-chloro-2-(3-fluoro-4-formyl-5-methoxyphenyl)pyridin-4-yl)-2-methylphenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (125 mg, 0.21 mmol) in methanol / dichloromethane (1:1 v/v, 2 mL) was added sodium acetate (51.8 mg, 0.63 mmol), and then the mixture stirred at room temperature for 2 hours under N2. Sodium cyanoborohydride (39.6 mg, 0.63 mmol), was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was then concentrated and the residue purified by reverse phase HPLC to afford N-(3-(2-(4-(((1-acetylpiperidin-4- yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (26.1 mg, 16 % yield0 as a white solid. MS: m/z found 720 [M+H]+, retention time = 2.66 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 7.87 (d, 1H), 7.42-7.37 (m, 2H), 7.17 (s, 1H), 7.18-7.10 (m, 2H), 4.60 (t, 1H), 4.50-4.46 (m, 2H), 3.97 (m, 9H), 3.59 (s, 2H), 3.18-3.11 (m, 1H), 2.96-2.93 (m, 2H), 2.81-2.72 (m, 6H), 2.15 (s, 3H), 2.11 (s, 3H), 2.07-1.97 (m, 4H), 1.41-1.28 (m, 2H). Example 64: (S)-N-(3-(3-Chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 45, replacing methyl 5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate with methyl 5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (Example 20, step (a)) in step (b). MS: m/z found 658 [M+H]+, retention time = 2.34 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.61 (d, 1H), 7.86 (d, 1H), 7.43-7.37 (m, 3H), 7.29-7.26 (m, 2H), 7.10 (d, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.93-3.85 (m, 3H), 3.81-3.78 (m, 2H), 3.64 (s, 2H), 3.00-2.98 (m, 2H), 2.82-2.78 (m, 4H), 2.71-2.68 (m, 2H), 2.37-2.30 (m, 3H), 2.15 (s, 3H), 1.82-1.78 (m, 1H). Example 65: 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo- 2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
(a) 5-(1-Acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4- formylphenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 60, step (c)) (50 mg, 0.074 mmol) and 2,6- diazaspiro[3.4]octan-7-one (18.6 mg, 0.147 mmol) in dichloromethane / methanol (1:1 v/v, 4 mL) was added sodium acetate (18.2 mg, 0.22 mmol), and then the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (13.9 mg, 0.22 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by prep-HPLC to afford 5-(1-acetylpiperidin-4-yl)- N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (9 mg, 14 % yield) as a white solid. MS: m/z found 787 [M+H]+, retention time = 2.59 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 7.86 (d, 1H), 7.61-7.55 (m, 2H), 7.51 (s, 1H), 7.41-7.37 (m, 2H), 7.13-6.76 (m, 2H), 4.65-4.60 (m, 1H), 4.05-4.02 (m, 1H), 4.02 (s, 3H), 3.81 (s, 2H), 3.71 (s, 2H), 3.60 (s, 2H), 3.46-3.44 (m, 4H), 3.24-3.17 (m, 1H), 3.04-3.01 (m, 2H), 2.88-2.78 (m, 1H), 2.77-2.75 (m, 2H), 2.68-2.67 (m, 1H), 2.59 (s, 2H), 2.15 (s, 3H), 2.14 (s, 3H), 2.07-2.00 (m, 2H), 1.65- 1.50 (m, 2H). Example 66: (S)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(3-(3-Chloro-2-(3-(difluoromethoxy)-4-formylphenyl)pyridin-4-yl)-2- methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 45, step (b)) and 2-(difluoromethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (93.9 mg, 0.31 mmol) in 1,4-dioxane / water (5:1 v/v, 6mL) was added potassium phosphate (133 mg, 0.63 mmol) and [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (13.7 mg, 0.21 mmol), and then the mixture stirred at 130 °C for 2 hours under N2. Water (50 mL) was then added, and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % ethyl acetate / Petroleum ether) to afford N-(3-(3-chloro-2-(3-(difluoromethoxy)-4- formylphenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (87 mg, 54% yield) as a white solid. MS: m/z found 612 [M+H]+. (b) (S)-N-(3-(3-Chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-formylphenyl)pyridin-4-yl)- 2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamide (80 mg, 0.13 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (39.4 mg, 0.26 mmol) in dichloromethane / methanol (1:1 v/v, 10 mL) was added sodium acetate (32.2 mg, 0.39 mmol), and then the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (24.6 mg, 0.39 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(3-(3-chloro-2-(3-(difluoromethoxy)- 4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3- fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (16 mg, 16 % yield) as a white solid. MS: m/z found 710 [M+H]+, retention time = 2.72 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.52 (d, 1H), 7.74 (d, 1H), 7.52-7.47 (m, 2H), 7.40 (s, 1H), 7.29-7.25 (m, 2H), 7.03-6.66 (m, 2H), 4.48 (t, 1H), 4.37 (t, 1H), 3.85 (s, 3H), 3.83 (s, 2H), 3.76-3.70 (m, 1H), 3.47 (s, 2H), 2.82 (t, 2H), 2.69-2.59 (m, 6H), 2.26-2.16 (m, 3H), 2.03 (s, 3H), 1.95-1.87 (m, 2H), 1.73-1.70 (m, 1H). Example 67: ((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)glycine A mixture of N-(2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (Example 35, step (d)) (30 mg, 0.05 mmol), glycine (8 mg, 0.10 mmol) and acetic acid (3 uL, 3 mg, 0.05 mmol) in dichloromethane/methanol (1:1 v/v) was stirred for 1 hour at room temperature and sodium cyanoborohydride (6 mg, 0.10 mmol) was added. The mixture was stirred for an additional 30 min, quenched with water, and directly purified by preparative HPLC to give ((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)glycine as the formic acid salt. White solid, MS: m/z found 656.2 [M+H]+, retention time = 2.47 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.54 (d, 1H), 8.39 (s, 1H), 7.93 (d, 1H), 7.78 (d, 1H), 7.55 – 7.45 (m, 2H), 7.22 (d, 1H), 4.58 (t, 1H), 4.47 (t, 1H), 4.31 (s, 2H), 4.11 (s, 3H), 3.98 (s, 3H), 3.65 (s, 2H), 3.55 (s, 2H), 3.06 – 2.95 (m, 2H), 2.89 – 2.73 (m, 4H), 2.10 – 1.93 (m, 2H). Example 68: 3-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)propanoic acid 3-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)propanoic acid was prepared in a similar fashion to Example 67, replacing glycine with 3-aminopropanoic acid. White solid, MS: m/z found 670.2 [M+H]+, retention time = 1.60 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.55 (d, 1H), 8.42 (s, 1H), 7.94 (d, 1H), 7.78 (d, 1H), 7.56 – 7.43 (m, 2H), 7.23 (d, 1H), 4.59 (t, 1H), 4.47 (t, 1H), 4.28 (s, 2H), 4.13 (s, 3H), 3.99 (s, 3H), 3.65 (s, 2H), 3.23 (t, 2H), 3.04 – 2.93 (m, 2H), 2.90 – 2.74 (m, 4H), 2.55 (t, 2H), 2.14 – 1.92 (m, 2H). Example 69: (R)-4-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)-3-hydroxybutanoic acid (R)-4-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid was prepared in a similar fashion to Example 67, replacing glycine with (R)-4-amino-3-hydroxy-butanoic acid. White solid, MS: m/z found 700.2 [M+H]+, retention time = 1.59 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.55 (d, 1H), 8.46 (s, 1H), 7.95 (d, 1H), 7.78 (d, 1H), 7.55 – 7.45 (m, 2H), 7.23 (d, 1H), 4.58 (t, 1H), 4.47 (t, 1H), 4.29 (s, 2H), 4.20 (s, 1H), 4.11 (s, 3H), 3.98 (s, 3H), 3.61 (s, 2H), 3.22 (d, 1H), 3.09 – 3.01 (m, 1H), 3.01 – 2.92 (m, 2H), 2.86 – 2.72 (m, 4H), 2.48 (d, 2H), 2.12 – 1.90 (m, 2H). Example 70: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 1, step (f)) (300 mg, 0.69 mmol) and 4-fluorobenzaldehyde (171 mg, 1.37 mmol) in dichloromethane / methanol (1:1 v/v, 10 mL) was added sodium acetate (169 mg, 2.06 mmol) and the mixture was stirred at room temperature for 11.5 hours under N2. Sodium cyanoborohydride (129 mg, 2.06 mmol) was then added, and the mixture was stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and purified by normal phase SiO2 chromatography (0- 90% ethyl acetate /petroleum ether) to afford N-(2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (330 mg, 88% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.91 (s, 1H), 8.52 (d, 1H), 8.39 (dd, 1H), 7.56-7.52 (m, 2H), 7.42-7.38 (m, 2H), 7.23-7.15 (m, 3H), 3.91 (s, 3H), 3.71 (s, 2H), 3.41 (s, 2H), 2.82-2.79 (m, 2H), 2.72-2.69 (m, 2H). (b) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(4- fluorobenzyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(4-fluorobenzyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (300 mg, 0.55 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (216 mg, 0.83 mmol) in 1,4-dioxane/water (5:1 v/v, 12 mL) was added potassium carbonate (228 mg, 1.65 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (45 mg, 0.06 mmol). The mixture was stirred at 130 °C for 1 hour under N2. Water (20 mL) was then added, and the residue was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-90% ethyl acetate /petroleum ether) to afford N-(2-chloro-3-(3-chloro-2- (4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (170 mg, 48% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.91 (s, 1H), 8.77 (d, 1H), 8.39 (dd, 1H), 7.82 (d, 1H), 7.55-7.51 (m, 3H), 7.41-7.37 (m, 3H), 7.24 (dd, 1H), 7.19-7.14 (m, 2H), 3.99 (s, 3H), 3.90 (s, 3H), 3.70 (s, 2H), 3.40 (s, 2H), 2.81-2.78 (m, 2H), 2.71-2.68 (m, 2H). (c) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (150 mg, 233 umol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (70.10 mg, 0.47 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (57 mg, 0.70 mmol) and the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (44 mg, 0.70 mmol) was then added, and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and purified by reversed phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (86 mg, 49% yield) as a white solid. MS: m/z found 742 [M+H]+, retention time = 3.06 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.51 (dd, 1H), 7.51 (d, 1H), 7.48-7.41 (m, 4H), 7.29-7.27 (m, 2H), 7.71 (dd, 1H), 7.56 (t, 1H), 7.44 (d, 1H), 7.34 (dd, 1H), 7.11-7.07 (m, 2H), 3.99 (s, 3H), 3.94 (s, 3H), 3.89-3.88 (m, 2H), 3.86-3.85 (m, 1H), 3.78 (s, 2H), 3.52 (s, 2H), 2.93-2.90 (m, 2H), 2.79-2.76 (m, 2H), 2.71-2.68 (m, 2H), 2.37-2.28 (m, 3H), 1.83-1.80 (m, 1H). Example 71: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 5-(4-fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate (1.0 g, 5.12 mmol) and 1-(2-bromoethyl)-4-fluorobenzene (1.56 g, 7.68 mmol) in acetonitrile (15 mL) was added potassium carbonate (7.08 g, 51.2 mmol), and then the mixture was stirred at 60 °C for 12 hours under N2. Water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 10 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-20% methanol/ ethyl acetate) to afford methyl 5-(4-fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate (310 mg).1H NMR (400 MHz, DMSO-d6): δ 7.31-7.28 (m, 2H), 7.11-7.07 (m, 2H), 3.79 (s, 3H), 3.77 (s, 3H), 3.44 (s, 2H), 2.81-2.79 (m, 4H), 2.76-2.74 (m, 2H), 2.65-2.63 (m, 2H). (b) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (323 mg, 1.18 mmol) in THF (2 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 1.58 mL, 1.58 mmol) at 0 °C, and then the mixture stirred at 0 °C for 0.5 hours under N2. A solution of methyl 5-(4-fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate (250 mg, 0.79 mmol) in THF (2 mL) was added and the mixture stirred at 0 °C for 0.5 hours under N2. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100% ethyl acetate /petroleum ether) to afford N-(2-chloro-3- (2,3-dichloropyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (170 mg, 38% yield) as a yellow oil. MS: m/z found 558 [M+H]+. (c) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(4- fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(4- fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (130 mg, 0.23 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde (91.5 mg, 0.35 mmol) in 1,4-dioxane/water (5:1 v/v, 6mL) was added potassium carbonate (97 mg, 0.69 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (19 mg, 0.23 mmol), and then the mixture stirred at 130 °C for 1 hour under N2. The reaction mixture was concentrated under reduced pressure and purified by prep-TLC (SiO2, ethyl acetate /petroleum ether, 4:1 v/v) to afford N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (57 mg, 37% yield) as a white solid. MS: m/z found 658 [M+H]+. (d) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-[2-chloro-3-[3-chloro-2-(4-formyl-3-methoxy-phenyl)-4- pyridyl]phenyl]-5-[2-(4-fluorophenyl)ethyl]-1-methyl-6,7-dihydro-4H-imidazo[4,5- c]pyridine-2-carboxamide (50 mg, 0.076 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (17 mg, 0.15 mmol) in dichloromethane / methanol (1:1 v/v, 10 mL) was added sodium acetate (19 mg, 0.23 mmol), and the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (14 mg, 0.23 mmol) was then added and the mixture was stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3- methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4- fluorophenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (13 mg, 21% yield) as a white solid. MS: m/z found 756 [M+H]+, retention time = 3.28 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.53 (dd, 1H), 7.51 (t, 1H), 7.44-7.43 (m, 2H), 7.31-7.28 (m, 4H), 7.18 (dd, 1H), 7.02 (t, 2H), 4.00 (s, 3H), 3.95 (s, 3H), 3.94-3.93 (m, 2H), 3.88-3.85 (m, 1H), 3.66 (s, 2H), 3.01-2.98 (m, 2H), 2.93-2.91 (m, 2H), 2.89-2.86 (m, 2H), 2.82-2.80 (m, 2H), 2.75-2.72 (m, 2H), 2.37-2.27(m, 3H), 1.86-1.78 (m, 1H). Example 72: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate A mixture of 5-tert-butyl 2-methyl 1-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridine- 2,5(4H)-dicarboxylate (5.0 g, 16.9 mmol) in 1.0 M HCl in 1,4-dioxane solution (15 mL) was stirred at room temperature for 1 hour and concentrated to afford methyl 1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate hydrochloride salt (4.4 g, crude) as a white solid. MS: m/z found 196 [M+H]+. (b) Methyl 5-(2-(cyclohexyloxy)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate hydrochloride salt (0.30 g, 1.29 mmol) and potassium carbonate (1.79 g, 13 mmol) in acetonitrile (7 mL) was added (2-bromoethoxy)cyclohexane (0.30 g, 1.42 mmol) in one portion under N2. The mixture was stirred at 60 °C for 12 hours and then concentrated. To the residue was added water (50 mL) and saturated aqueous brine solution (20 mL), and the mixture extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by normal phase SiO2 chromatography (50-100% ethyl acetate/petroleum ether to 50% methanol/ethyl acetate) to afford methyl 5-(2-(cyclohexyloxy)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate as a yellow gum (0.27 g, 64% yield).1H NMR (400 MHz, Methanol-d4): δ 3.91-3.89 (m, 6H), 3.71 (t, 2H), 3.63 (s, 3H), 3.49-3.40 (m, 1H), 2.98 (t, 2H), 2.84 (t, 2H), 2.78 (t, 2H), 1.96-1.92 (m, 2H), 1.77-1.74 (m, 2H), 1.51-1.50 (m, 1H), 1.35-1.25 (m, 5H). (c) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (0.04 g, 0.16 mmol) in THF (1 mL) was dropwise added lithium bis(trimethylsilyl)amide (1.0 M in THF, 0.5 mL, 0.5 mmol) at 0 °C under N2. The mixture was stirred at 0 °C for 30 min and then methyl 5-(2- (cyclohexyloxy)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (0.06 g, 0.17 mmol) in THF (1 mL) was added in one portion . After stirring at 0 °C for 30 min, water (5 mL) was added dropwise to quench the reaction. The mixture was combined with another 2 batches at 20 mg scale. Saturated aqueous brine solution (5 mL) was added, and the mixture was extracted with ethyl acetate/THF mixture (10:1 v/v, 20 mL). The organic phase was dried with anhydrous sodium sulfate, filtered and concentrated. The residue was purified by normal phase SiO2 chromatography (0-80% ethyl acetate/petroleum ether) to afford N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (140 mg, 50% yield) as a yellow solid. MS: m/z found 562 [M+H]+. (d) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(2- (cyclohexyloxy)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(2- (cyclohexyloxy)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (0.13 g, 0.23 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)benzaldehyde (0.1 g, 0.37 mmol) in 1,4-dioxane / water (6:1 v/v, 3.5 mL) was added potassium carbonate (0.1 g, 0.69 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.02 g, 0.02 mmol) in one portion under N2. The mixture was stirred at 110 °C for 12 hours and concentrated. The mixture was combined with another batch at 10 mg scale. Water (5 mL) and saturated aqueous brine solution (5 mL) were added, and the residue extracted with ethyl acetate / THF mixture (3:1 v/v, 10 mL). The organic phase was dried with anhydrous sodium sulfate, filtered and concentrated. The residue was purified by normal phase SiO2 chromatography (0-100% ethyl acetate/petroleum ether) to afford N-(2-chloro-3-(3-chloro-2- (4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (80 mg, 50% yield) as a yellow gum. MS: m/z found 662 [M+H]+. (e) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (0.07 g, 0.11 mmol) and (S)-5-(aminomethyl)-2-pyrrolidinone hydrochloride salt (0.02 g, 0.13 mmol) in THF / methanol mixture (1:2 v/v, 3 mL) was added sodium acetate (0.03 g, 0.32 mmol) in one portion under N2. The mixture was stirred at room temperature for 2 hours and then sodium cyanoborohydride (0.02 g, 0.32 mmol) was added. The mixture was stirred at room temperature for an additional 1 h. The mixture was combined with another batch at 10 mg scale and purified directly by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (21.3 mg, 25% yield) as a yellow solid. MS: m/z found 760 [M+H]+, retention time = 3.41 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.30- 7.27 (m, 2H), 7.17 (dd, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.93-3.83 (m, 3H), 3.73 (t, 2H), 3.65 (s, 2H), 3.34-3.33 (m, 1H), 3.00 (t, 2H), 2.86 (t, 2H), 2.80-2.78 (m, 2H), 2.75-2.68 (m, 2H), 2.36-2.26 (m, 3H), 1.97-1.92 (m, 2H), 1.81-1.76 (m, 3H), 1.58-1.54 (m, 1H), 1.36-1.27 (m, 5H). Example 73: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 1-methyl-5-(5,5,5-trifluoropentyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate hydrochloride salt (0.5 g, 2.16 mmol) and 5-bromo-1,1,1-trifluoropentane (0.44 g, 2.16 mmol) in acetonitrile (6 mL) was added potassium carbonate (2.68 g, 19.4 mmol) in one portion under N2. The mixture was stirred at 60 °C for 12 hours and combined with another batch at 100 mg scale. To the mixture was added water (15 mL) and extracted with ethyl acetate (2 x 15 mL). The combined organic phases were washed with saturated aqueous brine solution (2 x 15 mL), dried with anhydrous sodium sulfate, filtered and concentrated. The crude residue was purified by normal phase SiO2 chromatography (9-30% ethyl acetate/petroleum ether) to afford methyl 1-methyl-5-(5,5,5-trifluoropentyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (0.6 g, 72% yield) as a brown oil. MS: m/z found 320 [M+H]+. (b) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(5,5,5- trifluoropentyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (0.07 g, 0.24 mmol) in THF (1.5 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 0.48 mL, 0.48 mmol) in one portion at 0 °C under N2. The mixture was stirred at 0 °C for 0.5 hours and then a solution of methyl 1-methyl-5-(5,5,5-trifluoropentyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate (0.15 g, 0.48 mmol) in THF (1.5 mL) was added in one portion at 0 °C under N2. The mixture was stirred for 0.5 hours and then water was added dropwise to quench the reaction. The mixture was combined with another batch at 220 mg scale. Additional water (20 mL) was added, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with saturated aqueous brine solution (2 x 20 mL), dried with anhydrous sodium sulfate, filtered and concentrated. The residue was purified by normal phase SiO2 chromatography (9-100% ethyl acetate/petroleum ether) to afford N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (0.14 g, 42% yield) as a brown solid. MS: m/z found 560 [M+H]+; 1H NMR (400 MHz, DMSO-d6): δ 9.91 (s, 1H), 8.52 (d, 1H), 8.39 (dd, 1H), 7.56-7.52 (m, 2H), 7.21 (dd, 1H), 3.90 (s, 3H), 3.42 (s, 2H), 2.80-2.75 (m, 2H), 2.70-2.68 (m, 2H), 2.35-2.27 (m, 2H), 2.19-2.16 (m, 1H), 1.94-1.88 (m, 1H), 1.61-1.50 (m, 4H). (c) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1- methyl-5-(5,5,5-trifluoropentyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(5,5,5- trifluoropentyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (0.08 g, 0.14 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (0.05 g, 0.2 mmol) in 1,4-dioxane / water mixture (5:1 v/v, 2.4 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.01 g, 0.01 mmol) and potassium carbonate (0.06 g, 0.43 mmol) in one portion under N2. The mixture was stirred at 110 °C for 3 hours and combined with another batch at 50 mg scale. Water (15 mL) was added, and the mixture extracted with ethyl acetate (2 x 15 mL). The combined organic phases were washed with saturated aqueous brine solution (2 x 15 mL), dried with anhydrous sodium sulfate, filtered and concentrated. The residue was purified by normal phase SiO2 chromatography (9-25% ethyl acetate/petroleum ether) to afford N-(2- chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5- trifluoropentyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (0.14 g, 90% yield) as a brown solid. MS: m/z found 660 [M+H]+. (d) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamide (0.13 g, 0.20 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (0.04 g, 0.26 mmol) in THF / methanol mixture (1:1 v/v, 3 mL) was added sodium acetate (0.05 g, 0.59 mmol) in one portion under N2. The mixture was stirred at room temperature for 2 hours and then sodium cyanoborohydride (0.04 g, 0.59 mmol) was added under N2. The mixture was stirred at room temperature for 1 hour and combined with another batch at 10 mg scale. The mixture was concentrated and the residue purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (12.2 mg, 8% yield) as a yellow solid. MS: m/z found 758 [M+H]+, retention time = 3.20 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.42 (m, 2H), 7.32- 7.27 (m, 2H), 7.18 (dd, 1H), 4.00 (s, 3H), 3.95 (s, 3H), 3.91-3.89 (m, 2H), 3.87-3.84 (m, 1H), 3.57 (s, 2H), 2.94-2.91 (m, 2H), 2.81-2.78 (m, 2H), 2.72-2.65 (m, 4H), 2.40-2.18 (m, 5H), 1.85-1.60 (m, 5H). Example 74: (S)-N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl (S)-((3'-chloro-4-fluoro-2'-(3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of tert-butyl (S)-((2',3'-dichloro-4-fluoro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (Example 42, step (b)) (328 mg, 0.657 mmol) and 5-(3-fluoropropyl)-1-methyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 49, step (b)) (150 mg, 0.33 mmol) in THF / water (5:1 v/v, 2.4 mL) was added chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′- biphenyl)]palladium(II) (26 mg, 0.033 mmol) and potassium phosphate (209 mg, 0.99 mmol) and then the mixture was stirred at 80 °C for 12 hours under N2. Water (15 mL) was added, and the mixture was extracted with ethyl acetate (2 x 15 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-12% methanol / ethyl acetate) to afford tert-butyl (S)-((3'-chloro-4-fluoro-2'-(3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (80 mg, 23% yield). MS: m/z found 793 [M+H]+. (b) (S)-N-(3-(3'-Chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of tert-butyl (S)-((3'-chloro-4-fluoro-2'-(3-(5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (60 mg, 0.75 mmol) in dichloromethane (0.6 mL) was added trifluoroacetic acid (0.6 mL, 8.10 mmol). The mixture was stirred at room temperature for 0.5 hours under N2 and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to afford (S)-N-(3-(3'-chloro-4- fluoro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2- methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (5.9 mg, 22% yield) as a white solid. MS: m/z found 693 [M+H]+, retention time = 2.29 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 7.93 (d, 1H), 7.75 (d, 1H), 7.40 (t, 1H), 7.32 (d, 1H), 7.18 (d, 1H), 4.60 (t, 1H), 4.49 (t, 1H), 4.09 (s, 3H), 3.96 (s, 3H), 3.95 (s, 2H), 3.85-3.83 (m, 1H), 3.59 (s, 2H), 2.96-2.93 (m, 2H), 2.81-2.76 (m, 4H), 2.71-2.67 (m, 2H), 2.35-2.32 (m, 3H), 2.14 (s, 3H), 2.05-1.98 (m, 2H), 1.86-1.83 (m, 1H). Example 75: 2-(1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)azetidin-3-yl)acetic acid 2-(1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid was prepared in a similar fashion to Example 67, replacing glycine with 2-(azetidin-3-yl)acetic acid. White solid, MS: m/z found 696.2 [M+H]+, retention time = 2.58 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.55 (dd, 1H), 8.30 (s, 1H), 7.92 (d, 1H), 7.78 (d, 1H), 7.56 – 7.43 (m, 2H), 7.23 (dd, 1H), 4.61 (t, 1H), 4.56 – 4.44 (m, 2H), 4.17 (s, 2H), 4.16 – 4.11 (m, 1H), 4.10 (s, 3H), 4.00 (s, 3H), 3.82 (s, 2H), 3.17 (t, 2H), 3.11 (d, 2H), 3.02 – 2.94 (m, 3H), 2.89 (t, 2H), 2.77 (dd, 1H), 2.45 (dd, 1H), 2.18 – 1.99 (m, 2H). Example 76: (R)-1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)pyrrolidine-3-carboxylic acid (R)-1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid was prepared in a similar fashion to Example 67, replacing glycine with (R)-pyrrolidine-3-carboxylic acid. White solid, MS: m/z found 696.2 [M+H]+, retention time = 1.61 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.55 (dd, 1H), 8.32 (s, 1H), 7.99 (d, 1H), 7.79 (d, 1H), 7.57 – 7.41 (m, 2H), 7.23 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.44 (s, 2H), 4.12 (s, 3H), 4.00 (s, 3H), 3.76 (s, 2H), 3.60 (dd, 1H), 3.50 – 3.33 (m, 3H), 3.20 – 3.07 (m, 3H), 2.98 – 2.89 (m, 2H), 2.86 (t, 2H), 2.44 – 2.32 (m, 1H), 2.32 – 2.21 (m, 1H), 2.15 – 1.97 (m, 2H). Example 77: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3- trifluoropropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 3,3,3-Trifluoropropyl 4-methylbenzenesulfonate   To a solution of 3,3,3-trifluoropropan-1-ol (1.8 g, 15.8 mmol) in dichloromethane (20 mL) was added 4-methylbenzene-1-sulfonyl chloride (3.76 g, 19.7 mmol), N,N- dimethylpyridin-4-amine (193 mg, 1.58 mmol) and triethylamine (4.39 mL, 31.6 mmol). The reaction mixture was stirred at room temperature for 40 hours. The mixture was poured into water and extracted with dichloromethane (100 mL). The organic extract was washed with 1 N aqueous HCl solution (40 mL), saturated aqueous sodium bicarbonate solution (80 mL) and brine (80 mL), and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (3.8 g, 89% yield) as an orange oil, which was used in the next step without further purification.1H NMR (400 MHz, CDCl3): δ 7.73 (d, 2H), 7.30 (d, 2H), 4.15 (t, 2H), 2.48-2.40 (m, 2H), 2.39 (s, 3H). (b) Methyl 1-methyl-5-(3,3,3-trifluoropropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate   A mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate hydrochloride salt (1 g, 4.32 mmol), 3,3,3-trifluoropropyl 4- methylbenzenesulfonate (1.74 g, 6.47 mmol), potassium iodide (71.7 mg, 0.43 mmol) and potassium carbonate (2.98 g, 21.6 mmol) in acetonitrile (10 mL) was stirred for 4 hours at 100 °C. After cooling, water was added, and the mixture extracted with ethyl acetate (60 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0- 100% ethyl acetate /petroleum ether) to afford methyl 1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (750 mg, 53% yield) as a yellow solid.1H NMR (400 MHz, CDCl3): δ 3.92 (s, 3H), 3.86 (s, 3H), 3.57 (s, 2H), 2.89-2.82 (m, 4H), 2.70-2.68 (m, 2H), 2.42-2.35 (m, 2H). (c) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(3,3,3- trifluoropropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide   To a cooled (0 °C) solution of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (200 mg, 0.73 mmol) in THF (6 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 1.46 mL, 1.46 mmol) via syringe. The homogeneous solution was allowed to stir for 0.5 hours, and then a solution of methyl 1-methyl-5-(3,3,3-trifluoropropyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate (277 mg, 0.95 mmol) in THF (4 mL) was added via cannula. The solution was allowed to stir for 1 hour at 0 °C, quenched with water (20 mL) and extracted with ethyl acetate (80 mL). The mixture was combined with another batch at 100 mg scale. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-40% ethyl acetate /petroleum ether) to afford N-(2-chloro-3-(2,3- dichloropyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (340 mg, 58% yield) as an orange solid.1H NMR (400 MHz, CDCl3): δ 9.87 (s, 1H), 8.61 (dd, 1H), 8.39 (d, 1H), 7.42 (t, 1H), 7.20 (d, 1H), 6.99 (dd, 1H), 3.99 (s, 3H), 3.61 (s, 2H), 2.91-2.87 (m, 4H), 2.76-2.74 (m, 2H), 2.49-2.38 (m, 2H). (d) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1- methyl-5-(3,3,3-trifluoropropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide   To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-5-(3,3,3- trifluoropropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (260 mg, 0.49 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (153 mg, 0.59 mmol) in 1,4-dioxane / water (5:1 v/v, 12 mL) was added potassium phosphate (311 mg, 1.46 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2- (2′-amino-1,1′-biphenyl)]palladium(II) (38.4 mg, 0.05 mmol) in one portion under N2. The mixture was stirred at 110 °C for 2 hours and combined with another batch at 50 mg scale. Water (20 mL) was added, and the mixture was extracted with ethyl acetate (80 mL). The organic layer was washed with brine (40 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-200% ethyl acetate /petroleum ether) to afford N-(2-chloro-3-(3-chloro-2- (4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide. (254 mg, 69% yield) as a red oil.1H NMR (400 MHz, CDCl3): δ 10.55 (s, 1H), 9.89 (s, 1H), 8.70 (d, 1H), 8.61 (dd, 1H), 7.96 (d, 1H), 7.46-7.41 (m, 3H), 7.30 (s, 1H), 7.06 (dd, 1H), 4.03 (s, 3H), 3.99 (s, 3H), 3.61 (s, 2H), 2.92-2.87 (m, 4H), 2.76-2.75 (m, 2H), 2.49-2.38 (m, 2H). (e) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3- trifluoropropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
Figure imgf000298_0001
To a solution of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamide (230 mg, 0.36 mmol) in dichloromethane / methanol (1:1 v/v, 10 mL) was added (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (71.2 mg, 0.42 mmol) and sodium acetate (89.5 mg, 1.09 mmol). After 2 hours stirring, sodium cyanoborohydride (68.6 mg, 1.09 mmol) was added and the mixture was stirred for 10 hours at room temperature. Upon concentration, the residue was purified by reverse phase HPLC to afford (S)-N-(2- chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (133.3 mg, 49% yield) as a white solid. MS: m/z found 730 [M+H]+, retention time = 2.82 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.50 (dd, 1H), 7.48 (t, 1H), 7.41 (s, 1H), 7.39 (d, 1H), 7.26 (d, 2H), 7.15 (dd, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 3.87 (d, 2H), 3.84-3.81 (m, 1H), 3.58 (s, 2H), 2.94-2.86 (m, 4H), 2.78-2.75 (m, 2H), 2.70-2.62 (m, 2H), 2.55-2.48 (m, 2H), 2.34-2.23 (m, 3H), 1.79-1.76 (m, 1H). Example 78: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 5-(5-fluoropentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxylate hydrochloride salt (0.5 g, 2.16 mmol) and 1-bromo-5-fluoropentane (0.82 g, 4.86 mmol) in acetonitrile (5 mL) was added potassium carbonate (2.68 g, 19.4 mmol) in one portion under N2. The mixture was stirred at 60 °C for 12 hours. The mixture was combined with another batch at 500 mg scale and water (20 mL) was added. The mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with saturated aqueous brine solution (2 x 20 mL), dried with anhydrous sodium sulfate, filtered and concentrated. The crude was purified by normal phase SiO2 chromatography (9-30% ethyl acetate/petroleum ether) to afford methyl 5-(5-fluoropentyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate (0.7 g, 57% yield) as a brown oil. MS: m/z found 284 [M+H]+. (b) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (0.29 g, 1.06 mmol) in THF (5 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 2 mL) in one portion at 0 °C under N2. The mixture was stirred at 0 °C for 0.5 hours and methyl 5-(5-fluoropentyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (0.3 g, 1.06 mmol) in THF (5 mL) was added in one portion. The mixture was stirred at 0 °C for 4.5 hours and water (5 mL) was added to quench the reaction. The mixture was combined with another batch at 420 mg scale. After extraction with ethyl acetate (2 x 10 mL), the combined organic phases were washed with saturated aqueous brine solution (2 x 10 mL), dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by normal phase SiO2 chromatography (9-90% ethyl acetate/petroleum ether) to afford N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (0.74 g, 64% yield) as a brown solid. MS: m/z found 524 [M+H]+; 1H NMR (400 MHz, DMSO-d6): δ 9.97 (s, 1H), 8.57 (d, 1H), 8.44 (d, 1H), 7.61-7.57 (m, 2H), 7.26 (dd, 1H), 4.55 (t, 1H), 4.43 (t, 1H), 3.95 (s, 3H), 3.46 (s, 2H), 2.81-2.79 (m, 2H), 2.75-2.73 (m, 2H), 2.59-2.56 (m, 2H), 1.83-1.56 (m, 6H). (c) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5- (5-fluoropentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(5-fluoropentyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (0.5 g, 0.95 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (0.37 g, 1.43 mmol) in 1,4-dioxane / water mixture (5:1 v/v, 6 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.08 g, 0.1 mmol) and potassium carbonate (0.39 g, 2.86 mmol) in one portion under N2. The mixture was stirred at 110 °C for 6 hours and water (10 mL) was added. The mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed with saturated aqueous brine solution (2 x 10 mL), dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (9-100% ethyl acetate/petroleum ether) to afford N-(2-chloro-3-(3-chloro-2- (4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (0.14 g, 14% yield) as a brown solid. MS: m/z found 624 [M+H]+. (d) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (0.14 g, 0.22 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (0.04 g, 0.29 mmol) in THF / methanol (1:1 v/v, 3 mL) was added sodium acetate (0.06 g, 0.67 mmol) in one portion under N2. The mixture was stirred at room temperature for 12 hours and then sodium cyanoborohydride (0.04 g, 0.67 mmol) was added under N2. The mixture was stirred at room temperature for 1 hour and the mixture was combined with another batch at 80 mg scale. The mixture was purified by reverse phase HPLC twice to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (47.1 mg, 18% yield) as a white solid. MS: m/z found 722 [M+H]+, retention time = 2.91 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.66-8.64 (m, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.30-7.27 (m, 2H), 7.17 (dd, 1H), 4.52 (t, 1H), 4.40 (t, 1H), 4.06-3.99 (m, 3H), 3.95 (s, 3H), 3.89-3.84 (m, 3H), 3.57 (s, 2H), 2.94-2.91 (m, 2H), 2.81-2.78 (m, 2H), 2.75-2.64 (m, 4H), 2.37-2.26 (m, 3H), 1.82-1.67 (m, 5H), 1.53-1.47 (m, 2H). Example 79: 3-((4-(3-Chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2- methoxybenzyl)amino)propanoic acid (a) tert-Butyl 2-((2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate To a mixture of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, step (e)) (300 mg, 0.56 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde (176 mg, 0.67 mmol) in 1,4-dioxane / water (5:1 v/v, 12 mL) was added potassium carbonate (232 mg, 1.68 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (45.6 mg, 0.06 mmol), and then the mixture stirred at 130 °C for 2 hours under N2. Water (10 mL) was added, and mixture extracted into ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-60% ethyl acetate /petroleum ether) to afford tert-butyl 2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridine-5-carboxylate (250 mg, 70% yield) as a white solid. MS: m/z found 636 [M+H]+. (b) 3-((4-(4-(3-(5-(tert-Butoxycarbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2-yl)-2- methoxybenzyl)amino)propanoic acid To a mixture of tert-butyl 2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridine-5-carboxylate (80 mg, 0.126 mmol) and 3-aminopropanoic acid (22.4 mg, 0.25 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (30.9 mg, 0.377 mmol) and the mixture stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (23.7 mg, 0.377 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. Water (10 mL) was then added, and the mixture extracted with dichloromethane (2 x 20 mL). The combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to afford 3- ((4-(4-(3-(5-(tert-butoxycarbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)-2-chlorophenyl)-3-chloropyridin-2-yl)-2-methoxybenzyl)amino)propanoic acid (100 mg, crude). White solid, MS: m/z found 709 [M+H]+. The crude product was used in the next step without further purification. (c) 3-((4-(3-Chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)propanoic acid To a solution of 3-((4-(4-(3-(5-(tert-butoxycarbonyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2-yl)-2- methoxybenzyl)amino)propanoic acid (90 mg, 0.13 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1.29 mL, 17.4 mmol). The solution was stirred at room temperature for 10 min under N2, concentrated under reduced pressure and purified by reverse phase HPLC to afford 3-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2- methoxybenzyl)amino)propanoic acid (24.8 mg, 31% yield) as a white solid. MS: m/z found 609 [M+H]+, retention time = 2.59 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.52 (dd, 1H), 7.54-7.50 (m, 2H), 7.45 (d, 1H), 7.41 (d, 1H), 7.35 (dd, 1H), 7.19 (dd, 1H), 4.29 (s, 2H), 4.12 (s, 2H), 4.07-4.03 (m, 6H), 3.47-3.45 (m, 2H), 3.23 (t, 2H), 2.95- 2.94 (m, 2H), 2.55 (t, 2H). Example 80: (S)-1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)piperidine-3-carboxylic acid (S)-1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid was prepared in a similar fashion to Example 67, replacing glycine with (S)-piperidine-3-carboxylic acid. White solid, MS: m/z found 710.2 [M+H]+, retention time = 1.68 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.55 (d, 1H), 8.42 (s, 1H), 7.96 (d, 1H), 7.80 (d, 1H), 7.51 (t, 2H), 7.23 (d, 1H), 4.62 – 4.56 (m, 1H), 4.47 (t, 1H), 4.37 – 4.19 (m, 2H), 4.13 (s, 3H), 3.99 (s, 3H), 3.66 (s, 2H), 3.52 – 3.33 (m, 2H), 3.19 – 3.04 (m, 2H), 3.05 – 2.95 (m, 2H), 2.91 – 2.75 (m, 4H), 2.75 – 2.65 (m, 1H), 2.15 – 1.72 (m, 6H). Example 81: (S)-3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)butanoic acid (S)-3-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid was prepared in a similar fashion to Example 67, replacing glycine with (S)-3-aminobutanoic acid. White solid, MS: m/z found 684.2 [M+H]+, retention time = 1.64 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.55 (d, 1H), 8.39 (s, 1H), 7.96 (d, 1H), 7.78 (d, 1H), 7.51 (t, 2H), 7.23 (d, 1H), 4.59 (t, 1H), 4.47 (t, 1H), 4.40 – 4.20 (m, 2H), 4.12 (s, 3H), 3.99 (s, 3H), 3.68 (s, 2H), 3.59 – 3.43 (m, 1H), 3.14 – 2.97 (m, 2H), 2.94 – 2.73 (m, 4H), 2.65 – 2.49 (m, 1H), 2.46 – 2.32 (m, 1H), 2.14 – 1.93 (m, 2H), 1.43 (d, 3H). Example 82: 3-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)bicyclo[1.1.1]pentane-1-carboxylic acid 3-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)bicyclo[1.1.1]pentane-1-carboxylic acid was prepared in a similar fashion to Example 67, replacing glycine with 3-aminobicyclo[1.1.1]pentane-1-carboxylic acid. White solid, MS: m/z found 708.2 [M+H]+, retention time = 1.66 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.54 (d, 1H), 8.37 (s, 1H), 7.87 (d, 1H), 7.78 (d, 1H), 7.51 (t, 1H), 7.45 (d, 1H), 7.23 (d, 1H), 4.55 – 4.39 (m, 2H), 4.07 (s, 3H), 4.02 – 3.90 (m, 5H), 3.74 (s, 2H), 3.17 – 3.04 (m, 2H), 2.96 – 2.77 (m, 4H), 2.13 (s, 6H), 2.12 – 1.95 (m, 2H). Example 83: (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid (S)-1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid was prepared in a similar fashion to Example 67, replacing glycine with (S)-3-methylpyrrolidine-3-carboxylic acid. White solid, MS: m/z found 710.2 [M+H]+, retention time = 1.70 min (Method D).1H NMR (400 MHz, Methanol- d4): δ 8.67 (d, 1H), 8.55 (d, 1H), 8.35 (s, 1H), 7.97 (d, 1H), 7.79 (d, 1H), 7.57 – 7.44 (m, 2H), 7.23 (d, 1H), 4.60 (t, 1H), 4.53 – 4.36 (m, 3H), 4.13 (s, 3H), 3.99 (s, 3H), 3.79 – 3.64 (m, 3H), 3.56 – 3.45 (m, 1H), 3.42 – 3.33 (m, 1H), 3.10 – 3.03 (m, 2H), 2.99 (d, 1H), 2.93 – 2.76 (m, 4H), 2.41 (s, 1H), 2.14 – 1.87 (m, 3H), 1.35 (s, 3H). Example 84: 1-(2-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)ethyl)cyclopropane-1-carboxylic acid 1-(2-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)ethyl)cyclopropane-1-carboxylic acid was prepared in a similar fashion to Example 67, replacing glycine with 1-(2-aminoethyl)cyclopropanecarboxylic acid. White solid, MS: m/z found 710.2 [M+H]+, retention time = 1.74 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.55 (dd, 1H), 8.28 (s, 1H), 7.95 (d, 1H), 7.78 (d, 1H), 7.51 (t, 2H), 7.23 (dd, 1H), 4.61 (t, 1H), 4.49 (t, 1H), 4.27 (s, 2H), 4.11 (s, 3H), 4.00 (s, 3H), 3.80 (s, 2H), 3.24 (t, 2H), 3.15 (t, 2H), 2.96 (t, 2H), 2.88 (t, 2H), 2.16 – 1.99 (m, 2H), 1.87 (t, 2H), 1.24 – 1.15 (m, 2H), 0.77 – 0.64 (m, 2H). Example 85: 1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)piperidine-4-carboxylic acid 1-((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-4-carboxylic acid was prepared in a similar fashion to Example 67, replacing glycine with piperidine-4-carboxylic acid. White solid, MS: m/z found 710.2 [M+H]+, retention time = 1.69 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.55 (d, 1H), 8.33 (s, 1H), 7.97 (d, 1H), 7.80 (d, 1H), 7.60 – 7.46 (m, 2H), 7.23 (d, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.24 (s, 2H), 4.10 (s, 3H), 4.00 (s, 3H), 3.73 (s, 2H), 3.44 – 3.36 (m, 2H), 3.11 – 2.79 (m, 7H), 2.55 – 2.42 (m, 1H), 2.19 – 1.79 (m, 7H). Example 86: 4-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)butanoic acid 4-(((3'-Chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid was prepared in a similar fashion to Example 67, replacing glycine with 4-aminobutanoic acid. White solid, MS: m/z found 684.2 [M+H]+, retention time = 1.63 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.55 (dd, 1H), 8.33 (s, 1H), 7.95 (d, 1H), 7.78 (d, 1H), 7.51 (t, 2H), 7.23 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.27 (s, 2H), 4.11 (s, 3H), 3.99 (s, 3H), 3.77 (s, 2H), 3.21 – 3.00 (m, 4H), 2.93 (t, 2H), 2.89 – 2.76 (m, 2H), 2.46 (t, 2H), 2.17 – 1.83 (m, 4H). Example 87: 5-(1-Acetylpiperidin-4-yl)-N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)- 3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl 2-((2-chloro-3-(3'-chloro-5-(hydroxymethyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-5-carboxylate To a solution of tert-butyl 2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine- 5-carboxylate (Example 40, step (c)) (500 mg, 0.78 mmol) in THF / methanol (1:1 v/v, 8 mL) was added sodium borohydride (107 mg, 2.82 mmol) at 0 °C, and then the mixture was stirred at room temperature for 1 hour under N2. The mixture was combined with another twelve batches at the same scale. Water (100 mL) was then added, and the residue was extracted with ethyl acetate (2 x 200 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude was purified by normal phase SiO2 chromatography (0-90% ethyl acetate / petroleum ether) to afford tert-butyl 2-((2-chloro-3-(3'-chloro-5-(hydroxymethyl)-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (4.0 g, 66% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.94 (s, 1H), 8.72 (d, 1H), 8.32-8.30 (m, 1H), 7.89 (d, 1H), 7.77 (d, 1H), 7.53 (t, 1H), 7.46 (d, 1H), 7.29 (dd, 1H), 5.31 (s, 1H), 4.54 (s, 2H), 4.39 (s, 2H), 3.95 (s, 3H), 3.92 (s, 3H), 3.71-3.66 (m, 2H), 2.72- 2.69 (m, 2H), 1.43 (s, 9H). (b) N-(2-Chloro-3-(3'-chloro-5-(hydroxymethyl)-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of tert-butyl 2-((2-chloro-3-(3'-chloro-5-(hydroxymethyl)-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-5-carboxylate (3.5 g, 5.47 mmol) in dichloromethane (30 mL) was added trifluoroacetic acid (10 mL, 135 mmol). The mixture was stirred at room temperature for 1 hour under N2 and concentrated under reduced pressure. The crude mixture was combined with another batch at the 500 mg scale, neutralized with saturated sodium bicarbonate solution and extracted with dichloromethane (2 x 100 mL). The combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to afford N-(2-chloro-3-(3'-chloro-5-(hydroxymethyl)-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (3.7 g, crude, used directly in the next step) as a yellow solid. MS: m/z found 539 [M+H]+. (c) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-5-(hydroxymethyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3'-chloro-5-(hydroxymethyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (1.6 g, 2.97 mmol) and 1-acetylpiperidin-4-one (0.84 g, 5.93 mmol) in dichloromethane / methanol (1:1 v/v, 50 mL) was added titanium ethoxide (2.03 g, 8.90 mmol). The mixture was stirred at room temperature for 1.5 hours under N2. Then sodium cyanoborohydride (0.56 g, 8.90 mmol) was added and the mixture was stirred for another 0.5 hours under N2. The mixture was combined with another batch at 2.1 g scale. Water (100 mL) was added, and the residue was extracted with dichloromethane (2 x 200 mL). The combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-50% methanol / ethyl acetate) to afford 5-(1-acetylpiperidin-4-yl)-N-(2- chloro-3-(3'-chloro-5-(hydroxymethyl)-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide as a white solid. MS: m/z found 664 [M+H]+. (d) 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide
To a solution of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-5- (hydroxymethyl)-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (1.0 g, 1.50 mmol) in dichloromethane (15 mL) was added manganese dioxide (1.96 g, 22.6 mmol). The mixture was stirred at 45 °C for 24 hours under N2 and combined with another batch at 0.5 g scale. The reaction mixture was filtered to give the filtrate, which was concentrated and purified by normal phase SiO2 chromatography (0-40% methanol / ethyl acetate) to afford 5-(1-acetylpiperidin-4-yl)-N-(2- chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (700 mg) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H), 9.92 (s, 1H), 8.78 (d, 1H), 8.37 (dd, 1H), 8.28 (d, 1H), 7.82 (d, 1H), 7.60 (d, 1H), 7.53 (t, 1H), 7.29 (dd, 1H), 4.41-4.38 (m, 1H), 4.09 (s, 3H), 3.90 (s, 3H), 3.86-3.83 (m, 1H), 3.55 (s, 2H), 3.05-2.99 (m, 1H), 2.87-2.84 (m, 2H), 2.76- 2.71 (m, 1H), 2.67-2.65 (m, 2H), 2.57-2.54 (m, 1H), 1.84-1.77 (m, 2H), 1.54-1.48 (m, 1H), 1.35-1.26 (m, 1H). (e) 5-(1-Acetylpiperidin-4-yl)-N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'- chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-5-formyl-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (50 mg, 0.076 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one (22 mg, 0.15 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (19 mg, 0.226 mmol). The reaction mixture was stirred at room temperature for 1.5 hours under N2 and then sodium cyanoborohydride (14.2 mg, 0.226 mmol) was added. After stirring for 0.5 hours under N2, the mixture was concentrated and purified by reverse phase HPLC to afford 5-(1-acetylpiperidin-4-yl)-N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)- 3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (13.2 mg, 21% yield) as a white solid. MS: m/z found 788 [M+H]+, retention time = 2.53 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.56 (dd, 1H), 7.85 (d, 1H), 7.80 (d, 1H), 7.52 (t, 1H), 7.46 (d, 1H), 7.24 (dd, 1H), 4.64-4.60 (m, 1H), 4.52-4.48 (m, 1H), 4.07 (s, 3H), 4.06-4.04 (m, 2H), 4.00 (s, 3H), 3.94 (s, 2H), 3.71 (s, 2H), 3.17-3.14 (m, 2H), 3.04-3.01 (m, 2H), 2.87-2.68 (m, 6H), 2.13 (s, 3H), 2.12 (s, 3H), 2.10-1.99 (m, 4H), 1.64-1.31 (m, 4H). Example 88: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 2-Cyclopropoxyethyl trifluoromethanesulfonate To a mixture of trifluoromethanesulfonic anhydride (2.2 g, 7.78 mmol) and 2,6- dimethylpyridine (0.83 g, 7.78 mmol) in dichloromethane (10 mL) was added a solution of 2- cyclopropoxyethanol (0.53 g, 5.19 mmol) in dichloromethane (10 mL) at 0 °C and the reaction mixture was stirred at 0 °C for 1 hour under N2. The mixture was then washed with saturated aqueous solution of sodium chloride and 1.0 N aqueous HCl (3:1, 60 mL). The organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to afford 2-cyclopropoxyethyl trifluoromethanesulfonate (1.1 g, crude) as a brown oil. The crude product was used in the next step without further purification. (b) Methyl 5-(2-cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine-2- carboxylate (0.45 g, 2.31 mmol) and 2-cyclopropoxyethyl trifluoromethanesulfonate (1.08 g, 4.61 mmol) in acetonitrile (20 mL) was added potassium carbonate (0.96 g, 6.92 mmol). The mixture was stirred at room temperature for 1 hour under N2 and concentrated. Water (30 mL) was then added, and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-30% methanol / ethyl acetate) to afford methyl 5-(2-cyclopropoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (250 mg, 38% yield) as a brown oil.1H NMR (400 MHz, DMSO-d6): δ 3.79 (s, 3H), 3.77 (s, 3H), 3.61-3.58 (m, 2H), 3.43-3.41 (m, 2H), 2.80-2.77 (m, 2H), 2.70-2.62 (m, 2H), 1.20-1.16 (m, 1H), 0.50-0.42 (m, 4H). (c) N-(2-Chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (210 mg, 0.77 mmol) in THF (3 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 1.54 mL, 1.54 mmol) at 0 °C and then the mixture was stirred at 0 °C for 0.5 hours under N2. Methyl 5-(2- cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (214 mg, 0.77 mmol) in THF (3 mL) was then added and the mixture was stirred at 0 °C for 0.5 hours under N2. Water (20 mL) was added, and the mixture extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and the residue purified by normal phase SiO2 chromatography (0-100% ethyl acetate / petroleum ether) to afford N-(2-chloro-3-(2,3- dichloropyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (240 mg, 60% yield) as a yellow oil.1H NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 8.52 (d, 1H), 8.37 (dd, 1H), 7.56-7.52 (m, 2H), 7.21 (dd, 1H), 3.89 (s, 3H), 3.63-3.60 (m, 2H), 3.50-3.48 (m, 2H), 2.81-2.80 (m, 2H), 2.72-2.67 (m, 4H), 1.20-1.14 (m, 4H), 0.50-0.41 (m, 3H). (d) N-(2-Chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)-5-(2- cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide To a mixture of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-5-(2- cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (220 mg, 0.42 mmol) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzaldehyde (166 mg, 0.63 mmol) in 1,4-dioxane / water (5:1 v/v, 12 mL) was added potassium carbonate (175 mg, 1.27 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (34.5 mg, 0.04 mmol). The reaction mixture was then stirred at 130 °C for 1 hour under N2. Water (10 mL) was then added, and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0- 100% ethyl acetate / petroleum ether) to afford N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (45 mg, 17% yield) as a white solid. MS: m/z found 620 [M+H]+. (e) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamide (40 mg, 0.065 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (19.4 mg, 0.13 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (15.9 mg, 0.193 mmol). The reaction mixture was stirred at room temperature for 0.5 hours under N2 and then sodium cyanoborohydride (12.1 mg, 0.193 mmol) was added. The mixture was stirred at room temperature for 0.5 hours under N2, concentrated and purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2- cyclopropoxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (11.9 mg, 24% yield) as a white solid. MS: m/z found 718 [M+H]+, retention time = 2.92 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.52 (dd, 1H), 7.51 (t, 1H), 7.43-7.41 (m, 2H), 7.30-7.28 (m, 2H), 7.17 (dd, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.90-3.83 (m, 3H), 3.77-3.74 (m, 2H), 3.62 (s, 2H), 3.38-3.33 (m, 1H), 2.98-2.95 (m, 2H), 2.85-2.83 (m, 2H), 2.80-2.77 (m, 2H), 2.71-2.68 (m, 2H), 2.36-2.33 (m, 3H), 1.85-1.77 (m, 1H), 0.59-0.49 (m, 4H). Example 89: (S)-4-((4-(3-Chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3- hydroxybutanoic acid (S)-4-((4-(3-Chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid was prepared in a similar fashion to Example 79, replacing 3-aminopropanoic acid with (S)-4-amino-3-hydroxybutanoic acid in step (b). White solid, MS: m/z found 639 [M+H]+, retention time = 2.60 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.68 (d, 1H), 8.53 (d, 1H), 7.55-7.51 (m, 2H), 7.45 (d, 1H), 7.41 (s, 1H), 7.37 (d, 1H), 7.20 (d, 1H), 4.33 (s, 2H), 4.23-4.21 (s, 1H), 4.15 (s, 2H), 4.06 (s, 3H), 4.01 (s, 3H), 3.50-3.47 (m, 2H), 3.22-3.19 (m, 1H), 3.06-2.95 (m, 3H), 2.49-2.47 (m, 2H). Example 90: (4-(3-Chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)glycine (4-(3-Chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)glycine was prepared in a similar fashion to Example 79, replacing 3-aminopropanoic acid with glycine in step (b). White solid, MS: m/z found 595 [M+H]+, retention time = 2.52 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, 1H), 8.52 (dd, 1H), 7.53-7.49 (m, 2H), 7.45 (d, 1H), 7.40 (s, 1H), 7.36 (dd, 1H), 7.18 (dd, 1H), 4.31 (s, 2H), 4.02 (s, 3H), 3.99 (s, 3H), 3.85 (s, 2H), 3.52 (s, 2H), 3.18 (t, 2H), 2.77-2.74 (m, 2H). Example 91: 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo- 2,6-diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-(1-Acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 87, replacing 1-(4-aminopiperidin-1-yl)ethan-1-one with 2,6-diazaspiro[3.4]octan-7-one in step (e). White solid, MS: m/z found 772 [M+H]+, retention time = 2.38 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.56 (dd, 1H), 7.80-7.78 (m, 1H), 7.52 (t, 1H), 7.44 (d, 1H), 7.24 (dd, 1H), 4.64-4.59 (m, 1H), 4.05 (s, 3H), 4.01-3.99 (m, 4H), 3.83 (s, 2H), 3.72 (s, 2H), 3.62 (s, 2H), 3.54-3.50 (m, 4H), 3.20-3.17 (m, 1H), 3.05-3.03 (m, 2H), 2.92-2.89 (m, 1H), 2.80-2.77 (m, 2H), 2.70-2.64 (m, 1H), 2.62 (s, 2H), 2.13 (s, 3H), 2.06- 1.97 (m, 2H), 1.67-1.49 (m, 2H). Example 92: (S)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (a) 5-Acetyl-N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 1, step (f)) (180.0 mg, 0.41 mmol) in dichloromethane (5 mL) was added acetic anhydride (80 uL, 0.82 mmol) and N,N- diisopropylethylamine (0.36 mL, 2.06 mmol) at room temperature. The mixture was stirred at room temperature for 30 min, completion of the reaction was confirmed by UPLC-MS. Then, the mixture was poured onto ice, extracted with dichloromethane (2 x 20 mL). The combined organic layers were washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by ISCO on silica gel by eluting with 50% dichloromethane in hexanes, 100% dichloromethane, followed by 5% methanol in dichloromethane to elute the desired product. Evaporated the product containing fractions to obtain the desired compound 5-acetyl-N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (170.0 mg, 86.2% yield) as off-white fluffy solid. MS: m/z found 478 [M+H]+. (b) 5-Acetyl-N-(2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide: To a mixture of 5-acetyl-N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (180.0 mg, 0.38 mmol), 2- methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (147.8 mg, 0.56 mmol), in 1,4-dioxane / water (5:1, 6 mL) was added potassium carbonate (155.9 mg, 1.13 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (30.7 mg, 0.04 mmol), then the mixture stirred at 130 °C for 3.5 hours under N2. Completion was confirmed by UPLC-MS analysis, water (10 mL) was then added and the mixture extracted with ethyl acetate (2 x 20mL). The combined organic phases were dried over anhydrous Sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography by eluting with 50% dichloromethane in hexanes, 100% dichloromethane followed by 5% methanol in dichloromethane to get the desired 5-acetyl-N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (105.0 mg, 48.3%) as pale pink fluffy solid. MS: m/z found 578 [M+H]+. (c) (S)-5-Acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide: To a mixture of 5-acetyl-N-(2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (100.0 mg, 0.17 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one- hydrochloride (52.1 mg, 0.35 mmol) in dichloromethane/methanol (1:1, 6 mL) was added sodium acetate (42.5 mg, 0.52 mmol) and then the mixture was stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (32.6 mg, 0.52 mmol) was then added and the mixture was stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). The organic layer was evaporated and the residue was purified by reverse phase HPLC to afford (S)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (49.0 mg, 41.9%) as a white solid.1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.51 (ddd, 1H), 7.49 (ddd, 1H), 7.44 – 7.37 (m, 2H), 7.30 – 7.23 (m, 2H), 7.16 (dd, 1H), 4.58 (d, 2H), 3.98 (d, 3H), 4.00 – 3.90 (m, 1H), 3.92 (s, 3H), 3.87 (dd, 3H), 3.88 – 3.77 (m, 1H), 2.84 (t, 1H), 2.74 (t, 1H), 2.74 – 2.61 (m, 2H), 2.33 (dd, 1H), 2.34 – 2.21 (m, 2H), 2.20 (d, 3H), 1.85 – 1.72 (m, 1H). MS: m/z found 676 [M+H]+ , retention time = 3.80 min (Method A). Example 93: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl (2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-oxoethyl)carbamate To a solution of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (50.0 mg, 0.11 mmol), (tert- butoxycarbonyl)glycine (30.1 mg, 0.17 mmol) in dichloromethane (5 mL) was added HATU (65.3 mg, 0.17 mmol), and N,N-Diisopropylethylamine (0.06 mL, 44.4 mg, 0.34 mmol) at room temperature. The mixture was stirred for 1h and observed completion by UPLC-MS analysis. After completion, the mixture was poured into water (10 mL) and extracted with dichloromethane (2 x 10 mL). The combined organic layer was washed with brine (5 mL) and dried over anhydrous sodium sulfate. Evaporated the solvent, and the crude mixture was purified by ISCO on silica gel by sequential elution with 20% ethyl acetate in hexane, 50% ethyl acetate in hexanes followed by 100% ethyl acetate to get the desired product. Evaporated the compound containing fractions to obtain tert-butyl (2-(2-((2-chloro-3-(2,3- dichloropyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-2-oxoethyl)carbamate (34.0mg, 50.0%) as an off-white fluffy solid. MS: m/z found 593 [M+H]+. (b) tert-Butyl (2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2- oxoethyl)carbamate To a mixture of tert-butyl (2-(2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2- oxoethyl)carbamate (150.0 mg, 0.25 mmol), 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzaldehyde (99.3 mg, 0.38 mmol), in 1,4-dioxane/water (5:1, 6 mL) was added potassium carbonate (104.7 mg, 0.76 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (20.6 mg, 0.03 mmol) and then the mixture stirred at 130 °C for 3.5 hours under N2. Water (10 mL) was then added, and the mixture extracted with ethyl acetate (2 x 20mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography by eluting with 50% dichloromethane in hexanes, 100% dichloromethane, followed by 5% methanol in dichloromethane to afford tert-butyl (2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)-2-oxoethyl)carbamate (90.0 mg, 51.4%) as off-white fluffy solid. MS: m/z found 693 [M+H]+. (c) tert-Butyl (S)-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl) methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-oxoethyl)carbamate To a mixture of tert-butyl (2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)-2-oxoethyl)carbamate (80.0 mg, 0.12 mmol), (S)-5- (aminomethyl)pyrrolidin-2-one-hydrochloride (34.7 mg, 0.23 mmol) in dichloromethane/methanol (1:1, 6 mL) was added sodium acetate (28.4 mg, 0.35 mmol) and then the mixture was stirred at room temperature for 1 hours under N2. Sodium cyanoborohydride (21.7 mg, 0.35 mmol) was then added and the mixture was stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). The organic layer was evaporated to get the crude compound, which was used in next step without further purification. MS: m/z found 791 [M+H]+. (d) (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide A mixture of tert-butyl (S)-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl) methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-oxoethyl)carbamate (35 mg, 0.04 mmol) in Dichloromethane/trifluoroacetic acid (1:1, 4 mL) was added and then the mixture was stirred at room temperature for 0.5 hours under N2. Completion of the reaction was confirmed by UPLC-MS, and after completion, the mixture was concentrated to get the crude mixture. The crude compound was dissolved in methanol (5 mL) and purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide (18.20mg, 59.5%) as white fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.55 – 8.42 (m, 1H), 7.49 (t, 1H), 7.45 – 7.36 (m, 2H), 7.34 – 7.23 (m, 2H), 7.16 (dd, 1H), 4.62 (s, 1H), 4.47 (s, 1H), 3.98 (s, 4H), 3.92 (s, 3H), 3.90 – 3.71 (m, 3H), 3.64 (d, 2H), 2.96 – 2.56 (m, 4H), 2.49 – 2.14 (m, 3H), 1.77 (dt, 1H). MS: m/z found 691 [M+H]+, retention time = 2.71 min (Method A). Example 94: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93 (steps (a) to (c)), replacing (tert-butoxycarbonyl)glycine with 2-methoxyacetic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (dd, 1H), 8.51 (td, 1H), 7.49 (td, 1H), 7.45 – 7.35 (m, 2H), 7.30 – 7.22 (m, 2H), 7.16 (ddd, 1H), 4.55 (d, 2H), 4.25 (d, 2H), 3.98 (d, 3H), 3.92 (s, 3H), 3.89 – 3.80 (m, 4H), 3.48 – 3.36 (m, 3H), 2.83 (t, 1H), 2.78 – 2.70 (m, 1H), 2.66 (m, 2H), 2.40 – 2.13 (m, 3H), 1.87 – 1.73 (m, 1H). MS: m/z found 706 [M+H]+, retention time = 3.30 min (Method A). Example 95: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of (S)-5-(2-((tert-butyldimethylsilyl)oxy)acetyl)-N-(2-chloro-3-(3- chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide [prepared in a similar fashion to Example 93 (steps (a) to (c)), replacing (tert-butoxycarbonyl)glycine with 2-((tert-butyldimethylsilyl)oxy)acetic acid in step (a)] (30.0 mg, 0.04 mmol) in THF was added 1.0 M tetrabutylammonium fluoride solution in tetrahydrofuran (0.11 mL, 0.11 mmol), and the mixture was stirred at room temperature for 15 min. Completion of the reaction was confirmed by UPLC-MS, then, the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane (20 mL) and washed with aqueous sodium bicarbonate (5 mL), separated the layers and the solvent was removed under reduced pressure. The crude compound was purified by reverse-phase HPLC to afford (S)-N-(2-chloro-3-(3-chloro-2-(3- methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2- hydroxyacetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (4.10mg, 14.8%) as an off-white solid.1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.56 – 8.45 (m, 1H), 7.49 (t, 1H), 7.45 – 7.38 (m, 2H), 7.26 (dd, 2H), 7.16 (dd, 1H), 4.61 (s, 1H), 4.46 (s, 1H), 4.36 (s, 1H), 4.29 (s, 1H), 3.98 (s, 4H), 3.93 (s, 3H), 3.87 (d, 2H), 3.80 (dt, 2H), 2.82 (d, 1H), 2.78 (d, 1H), 2.74 – 2.61 (m, 2H), 2.42 – 2.19 (m, 3H). MS: m/z found 596 [M+H]+, retention time = 3.11 min (Method A). Example 96: 3-(((2'-(3-(5-(1-Acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)propanoic acid A mixture of 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-5-formyl-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide (Example 87, step (d)) (40 mg, 0.06 mmol), 3-aminopropanoic acid (11 mg, 0.12 mmol) and acetic acid (4 uL, 4 mg, 0.06 mmol) in dichloromethane/methanol (1:1 v/v) was stirred for 1 hour at room temperature and sodium cyanoborohydride (8 mg, 0.12 mmol) was added. The mixture was stirred for an additional 30 min, quenched with water, and directly purified by preparative HPLC to give the product as TFA salt. White solid, MS: m/z found 735.3 [M+H]+, retention time = 1.54 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.72 – 8.64 (m, 1H), 8.59 – 8.50 (m, 1H), 7.96 (d, 1H), 7.78 (d, 1H), 7.57 – 7.45 (m, 2H), 7.25 (dd, 1H), 4.76 (d, 1H), 4.44 (s, 2H), 4.34 (s, 2H), 4.19 – 4.09 (m, 4H), 4.04 (s, 3H), 3.75 (t, 1H), 3.36 (t, 2H), 3.33 – 3.31 (m, 17H), 3.22 (t, 1H), 3.17 – 3.09 (m, 2H), 2.82 (t, 2H), 2.69 (t, 1H), 2.30 – 2.18 (m, 2H), 2.15 (s, 3H), 1.92 – 1.79 (m, 1H), 1.77 – 1.64 (m, 1H). Example 97: (R)-1-((2'-(3-(5-(1-Acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)pyrrolidine-3-carboxylic acid (R)-1-((2'-(3-(5-(1-Acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)pyrrolidine-3-carboxylic acid was prepared in a similar fashion to Example 96, replacing 3-aminopropanoic acid with (R)-pyrrolidine-3-carboxylic acid. White solid, MS: m/z found 761.3 [M+H]+, retention time = 1.58 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.68 (d, 1H), 8.59 – 8.50 (m, 1H), 8.01 (d, 1H), 7.79 (d, 1H), 7.59 – 7.45 (m, 2H), 7.25 (d, 1H), 4.75 (d, 1H), 4.52 (s, 2H), 4.43 (s, 2H), 4.12 (s, 4H), 4.04 (s, 3H), 3.94 – 3.35 (m, 8H), 3.22 (t, 1H), 3.17 – 3.05 (m, 2H), 2.69 (t, 1H), 2.58 – 2.32 (m, 2H), 2.30 – 2.18 (m, 2H), 2.14 (s, 3H), 1.92 – 1.78 (m, 1H), 1.79 – 1.61 (m, 1H). Example 98: 2-(1-((2'-(3-(5-(1-Acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)azetidin-3-yl)acetic acid 2-(1-((2'-(3-(5-(1-Acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid was prepared in a similar fashion to Example 96, replacing 3-aminopropanoic acid with 2-(azetidin-3-yl)acetic acid. White solid, MS: m/z found 761.3 [M+H]+, retention time = 1.58 min (Method D).1H NMR (400 MHz, Methanol- d4): δ 8.68 (d, 1H), 8.61 – 8.47 (m, 1H), 7.97 (d, 1H), 7.78 (d, 1H), 7.53 (dt, 2H), 7.34 – 7.18 (m, 1H), 4.76 (d, 1H), 4.53 (t, 1H), 4.49 – 4.39 (m, 2H), 4.38 – 4.24 (m, 2H), 4.21 – 4.06 (m, 5H), 4.04 (s, 3H), 3.75 (t, 1H), 3.40 – 3.30 (m, 3H), 3.27 – 3.00 (m, 5H), 2.81 (dd, 1H), 2.76 – 2.61 (m, 1H), 2.49 (dd, 1H), 2.31 – 2.18 (m, 2H), 2.14 (s, 3H), 1.93 – 1.78 (m, 1H), 1.79 – 1.63 (m, 1H). Example 99: (R)-4-(((2'-(3-(5-(1-Acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)-3-hydroxybutanoic acid (R)-4-(((2'-(3-(5-(1-Acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)amino)-3-hydroxybutanoic acid was prepared in a similar fashion to Example 96, replacing 3-aminopropanoic acid with (R)-4-amino-3-hydroxy-butanoic acid. White solid, MS: m/z found 765.3 [M+H]+, retention time = 1.51 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.68 (dd, 1H), 8.55 (d, 1H), 7.96 (d, 1H), 7.79 (d, 1H), 7.59 – 7.47 (m, 2H), 7.25 (d, 1H), 4.76 (d, 1H), 4.44 (s, 2H), 4.41 – 4.27 (m, 3H), 4.21 – 4.09 (m, 4H), 4.04 (s, 3H), 3.75 (t, 1H), 3.30 – 3.27 (m, 3H), 3.22 (t, 1H), 3.17 – 3.02 (m, 3H), 2.69 (t, 1H), 2.58 (d, 2H), 2.31 – 2.18 (m, 3H), 2.14 (s, 3H), 1.93 – 1.79 (m, 1H), 1.77 – 1.64 (m, 1H). Example 100: Methyl (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate (a) Methyl 2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate To a solution of N-(2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (40.0 mg, 0.09 mmol) in acetonitrile (3 mL) was added N,N-diisopropylethylamine (0.03 mL, 23.7 mg, 0.18 mmol), and methyl 2- bromoacetate (28.0 mg, 0.18 mmol) at room temperature for 30 min. Completion was observed by UPLC-MS analysis. After completion, water (10 mL) was added, and the mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The crude compound was purified by ISCO on silica gel by sequential elution with 10% ethyl acetate in hexanes, 50% ethyl acetate in hexanes followed by ethyl acetate to get the desired compound Methyl 2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate (32.00mg, 68.7%) pale brown fluffy solid. MS: m/z found 508 [M+H]+. (b) Methyl 2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)acetate To a mixture of methyl 2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate (30.0 mg, 0.06 mmol), 2- methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (18.5 mg, 0.07 mmol) in 1,4-dioxane (5 mL)/water (1 mL) was added, sodium carbonate (12.5 mg, 0.12 mmol) and Tetrakis(triphenylphosphine)palladium(0) (13.6 mg, 0.01 mmol) then the mixture was stirred at 120 °C for 1.5 hours under N2. Completion was confirmed by UPLC-MS analysis, then water (10 mL) was added, and the mixture extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sulfate, filtered, and concentrated under reduced pressure. The crude compound was used directly in the next step. MS: m/z found 608 [M+H]+. (c) Methyl 2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)acetate To a mixture of methyl 2-(2-((2-chloro-3-(3-chloro-2-(4-formyl-3-ethoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate (30.0 mg, 0.05 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one-hydrochloride (14.8 mg, 0.10 mmol) in dichloromethane/methanol (1:1, 4 mL) was added sodium acetate (12.1 mg, 0.15 mmol) and then the mixture was stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (9.3 mg, 0.15 mmol) was then added and the mixture was stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). The organic layer was evaporated and the residue was purified by reverse phase HPLC to afford methyl (S)-2- (2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate (11.0 mg, 31.6%).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.50 (dd, 1H), 7.49 (dd, 1H), 7.45 – 7.37 (m, 2H), 7.31 – 7.22 (m, 2H), 7.15 (dd, 1H), 3.95 (d, 7H), 3.90 – 3.80 (m, 1H), 3.73 (s, 3H), 3.68 (d, 2H), 3.54 (s, 2H), 3.02 (t, 2H), 2.76 (dt, 4H), 2.37 – 2.21 (m, 2H), 1.80 (s, 1H), 1.60 (s, 1H). MS: m/z found 706 [M+H]+, retention time = 2.64 min (Method A). Example 101: (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid A mixture of methyl (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate (Example 100) (30.0 mg, 0.049 mmol) in methanol (1 mL) was added lithium hydroxide monohydarate (1.7 mg, 0.04 mmol) and then the mixture was stirred at room temperature for 30 min. Completion of the reaction was confirmed by UPLC-MS. The mixture was concentrated, and the residue was purified by reverse phase HPLC to afford (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid (9.2 mg, 27%).1H NMR (400 MHz, Methanol-d4): δ 8.67 (d, J = 4.9 Hz, 1H), 8.50 (dd, J = 8.3, 1.5 Hz, 1H), 7.60 – 7.47 (m, 2H), 7.45 (d, J = 4.9 Hz, 1H), 7.44 – 7.31 (m, 3H), 7.18 (dd, J = 7.7, 1.6 Hz, 1H), 4.55 – 4.24 (m, 5H), 4.14 (s, 2H), 4.02 (d, J = 8.9 Hz, 6H), 3.76 (t, J = 6.1 Hz, 2H), 3.23 (dd, J = 6.1, 3.3 Hz, 2H), 3.16 – 3.09 (m, 3H), 3.03 – 2.66 (m, 1H), 2.57 – 2.30 (m, 3H), 1.98 – 1.85 (m, 1H). MS: m/z found 692 [M+H]+, retention time = 2.53 min (Method A). Example 102: (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid in a similar fashion to Example 100, replacing methyl 2-bromoacetate with 3-bromo-2,2-dimethylpropanoic acid in step (a). White solid.1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.50 (dd, 1H), 7.61 – 7.48 (m, 2H), 7.45 (dd, 1H), 7.43 – 7.30 (m, 2H), 7.19 (ddd, 1H), 4.64 – 4.19 (m, 4H), 4.23 – 3.88 (m, 6H), 3.81 (t, 2H), 3.45 (s, 2H), 3.26 – 3.01 (m, 4H), 2.64 – 2.25 (m, 3H), 2.10 – 1.82 (m, 1H), 1.39 (s, 7H). MS: m/z found 734 [M+H]+, retention time = 2.71 min (Method A). Example 103: (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with methyl 3-bromopropanoate in step (a). White fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.51 (ddd, 1H), 7.60 – 7.47 (m, 2H), 7.47 – 7.34 (m, 3H), 7.19 (ddd, 1H), 4.62 – 4.24 (m, 4H), 4.03 (d, 3H), 4.01 (s, 3H), 3.77 (d, 2H), 3.62 (t, 2H), 3.23 (dd, 2H), 3.18 – 3.03 (m, 2H), 2.94 (t, 2H), 2.51 – 2.29 (m, 3H), 1.98 – 1.85 (m, 1H). MS: m/z found 706 [M+H]+, retention time = 2.54 min (Method A). Example 104: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1- yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2-(pyrrolidin-1-yl)acetic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.57 –8.45 (m, 1H), 7.62 –7.45 (m, 1H), 7.43 –7.35 (m, 2H), 7.26 (dd, 2H), 7.16 (dd, 1H), 4.60 (d, 2H), 3.98 (d, 3H), 3.93 (s, 2H), 3.91 –3.80 (m, 3H), 3.57 (d, 2H), 2.96 –2.58 (m, 8H), 2.47 –2.18 (m, 2H), 2.01 –1.73 (m, 1H), 1.51 –1.20 (m, 6H). MS: m/z found 745 [M+H]+, retention time = 2.81 min (Method A). Example 105: (S)-N-(3-(5-((7-Acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl (S)-7-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)-2,7-diazaspiro[4.4]nonane-2-carboxylate To a mixture of N-(2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (Example 35, step (d)) (0.08 g, 0.13 mmol), and tert-butyl (S)-2,7- diazaspiro[4.4]nonane-2-carboxylate (0.06 g, 0.27 mmol), in THF / methanol (1:1 v/v, 10 mL) was added acetic acid (0.02 g, 0.27 mmol) and 4 Å molecular sieve (1 g) and the mixture stirred at room temperature overnight. Sodium cyanoborohydride (0.02 g, 0.33 mmol) was then added and the mixture was stirred at room temperature for 1 hour. The reaction was quenched by addition of water (1 mL), diluted with ethyl acetate (50 mL), and washed with saturated aqueous brine solution (1 x 30 mL). The aqueous layer was back extracted with extracted with ethyl acetate (3 x 30 mL), and then the combined organic phases dried over sodium sulfate, filtered and concentrated under reduced pressure to give tert-butyl (S)-7-((3'- chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-2,7- diazaspiro[4.4]nonane-2-carboxylate (0.1 g, 93% crude yield). MS: m/z found 807 [M+H] +. The crude product was used in the next reaction without further purification. (b) (S)-N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of tert-butyl (S)-7-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)-2,7-diazaspiro[4.4]nonane-2-carboxylate (0.10 g, 0.12 mmol) in dichloromethane (6 mL) was added trifluoroacetic acid (2 mL) and the reaction stirred at room temp for 30 min, then evaporated under reduced pressure, and dried on high vac pump for 2 hr. MS: m/z found 707 [M+H]+. To the resulting trifluoroacetate salt was added potassium carbonate (0.12 g, 0.89 mmol), and reaction was purged with N2 for 5 minutes. Dry acetonitrile (3 mL) was added, followed by acetyl chloride (0.05 g, 0.64 mmol) and the reaction stirred at 90oC for 2 hours, then filtered, and evaporated under reduced pressure. The residue was purified by reverse phase HPLC (with 0.05% Formic acid modifier). Fractions containing product were concentrated to remove acetonitrile, then the aqueous phase was basified to pH 8 with 5% aqueous sodium carbonate and extracted with ethyl acetate (5 x 5 ml). The combined organic phases were evaporated, then a small amount of water added, and the material lyophilized to give (S)-N-(3-(5-((7-acetyl-2,7- diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (20.1 mg, 21% yield) as a white solid (free base). MS: m/z found 749 [M+H]+, retention time = 1.61 min (Method D). 1H NMR (400 MHz, Methanol-d4): δ 8.59 (d, 1H), 8.51 (dd, 1H), 7.84 – 7.70 (m, 2H), 7.46 (t, 1H), 7.40 (dd, 1H), 7.18 (dd, 1H), 4.54 (t, 1H), 4.42 (t, 1H), 3.97 (d, 6H), 3.69 (d, 2H), 3.52 (s, 3H), 3.41 – 3.26 (m, 5H), 2.88 (t, 2H), 2.81 – 2.65 (m, 6H), 2.64 – 2.52 (m, 2H), 2.06 – 1.98 (m, 4H), 1.96 – 1.75 (m, 3H). Example 106: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine- 4-carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 1- (2-hydroxyethyl)piperidine-4-carboxylic acid white solid in step (a).1H NMR (400 MHz, Methanol-d4) δ 8.63 (dd, 1H), 8.59 – 8.41 (m, 1H), 7.49 (td, 1H), 7.45 – 7.33 (m, 2H), 7.26 (d, 2H), 7.16 (dd, 1H), 4.61 (d, 2H), 3.98 (d, 3H), 3.92 (s, 4H), 3.87 (d, 2H), 3.85 – 3.80 (m, 1H), 3.67 (dt, 2H), 3.02 (t, 2H), 2.95 – 2.70 (m, 2H), 2.72 – 2.62 (m, 2H), 2.53 (dt, 6.2 Hz, 2H), 2.40 – 2.10 (m, 4H), 1.92 – 1.65 (m, 5H). MS: m/z found 789 [M+H]+, retention time = 2.80 min (Method A). Example 107: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2-(4-acetylpiperazin-1- yl)acetic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.58 –8.44 (m, 1H), 7.55 – 7.44 (m, 1H), 7.46 – 7.35 (m, 2H), 7.33 – 7.22 (m, 2H), 7.16 (dd, 1H), 4.65 (d, 2H), 3.99 (d, 3H), 3.93 (d, 4H), 3.88 (d, 1H), 3.84 (d, 1H), 3.71 – 3.41 (m, 3H), 2.88 (s, 1H), 2.77 (s, 1H), 2.68 (t, 2H), 2.57 – 2.40 (m, 4H), 2.37 – 2.21 (m, 2H), 2.07 (d, 2H), 1.78 (dd, 1H). MS: m/z found 802 [M+H]+, retention time = 2.69 min (Method A). Example 108: N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with methyl-L-proline white solid in step (a).1H NMR (400 MHz, Methanol-d4): δ 8.70 – 8.64 (m, 1H), 8.57 – 8.48 (m, 1H), 7.57 – 7.40 (m, 4H), 7.38 (dd, 1H), 7.21 – 7.14 (m, 1H), 4.71 – 4.64 (m, 1H), 4.63 – 4.47 (m, 1H), 4.37 (d, 2H), 4.10 – 4.03 (m, 1H), 4.03 – 3.97 (m, 6H), 3.84 (d, 1H), 3.73 (dd, 1H), 3.26 – 3.20 (m, 2H), 2.93 (d, 3H), 2.82 (t, 1H), 2.78 – 2.60 (m, 1H), 2.51 – 2.32 (m, 3H), 2.32 – 2.11 (m, 1H), 2.06 (q, 1H), 2.00 – 1.86 (m, 1H). MS: m/z found 745 [M+H]+, retention time = 2.84 min (Method A). Example 109: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl (2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2- oxoethyl)(methyl)carbamate To a solution of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, step (e)) (50.0 mg, 0.09 mmol) in dichloromethane (2 mL), was added trifluoroacetic acid (2 mL) and stirred at room temperature for 1 hour. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure, dried under high vacuum. The crude compound in dichloromethane (4 mL), was added 2,5-dioxopyrrolidin-1-yl N-(tert-butoxycarbonyl)-N-methylglycinate (32.0 mg, 0.11 mmol), N, N-diisopropylethylamine (36.1 mg, 0.28 mmol), and the mixture was stirred at room temperature for 30 min. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in aqueous sodium bicarbonate (5 mL), extracted with dichloromethane (2 x 10 mL). The combined organic layer was dried over Na2SO4, and evaporated the solvent to get, tert-butyl (2-(2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2- oxoethyl)(methyl)carbamate. MS: m/z found 607 [M+H]+. The crude compound was used in next step directly. Steps (b)-(d): tert-Butyl (2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)- 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2- oxoethyl)(methyl)carbamate The following steps (b)-(d) were performed in a similar fashion to Example 93, to obtain tert-butyl (2-(2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2-oxoethyl)(methyl)carbamate as white fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.52 (ddd, 1H), 7.54 – 7.46 (m, 1H), 7.44 – 7.38 (m, 2H), 7.33 – 7.24 (m, 2H), 7.16 (dd, 1H), 4.56 (d, 2H), 4.03 – 3.96 (m, 4H), 3.93 (s, 3H), 3.91 (d, 2H), 3.88 – 3.77 (m, 2H), 3.03 – 2.66 (m, 4H), 2.44 – 2.22 (m, 3H), 1.97 – 1.69 (m, 1H), 1.29 (s, 3H), 0.95 – 0.84 (m, 1H). MS: m/z found 705 [M+H]+, retention time = 2.62 min (Method A). Example 110: (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate: To a solution of 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-2,5-dicarboxylate (100.0 mg, 0.34 mmol) in dichloromethane (2 mL), was added trifluoroacetic acid (2 mL) and stirred at room temperature for 30 min. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. The crude compound was dried under high vacuum and used for N-alkylation. The crude compound in acetonitrile (4 mL), was added 2-iodoethan-1-ol (87.3 mg, 0.51 mmol), N,N-diisopropylethylamine (0.18 mL, 131.3 mg, 1.02 mmol), and the mixture was stirred at 90 oC for 16 hours. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in aqueous Sodium bicarbonate (3 mL), extracted with dichloromethane (2 x10 mL). The combined organic layer was dried over sodium sulfate, and evaporated the solvent, the crude mixture of methyl 5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate was used in next step directly. MS: m/z found 240 [M+H]+. (b) tert-Butyl (S)-((3'-chloro-2'-(3-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of tert-butyl (S)-((2'-(3-amino-2-methylphenyl)-3'-chloro-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (40.0 mg, 0.07 mmol) in tetrahydrofuran (6 mL) was added lithium bis(trimethylsilyl)amide solution in tetrahydrofuran (1M, 0.27 mL, 0.27 mmol) at 0 °C and the mixture was stirred at 0 °C for 30 min. under N2. A solution of methyl 5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate (20.8 mg, 0.09 mmol) in tetrahydrofuran (6 mL) was then added at 0 °C, and the mixture was stirred at 0 °C for 30 min. under N2. Completion was confirmed by UPLC-MS analysis, after completion, water (10 mL) was added, and the combined mixture extracted with ethyl acetate (2 x 25 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude tert-butyl (S)-((3'-chloro-2'-(3-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate was used in the next step directly. MS: m/z found 759 [M+H]+. (c) (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of tert-butyl (S)-((3'-chloro-2'-(3-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (30.0 mg, 0.04 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (2 mL), and the mixture was stirred at room temperature for 15 min. Completion was confirmed by UPLC-MS analysis, after completion, the mixture was concentrated under reduced pressure. The residue was purified by reverse-phase HPLC to afford (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (4.0 mg, 11.4%) as an off-white solid.1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 7.96 (d, 1H), 7.85 (d, 1H), 7.73 (d, 1H), 7.52 (d, 1H), 7.39 (t, 1H), 7.19 (d, 1H), 4.36 (s, 3H), 4.12 (d, 3H), 4.05 (d, 1H), 4.00 (d, 3H), 3.96 (t, 2H), 3.62 (s, 0H), 3.46 (s, 2H), 3.27 – 3.24 (m, 1H), 3.11 (t, 2H), 2.59 – 2.30 (m, 3H), 2.11 (s, 3H), 1.92 (d, 1H).MS: m/z found 659 [M+H]+, retention time = 1.99 min (Method A). Example 111: N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with (R)-2-(3-hydroxypyrrolidin-1-yl)acetic acid in step (a). white solid.1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.56 – 8.43 (m, 1H), 7.56 – 7.44 (m, 1H), 7.44 – 7.34 (m, 2H), 7.36 – 7.19 (m, 2H), 7.16 (ddd, 1H), 4.74 – 4.42 (m, 2H), 4.32 (s, 0H), 3.98 (d, 2H), 3.93 (s, 3H), 3.87 (d, 2H), 3.83 (t, 1H), 3.66 – 3.38 (m, 2H), 2.97 – 2.72 (m, 3H), 2.73 – 2.49 (m, 4H), 2.40 – 2.22 (m, 3H), 2.13 (dq, 1H), 1.86 – 1.68 (m, 2H). MS: m/z found 761 [M+H]+, retention time = 2.69 min (Method A). Example 112: 5-(L-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-(L-Prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with (tert-butoxycarbonyl)-L-proline in step (a). White fluffy solid, 1HNMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.52 (dd, 1H), 7.56 – 7.45 (m, 1H), 7.45 – 7.35 (m, 2H), 7.32 – 7.22 (m, 2H), 7.16 (dd, 1H), 4.81 – 4.45 (m, 2H), 4.12 (dd, 1H), 3.99 (d, 3H), 3.93 (s, 3H), 3.89 – 3.80 (m, 3H), 3.24 – 3.06 (m, 1H), 2.92 – 2.71 (m, 3H), 2.75 – 2.55 (m, 2H), 2.38 – 2.16 (m, 3H), 2.02 – 1.63 (m, 1H). MS: m/z found 731 [M+H]+, retention time = 2.83 min (Method A). Example 113: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1- yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
(S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2-(piperidin-1-yl)acetic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.56 – 8.47 (m, 1H), 7.57 – 7.40 (m, 4H), 7.37 (dd, 1H), 7.21 – 7.14 (m, 1H), 4.77 – 4.59 (m, 1H), 4.49 (s, 1H), 4.42 – 4.32 (m, 3H), 4.28 (s, 1H), 4.10 – 4.03 (m, 1H), 4.01 (s, 3H), 4.00 (dd, 3H), 3.78 (t, 1H), 3.58 (s, 2H), 3.23 (dd, 2H), 3.13 – 2.93 (m, 2H), 2.85 (dt, 2H), 2.55 – 2.27 (m, 3H), 2.04 – 1.77 (m, 4H), 1.55 (s, 1H). MS: m/z found 759 [M+H]+, retention time = 2.81 min (Method A). Example 114: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 3-(piperidin-1- yl)propanoic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.83 – 8.62 (m, 1H), 8.52 (t, 1H), 7.58 – 7.47 (m, 2H), 7.45 (d, 1H), 7.42 (s, 1H), 7.40 – 7.34 (m, 1H), 7.25 – 7.12 (m, 1H), 4.61 (d, 2H), 4.37 (d, 2H), 4.02 – 3.97 (m, 5H), 3.88 (t, 1H), 3.57 (s, 3H), 3.41 (q, 2H), 3.23 (dd, 2H), 3.12 – 2.95 (m, 3H), 2.82 (d, 2H), 2.56 – 2.21 (m, 3H), 2.09 – 1.88 (m, 3H), 1.79 (dd, 3H), 1.53 (d, 1H). MS: m/z found 773 [M+H]+ retention time = 2.90 min (Method A). Example 115: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2-morpholinoacetic acid in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ8.63 (dd, 1H), 8.51 (ddd, 1H), 7.49 (td, 1H), 7.45 –7.36 (m, 2H), 7.26 (d, 2H), 7.16 (dd, 1H), 4.64 (d, 2H), 3.99 (d, 3H), 3.97 –3.93 (m, 1H), 3.92 (s, 3H), 3.86 (d, 2H), 3.82 (t, 1H), 3.71 (t, 2H), 3.65 (t, 2H), 3.36 (s, 1H), 2.88 (t, 1H), 2.75 (t, 1H), 2.71 –2.61 (m, 2H), 2.51 (s, 4H), 2.40 –2.18 (m, 3H), 1.89 –1.69 (m, 1H). MS: m/z found 761 [M+H]+, retention time = 2.72 min (Method A). Example 116: (S)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2-(1H-tetrazol-5-yl)acetic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.52 (td, 1H), 7.59 –7.27 (m, 6H), 7.16 (dd, 1H), 4.77 –4.47 (m, 2H), 4.37 (s, 2H), 4.31 (s, 1H), 4.05 (t, 1H), 4.02 –3.98 (m, 7H), 3.23 (dd, 2H), 2.90 (t, 1H), 2.79 (t, 1H), 2.55 –2.26 (m, 3H), 1.98 –1.86 (m, 1H). MS: m/z found 744 [M+H]+, retention time = 3.16 min (Method A). Example 117: Methyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate Methyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with methyl 3-bromopropanoate in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.56 – 8.46 (m, 1H), 7.48 (ddd, 1H), 7.44 – 7.33 (m, 2H), 7.33 – 7.24 (m, 2H), 7.15 (ddd, 1H), 4.01 – 3.87 (m, 6H), 3.89 – 3.76 (m, 3H), 3.68 (d, 3H), 3.56 (s, 2H), 3.04 – 2.86 (m, 4H), 2.75 (t, 2H), 2.65 (dt, 4H), 2.45 – 2.14 (m, 3H), 1.92 – 1.72 (m, 1H). MS: m/z found 720 [M+H]+, retention time = 2.89 min (Method A). Example 118: tert-Butyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate tert-Butyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with tert-butyl 3-bromopropanoate in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.56 – 8.44 (m, 1H), 7.48 (dd, 1H), 7.44 – 7.33 (m, 2H), 7.33 – 7.19 (m, 3H), 7.15 (ddd, 1H), 3.94 (d, 6H), 3.86 (dd, 3H), 3.55 (s, 3H), 3.02 – 2.79 (m, 5H), 2.72 (dt, 5H), 2.60 – 2.45 (m, 2H), 2.42 – 2.18 (m, 3H), 1.88 – 1.71 (m, 1H), 1.45 (d, 10H). MS: m/z found 762 [M+H]+, retention time = 3.22 min (Method A). Example 119: (S)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3- methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2-((tert-butoxycarbonyl)amino)-2- methylpropanoic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.52 (dd, 1H), 7.54 (d, 1H), 7.51 (dd, 1H), 7.47 – 7.40 (m, 2H), 7.37 (dd, 1H), 7.17 (dd, 1H), 4.68 (s, 2H), 4.37 (d, 2H), 4.13 – 3.91 (m, 9H), 3.23 (dd, 2H), 2.84 (s, 2H), 2.55 – 2.29 (m, 3H), 2.01 – 1.87 (m, 1H), 1.71 (s, 6H). MS: m/z found 719 [M+H]+, retention time = 2.77 min (Method A). Example 120: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4- triazol-1-yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2- (3,5-dimethyl-1H-1,2,4-triazol-1-yl)acetic acid in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.76 – 8.63 (m, 1H), 8.52 (ddd, 1H), 7.58 – 7.30 (m, 5H), 7.26 – 7.08 (m, 1H), 5.36 (d, 2H), 4.64 (d, 2H), 4.36 (s, 1H), 4.15 – 3.85 (m, 8H), 3.23 (dd, 2H), 2.94 (t, 1H), 2.80 (t, 1H), 2.51 – 2.45 (m, 3H), 2.45 – 2.37 (m, 2H), 2.36 (t, 3H), 1.98 – 1.84 (m, 1H). MS: m/z found 771 [M+H]+, retention time = 2.94 min (Method A). Example 121: (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4- triazol-1-yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, replacing (tert-butoxycarbonyl)glycine with 2- (3,5-dimethyl-1H-1,2,4-triazol-1-yl)acetic acid in step (a). White solid, 1HNMR(400 MHz, Methanol-d4): δ 8.90 – 8.58 (m, 1H), 8.51 (dd, 1H), 7.69 – 7.29 (m, 5H), 7.29 – 6.96 (m, 1H), 4.74 – 4.56 (m, 2H), 4.36 (d, 2H), 4.06 (s, 1H), 4.04 – 3.90 (m, 6H), 3.23 (dd, 2H), 2.87 (t, 1H), 2.78 (t, 1H), 2.58 (s, 1H), 2.55 (s, 1H), 2.49 – 2.31 (m, 2H), 2.02 – 1.84 (m, 1H). MS: m/z found 759 [M+H]+, retention time = 3.36 min (Method A). Example 122: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl (S)-5-(1-(tert-butoxycarbonyl)pyrrolidine-3-carbonyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate To a mixture of methyl 1-methyl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine-2- carboxylate hydrochloride salt (1 g, 4.32 mmol) and (S)-1-(tert-butoxycarbonyl)pyrrolidine- 3-carboxylic acid (929 mg, 4.32 mmol) in dichloromethane (20 mL) was added N-ethyl-N- propan-2-ylpropan-2-amine (2.26 mL, 13.0 mmol) and 2-chloro-1-methylpyridin-1-ium iodide (2.21 g, 8.63 mmol). The reaction mixture was stirred at room temperature for 2 hours under N2 and then water (10 mL) was added to the mixture. The organic phase was separated, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to afford methyl (S)-5-(1-(tert-butoxycarbonyl)pyrrolidine-3-carbonyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (2 g, crude) as a yellow oil. MS: m/z found 393 [M+H]+. The crude product was used in the next step without further purification. (b) tert-Butyl (S)-3-(2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate
To a solution of 3-bromo-2-chloro-aniline (550 mg, 2.66 mmol) in THF (15 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 5.33 mL, 5.32 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 hours under N2 and then a solution of methyl (S)- 5-(1-(tert-butoxycarbonyl)pyrrolidine-3-carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate (1.46 g, 3.73 mmol) in THF (15 mL) was added. The mixture was stirred at 0 °C for 0.5 hours under N2 and combined with another batch at 180 mg scale. Water was added and the mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude was purified by normal phase SiO2 chromatography (0- 100% ethyl acetate / petroleum ether) to afford 1.4 g of tert-butyl (S)-3-(2-((3-bromo-2- chlorophenyl)carbamoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)pyrrolidine-1-carboxylate as a yellow oil.1H NMR (400 MHz, DMSO-d6): δ 9.98 (d, 1H), 8.24-8.13 (m, 1H), 7.59 (d, 1H), 7.37-7.32 (m, 1H), 4.62 (s, 1H), 4.53 (s, 1H), 3.90- 3.85 (m, 5H), 3.41-3.36 (m, 3H), 3.27-3.25 (m, 2H), 2.81-2.79 (m, 1H), 2.69-2.68 (m, 1H), 1.92-1.79 (m, 2H), 1.40 (s, 9H). (c) tert-Butyl (S)-3-(2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)pyrrolidine-1-carboxylate To a mixture of tert-butyl (S)-3-(2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate (0.5 g, 0.88 mmol) and bis(pinacolato)diboron (1.12 g, 4.41 mmol) in 1,4-dioxane (10 mL) was added potassium acetate (0.26 g, 2.65 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (72 mg, 0.09 mmol). The mixture was stirred at 130 °C for 6 hours under N2 and then filtered. The filtrate was concentrated to afford tert-butyl (S)-3-(2-((2-chloro-3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate (500 mg, crude), which was used in the next step without further purification. MS: m/z found 614 [M+H]+. (d) tert-Butyl (S)-3-(2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]- 2'-yl)phenyl)carbamoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)pyrrolidine-1-carboxylate To a mixture of tert-butyl (S)-3-(2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate (500 mg, 0.81 mmol) and 2',3'-dichloro-6- methoxy-[2,4'-bipyridine]-5-carbaldehyde (230 mg, 0.81 mmol) in THF / water (5:1 v/v, 12 mL) was added [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (64 mg, 0.08 mmol) and potassium phosphate (518 mg, 2.44 mmol) and then the mixture was stirred at 80 °C for 2 hours under N2. Water (50 mL) was then added, and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100% ethyl acetate / petroleum ether) to afford tert-butyl (S)-3-(2- ((2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate (370 mg, 23% yield) as a yellow solid, MS: m/z found 734 [M+H]+. (e) tert-Butyl (S)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate To a mixture of tert-butyl (S)-3-(2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 5-carbonyl)pyrrolidine-1-carboxylate (150 mg, 0.204 mmol) and (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt (61.5 mg, 0.41 mmol) in dichloromethane / methanol (1:1 v/v, 6 mL) was added sodium acetate (50 mg, 0.613 mmol). The reaction mixture was stirred at room temperature for 1.5 hours under N2 and then sodium cyanoborohydride (38.5 mg, 0.613 mmol) was added. After stirring at room temperature for 0.5 hours under N2, water (20 mL) was added, and the residue was extracted with dichloromethane (2 x 30 mL). The combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, ethyl acetate : methanol = 2:1 v/v) to afford tert-butyl (S)-3-(2- ((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate (85 mg, 50% yield) as a white solid. MS: m/z found 832 [M+H]+. (f) N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of tert-butyl (S)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)pyrrolidine-1-carboxylate (80 mg, 0.1 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2 mL, 27.0 mmol) and then the mixture was stirred at room temperature for 0.5 hours under N2. The mixture was concentrated and purified by reverse phase HPLC to afford N-(2-chloro-3-(3'-chloro-6- methoxy-5-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)- 1-methyl-5-((S)-pyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (4.6 mg, 6% yield) as a white solid. MS: m/z found 732 [M+H]+, retention time = 2.67 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.59-8.42 (m, 1H), 7.83 (d, 1H), 7.80 (d, 1H), 7.55-7.50 (m, 1H), 7.45 (d, 1H), 7.25 (dd, 1H), 4.71-4.68 (m, 2H), 4.06 (s, 3H), 4.02-3.92 (m, 5H), 3.87-3.85 (m, 3H), 3.51-3.50 (m, 1H), 3.16-3.12 (m, 4H), 2.88-2.87 (m, 1H), 2.78-2.69 (m, 3H), 2.38-2.21 (m, 4H), 1.91-1.81 (m, 2H). Example 123: Methyl (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate Methyl (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with methyl methyl 4-bromobutanoate in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.51 (dd, 1H), 7.48 (dd, 1H), 7.44 –7.37 (m, 2H), 7.30 –7.24 (m, 2H), 7.15 (dd, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 3.87 (d, 2H), 3.83 (t, 1H), 3.63 (s, 3H), 3.53 (s, 2H), 2.89 (t, 3H), 2.76 (t, 3H), 2.72 –2.56 (m, 4H), 2.40 (t, 2H), 2.35 –2.19 (m, 3H), 2.03 –1.83 (m, 2H), 1.84 –1.74 (m, 1H). MS: m/z found 734 [M+H]+, retention time = 2.65 min (Method A). Example 124: (S)-4-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid (S)-4-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid in a similar fashion to Example 100, replacing methyl 2-bromoacetate with methyl 3-bromopropanoate in step (a). White fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.58 –8.39 (m, 1H), 7.64 –7.47 (m, 2H), 7.48 –7.38 (m, 2H), 7.37 (dd, 1H), 7.22 –7.14 (m, 1H), 4.37 (d, 2H), 4.06 (d, 1H), 4.03 (d, 3H), 4.01 (d, 3H), 3.46 –3.35 (m, 2H), 3.23 (dd, 2H), 3.12 (t, 3H), 2.50 (t, 2H), 2.46 –2.31 (m, 3H), 2.18 –2.05 (m, 2H), 1.98 –1.85 (m, 1H). MS: m/z found 720 [M+H]+, retention time = 2.58 min (Method A). Example 125: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with (bromomethyl)cyclopropane in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.55 (dd, 1H), 7.90 –7.70 (m, 3H), 7.60 –7.35 (m, 2H), 7.22 (dd, 1H), 4.04 (s, 3H), 3.98 (s, 3H), 3.84 (d, 3H), 3.65 (s, 3H), 2.98 (t, 2H), 2.79 (t, 3H), 2.75 –2.62 (m, 3H), 2.53 (d, 3H), 2.39 –2.20 (m, 4H), 1.93 –1.72 (m, 1H), 1.06 –0.80 (m, 1H), 0.73 –0.49 (m, 2H), 0.22 (d, 2H). MS: m/z found 689 [M+H]+, retention time = 2.49 min (Method A). Example 126: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3- carboxylic acid with (R)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid in step (a). White solid, MS: m/z found 732 [M+H]+, retention time = 2.77 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.59-8.54 (m, 1H), 7.83 (d, 1H), 7.80 (d, 1H), 7.55- 7.50 (m, 1H), 7.45 (d, 1H), 7.25 (d, 1H), 4.68-4.64 (m, 2H), 4.06 (s, 3H), 4.02-3.97 (m, 5H), 3.87-3.85 (m, 3H), 3.53-3.49 (m, 1H), 3.23-3.09 (m, 4H), 2.89-2.86 (m, 1H), 2.78-2.69 (m, 3H), 2.38-2.29 (m, 4H), 2.07-2.01 (m, 1H), 1.87-1.83 (m, 1H). Example 127: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3- carboxylic acid with (S)-1-tert-butoxycarbonylpiperidine-3-carboxylic acid in step (a). White solid, MS: m/z found 746 [M+H]+, retention time = 2.77 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.66 - 8.57 (m, 1H), 7.86 (d, 1H), 7.80 (d, 1H), 7.52 (t, 1H), 7.46 (d, 1H), 7.26 (t, 1H), 4.71 - 4.60 (m, 3 H), 4.08 (s, 3H), 4.02 - 3.90 (m, 8H), 3.38 - 3.33 (m, 2H), 3.33 - 3.18 (m, 3H), 2.81 - 2.78 (m, 4H), 2.36 - 2.35 (m, 3H), 1.90 - 1.83 (m, 5H). Example 128: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 5-((2,4-dimethyloxazol-5-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate To a solution of 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-2,5-dicarboxylate (50.00 mg, 0.17 mmol) in dichloromethane (2 mL), was added trifluoroacetic acid (1.3 mL) and the mixture stirred at room temperature for 15 min. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. The mixture was suspended in aqueous sodium bicarbonate (3 mL), extracted with dichloromethane (2 x10 mL). The combined organic layer was dried over sodium sulfate and evaporated the solvent to get the crude compound. The crude compound was dried under high vacuum and used for reductive amination. To the crude compound in dichloromethane/methanol (4 mL), was added 2,4-dimethyloxazole-5-carbaldehyde (31.78 mg, 0.25 mmol), sodium acetate (41.66 mg, 0.51 mmol) and stirred for 30 min. Then, added sodium cyanoborohydride (31.9 mg, 0.51 mmol), and the mixture was stirred at room temperature for 16 hours. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in aqueous sodium bicarbonate (3 mL), extracted with dichloromethane (2 x10 mL). The combined organic layer was dried over sodium sulfate, and evaporated the solvent, the crude compound was used in next step directly. MS: m/z found 305 [M+H]+. Steps (b) and (c): (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide The following steps (b) and (c) were performed in a similar fashion to Example 110 to obtain (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide as white fluffy solid. 1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.54 (ddd, 1H), 7.97 (d, 1H), 7.78 (dd, 1H), 7.52 (t, 2H), 7.25 (ddd, 1H), 4.63 (s, 2H), 4.45 –4.20 (m, 4H), 4.12 (d, 3H), 4.03 (d, 4H), 3.74 (s, 1H), 3.26 (d, 1H), 3.11 (t, 3H), 2.47 (d, 3H), 2.45 –2.33 (m, 3H), 2.22 (s, 3H), 1.98 – 1.87 (m, 1H). MS: m/z found 744 [M+H]+ retention time = 2.50 min (Method A). Example 129: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 128, replacing 2,4-dimethyloxazole-5-carbaldehyde with 1,5-dimethyl-1H-imidazole-4-carbaldehyde in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.62 – 8.33 (m, 1H), 8.27 (s, 1H), 7.97 (d, 1H), 7.93 – 7.64 (m, 1H), 7.65 – 7.43 (m, 2H), 7.35 – 7.04 (m, 1H), 4.37 (d, 2H), 4.20 (s, 2H), 4.13 (d, 3H), 4.06 – 3.90 (m, 5H), 3.81 – 3.62 (m, 3H), 3.42 (s, 2H), 3.27 (dd, 2H), 2.97 (t, 2H), 2.48 – 2.36 (m, 3H), 2.35 (d, 3H), 1.91 (dd, 1H). MS: m/z found 743 [M+H]+, retention time = 2.26 min (Method A). Example 130: 5-((S)-Azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5- (((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-((S)-Azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid with (S)-1- (tert-butoxycarbonyl)azetidine-2-carboxylic acid in step (a). White solid, MS: m/z found 718 [M+H]+, retention time = 3.03 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.56-8.52 (m, 1H), 7.81 (d, 1H), 7.78 (d, 1H), 7.50 (t, 1H), 7.43 (d, 1H), 7.23 (d, 1H), 4.70-4.53 (m, 2H), 4.42-4.29 (m, 1H), 4.05 (s, 3H), 3.99 (s, 3H), 3.90-3.81 (m, 3H), 3.66 (s, 1H), 3.55-3.48 (m, 2H), 2.85-2.68 (m, 5H), 2.36-2.27 (m, 4H), 1.85-1.78 (m, 1H). Example 131: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid with 1-tert-butoxycarbonylpiperidine-4-carboxylic acid in step (a). White solid, MS: m/z found 746 [M+H]+, retention time = 3.07 min (Method A).1H NMR (400 MHz, Methanol- d4): δ 8.53 (d, 1H), 8.47-8.42 (m, 1H), 7.71 (d, 1H), 7.68 (d, 1H), 7.41 (t,1H), 7.33 (d, 1H), 7.13 (dd, 1H), 4.55 (s, 1H), 4.49(s, 1H), 3.95 (s, 3H), 3.91-3.85 (m, 5H), 3.75-3.71 (m, 3H), 3.10-3.03 (m, 2H), 2.95-2.85 (m, 1H), 2.75-2.55 (m, 6H), 2.25-2.15 (m, 3H), 1.73-1.56 (m, 5H). Example 132: (S)-5-(2-(Azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(Azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid with 2-(1- (tert-butoxycarbonyl)azetidin-3-yl)acetic acid in step (a). White solid, MS: m/z found 732 [M+H]+; 1H NMR (400 MHz, Methanol-d4): δ 8.66-8.64 (m, 1H), 8.59-8.54 (m, 1H), 7.84- 7.79 (m, 2H), 7.55-7.50 (m, 1H), 7.54 (d, 1H), 7.25 (d, 1H), 4.06 (s, 3H), 4.02-3.96 (m, 7H), 3.90-3.86 (m, 5H), 3.66-3.63 (m, 2H), 2.94-2.87 (m, 3H), 2.78-2.69 (m, 4H), 2.38-2.27 (m, 3H), 1.87-1.81 (m, 1H). Example 133: (S)-5-(1-Acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6- methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(1-Acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid with 1- acetylpiperidine-4-carboxylic acid in step (a). White solid, MS: m/z found 788 [M+H]+, retention time = 3.23 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.60-8.54 (m, 1H), 7.83 (d, 1H), 7.80 (d, 1H), 7.53 (t, 1H), 7.45 (d, 1H), 7.25 (dd, 1H), 4.63- 4.51 (m, 3H), 4.07 (s, 3H), 4.02-3.96 (m, 6H), 3.89-3.83 (m, 3H), 3.23-3.09 (m, 2H), 2.90- 2.67 (m, 5H), 2.38-2.27 (m, 3H), 2.12 (d, 3H), 1.87-1.58 (m, 5H). Example 134: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4- triazol-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol- 1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 1-(2- bromoethyl)-3,5-dimethyl-1H-1,2,4-triazole in step (a). White fluffy solid, 1HNMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.54 (dd, 1H), 7.87 – 7.67 (m, 3H), 7.61 – 7.47 (m, 1H), 7.43 (d, 1H), 7.22 (dd, 1H), 4.24 (t, 2H), 4.04 (s, 3H), 3.97 (d, 4H), 3.87 – 3.77 (m, 3H), 3.58 (s, 2H), 3.11 – 2.97 (m, 2H), 2.91 (t, 2H), 2.81 – 2.60 (m, 6H), 2.41 (s, 3H), 2.34 (d, 1H), 2.26 (s, 3H). MS: m/z found 758 [M+H]+, retention time = 3.26 min (Method A). Example 135: Isopropyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate Isopropyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with isopropyl 3-bromopropanoate in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.50 (dd, 1H), 7.49 (dd, 1H), 7.44 – 7.35 (m, 2H), 7.32 – 7.21 (m, 3H), 7.15 (dd, 1H), 5.09 – 4.93 (m, 1H), 3.97 (s, 3H), 3.92 (s, 4H), 3.90 – 3.72 (m, 4H), 3.56 (s, 3H), 2.92 (dt, 5H), 2.75 (t, 3H), 2.74 – 2.62 (m, 2H), 2.59 (t, 3H), 2.45 – 2.20 (m, 3H), 1.94 – 1.73 (m, 1H), 1.23 (d, 7H). MS: m/z found 748 [M+H]+, retention time = 4.13 min (Method A). Example 136: 5-((S)-1-Acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6- methoxy-5-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-((S)-1-Acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)- 5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid with (S)-1- (tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid in step (a). White solid, MS: m/z found 774 [M+H]+, retention time = 3.29 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.59-8.54 (m, 1H), 7.83 (d, 1H), 7.80 (d, 1H), 7.53 (t, 1H), 7.45 (d, 1H), 7.25 (dd, 1H), 4.70 (d, 1H), 4.66-4.61 (m, 1H), 4.06 (s, 3H), 4.02-3.97 (m, 5H), 3.89-3.83 (m, 3H), 3.78-3.57 (m, 5H), 2.90-2.88 (m, 1H), 2.79-2.75 (m, 1H), 2.74-2.67 (m, 2H) , 2.38-2.23 (m, 4H), 2.10-2.06 (m, 4H), 1.89-1.80 (m, 1H). Example 137: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine- 4-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3- carboxylic acid with 1-methylpiperidine-4-carboxylic acid in step (a). White solid, MS: m/z found 760 [M+H]+, retention time = 3.23 min (Method A).1H NMR (400 MHz, Methanol- d4): δ 8.65 (d, 1H), 8.59-8.54 (m, 1H), 7.84-7.80 (m, 2H), 7.56-7.51 (m, 1H), 7.44 (d, 1H), 7.24 (dd, 1H), 4.66-4.60 (m, 2H), 4.01 (s, 3H), 4.01-3.98 (m, 3H), 3.97-3.91 (m, 2H), 3.87- 3.85 (m, 3H), 3.03-2.98 (m, 2H), 2.85-2.86 (m, 1H), 2.80-2.70 (m, 4H), 2.37-2.31 (m, 6H), 2.29-2.21 (m, 2H), 1.87-1.77 (m, 1H). Example 138: (S)-5-(2-(1H-1,2,4-Triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy- 5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(1H-1,2,4-Triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 1-(2-bromoethyl)-1H-1,2,4-triazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.54 (dd, 1H), 8.48 (s, 1H), 7.98 (s, 1H), 7.86 – 7.71 (m, 2H), 7.49 (dd, 1H), 7.42 (d, 1H), 7.22 (dd, 1H), 4.45 (t, 2H), 4.04 (s, 3H), 3.97 (d, 3H), 3.84 (d, 3H), 3.58 (s, 2H), 3.16 – 3.04 (m, 2H), 2.91 (t, 2H), 2.78 – 2.61 (m, 5H), 2.41 – 2.19 (m, 3H), 1.87 – 1.75 (m, 1H). MS: m/z found 730 [M+H]+, retention time = 2.34 min (Method A). Example 139: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-bromo-1,1,1- trifluoropropan-2-ol in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.54 (dd, 1H), 7.88 – 7.72 (m, 2H), 7.50 (dd, 1H), 7.42 (d, 1H), 7.22 (dd, 1H), 4.23 (q, 1H), 4.04 (s, 3H), 3.97 (s, 3H), 3.86 – 3.81 (m, 3H), 3.66 (s, 2H), 3.00 (t, 2H), 2.93 – 2.80 (m, 2H), 2.77 (t, 2H), 2.75 – 2.62 (m, 3H), 2.41 – 2.18 (m, 4H), 1.88 – 1.76 (m, 1H). MS: m/z found 747 [M+H]+, retention time = 2.59 min (Method A). Example 140: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert- butoxycarbonyl)pyrrolidine-3-carboxylic acid with 3-((tert- butoxycarbonyl)(methyl)amino)propanoic acid in step (a). White solid, MS: m/z found 720 [M+H]+, retention time = 2.61 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.58-8.54 (m, 1H), 7.83 (d, H), 7.80 (d, 1H), 7.54-7.50 (m, 1H), 7.44 (d, 1H), 7.25 (dd, 1H), 4.63-4.60 (m, 2H), 4.06 (s, 3H), 4.05-3.94 (m, 4H), 3.91-3.83 (m, 4H), 2.97-2.90 (m, 2H), 2.89-2.82 (m, 1H), 2.81-2.66 (m, 5H), 2.49-2.47 (m, 3H), 2.38-2.25 (m, 3H), 1.88-1.80 (m, 1H). Example 141: (S)-5-(Azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(Azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid with 1- (tert-butoxycarbonyl)azetidine-3-carboxylic acid in step (a). White solid, MS: m/z found 718 [M+H]+, retention time = 2.63 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.53 (d, 1H), 8.47-8.42 (m, 1H), 7.72-7.68 (m, 2H), 7.43-7.39 (m, 1H), 7.33 (d, 1H), 7.13 (dd, 1H), 4.56-4.49 (m, 1H), 4.31-4.29 (m, 1H), 4.00-3.79 (m, 14H), 3.76-3.58 (m, 1H), 3.55-3.21 (m, 1H), 2.69-2.58 (m, 4H), 2.26-2.15 (m, 3H), 1.75-1.71 (m, 1H). Example 142: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol- 4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 4-(2- bromoethyl)-3,5-dimethyl-1H-pyrazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.55 (dd, 1H), 7.87 – 7.71 (m, 2H), 7.50 (dd, 1H), 7.43 (d, 1H), 7.22 (dd, 1H), 4.04 (s, 3H), 3.99 (s, 3H), 3.84 (d, 3H), 3.64 (s, 2H), 2.97 (t, 2H), 2.81 (d, 2H), 2.74 – 2.60 (m, 7H), 2.40 – 2.23 (m, 3H), 2.19 (s, 7H), 1.90 – 1.76 (m, 1H). MS: m/z found 757 [M+H]+, retention time = 2.35 min (Method A). Example 143: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 128, replacing 2,4-dimethyloxazole-5-carbaldehyde with 2,4- dimethylthiazole-5-carbaldehyde in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.54 (dd, 1H), 7.87 – 7.68 (m, 2H), 7.61 – 7.45 (m, 2H), 7.43 (d, 1H), 7.21 (dd, 1H), 4.04 (s, 3H), 3.96 (s, 3H), 3.84 (d, 2H), 3.69 (s, 2H), 3.57 (d, 4H), 2.94 (t, 2H), 2.83 – 2.54 (m, 4H), 2.37 – 2.27 (m, 2H), 2.25 (s, 3H). MS: m/z found 743 [M+H]+, retention time = 2.56 min (Method A). Example 144: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 2-(bromomethyl)thiazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.54 (dd, 1H), 7.87 – 7.70 (m, 3H), 7.57 (d, 1H), 7.49 (dd, 1H), 7.42 (d, 1H), 7.21 (dd, 1H), 4.13 (s, 3H), 4.04 (s, 4H), 3.98 (s, 3H), 3.84 (d, 3H), 3.66 (s, 3H), 2.99 (t, 3H), 2.89 – 2.60 (m, 5H), 2.43 – 2.20 (m, 4H), 1.89 – 1.74 (m, 1H). MS: m/z found 732 [M+H]+, retention time = 2.56 min (Method A). Example 145: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 2-(bromomethyl)oxazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.71 – 8.59 (m, 1H), 8.53 (dd, 1H), 7.93 (d, 1H), 7.83 – 7.70 (m, 3H), 7.49 (dd, 1H), 7.42 (d, 1H), 7.29 – 7.12 (m, 2H), 4.04 (d, 4H), 3.98 (d, 5H), 3.84 (d, 3H), 3.62 (s, 3H), 2.98 (t, 3H), 2.78 (t, 3H), 2.74 – 2.62 (m, 3H), 2.37 – 2.21 (m, 4H), 1.89 – 1.76 (m, 1H). MS: m/z found 716 [M+H]+, retention time = 2.51 min (Method A). Example 146: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide was prepared in a similar fashion to Example 128, replacing 2,4- dimethyloxazole-5-carbaldehyde with imidazo[1,2-a]pyrimidine-3-carbaldehyde in step (a). However, partial reduction of the pyrimidine was observed during the Boc deprotection reaction using trifluoroacetic acid (step-c), probably due to traces of sodium cyanoborohydride carried over from earlier reductive amination reaction. White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.54 (dd, 1H), 7.90 – 7.72 (m, 3H), 7.59 – 7.45 (m, 1H), 7.42 (d, 1H), 7.21 (dd, 1H), 7.01 – 6.81 (m, 1H), 6.38 (s, 1H), 5.20 (dt, 1H), 4.03 (d, 6H), 3.96 (d, 3H), 3.84 (d, 3H), 3.64 (s, 2H), 3.49 (s, 2H), 2.87 (t, 2H), 2.81 – 2.59 (m, 5H), 2.44 – 2.19 (m, 3H), 1.93 – 1.72 (m, 1H). MS: m/z found 768 [M+H]+, retention time = 2.33 min (Method A). Example 147: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1- methylpiperidine-3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3- carboxylic acid with (S)-1-methylpiperidine-3-carboxylic acid in step (a). White solid, MS: m/z found 760 [M+H]+, retention time = 2.75 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.52 (d, 1H), 8.46-8.41 (m, 1H), 7.70 (d, 1H), 7.67 (d, 1H), 7.39 (t, 1H), 7.31 (d, 1H), 7.11 (dd, 1H), 4.54 (s, 1H), 4.47 (s, 1H), 3.94 (s, 3H), 3.91-3.84 (m, 5H), 3.78-3.70 (m, 3H), 2.85-2.75 (m, 4H), 2.63-2.57 (m, 3H), 2.25-2.14 (m, 7H), 2.04-2.08 (m, 1H), 1.90- 1.82 (m, 1H), 1.74-1.63 (m, 4H). Example 148: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1- methylpyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3- carboxylic acid with (S)-1-methylpyrrolidine-3-carboxylic acid in step (a). White solid, MS: m/z found 746 [M+H]+, retention time = 3.05 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.57-8.52 (m, 1H), 7.81 (d, 1H), 7.78 (d, 1H), 7.52-7.48 (m, 1H), 7.43 (d, 1H), 7.23 (dd, 1H), 4.61-4.60 (m, 2H), 4.05 (s, 3H), 3.99-3.92 (m, 5H), 3.85- 3.81 (m, 3H), 3.50-3.45 (m, 1H), 2.98-2.89 (m, 1H), 2.85-2.65 (m, 6H), 2.57-2.50 (m, 1H), 2.40-2.37 (m, 3H), 2.35-1.96 (m, 5H), 1.85-1.78 (m, 1H). Example 149: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 128, replacing 2,4-dimethyloxazole-5-carbaldehyde with imidazo[1,2-a]pyrimidine-3-carbaldehyde in step (a). White solid, 1H NMR (400 MHz, Methanol-d4): δ 8.96 (dd, 1H), 8.62 (d, 1H), 8.58 (dd, 1H), 8.56 –8.48 (m, 1H), 7.86 –7.75 (m, 2H), 7.73 (s, 1H), 7.49 (dd, 1H), 7.42 (d, 1H), 7.21 (dd, 1H), 7.06 (dd, 1H), 4.16 (s, 2H), 4.04 (d, 3H), 3.96 (s, 2H), 3.84 (d, 3H), 3.55 (s, 2H), 2.93 (t, 2H), 2.80 –2.59 (m, 4H), 2.45 – 2.19 (m, 3H), 1.89 –1.76 (m, 1H). MS: m/z found 766 [M+H]+, retention time = 2.70 min (Method A). Example 150: 5-((S)-1-Acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6- methoxy-5-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 5-((S)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)- 5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid with (S)-1- (tert-butoxycarbonyl)piperidine-3-carboxylic acid in step (a). White solid, MS: m/z found 788 [M+H]+, retention time = 3.18 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.53 (d, 1H), 8.46-8.42 (m, 1H), 7.71 (d, 1H), 7.68 (d, 1H), 7.40 (t, 1H), 7.33 (d, 1H), 7.13 (d, 1H), 4.57-4.25 (m, 3H), 3.96-3.71 (m, 12H), 2.94-2.58 (m, 6H), 2.26-2.17 (m, 3H), 2.03-1.99 (m, 3H), 1.95-1.43(m, 6H). Example 151: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl- 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide (a) Methyl 5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine-2-carboxylate To a solution of 5-(tert-butyl) 2-methyl 3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-2,5-dicarboxylate (200 mg, 0.68 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) and stirred for 30 min at room temperature. After completion, the mixture was concentrated, dried under high vacuum, and used directly in the next step. To the residue in DMF (2 mL) was added N,N-diisopropylethylamine (0.35 mL, 263 mg, 2.03 mmol) and 1-fluoro-3-iodo-propane (140 mg, 0.74 mmol) at room temperature. The mixture was heated at 65 oC 1 hour, and completion was observed by UPLC-MS analysis. After completion, water was added, and the mixture was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure to give methyl 5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H- imidazo[4,5-c]pyridine-2-carboxylate (160 mg, 93% yield). MS: m/z found 256.1 [M+H]+, retention time = 0.71 min (Method B). (b) tert-Butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of tert-butyl (S)-((2'-(3-amino-2-chlorophenyl)-3'-chloro-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (Example 187, step (b)) (250 mg, 0.44 mmol) in THF was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 0.87 mL, 0.87 mmol) at 0 °C under N2, and the mixture was stirred for 30 minutes. A solution of methyl 5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine-2-carboxylate (134 mg, 0.52 mmol) in THF was then added at 0 °C, and the mixture was stirred for an additional 2 hours. Upon completion, water was added, and the mixture was extracted with ethyl acetate three times. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude tert-butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate. MS: m/z found 795.3 [M+H]+, retention time = 0.90 min (Method B). (c) (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl- 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide A solution of methyl 5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine-2-carboxylate (150 mg, 0.09 mmol) in dichloromethane / trifluoroacetic acid (2:1 v/v) was stirred for 30 min, concentrated to dryness and purified by preparative HPLC. The final product was converted to free base. White solid, MS: m/z found 695.2 [M+H]+, retention time = 3.17 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.54 (d, 1H), 7.81 (d, 1H), 7.78 (d, 1H), 7.50 (dd, 1H), 7.43 (d, 1H), 7.23 (d, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 4.04 (s, 3H), 3.97 (s, 3H), 3.91 – 3.77 (m, 3H), 3.71 – 3.61 (m, 2H), 2.89 (t, 2H), 2.84 – 2.76 (m, 2H), 2.75 – 2.62 (m, 4H), 2.39 – 2.22 (m, 3H), 2.12 – 1.93 (m, 2H), 1.89 – 1.75 (m, 1H). Example 152: (S)-5-(2-(1H-Pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(1H-Pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 4-(2-bromoethyl)-1H-pyrazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.55 (ddd, 1H), 7.92 – 7.62 (m, 2H), 7.50 (ddd, 1H), 7.43 (dd, 1H), 7.32 – 7.09 (m, 1H), 4.06 – 4.01 (m, 4H), 3.98 (d, 3H), 3.84 (d, 3H), 3.62 (s, 2H), 2.97 (t, 2H), 2.81 (d, 7H), 2.74 – 2.63 (m, 3H), 2.41 – 2.16 (m, 4H), 1.88 – 1.75 (m, 1H). MS: m/z found 729 [M+H]+, retention time = 3.23 min (Method A). Example 153: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl- 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl (S)-(4-(4-(3-amino-2-chlorophenyl)-3-chloropyridin-2-yl)-2- methoxybenzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of 2-chloro-3-(2,3-dichloropyridin-4-yl)aniline (3 g, 11 mmol) (Example 1, step (d)) and tert-butyl (S)-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (5.55 g, 12.1 mmol) (Example 9, step (b)) in 1,4-dioxane / water mixture (10:1 v/v, 99 mL) was added potassium phosphate (6.98 g, 32.9 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′- biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.35 g, 0.44 mmol) in one portion under N2. The mixture was stirred at 100 °C for 2 hr. The mixture was concentrated, water (200 mL) and saturated aqueous brine solution (50 mL) were added to the residue, and the mixture was extracted with ethyl acetate/THF mixture (1:1 v/v, 200 mL). The organic phase was dried with anhydrous sodium sulfate, filtered and concentrated. The residue was purified by normal phase SiO2 chromatography (30-80% ethyl acetate/petroleum ether) to afford the product (2.9 g). The product was combined with another batch at 3.2 g scale. The product was purified by reverse phase HPLC to afford the product in acetonitrile / water mixture (2:3 v/v, 1 L). The mixture was extracted with ethyl acetate (200 mL). The organic phase was dried with anhydrous sodium sulfate, filtered and concentrated to afford tert-butyl (S)-(4-(4-(3-amino-2- chlorophenyl)-3-chloropyridin-2-yl)-2-methoxybenzyl)((5-oxopyrrolidin-2- yl)methyl)carbamate (2.44 g, 20% yield) as a yellow solid. MS: m/z found 571 [M+H]+.1H NMR (400 MHz, Methanol-d4): 8.58 (d, 1H), 7.36-7.34 (m, 1H), 7.28-7.24 (m, 3H), 7.17 (t, 1H), 6.94 (dd, 1H), 6.61 (dd, 1H), 4.65-4.57 (m, 2H), 3.98-3.92 (m, 4H), 3.42-3.33 (m, 2H), 2.41-2.20 (m, 3H), 1.96-1.87 (m, 1H), 1.53-1.44 (m, 9H). (b) tert-Butyl (S)-(4-(3-chloro-4-(2-chloro-3-(5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2- methoxybenzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of tert-butyl (S)-(4-(4-(3-amino-2-chlorophenyl)-3-chloropyridin-2-yl)- 2-methoxybenzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (250 mg, 0.44 mmol) in THF was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 0.87 mL, 0.87 mmol) at 0 °C under N2, and the mixture was stirred for 30 minutes. A solution of methyl 5-(3-fluoropropyl)-3- methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate (Example 151, step (a)) (134 mg, 0.52 mmol) in THF was then added at 0 °C, and the mixture was stirred for an additional 2 hours. Upon completion, water was added, and the mixture was extracted with ethyl acetate three times. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude tert-butyl (S)-(4- (3-chloro-4-(2-chloro-3-(5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)((5-oxopyrrolidin-2- yl)methyl)carbamate. MS: m/z found 794.3 [M+H]+, retention time = 2.95 min (Method D). (c) (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl- 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide A solution of tert-butyl (S)-(4-(3-chloro-4-(2-chloro-3-(5-(3-fluoropropyl)-3-methyl- 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2- methoxybenzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (250 mg, 0.16 mmol) in dichloromethane / trifluoroacetic acid (2:1 v/v) was stirred for 30 min, concentrated to dryness and purified by preparative HPLC to give (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy- 4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3- fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide. The final product was converted to free base. White solid, MS: m/z found 694.2 [M+H]+, retention time = 3.77 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.51 (dd, 1H), 7.54 – 7.46 (m, 1H), 7.44 – 7.36 (m, 2H), 7.32 – 7.24 (m, 2H), 7.16 (dd, 1H), 4.60 (t, 1H), 4.48 (t, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.89 – 3.81 (m, 3H), 3.66 (s, 2H), 2.89 (t, 2H), 2.82 – 2.76 (m, 2H), 2.72 (t, 2H), 2.70 – 2.62 (m, 2H), 2.36 – 2.22 (m, 3H), 2.09 – 1.93 (m, 2H), 1.85 – 1.73 (m, 1H). Example 154: N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy- [2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 1-(4-(((2',3'-Dichloro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)amino)piperidin-1- yl)ethan-1-one To a solution of 2',3'-dichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (300.0 mg, 1.06 mmol) in dichloromethane/methanol (1:1, 4 mL) was added 1-(4-aminopiperidin-1- yl)ethan-1-one (165.7 mg, 1.17 mmol), sodium triacetoxyborohydride (673.7 mg, 3.18 mmol) and the mixture was stirred at room temperature for 3 hours under N2. Completion of the reaction was confirmed by UPLC-MS, and after completion, the mixture was concentrated and, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). Evaporated the solvent to get the crude compound, used in the next step directly. MS: m/z found 409 [M+H]+. (b) tert-Butyl (1-acetylpiperidin-4-yl)((2',3'-dichloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)carbamate To a solution of 1-(4-(((2',3'-dichloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)piperidin-1-yl)ethan-1-one (300.0 mg, 0.73 mmol) in methanol (10 mL), was added triethyl amine (0.41 mL, 296.7 mg, 2.93 mmol) and stirred at room temperature for 2 hours. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. The residue was dissolved ethyl acetate (20 mL), washed with aqueous sodium bicarbonate (5 mL), and dried over sodium sulfate. Evaporated the solvent to get the crude compound, it was purified by ISCO on silica gel by eluting with ethyl acetate in hexanes to get the desired product, tert-butyl (1-acetylpiperidin-4-yl)((2',3'- dichloro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)carbamate (220.0 mg, 58.9%). MS: m/z found 509 [M+H]+. (c) tert-Butyl (1-acetylpiperidin-4-yl)((2'-(3-amino-2-chlorophenyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-5-yl)methyl)carbamate To a mixture of tert-butyl (1-acetylpiperidin-4-yl)((2',3'-dichloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)carbamate (200.0 mg, 0.39 mmol), 2-chloro-3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)aniline (99.5 mg, 0.39 mmol) in 1,4-dioxane (5 mL)/water (1mL) was added, palladium-tetrakis(triphenylphosphine) (90.7 mg, 0.08 mmol), and sodium carbonate (124.8 mg, 1.18 mmol) then the mixture was stirred at 105 °C for 1 hour under N2. Progress was monitored by UPLC-MS, after completion, then water (10 mL) was added, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude compound tert-butyl (1-acetylpiperidin-4-yl)((2'-(3-amino-2-chlorophenyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-5-yl)methyl)carbamate (146.0 mg, 62%) was used directly in the next step. MS: m/z found 600 [M+H]+. (d) tert-Butyl (1-acetylpiperidin-4-yl)((3'-chloro-2'-(2-chloro-3-(5-(2-(3,5-dimethyl- 1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)carbamate To a mixture of tert-butyl (1-acetylpiperidin-4-yl)((2'-(3-amino-2-chlorophenyl)-3'- chloro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)carbamate (60.0 mg, 0.10 mmol) in THF (6 mL) was added lithium bis(trimethylsilyl)amide solution in tetrahydrofuran (1.0 M, 0.18 mL, 30.69 mg, 0.18 mmol) at 0 °C, and the mixture was stirred at 0 °C for 1 hour under N2. A solution of methyl 5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxylate (38.05 mg, 0.12 mmol) in tetrahydrofuran (6 mL) was then added at 0 °C, and the mixture was stirred at 0 °C to room temperature for 30min under N2. Completion was confirmed by UPLC-MS analysis, water (10 mL) was added, and the combined mixture was extracted with ethyl acetate (2 x 15 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to get the crude tert-butyl (1-acetylpiperidin-4-yl)((3'-chloro-2'-(2-chloro-3-(5-(2- (3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)carbamate as a pale yellow gummy solid. It was used in the next step directly. MS: m/z found 885 [M+H]+. (e) N-(3-(5-(((1-Acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a mixture of tert-butyl (1-acetylpiperidin-4-yl)((3'-chloro-2'-(2-chloro-3-(5-(2- (3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)carbamate (34.0 mg, 0.04 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (1.5 mL, 2188.0 mg, 19.19 mmol) at room temperature, and the mixture was stirred at room temperature for 30 min. Completion was confirmed by UPLC-MS analysis, and after completion, the mixture was concentrated under reduced pressure to get the crude compound. It was purified by reverse phase HPLC to get the desired N-(3-(5-(((1- acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (4.2 mg, 13.9%) as a white fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.66 – 8.60 (m, 1H), 8.59 – 8.46 (m, 2H), 7.85 (d, 1H), 7.78 (dd, 1H), 7.55 – 7.47 (m, 1H), 7.47 – 7.40 (m, 1H), 7.22 (dd, 1H), 4.50 (d, 1H), 4.06 (d, 3H), 4.01 – 3.92 (m, 9H), 3.65 (s, 3H), 3.21 – 3.08 (m, 1H), 2.98 (d, 2H), 2.81 (s, 2H), 2.67 (s, 6H), 2.20 (d, 6H), 2.11 (d, 3H). MS: m/z found 785 [M+H]+, retention time = 2.39 min (Method A). Example 155: (S)-5-(2-(4H-1,2,4-Triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy- 5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(4H-1,2,4-Triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 4-(2-bromoethyl)-4H-1,2,4-triazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.54 (dd, 1H), 7.86 – 7.73 (m, 2H), 7.68 (dd, 1H), 7.56 – 7.44 (m, 2H), 7.42 (d, 1H), 7.21 (dd, 1H), 6.30 – 6.24 (m, 1H), 4.37 (t, 2H), 4.04 (s, 4H), 3.96 (s, 4H), 3.84 (t, 4H), 3.56 (s, 3H), 3.05 (t, 2H), 2.87 (t, 2H), 2.75 – 2.62 (m, 5H), 2.38 – 2.22 (m, 3H), 1.91 – 1.71 (m, 1H). MS: m/z found 729 [M+H]+, retention time = 2.93 min (Method A). Example 156: (S)-5-(2-(Benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6- methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'- yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(Benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-(2-bromoethyl)benzo[d]isoxazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.54 (dd, 1H), 7.96 (d, 1H), 7.88 (dt, 1H), 7.77 (dd, 1H), 7.72 –7.61 (m, 2H), 7.52 (dd, 2H), 7.41 (ddd, 1H), 7.24 (dd, 1H), 4.34 (s, 2H), 4.12 (d, 3H), 4.01 (s, 4H), 3.73 –3.39 (m, 5H), 3.22 (d, 4H), 3.16 –2.91 (m, 3H), 2.54 –2.20 (m, 3H), 2.03 –1.78 (m, 1H). MS: m/z found 780 [M+H]+, retention time = 3.73 min (Method A). Example 157: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-(bromomethyl)oxetane in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.65 (dd, 1H), 8.54 (dd, 1H), 7.88 (d, 1H), 7.78 (dd, 1H), 7.49 (dt, 2H), 7.22 (dt, 1H), 4.84 (dd, 2H), 4.47 (t, 2H), 4.15 – 4.02 (m, 5H), 3.97 (d, 5H), 3.54 (s, 2H), 3.03 (d, 2H), 2.92 (s, 5H), 2.79 (d, 3H), 2.45 – 2.23 (m, 4H), 1.97 – 1.79 (m, 1H). MS: m/z found 705 [M+H]+, retention time = 2.98 min (Method A). Example 158: N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, steps (a) to (c), replacing (tert-butoxycarbonyl)glycine with methyl-L-proline in step (a), and (S)-5-(aminomethyl)pyrrolidin-2-one-hydrochloride with 1-(4-aminopiperidin-1-yl)ethan-1- one in step (c). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.52 (t, 1H), 7.56 – 7.37 (m, 3H), 7.37 – 7.23 (m, 2H), 7.16 (dd, 1.5 Hz, 1H), 4.57 (d, 4H), 4.23 – 3.69 (m, 11H), 3.78 – 3.42 (m, 2H), 3.13 (d, 1H), 2.96 – 2.60 (m, 3H), 2.44 (s, 3H), 2.11 (s, 4H), 1.28 (s, 1H). MS: m/z found 773 [M+H]+, retention time = 3.73 min (Method A). Example 159: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H- pyrazol-4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 4-(2-bromoethyl)-1-methyl- 1H-pyrazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.65 (dd, 1H), 8.55 (dd, 1H), 7.89 (d, 1H), 7.78 (dd, 1H), 7.62 – 7.42 (m, 3H), 7.39 (s, 1H), 7.23 (dd, 1H), 4.09 (d, 5H), 4.00 (d, 3H), 3.94 (s, 4H), 3.84 (d, 3H), 3.06 (d, 4H), 2.88 (dd, 5H), 2.44 – 2.27 (m, 3H), 1.95 – 1.76 (m, 1H), 1.29 (s, 2H). MS: m/z found 743 [M+H]+, retention time = 3.23 min (Method A). Example 160: N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide N-(3-(2-(4-(((1-Acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 109, replacing (S)-5-(aminomethyl)pyrrolidin-2-one-hydrochloride with 1-(4-aminopiperidin-1- yl)ethan-1-one in step (c). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.56 – 8.45 (m, 1H), 7.54 – 7.46 (m, 1H), 7.45 – 7.38 (m, 2H), 7.36 – 7.22 (m, 2H), 7.16 (dd, 1H), 4.56 (d, 3H), 3.99 (d, 4H), 3.94 (s, 3H), 3.86 – 3.69 (m, 4H), 3.19 – 3.05 (m, 1H), 2.85 (s, 1H), 2.78 (s, 1H), 2.73 – 2.63 (m, 1H), 2.54 (t, 4H), 2.10 (s, 3H), 2.06 (s, 3H), 1.29 (s, 1H). MS: m/z found 733 [[M+H]+, retention time = 2.85 min (Method A). Example 161: N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan- 2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 93, steps (a) to (c), replacing (tert-butoxycarbonyl)glycine with methyl-L-proline in step (a), and (S)-5-(aminomethyl)pyrrolidin-2-one-hydrochloride with 2,6-diazaspiro[3.4]octan-7-one in step (c). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.58 – 8.45 (m, 1H), 7.50 (t, 1H), 7.46 – 7.32 (m, 2H), 7.28 (d, 2H), 7.16 (dt, 1H), 4.78 – 4.40 (m, 2H), 3.99 (dd, 3H), 3.95 – 3.82 (m, 6H), 3.56 (d, 6H), 2.96 – 2.70 (m, 3H), 2.72 – 2.41 (m, 5H), 1.94 (s, 1H). MS: m/z found 757 [M+H]+, retention time = 2.91 min (Method A). Example 162: N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan- 2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 109, replacing (S)-5-(aminomethyl)pyrrolidin-2-one-hydrochloride with 2,6-diazaspiro[3.4]octan- 7-one in step (c). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.58 – 8.45 (m, 1H), 7.50 (t, 1H), 7.46 – 7.32 (m, 2H), 7.28 (d, 2H), 7.16 (dt, 1H), 4.78 – 4.40 (m, 2H), 3.99 (dd, 3H), 3.95 – 3.82 (m, 6H), 3.56 (d, 6H), 2.96 – 2.70 (m, 3H), 2.72 – 2.41 (m, 5H), 1.94 (s, 1H). MS: m/z found 717 [M+H]+, retention time = 2.78 min (Method A). Example 163: (S)-5-(2-(1H-Pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(1H-Pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 1-(2-bromoethyl)-1H-pyrazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.54 (dt, 1H), 7.84 (d, 1H), 7.78 (dd, 1H), 7.68 (dd, 1H), 7.59 – 7.38 (m, 3H), 7.22 (dt, 1H), 6.27 (td, 1H), 4.37 (t, 2H), 4.06 (d, 3H), 4.00 – 3.90 (m, 5H), 3.88 (t, 1H), 3.57 (s, 3H), 3.06 (t, 3H), 2.88 (t, 2H), 2.84 – 2.62 (m, 5H), 2.52 – 2.21 (m, 3H), 1.96 – 1.72 (m, 1H). MS: m/z found 729 [M+H]+, retention time = 2.57 min (Method A). Example 164: (S)-5-(3-Amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(3-Amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-bromopropanamide in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.54 (dt, 1H), 7.84 (d, 1H), 7.78 (dd, 1H), 7.68 (dd, 1H), 7.59 – 7.38 (m, 3H), 7.22 (dt, 1H), 6.27 (td, 1H), 4.37 (t, 2H), 4.06 (d, 3H), 4.00 – 3.90 (m, 5H), 3.88 (t, 1H), 3.57 (s, 3H), 3.06 (t, 3H), 2.88 (t, 2H), 2.84 – 2.62 (m, 5H), 2.52 – 2.21 (m, 3H), 1.96 – 1.72 (m, 1H). MS: m/z found 706 [M+H]+, retention time = 2.34 min (Method A). Example 165: (S)-5-(2-Amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-Amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 2-bromoacetamide in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.54 (dd, 1H), 7.91 – 7.67 (m, 2H), 7.60 – 7.33 (m, 2H), 7.22 (dd, 1H), 4.05 (d, 4H), 3.98 (d, 3H), 3.92 (s, 2H), 3.87 (t, 1H), 3.63 (s, 2H), 3.27 (d, 2H), 2.96 (t, 2H), 2.79 (d, 5H), 2.42 – 2.19 (m, 3H), 1.92 – 1.75 (m, 1H). MS: m/z found 692 [M+H]+, retention time = 2.31 min (Method A). Example 166: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3- (dimethylamino)propanoyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 122, replacing (S)-1-(tert-butoxycarbonyl)pyrrolidine-3- carboxylic acid with 3-(dimethylamino)propanoic acid hydrochloride salt in step (a). White solid, MS: m/z found 734 [M+H]+, retention time = 2.65 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.54 (t, 1H), 7.81 (d, 1H), 7.78 (d, 1H), 7.50 (t, 1H), 7.43 (d, 1H), 7.23 (d, 1H), 4.60 (s, 2H), 4.05 (s, 3H), 4.00-3.95 (m, 4H), 3.91-3.83 (m, 4H), 2.85- 2.66 (m, 8H), 2.41 (d, J = 8.8 Hz, 6H), 2.36-2.23 (m, 3H), 1.87-1.78 (m, 1H). Example 167: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-bromo-N- methylpropanamide in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.64 (dd, 1H), 8.57 – 8.47 (m, 1H), 7.89 – 7.71 (m, 2H), 7.55 – 7.37 (m, 2H), 7.22 (dd, 1H), 4.06 (s, 4H), 3.97 (s, 5H), 3.89 (d, 1H), 3.61 (s, 3H), 3.01 – 2.88 (m, 5H), 2.79 (d, 5H), 2.71 (s, 3H), 2.49 (t, 2H), 2.43 – 2.24 (m, 3H), 1.91 – 1.78 (m, 1H). MS: m/z found 720 [M+H]+, retention time = 2.36 min (Method A). Example 168: (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (a) tert-Butyl (1r,4r)-4-((2-((3-(5-(((tert-butoxycarbonyl)(((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate tert-Butyl (1r,4r)-4-((2-((3-(5-(((tert-butoxycarbonyl)(((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate was prepared in a similar fashion to Example 110, step (a) and (b), replacing 2-iodoethan-1-ol with tert-butyl (1r,4r)-4-(bromomethyl)cyclohexane- 1-carboxylate in step (a). (b) (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid To a mixture of tert-butyl (1r,4r)-4-((2-((3-(5-(((tert-butoxycarbonyl)(((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate (38.0 mg, 0.04 mmol) in 1,4-dioxane (1 mL) was added HCl in 1,4-dioxane (4 N) (2.5 mL, 10.19 mmol) at room temperature, and the mixture was stirred at room temperature for 30 min. Completion was confirmed by UPLC-MS analysis, and after completion, the mixture was concentrated and lyophilized to obtain (1r,4r)-4-((2- ((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (32.0 mg, 92.5%) as a pale yellow solid.1H NMR (400 MHz, Methanol-d4): δ 8.71 (dd, 1H), 8.63 – 8.47 (m, 1H), 8.01 (dd, 1H), 7.84 (dd, 1H), 7.63 – 7.43 (m, 2H), 7.27 (ddd, 1H), 4.55 (d, 1H), 4.37 (d, 2H), 4.26 (d, 1H), 4.13 (d, 3H), 4.11 – 4.05 (m, 2H), 4.04 (d, 4H), 3.92 (d, 1H), 3.78 – 3.62 (m, 0H), 3.57 (dd, 1H), 3.27 (d, 1H), 3.22 (d, 2H), 3.18 – 3.05 (m, 2H), 2.49 – 2.34 (m, 3H), 2.32 – 2.23 (m, 1H), 2.07 (d, 2H), 2.01 – 1.84 (m, 6H), 1.51 (q, 2H), 1.16 (q, 2H). MS: m/z found 775 [M+H]+, retention time = 2.69 min (Method A). Example 169: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with (S)-2- (bromomethyl)oxetane in step (a). White fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.66 (dd, 1H), 8.61 – 8.39 (m, 1H), 7.94 (d, 1H), 7.77 (dd, 1H), 7.56 – 7.43 (m, 2H), 7.33 – 7.16 (m, 1H), 5.19 (d, 1H), 4.79 – 4.65 (m, 1H), 4.59 (dt, 1H), 4.26 (s, 2H), 4.11 (d, 3H), 3.99 (d, 3H), 3.93 (s, 2H), 3.21 – 3.05 (m, 2H), 2.99 – 2.71 (m, 2H), 2.62 – 2.28 (m, 3H), 2.04 – 1.79 (m, 1H). MS: m/z found 705 [M+H]+, retention time = 2.46 min (Method A). Example 170: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3- oxopropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-bromo-N,N- dimethylpropanamide in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.74 – 8.60 (m, 1H), 8.54 (dd, 1H), 7.85 (d, 2H), 7.77 (d, 1H), 7.60 – 7.39 (m, 3H), 7.22 (dd, 1H), 4.07 (d, 4H), 3.99 (d, 7H), 3.90 (s, 2H), 3.78 (s, 2H), 3.21 – 3.04 (m, 10H), 2.94 (s, 4H), 2.86 (s, 5H), 2.76 (t, 3H), 2.45 – 2.18 (m, 4H), 1.95 – 1.72 (m, 1H). MS: m/z found 734 [M+H]+, retention time = 2.44 min (Method A). Example 171: (S)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) Methyl 4-((2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane- 1-carboxylate To a solution of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, step (e)) (80.00 mg, 0.15 mmol) in dichloromethane (2 mL), was added trifluoroacetic acid (2.28 mL, 3398.27 mg, 29.80 mmol) and stirred at room temperature for 15 min. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. aqueous sodium bicarbonate (3 mL) was added to the residue and extracted with dichloromethane (2 x15 mL). The combined organic layer was dried over sodium sulfate, and evaporated the solvent, the crude compound was used in the reductive amination. To the crude compound in dichloromethane/methanol (4 mL), was added methyl 4-formylbicyclo[2.2.1]heptane-1-carboxylate (27.1 mg, 0.15 mmol) and sodium acetate (36.7 mg, 0.45 mmol), and the mixture was stirred for 30 min. Then, sodium cyanoborohydride (61.8 mg, 0.45 mmol) was added, and the mixture was stirred at room temperature for 16 hours. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in aqueous sodium bicarbonate (3 mL), extracted with dichloromethane (2 x10 mL). The combined organic layer was dried over sodium sulfate, and evaporated the solvent, the crude compound was used in next step directly. MS: m/z found 602 [M+H]+. (b) Methyl 4-((2-((2-chloro-3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-((2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[2.2.1]heptane-1-carboxylate (80.0 mg, 0.13 mmol) and 2-methoxy-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (52.2 mg, 0.20 mmol) in 1,4- dioxane (5 mL)/water (1 mL) was added sodium carbonate (28.1 mg, 0.27 mmol) and tetrakis(triphenylphosphine)palladium(0) (30.7 mg, 0.03 mmol) then the mixture was stirred at 120 °C for 6 hours under N2. Progress was monitored by UPLC-MS, after completion, water (10 mL) was added, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was used directly in the next step. MS: m/z found 702 [M+H]+. (c) Methyl (S)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-((2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylate (60.0 mg, 0.09 mmol) and (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride (27.8 mg, 0.18 mmol) in dichloromethane/methanol (1:1 v/v, 4 mL) was added sodium acetate (22.7 mg, 0.28 mmol) and then the mixture was stirred at room temperature for 30 min under N2. Sodium cyanoborohydride (17.4 mg, 0.28 mmol) was then added and the mixture was stirred at room temperature for 1h under N2. Completion of the reaction was confirmed by UPLC-MS, and after completion, the mixture was concentrated and, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). Evaporated the solvent to give bethyl (S)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylate that was used in the next step without further purification. MS: m/z found 800 [M+H]+. (d) (S)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of methyl (S)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1- carboxylate (30.00 mg, 0.04 mmol) in methanol/water (4 mL, 4:1 v/v) was added lithium hydroxide (4.72 mg, 0.11 mmol) at room temperature, and the mixture was stirred at room temperature for 30 min. Completion was confirmed by UPLC-MS analysis, and after completion, the mixture was concentrated under reduced pressure to get the crude compound. It was purified by reverse phase HPLC to give (S)-4-((2-((2-chloro-3-(3- chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl) phenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid (11.2 mg, 38%) as a white fluffy solid. 1H NMR (400 MHz, Methanol-d4) δ 8.66 – 8.57 (m, 1H), 8.56 – 8.44 (m, 1H), 7.52 – 7.44 (m, 1H), 7.45 – 7.36 (m, 2H), 7.33 – 7.22 (m, 2H), 7.15 (dd, 1H), 4.07 – 3.76 (m, 9H), 3.60 (s, 2H), 2.94 (t, 2H), 2.80 – 2.65 (m, 7H), 2.46 – 2.12 (m, 3H), 1.95 (d, 2H), 1.86 – 1.56 (m, 8H), 1.45 (s, 2H). MS: m/z found 786 [M+H]+, retention time = 2.83 min (Method A). Example 172: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with (R)-2- (bromomethyl)oxetane in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.54 (dd, 1H), 7.86 (d, 1H), 7.77 (d, 1H), 7.57 – 7.39 (m, 2H), 7.22 (dd, 1H), 5.26 – 5.05 (m, 1H), 4.79 – 4.43 (m, 2H), 4.07 (s, 3H), 4.00 (s, 3H), 3.97 (s, 3H), 3.91 (s, 1H), 3.66 (s, 2H), 3.56 – 3.41 (m, 1H), 3.13 (d, 1H), 2.95 – 2.69 (m, 5H), 2.36 (dd, 3H). MS: m/z found 705 [M+H]+, retention time = 2.45 min (Method A). Example 173: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with 3-bromopropane-1- sulfonamide in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.64 (dd, 1H), 8.51 (dd, 1H), 7.55 – 7.37 (m, 3H), 7.36 – 7.24 (m, 2H), 7.15 (dt, 1H), 4.01 (t, 2H), 3.97 (d, 3H), 3.95 (d, 3H), 3.90 (d, 1H), 3.57 (s, 3H), 3.23 – 3.07 (m, 2H), 3.00 – 2.64 (m, 10H), 2.46 – 2.21 (m, 3H), 2.10 (t, 2H), 1.91 – 1.71 (m, 1H). MS: m/z found 755 [M+H]+, retention time = 2.63 min (Method A). Example 174: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-bromopropane-1-sulfonamide in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.54 (dd, 1H), 7.88 – 7.71 (m, 2H), 7.50 (t, 1H), 7.43 (dd, 1H), 7.31 – 7.15 (m, 1H), 4.04 (d, 3H), 4.01 – 3.92 (m, 3H), 3.92 – 3.79 (m, 4H), 3.57 (s, 2H), 3.23 – 3.08 (m, 2H), 2.92 (d, 2H), 2.81 – 2.64 (m, 7H), 2.43 – 2.22 (m, 3H), 2.10 (t, 2H), 1.88 – 1.76 (m, 1H). MS: m/z found 756 [M+H]+, retention time = 2.44 min (Method A). Example 175: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H- pyran-4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 4-(2- bromoethyl)tetrahydro-2H-pyran in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (dd, 1H), 8.54 (dd, 1H), 7.87 – 7.72 (m, 3H), 7.55 – 7.46 (m, 1H), 7.43 (dd, 1H), 7.22 (dd, 1H), 4.05 (d, 4H), 3.98 (d, 3H), 3.89 (qd, 6H), 3.61 (s, 3H), 3.40 (td, 3H), 2.96 (s, 3H), 2.84 – 2.61 (m, 8H), 2.44 – 2.20 (m, 4H), 1.88 – 1.77 (m, 1H), 1.74 – 1.50 (m, 6H), 1.44 – 1.16 (m, 4H). MS: m/z found 747 [M+H]+, retention time = 2.60 min (Method A). Example 176: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H- pyran-4-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 171, replacing methyl 4-formylbicyclo[2.2.1]heptane-1- carboxylate with tetrahydro-2H-pyran-4-carbaldehyde in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.64 (dd, 1H), 8.52 (dt, 1H), 7.54 – 7.38 (m, 3H), 7.36 – 7.26 (m, 2H), 7.15 (dt, 1H), 4.02 (s, 2H), 3.99 – 3.82 (m, 10H), 3.52 (s, 2H), 3.44 (td, 3H), 2.97 – 2.82 (m, 5H), 2.76 (d, 2H), 2.48 (d, 3H), 2.40 – 2.26 (m, 3H), 1.99 – 1.87 (m, 1H), 1.87 – 1.68 (m, 3H), 1.44 – 1.13 (m, 4H). MS: m/z found 732 [M+H]+, retention time = 2.72 min (Method A). Example 177: (1s,4s)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1- carboxylic acid (a) Methyl (1s,4s)-4-((2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1- carboxylate To a solution of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, step (e)) (100.0 mg, 0.19 mmol) in dichloromethane (3 mL), was added trifluoroacetic acid (2.9 mL, 37.3 mmol) and the mixture stirred at room temperature for 30 min. Completion of the boc-deprotection was confirmed by UPLC-MS, and the mixture was concentrated to dryness. Aqueous sodium bicarbonate (3 mL) was added to the residue and extracted with dichloromethane (2 x15 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated, to give the crude product that was used for N- alkylation. To the crude compound in acetonitrile (4 mL), was added potassium carbonate (77.23 mg, 0.56 mmol), and methyl 4-(methylsulfonyloxymethyl)cyclohexanecarboxylate (93.2 mg, 0.37 mmol) at room temperature. The mixture was heated at 80 oC for 48 h, and completion was observed by UPLC-MS analysis. After completion, water (10 mL) was added, and the mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to afford methyl (1s,4s)-4-((2-((2-chloro-3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate. The crude product was used in next step without further purification. MS: m/z found 590 [M+H]+. Steps (b)-(d): (1s,4s)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1- carboxylic acid Steps (b)-(d) were performed in a similar fashion to Example 171 steps (b)-(d), to obtain (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl) phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid. White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.67 (dd, 1H), 8.56 – 8.41 (m, 1H), 7.61 – 7.48 (m, 2H), 7.47 – 7.40 (m, 2H), 7.37 (dd, 1H), 7.25 – 7.08 (m, 1H), 4.37 (d, 2H), 3.81 – 3.41 (m, 2H), 3.26 – 3.20 (m, 4H), 3.16 – 3.08 (m, 2H), 2.64 (d, 1H), 2.48 – 2.33 (m, 3H), 2.10 (d, 4H), 1.98 – 1.83 (m, 1H), 1.78 – 1.52 (m, 5H), 1.50 – 1.10 (m, 3H). MS: m/z found 774 [M+H]+, retention time = 2.88 min (Method A). Example 178: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H- pyran-4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl) phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with 4-(2- bromoethyl)tetrahydro-2H-pyran in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.51 (dd, 1H), 7.49 (dd, 1H), 7.44 – 7.36 (m, 2H), 7.30 – 7.23 (m, 2H), 7.15 (dd, 1H), 3.97 (s, 3H), 3.92 (s, 4H), 3.90 (d, 1H), 3.87 (d, 2H), 3.85 – 3.80 (m, 1H), 3.54 (s, 2H), 3.40 (td, 2H), 2.90 (t, 2H), 2.77 (t, 2H), 2.67 (dd, 4H), 2.47 – 2.14 (m, 3H), 1.84 – 1.50 (m, 6H), 1.30 (d, 3H). MS: m/z found 746 [M+H]+, retention time = 2.79 min (Method A). Example 179: (S)-N-(2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl) phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 100, replacing methyl 2-bromoacetate with 3-(bromomethyl)-3- methyloxetane in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.57 – 8.47 (m, 1H), 7.48 (dd, 1H), 7.44 – 7.35 (m, 2H), 7.30 – 7.22 (m, 2H), 7.15 (dd, 1H), 4.57 (d, 2H), 4.36 (d, 2H), 3.97 (s, 3H), 3.92 (s, 3H), 3.87 (d, 2H), 3.85 – 3.79 (m, 1H), 3.60 – 3.39 (m, 3H), 2.91 – 2.55 (m, 8H), 2.45 – 2.14 (m, 3H), 1.90 – 1.70 (m, 1H), 1.43 (s, 3H). MS: m/z found 718 [M+H]+, retention time = 2.57 min (Method A). Example 180: (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid (S)-3-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid was prepared in a similar fashion to Example 100 and 101, replacing methyl 2-bromoacetate with methyl 3-(bromomethyl)bicyclo[1.1.1]pentane-1-carboxylate in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.55 – 8.43 (m, 1H), 7.57 – 7.46 (m, 2H), 7.44 (d, 1H), 7.36 – 7.26 (m, 2H), 7.16 (dd, 1H), 5.25 (s, 8H), 4.15 (d, 2H), 3.97 (d, 7H), 3.72 (s, 2H), 3.08 – 2.96 (m, 4H), 2.83 (d, 5H), 2.50 – 2.25 (m, 3H), 2.02 (s, 7H), 1.91 – 1.80 (m, 1H). MS: m/z found 758 [M+H]+, retention time = 2.70 min (Method A). Example 181: 3-(((4-(4-(3-(5-((3-Carboxybicyclo[1.1.1]pentan-1-yl)methyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3- chloropyridin-2-yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid (a) Methyl 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((3- (methoxycarbonyl)bicyclo[1.1.1]pentan-1-yl)methyl)amino)methyl)phenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate To a mixture of methyl 3-((2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate [prepared in a similar fashion to Example 100, steps-(a) and (b), replacing methyl 2-bromoacetate with methyl 3- (bromomethyl)bicyclo[1.1.1]pentane-1-carboxylate in step (a)] (50.0 mg, 0.07 mmol) and methyl 3-(aminomethyl)bicyclo[1.1.1]pentane-1-carboxylate (11.5 mg, 0.07 mmol) in dichloromethane/methanol (1:1 v/v, 4 mL) was added sodium acetate (18.2 mg, 0.22 mmol) and then the mixture was stirred at room temperature for 30 min under N2. Sodium cyanoborohydride (14.0 mg, 0.22 mmol) was then added and the mixture was stirred at room temperature for 1 hour under N2. Completion of the reaction was confirmed by UPLC-MS, and after completion, the mixture was concentrated and, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). The solvent was evaporated to give crude methyl 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((3- (methoxycarbonyl)bicyclo[1.1.1]pentan-1-yl)methyl)amino)methyl)phenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate that was used in the next step without further purification. MS: m/z found 813 [M+H]+. (b) 3-(((4-(4-(3-(5-((3-Carboxybicyclo[1.1.1]pentan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3- chloropyridin-2-yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid To a mixture of methyl 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((3- (methoxycarbonyl)bicyclo[1.1.1]pentan-1-yl)methyl)amino)methyl)phenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate (30.0 mg, 0.04 mmol) in methanol / water (4 mL, 4:1 v/v) was added lithium hydroxide monohydrate (4.7 mg, 0.11 mmol) at room temperature, and the mixture was stirred at room temperature for 30 min. Completion was confirmed by UPLC-MS analysis, and after completion, the mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC to obtain 3-(((4-(4-(3-(5- ((3-carboxybicyclo [1.1.1]pentan-1-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2-yl)-2- methoxybenzyl)amino)methyl) bicyclo[1.1.1]pentane-1-carboxylic acid (11.2 mg, 38.0% yield) as a white fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.51 (dd, 1H), 7.56 – 7.47 (m, 2H), 7.45 (d, 1H), 7.40 (d, 1H), 7.35 (dd, 1H), 7.16 (dd, 1H), 4.29 (s, 2H), 3.99 (d, 6H), 3.74 (s, 2H), 3.18 (s, 2H), 3.07 (d, 2H), 2.99 – 2.72 (m, 4H), 2.05 (d, 13H), 2.03 (s, 5H). MS: m/z found 785 [M+H]+, retention time = 2.92 min (Method A). Example 182: (S)-4-(2-(2-((3-(3-Chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylic acid (a) Methyl 4-(2-(2-((3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylate To a solution of N-(3-(2,3-dichloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (Example 47, step (b)) (700 mg, 1.68 mmol) and methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, step (c)) (495 mg, 2.52 mmol) in dichloromethane / methanol (1:1 v/v, 8 mL) was added sodium acetate (414 mg, 5.04 mmol), and the mixture stirred at room temperature for 1 hour under N2. Sodium cyanoborohydride (317 mg, 5.04 mmol) was then added and the mixture was stirred at room temperature for 0.5 hours under N2. Water (20 mL) was then added, and the mixture extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude was purified by normal phase SiO2 chromatography (0-100% ethyl acetate / petroleum ether) to afford methyl 4-(2-(2-((3-(2,3-dichloropyridin-4-yl)-2- methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (740 mg) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ.9.81 (s, 1H), 8.46 (d, 1H), 7.73 (d, 1H), 7.42 (d, 1H), 7.33 (t, 1H), 7.04 (d, 1H), 3.85 (s, 3H), 3.58 (s, 3H), 3.41 (s, 2H), 2.76-2.74 (m, 2H), 2.66-2.64 (m, 2H), 2.55-2.52 (m, 2H), 1.97 (s, 3H), 1.91-1.83 (m, 2H), 1.75-1.71 (m, 2H), 1.58-1.52 (m, 4H), 1.47 (s, 2H), 1.42-1.35 (m, 2H). (b) Methyl 4-(2-(2-((3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin-4-yl)-2- methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a solution of methyl 4-(2-(2-((3-(2,3-dichloropyridin-4-yl)-2- methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (300 mg, 0.50 mmol) and 2-methoxy-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (198 mg, 0.75 mmol) in 1,4- dioxane / water (5:1 v/v, 9.6 mL) was added potassium phosphate (320 mg, 1.51 mmol) and [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (32.8 mg, 0.05 mmol). The reaction was stirred at 130 °C for 2 hours under N2 and combined with another batch at 40 mg scale. Water (30 mL) was then added and the mixture extracted with ethyl acetate (2 x 60 mL). The combined organic layers were washed with saturated aqueous brine solution (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100% ethyl acetate / petroleum ether) to afford methyl 4-(2-(2-((3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (340 mg) as a yellow solid, MS: m/z found 696 [M+H]+. (c) Methyl (S)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylate To a solution of methyl 4-(2-(2-((3-(3-chloro-2-(4-formyl-3-methoxyphenyl)pyridin- 4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (100 mg, 0.144 mmol) and (S)-5- (aminomethyl)pyrrolidin-2-one hydrochloride salt (32.5 mg, 0.22 mmol) in dichloromethane / methanol (1:1 v/v, 3 mL) was added sodium acetate (35.4 mg, 0.43 mmol), and the reaction mixture stirred at room temperature for 3 hours under N2. Sodium cyanoborohydride (27.1 mg, 0.43 mmol) was then added and the mixture stirred at room temperature for 0.5 hours under N2. The mixture was combined with another two batches at 40 mg and 200 mg scales. Water (40 mL) was then added, and the mixture was extracted with dichloromethane (2 x 30 mL). The combined organic layers were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-30% methanol / ethyl acetate) to afford methyl (S)-4-(2-(2-((3-(3-chloro- 2-(3-methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2- methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (230 mg) as a yellow solid, MS: m/z found 794 [M+H]+. (d) (S)-4-(2-(2-((3-(3-Chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylic acid To a solution of methyl (S)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (200 mg, 0.25 mmol) in THF / water (2:1 v/v, 9 mL) was added lithium hydroxide monohydrate (106 mg, 2.52 mmol). The reaction mixture was stirred at room temperature for 12 hours under N2, concentrated under reduced pressure and purified by reverse phase HPLC to afford (S)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (142.9 mg) as a white solid. MS: m/z found 780 [M+H]+, retention time = 2.75 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.60 (d, 1H), 7.84 (d, 1H), 7.43-7.35 (m, 3H), 7.30- 7.26 (m, 2H), 7.09 (dd, 1H), 4.00-3.94 (m, 8H), 3.92-3.84 (m, 1H), 3.61 (s, 2H), 2.97 (t, 1H), 2.81-2.70 (m, 6H), 2.35-2.26 (m, 3H), 2.13 (s, 3H), 2.01-1.95 (m, 2H), 1.88-1.84 (m, 3H), 1.67-1.54 (m, 6H), 1.48-1.43 (m, 2H). Example 183: 3-(((4-(4-(3-(5-((4-Carboxybicyclo[2.2.1]heptan-1-yl)methyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3- chloropyridin-2-yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid 3-(((4-(4-(3-(5-((4-Carboxybicyclo[2.2.1]heptan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2- yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid was prepared in a similar fashion to Example 171, replacing (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride with methyl 3-(aminomethyl)bicyclo[1.1.1]pentane-1-carboxylate in step (c). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.56 – 8.41 (m, 2H), 7.56 – 7.42 (m, 3H), 7.40 (d, 1H), 7.35 (dd, 1H), 7.15 (dd, 1H), 4.29 (s, 2H), 3.99 (d, 6H), 3.63 (s, 2H), 3.17 (s, 2H), 2.96 (d, 2H), 2.77 (s, 3H), 1.98 (s, 3H), 1.71 (d, 1H), 1.61 (s, 2H), 1.47 (s, 2H). MS: m/z found 813 [M+H]+ , retention time = 3.05 min (Method A). Example 184: (S)-5-(2-(2H-Tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5- ((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-5-(2-(2H-Tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 5-(2-bromoethyl)-1H-tetrazole in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.54 (dd, 1H), 7.88 (d, 1H), 7.77 (d, 1H), 7.59 – 7.40 (m, 2H), 7.22 (dd, 1H), 5.11 – 4.97 (m, 1H), 4.18 – 4.03 (m, 5H), 3.99 (d, 3H), 3.93 (s, 3H), 3.66 – 3.42 (m, 1H), 3.06 – 2.94 (m, 2H), 2.94 – 2.79 (m, 2H), 2.48 – 2.22 (m, 3H), 1.87 (dd, 1H). MS: m/z found 731 [M+H]+, retention time = 2.40 min (Method A). Example 185: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H- pyran-4-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 128, replacing 2,4-dimethyloxazole-5-carbaldehyde with tetrahydro-2H-pyran-4-carbaldehyde in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (dd, 1H), 8.54 (dd, 1H), 7.88 – 7.70 (m, 3H), 7.50 (dd, 1H), 7.47 – 7.39 (m, 2H), 7.22 (dd, 1H), 4.04 (d, 4H), 3.97 (s, 3H), 3.96 – 3.90 (m, 2H), 3.85 (d, 4H), 3.51 (s, 2H), 3.49 – 3.39 (m, 2H), 2.86 (d, 2H), 2.79 – 2.64 (m, 5H), 2.47 (d, 2H), 2.45 – 2.17 (m, 5H), 1.98 – 1.64 (m, 4H), 1.29 (q, 3H). MS: m/z found 733 [M+H]+, retention time = 1.61 min (Method D). Example 186: (S)-3-(2-((2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid (S)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid was prepared in a similar fashion to Example 168, replacing tert-butyl (1r,4r)-4-(bromomethyl)cyclohexane-1-carboxylate with tert-butyl 3-bromopropanoate in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol- d4): δ 8.64 (d, 1H), 8.54 (dd, 1H), 7.85 (d, 1H), 7.78 (d, 1H), 7.51 (dd, 1H), 7.45 (d, 1H), 7.23 (dd, 1H), 4.06 (s, 3H), 4.03 (s, 2H), 4.00 (s, 3H), 3.98 (d, 2H), 3.95 – 3.87 (m, 1H), 3.38 (t, 2H), 3.25 (t, 2H), 2.96 (t, 2H), 2.89 – 2.78 (m, 1H), 2.63 (t, 2H), 2.47 – 2.25 (m, 3H), 1.92 – 1.79 (m, 1H). MS: m/z found 707 [M+H]+, retention time = 2.41 min (Method A). Example 187: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) tert-Butyl (S)-((2',3'-dichloro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)((5- oxopyrrolidin-2-yl)methyl)carbamate A mixture of 2',3'-dichloro-6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (Example 35, step (c)) (5.0 g, 5.3 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride salt (1.6 g, 10.6 mmol) in dichloromethane (15 mL) was added sodium acetate (1.74 g, 21.2 mmol) and the mixture was stirred at room temperature for 1.5 hours under N2. Sodium cyanoborohydride (0.67 g, 10.6 mmol) was then added and the mixture stirred at room temperature for 1.5 hours under N2. Di-tert-butyl dicarbonate (3.66 g, 16.8 mmol) and triethylamine (1.33 g, 13.11 mmol, 1.83 mL, 2.5 eq) were then added and the mixture stirred at room temperature for 1 hour under N2. The mixture was concentrated, and the residue purified by normal phase SiO2 chromatography (0-100 % ethyl acetate / petroleum ether) to afford semi-purified product (1.9 g). Semi-purified product (800 mg) was purified by reverse phase HPLC to afford tert-butyl (S)-((2',3'-dichloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (500 mg, 62% yield).1H NMR (400 MHz, DMSO-d6): δ 8.54 (d, 1H), 7.83 (s, 1H), 7.75 (d, 1H), 7.62-7.47 (m, 2H), 4.54-4.41 (m, 2H), 4.00 (s, 3H), 3.83-3.82 (m, 1H), 3.36-3.33 (m, 2H), 2.24-2.12 (m, 3H), 1.79-1.78 (m, 1H), 1.49-1.36 (m, 9H). (b) tert-Butyl (S)-((2'-(3-amino-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a mixture of tert-butyl (S)-((2',3'-dichloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (2 g, 4.15 mmol) and 2-chloro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.58 g, 6.23 mmol) in 1,4-dioxane / water (5:1 v/v, 24 mL) was added potassium carbonate (1.72 g, 12.5 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.34 g, 0.42 mmol), and then the mixture stirred at 110 °C for 1 hour under N2. Water (30 mL) was then added and the mixture extracted with ethyl acetate (2 x 50 mL). The combined organic phases were dried over anhydrous sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-100 % ethyl acetate / petroleum ether) to afford tert-butyl (S)-((2'-(3-amino-2-chlorophenyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (1.6 g, 67% yield) as a yellow solid.1H NMR (400 MHz, DMSO-d6): δ 8.66 (d, 1H), 7.77 (s, 1H), 7.69 (d, 1H), 7.54-7.49 (m, 1H), 7.47-7.43 (m, 1H), 7.13 (t, 1H), 6.88 (dd, 1H), 6.58 (dd, 1H), 5.49 (s, 2H), 4.48-4.36 (m, 2H), 3.96 (s, 3H), 3.78-3.76 (m, 1H), 3.33-3.28 (m, 2H), 2.18-2.06 (m, 3H), 1.76-1.73 (m, 1H), 1.38-1.24 (m, 9H). (c) 2-(1-Isopropyl-1H-pyrazol-4-yl)ethan-1-ol To a solution of 2-(1H-pyrazol-4-yl)ethan-1-ol (3 g, 26.8 mmol) and 2-bromopropane (12.6 mL, 134 mmol) in DMF (30 mL) was added potassium carbonate (11.1 g, 80.3 mmol) in one portion under N2. The mixture was stirred at 60 °C for 48 hours, filtered and concentrated. Water (20 mL) and saturated aqueous brine solution (20 mL) were added and the mixture was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried with anhydrous sodium sulfate, filtered, concentrated and purified by normal phase SiO2 chromatography (0-50% ethyl acetate/petroleum ether) to afford 2-(1-isopropyl-1H- pyrazol-4-yl)ethan-1-ol as a light yellow gum (0.8 g, 25% yield) (80% purity) and 2-(1- isopropyl-1H-pyrazol-4-yl)ethan-1-ol (1 g, 30% yield, 67% purity) as a light yellow gum.1H NMR (400 MHz, Methanol-d4): δ 7.41 (s, 1H), 7.33 (s, 1H), 4.52-4.45 (m, 1H), 3.80 (d, 2H), 2.75 (d, 2H), 1.51 (d, 6H). (d) 2-(1-Isopropyl-1H-pyrazol-4-yl)ethyl methanesulfonate To a mixture of 2-(1-isopropyl-1H-pyrazol-4-yl)ethan-1-ol (1 g, 6.48 mmol) and triethylamine (2.7 mL, 19.5 mmol) in dichloromethane (10 mL) was added dropwise methanesulfonyl chloride (1.6 mL, 21.1 mmol) at 0 °C under N2. The mixture was stirred at room temperature for 2 hours and then water (20 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic phases were dried with anhydrous sodium sulfate, filtered and concentrated to give 2-(1- isopropyl-1H-pyrazol-4-yl)ethyl methanesulfonate (1.5 g, crude). MS: m/z found 233 [M+H]+. (e) Methyl 5-(2-(1-isopropyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxylate To a mixture of 2-(1-isopropyl-1H-pyrazol-4-yl)ethyl methanesulfonate (1.11 g, 4.78 mmol) and methyl 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate trifluoroacetate salt (3.69 g, 12 mmol) in DMF (10 mL) was added potassium carbonate (5.28 g, 38.2 mmol) in one portion under N2. The mixture was stirred at 100 °C for 12 hours, filtered and concentrated and combined with another batch at 390 mg scale. The crude product was purified by reverse phase HPLC to afford methyl 5-(2-(1-isopropyl-1H-pyrazol- 4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate as a light yellow gum (160 mg, 7% yield).1H NMR (400 MHz, Methanol-d4): δ 7.56 (s, 1H), 7.39 (s, 1H), 4.49-4.44 (m, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.60 (s, 2H), 2.98-2.95 (m, 2H), 2.84-2.78 (m, 6H), 1.47 (d, 6H). (f) tert-Butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2- yl)methyl)carbamate
To a solution of tert-butyl (S)-((2'-(3-amino-2-chlorophenyl)-3'-chloro-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (Example 187, step (b)) (0.1 g, 0.18 mmol) in THF (3 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 0.5 mL, 0.5 mmol) dropwise at 0 °C under N2. The mixture was stirred at 0 °C for 30 min and then a solution of methyl 5-(2-(1-isopropyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (0.06 g, 0.18 mmol) in THF (1.5 mL) was added. The mixture was stirred at room temperature for 2.5 hours and then water (5 mL) was added to quench the reaction. The mixture was combined with another batch at 40 mg scale. After concentration and extraction with ethyl acetate, the organic layer was dried, concentrated and purified by normal phase SiO2 chromatography (0-20% methanol / ethyl acetate) to afford tert-butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6- methoxy-[2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (210 mg, 50% yield) as a yellow solid. MS: m/z found 871 [M+H]+. (g) (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of tert-butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(2-(1-isopropyl-1H- pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2- yl)methyl)carbamate (0.2 g, 0.23 mmol) in 1,4-dioxane (1.5 mL) was added concentrated HCl solution (0.6 mL) in one portion. The mixture was stirred at room temperature for 1 hour, neutralized with saturated aqueous sodium bicarbonate solution and purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (40.4 mg, 20% yield) as a white solid. MS: m/z found 771 [M+H]+, retention time = 2.78 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.56 (d, 1H), 7.83 (d, 1H), 7.80 (d, 1H), 7.57 (s, 1H), 7.52 (t, 1H), 7.44 (d, 1H), 7.39 (s, 1H), 7.24 (d, 1H), 4.51-4.44 (m, 1H), 4.06 (s, 3H), 4.00 (s, 2H), 3.89-3.83 (m, 3H), 3.64 (s, 2H), 3.00-2.97 (m, 2H), 2.85-2.75 (m, 6H), 2.74-2.69 (m, 2H), 2.38-2.29 (m, 3H), 1.87-1.81 (m, 1H), 1.47 (d, 6H). Example 188: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with 3-(bromomethyl)-3- methyloxetane in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.62 (d, 1H), 8.55 (dd, 1H), 7.89 – 7.71 (m, 2H), 7.50 (dd, 1H), 7.42 (d, 1H), 7.21 (dd, 1H), 4.57 (d, 2H), 4.36 (d, 2H), 4.04 (s, 3H), 3.97 (s, 3H), 3.86 – 3.81 (m, 3H), 3.42 (s, 2H), 2.92 – 2.77 (m, 4H), 2.77 – 2.55 (m, 5H), 2.44 – 2.20 (m, 4H), 1.89 – 1.77 (m, 1H), 1.43 (s, 3H). MS: m/z found 719 [M+H]+, retention time = 2.45 min (Method A). Example 189: (S)-3-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid (a) Methyl 5-((3-(methoxycarbonyl)bicyclo[1.1.1]pentan-1-yl)methyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate To a solution of 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-2,5-dicarboxylate (75.0 mg, 0.25 mmol) in dichloromethane (2 mL), was added trifluoroacetic acid (2 mL) and the mixture stirred at room temperature for 30 min. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. The crude compound was dried under high vacuum and used for the N-alkylation reaction. To the crude product in acetonitrile (4 mL), was added methyl 3- (bromomethyl)bicyclo[1.1.1]pentane-1-carboxylate (61.2 mg, 0.28 mmol), N,N- diisopropylethylamine (0.13 mL, 98.5 mg, 0.76 mmol), and the mixture was stirred at 90 oC for 48 hours. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in aqueous sodium bicarbonate (3 mL), extracted with dichloromethane (2 x 10 mL). The combined organic layers were dried over sodium sulfate, and evaporated to give methyl 5-((3-(methoxycarbonyl)bicyclo[1.1.1]pentan-1-yl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate that was used in next step without further purification. MS: m/z found 334 [M+H]+. (b) Methyl (S)-3-((2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino) methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate To a mixture of tert-butyl N-[[6-[2-(3-amino-2-chloro-phenyl)-3-chloro-4-pyridyl]-2- methoxy-3-pyridyl]methyl]-N-[[(2S)-5-oxopyrrolidin-2-yl]methyl]carbamate (60.00 mg, 0.10 mmol) in THF (6 mL) was added lithium bis(trimethylsilyl)amide solution in tetrahydrofuran (1M, 0.22 mL, 0.22 mmol) at 0 °C, and the mixture stirred for 30 min under N2. A solution of methyl 5-((3-(methoxycarbonyl)bicyclo[1.1.1]pentan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (38.4 mg, 0.12 mmol) in tetrahydrofuran (6 mL) was then added at 0°C, and the mixture was stirred at 0 °C to room temperature for 30 min under N2. Completion was confirmed by UPLC-MS analysis, after completion, water (10 mL) was added, and the combined mixture extracted with ethyl acetate (2 x 15 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give methyl (S)-3-((2-((3-(5-(((tert-butoxycarbonyl)((5- oxopyrrolidin-2-yl)methyl)amino) methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate as a pale-yellow gummy solid, that was used in the next step without further purification. MS: m/z found 873 [M+H]+. (c) Methyl (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate To a mixture of methyl (S)-3-((2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate (28.0 mg, 0.03 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (0.25 mL, 372.6 mg, 3.27 mmol) at room temperature, and the mixture was stirred at room temperature for 30 min. After completion the solvent was evaporated, and the crude product was dried under high vacuum to give Methyl (S)-3-((2-((2- chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylate that was used in the next step without further purification. MS: m/z found 773 [M+H]+. (d) (S)-3-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid To a mixture of methyl (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1- carboxylate (30.0 mg, 0.04 mmol) in methanol / water (4 mL, 4:1 v/v) was added lithium hydroxide monohydrate (4.7 mg, 0.11 mmol) at room temperature, and the mixture was stirred at room temperature for 30 min. Completion was confirmed by UPLC-MS analysis, and after completion, the mixture was concentrated under reduced pressure. The residue was purified by reverse phase HPLC to obtain, (S)-3-((2-((2-chloro-3-(3'-chloro-6- methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid (11.2 mg, 38%) as a white fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.54 (dd, 1.5 Hz, 1H), 7.84 (d, 1H), 7.78 (d, 1H), 7.61 – 7.38 (m, 2H), 7.22 (dd, 1.5 Hz, 1H), 4.05 (s, 3H), 3.99 (s, 3H), 3.94 (d, 2H), 3.88 (t, 1H), 3.76 (s, 2H), 3.11 (d, 2H), 2.95 – 2.69 (m, 6H), 2.49 – 2.22 (m, 3H), 2.05 (s, 6H), 1.90 – 1.76 (m, 1H). MS: m/z found 759 [M+H]+, retention time = 2.51 min (Method A). Example 190: (1r,4r)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1- carboxylic acid (a) tert-Butyl (1r,4r)-4-((2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate To a solution of tert-butyl 2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, step (e)) (75 mg, 0.14 mmol) in dichloromethane (3 mL), was added trifluoracetic acid (2.21 mL) and the mixture stirred at room temperature for 30 min. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. The crude compound was dried under high vacuum and used for the N-alkylation. To the crude product in acetonitrile (3 mL), was added tert-butyl (1r,4r)-4- (bromomethyl)cyclohexane-1-carboxylate (77.5 mg, 0.28 mmol) and potassium carbonate (58 mg, 0.42 mmol), and the mixture was stirred at 70 oC for 16 hours. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in water (10 mL), and extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give tert-butyl (1r,4r)-4-((2-((2-chloro- 3-(2,3-dichloropyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate that was used in next step without further purification. MS: m/z found 632 [M+H]+. (b) tert-Butyl (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate To a mixture of tert-butyl (1r,4r)-4-((2-((2-chloro-3-(2,3-dichloropyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate (60 mg, 0.09 mmol) and 2-methoxy-4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (37.3 mg, 0.14 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was added sodium carbonate (20 mg, 0.19 mmol) and tetrakis(triphenylphosphine)palladium(0) (21.9 mg, 0.02 mmol) then the mixture was stirred at 120 °C for 2 hours under N2. Progress was monitored by UPLC-MS, after completion, water (10 mL) was added, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give tert-butyl (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2- (4-formyl-3-methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate (51 mg, 73% yield) that was used in the next step without further purification. MS: m/z found 732 [M+H]+. (c) tert-Butyl (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1- carboxylate To a mixture of tert-butyl (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(4-formyl-3- methoxyphenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate (36.0 mg, 0.05 mmol) and (S)- 5-(aminomethyl)pyrrolidin-2-one hydrochloride (14.8 mg, 0.10 mmol) in dichloromethane / methanol (1:1 v/v, 4 mL) was added sodium acetate (12.1 mg, 0.15 mmol) and then the mixture was stirred at room temperature for 30 min under N2. Sodium cyanoborohydride (9.3 mg, 0.15 mmol) was then added and the mixture was stirred at room temperature for 1 hour under N2. Completion of the reaction was confirmed by UPLC-MS, and after completion, the mixture was concentrated, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). The solvent was evaporated to give tert-butyl (1r,4r)-4-((2-((2-chloro-3- (3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin- 4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate that was used in the next step without further purification. MS: m/z found 830 [M+H]+. (d) (1r,4r)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid To a mixture of tert-butyl (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)- 5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate (38 mg, 0.04 mmol) in 1,4-dioxane (1 mL) was added HCl in 1,4-dixoane (4N, 2.5 mL, 10.2 mmol) and the mixture was stirred at room temperature for 30 min. Completion was confirmed by UPLC-MS analysis. After completion, the mixture was concentrated under reduced pressure and then lyophilized to give (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3- methoxy-4-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid (17.0 mg, 54% yield) as a pale yellow solid.1H NMR (400 MHz, Methanol-d4): δ 8.69 (d, 1H), 8.51 (dd, 1H), 7.62 – 7.46 (m, 3H), 7.43 (d, 1H), 7.38 (dd, 1H), 7.19 (dd, 1H), 4.55 (d, 1H), 4.37 (d, 2H), 4.26 (d, 1H), 4.02 (d, 6H), 3.92 (d, 1H), 3.76 – 3.42 (m, 1H), 3.27 – 3.08 (m, 5H), 2.53 – 2.20 (m, 4H), 2.13 – 1.80 (m, 5H), 1.50 (dt, 2H), 1.33 – 1.01 (m, 2H). MS: m/z found 774 [M+H]+, retention time = 2.78 min (Method A). Example 191: (1r,4r)-4-((2-((3-(5-(((1-Acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (a) Methyl 5-(((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate To a solution of 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-2,5-dicarboxylate (250.0 mg, 0.85 mmol) in dichloomethane (2 mL), was added trifluoracetic acid (2 mL) and the mixture stirred at room temperature for 30 min. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. The crude compound was dried under high vacuum and used for the N-alkylation. To the crude product in acetonitrile (10 mL), was added tert-butyl (1r,4r)-4- (bromomethyl)cyclohexane-1-carboxylate (258.1 mg, 0.93 mmol) and N, N- diisopropylethylamine (0.44 mL, 328.2 mg, 2.54 mmol), and the mixture was stirred at 90 oC for 48 h. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in aqueous sodium bicarbonate (5 mL), extracted with dichloromethane (2 x 25 mL). The combined organic layers were dried over sodium sulfate, and the solvent evaporated to give methyl 5-(((1r,4r)-4-(tert- butoxycarbonyl)cyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine- 2-carboxylate that was used in next step without further purification. MS: m/z found 392 [M+H]+. (b) tert-Butyl (1r,4r)-4-((2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate To a mixture of methyl 5-(((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (280.00 mg, 0.72 mmol) in tetrahydrofuran (6 mL) was added lithium bis(trimethylsilyl)amide solution in tetrahydrofuran (1M, 1.5 mL, 1.50 mmol) at 0 °C, and the mixture was stirred at 0 °C for 30 min under N2. A solution of 2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (217.6 mg, 0.86 mmol) in THF (6 mL) was then added at 0°C, and the mixture stirred for 1 hour under N2. Completion was confirmed by UPLC-MS analysis, after completion, water (10 mL) was added, and the combined mixture extracted with ethyl acetate (2 x 25 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give tert-butyl (1r,4r)-4-((2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate as a pale-yellow gummy solid that was used in the next step without further purification. MS: m/z found 613 [M+H]+. (c) tert-Butyl (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate To a mixture of tert-butyl (1r,4r)-4-((2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate (390.0 mg, 0.64 mmol) and 2',3'-dichloro- 6-methoxy-[2,4'-bipyridine]-5-carbaldehyde (198.1 mg, 0.70 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was added, sodium carbonate (134.9 mg, 1.27 mmol) and tetrakis(triphenylphosphine)palladium(0) (147 mg, 0.13 mmol) and then the mixture was stirred at 100 °C for 10 hours under N2. Progress was monitored by UPLC-MS, after completion, water (10 mL) was added, and the mixture was extracted with ethyl acetate (2 x 25 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude compound was purified by ISCO on silica gel column by sequential elution with 20% ethyl acetate in hexanes, 50% ethyl acetate in hexanes followed by 90% ethyl acetate in hexanes to obtain tert-butyl (1r,4r)-4-((2-((2- chloro-3-(3'-chloro-5-formyl-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate (261.0 mg, 56 % yield) as pale yellow fluffy solid. MS: m/z found 733 [M+H]+. (d) tert-Butyl (1r,4r)-4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro- 6-methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate To a mixture of tert-butyl (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-formyl-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate (30 mg, 0.04 mmol) in dichloromethane/methanol (1:1 v/v, 4 mL) was added sodium acetate (10 mg, 0.12 mmol) and 1-(4-aminopiperidin-1-yl)ethan-1-one (11.6 mg, 0.08 mmol) and then the mixture was stirred at room temperature for 30 min under N2. Sodium cyanoborohydride (7.71 mg, 0.12 mmol) was then added and the mixture was stirred at room temperature for 1 hour under N2. Completion of the reaction was confirmed by UPLC-MS, and after completion, the mixture was concentrated and, the residue was dissolved in dichloromethane (25 mL) and washed with water (10 mL). The solvent was evaporated to give tert-butyl (1r,4r)-4-((2-((3-(5-(((1- acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate (40 mg) that was used in the next step without further purification. MS: m/z found 859 [M+H]+. (e) (1r,4r)-4-((2-((3-(5-(((1-Acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid To a mixture of tert-butyl (1r,4r)-4-((2-((3-(5-(((1-acetylpiperidin-4- yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylate (38 mg, 0.04 mmol) in 1,4-dioxane (1 mL) was added HCl in 1,4-dioxane (4 N, 2.55 mL, 10.19 mmol) at room temperature, and the mixture was stirred for 30 min. Completion was confirmed by UPLC-MS analysis, and after completion, the mixture was concentrated under reduced pressure. The residue was re-dissolved in 20% acetonitrile in water and lyophilized to give (1r,4r)-4-((2-((3-(5-(((1-Acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy- [2,4'-bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (32 mg, 93% yield) as a pale yellow solid (dihydrochloride salt).1H NMR (400 MHz, Methanol-d4): δ 8.68 (d, 1H), 8.54 (d, 1H), 7.98 (d, 1H), 7.78 (d, 1H), 7.59 – 7.41 (m, 2H), 7.25 (dd, 1H), 4.70 (s, 1H), 4.35 (s, 2H), 4.12 (s, 3H), 4.04 (s, 3H), 3.75 – 3.37 (m, 1H), 3.24 – 3.08 (m, 5H), 2.69 (d, 1H), 2.35 – 2.22 (m, 4H), 2.14 (s, 3H), 2.07 (d, 2H), 1.92 (d, 3H), 1.62 – 1.38 (m, 2H), 1.18 (s, 1H). MS: m/z found 803 [M+H]+, retention time = 2.71 min (Method A). Example 192: (1s,4s)-4-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (a) Methyl 5-(((1s,4s)-4-(methoxycarbonyl)cyclohexyl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate To a solution of 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridine-2,5-dicarboxylate (75.0 mg, 0.25 mmol) in dichloromethane (2 mL), was added trifluoroacetic acid (2 mL) and the mixture stirred at room temperature for 30 min. Completion of the reaction was confirmed by UPLC-MS, and the mixture was evaporated under reduced pressure. The crude product was dried under high vacuum and used for the N- alkylation. To the crude product in acetonitrile (4 mL), was added methyl (1s,4s)-4- (((methylsulfonyl)oxy)methyl)cyclohexane-1-carboxylate (69.9 mg, 0.28 mmol), N,N- diisopropylethylamine (0.13 mL, 0.76 mmol) and potassium carbonate (105.3 mg, 0.76 mmol) and the mixture was stirred at 90 oC for 48 hours. Completion of the reaction was confirmed by UPLC-MS. After completion, the mixture was suspended in aqueous sodium bicarbonate (3 mL), extracted with ethyl acetate (2 x10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give methyl 5-(((1s,4s)-4- (methoxycarbonyl)cyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate was used in next step without further purification. MS: m/z found 350 [M+H]+. Steps (b)-(d): (1s,4s)-4-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid Steps-(b), (c) and (d) were performed in a similar fashion to Example 189, to obtain (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid as white fluffy solid.1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.55 (dd, 1H), 7.83 (d, 1H), 7.78 (d, 1H), 7.51 (dd, 1H), 7.44 (d, 1H), 7.23 (dd, 1H), 4.05 (s, 3H), 3.99 (s, 3H), 3.91 (d, 2H), 3.89 – 3.85 (m, 1H), 3.65 (s, 2H), 3.39 (d, 1H), 3.01 (s, 2H), 2.90 – 2.69 (m, 4H), 2.67 – 2.47 (m, 4H), 2.45 – 2.23 (m, 3H), 1.99 (d, 3H), 1.90 – 1.75 (m, 2H), 1.73 – 1.50 (m, 6H), 1.33 (dd, 4H). MS: m/z found 775 [M+H]+, retention time = 2.64 min (Method A). Example 193: (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (a) Methyl 5-(((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate Methyl 5-(((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate was prepared in a similar fashion to Example 151, step (a), replacing 1-fluoro-3-iodo-propane with tert-butyl (1r,4r)-4- (bromomethyl)cyclohexane-1-carboxylate. MS: m/z found 392.3 [M+H]+, retention time = 0.73 min (Method B). (b) tert-Butyl (1r,4r)-4-((2-((3-(5-(((tert-butoxycarbonyl)(((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate
tert-Butyl (1r,4r)-4-((2-((3-(5-(((tert-butoxycarbonyl)(((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate was prepared in a similar fashion to Example 151, step (b), replacing methyl 5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine-2-carboxylate with methyl 5-(((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)- 3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate. MS: m/z found 931.4 [M+H]+, retention time = 0.94 min (Method B). (c) (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid To a mixture of tert-butyl (1r,4r)-4-((2-((3-(5-(((tert-butoxycarbonyl)(((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate (50 mg, 0.05 mmol) in 1,4-dioxane (1 mL) was added HCl (4.0 M in 1,4-dioxane, 1.5 mL) at room temperature and the mixture was stirred at room temperature for 30 min. The formed precipitate was filtered off, washed with diethyl ether, and subjected to preparative HPLC to give (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5- (((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)- 3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid. MS: m/z found 775.3 [M+H]+, retention time = 2.62 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (d, 1H), 8.54 (dd, 1H), 7.83 (d, 1H), 7.78 (d, 1H), 7.50 (dd, 1H), 7.44 (d, 1H), 7.22 (dd, 1H), 4.05 (s, 3H), 3.97 (s, 3H), 3.92 – 3.82 (m, 3H), 3.62 (s, 2H), 2.86 (t, 2H), 2.78 – 2.62 (m, 4H), 2.54 – 2.43 (m, 2H), 2.39 – 2.17 (m, 4H), 2.06 – 1.90 (m, 4H), 1.89 – 1.77 (m, 1H), 1.73 – 1.63 (m, 1H), 1.46 (q, 2H), 1.01 (q, 2H). Example 194: (1r,4r)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3- methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1- carboxylic acid (a) tert-Butyl (1r,4r)-4-((2-((3-(2-(4-(((tert-butoxycarbonyl)(((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate tert-Butyl (1r,4r)-4-((2-((3-(2-(4-(((tert-butoxycarbonyl)(((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate was prepared in a similar fashion to Example 193, step (b), replacing tert-butyl (S)-((2'-(3-amino-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate with tert-butyl (S)-(4-(4-(3- amino-2-chlorophenyl)-3-chloropyridin-2-yl)-2-methoxybenzyl)((5-oxopyrrolidin-2- yl)methyl)carbamate (Example 153, step (a)). MS: m/z found 930.4 [M+H]+, retention time = 0.94 min (Method B). (b) (1r,4r)-4-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid To a mixture of tert-butyl (1r,4r)-4-((2-((3-(2-(4-(((tert-butoxycarbonyl)(((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylate (50 mg, 0.05 mmol) in 1,4-dioxane (1 mL) was added HCl (4.0 M in 1,4-dioxane, 1.5 mL) at room temperature and the mixture was stirred at room temperature for 30 min. The formed precipitate was filtered off, washed with diethyl ether, and subjected to preparative HPLC to give (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3- methoxy-4-(((((S)-5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4- yl)phenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid (formic acid salt). MS: m/z found 774.3 [M+H]+, retention time = 2.88 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.64 (dd, 1H), 8.51 (dt, 1H), 7.54 – 7.47 (m, 1H), 7.46 – 7.40 (m, 2H), 7.36 – 7.23 (m, 2H), 7.16 (dt, 1H), 4.06 – 3.98 (m, 2H), 3.98 – 3.93 (m, 6H), 3.93 – 3.84 (m, 1H), 3.60 (s, 2H), 2.89 – 2.76 (m, 4H), 2.74 – 2.66 (m, 2H), 2.52 – 2.42 (m, 2H), 2.41 – 2.27 (m, 3H), 2.19 (t, 1H), 2.04 – 1.90 (m, 4H), 1.87 – 1.76 (m, 1H), 1.73 – 1.59 (m, 1H), 1.46 (q, 2H), 1.00 (q, 2H). Example 195: (S)-4-(2-(2-((2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
(a) tert-Butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridine-5-carboxylate To a solution of 3-bromo-2-chloroaniline (500 mg, 2.42 mmol) in THF (5 mL) at 0 °C was added a 1.0 M lithium bis(trimethylsilyl)amide solution in THF (4.84 mL, 4.84 mmol) and the mixture was stirred at 0 °C for 0.5 hours under N2. A solution of 5-(tert-butyl) 2- methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-dicarboxylate (858 mg, 2.91 mmol) in THF (5 mL) was then added and the mixture stirred at 0 °C for 0.5 hours under N2. Water (15 mL) was then added and the mixture extracted with ethyl acetate (2 x 15 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-16% ethyl acetate / petroleum ether) to afford tert-butyl 2-((3-bromo-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5- carboxylate (900 mg, 79 % yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 10.05 (s, 1H), 8.22 (s, 1H), 7.64 (dd, 1H), 7.40 (t, 1H), 4.45 (s, 2H), 3.94 (s, 3H), 3.74 (t, 2H), 2.76 (t, 2H), 1.49 (s, 9H). (b) N-(3-Bromo-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide To a mixture of tert-butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (2.92 g, 6.22 mmol) in dichloromethane (15 mL) was added trifluoroacetic acid (5 mL, 6.22 mmol) in one portion. The mixture was stirred at room temperature for 1 hour, neutralized with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane (3 x 15 mL). The organic phase was concentrated to afford N-(3-bromo-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (3 g, crude). MS: m/z found 369 [M+H]+. (c) Methyl 4-(2-(2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a solution of N-(3-bromo-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide (1 g, 2.71 mmol) and methyl 4-(2- oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, step (c)) (0.53 g, 2.71 mmol in THF / methanol mixture (1:1 v/v, 10 mL) was added sodium acetate (0.67 g, 8.12 mmol) in one portion under N2. The mixture was stirred at room temperature for 1 hour and then sodium cyanoborohydride (0.43 g, 6.76 mmol) was added. The mixture was stirred at room temperature for 1 h, concentrated and purified by normal phase SiO2 chromatography (20- 60% ethyl acetate / petroleum ether) to afford methyl 4-(2-(2-((3-bromo-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (500 mg, 34% yield) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 8.22 (dd, 1H), 7.59 (dd, 1H), 7.35 (t, 1H), 3.89 (s, 3H), 3.61 (s, 3H), 3.45 (s, 2H), 2.81-2.78 (m, 2H), 2.69-2.68 (m, 2H), 2.58-2.52 (m, 2H), 1.93- 1.86 (m, 2H), 1.78-1.74 (m, 2H), 1.60-1.40 (m, 8H). (d) Methyl 4-(2-(2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate
To a mixture of methyl 4-(2-(2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (0.13 g, 0.23 mmol) and bis(pinacolato)diboron (0.29 g, 1.14 mmol) in 1,4-dioxane (2 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.04 g, 0.05 mmol) and potassium acetate (0.07 g, 0.68 mmol) in one portion under N2. The mixture was stirred at 130 °C for 12 h, and combined with another 4 batches at 125 mg, 125 mg, 50 mg and 150 mg scale. After filtration and concentration, the crude was purified by normal phase SiO2 chromatography (50-90% ethyl acetate / petroleum ether) to afford methyl 4-(2-(2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (275 mg, 55% yield) as a black solid. MS: m/z found 597 [M+H]+. (e) Methyl (S)-4-(2-(2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a mixture of methyl 4-(2-(2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (85 mg, 0.14 mmol) and tert-butyl (S)-((2',3'- dichloro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (Example 187, step (a)) (62 mg, 0.13 mmol) in 1,4-dioxane / water (10:1 v/v, 1.1 mL) was added chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′- biphenyl)]palladium(II) (22 mg, 0.03 mmol) and potassium phosphate (90 mg, 0.43 mmol) in one portion under N2. The mixture was stirred at 110 °C for 3 hours and combined with another batch at 190 mg scale. Upon concentration, water (50 mL) and saturated aqueous brine solution (15 mL) were added, and the mixture was extracted with ethyl acetate / THF mixture (10:1 v/v, 50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by normal phase SiO2 chromatography (0-5% MeOH/ethyl acetate) to afford methyl (S)-4-(2-(2-((3-(5-(((tert-butoxycarbonyl)((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (130 mg, 30% yield) as a yellow solid. MS: m/z found 915 [M+H]+. (f) Methyl (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate To a solution of methyl (S)-4-(2-(2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (125 mg, 0.14 mmol) in 1,4-dioxane (1 mL) was added concentrated HCl solution (0.3 mL) in one portion. The mixture was stirred at room temperature for 1 hour and concentrated to afford methyl (S)-4-(2-(2-((2-chloro-3-(3'- chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate. MS: m/z found 815 [M+H]+. (g) (S)-4-(2-(2-((2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a solution of methyl (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylate in 1,4-dioxane (1 mL) was added lithium hydroxide monohydrate (0.06 g, 1.53 mmol) and water (0.1 mL) in one portion under N2. The mixture was stirred at room temperature for 12 hours and purified by reverse phase HPLC to afford (S)-4-(2-(2-((2- chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (33.6 mg, 30% yield) as a white solid. MS: m/z found 801 [M+H]+, retention time = 2.74 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.56 (dd, 1H), 7.84 (d, 1H), 7.80 (d, 1H), 7.52 (t, 1H), 7.45 (d, 1H), 7.24 (dd, 1H), 4.07 (s, 3H), 4.00 (s, 3H), 3.93-3.85 (m, 3H), 3.67 (s, 2H), 3.04-3.01 (m, 2H), 2.85-2.82 (m, 2H), 2.79-2.70 (m, 4H), 2.39-2.28 (m, 3H), 2.03-1.97 (m, 2H), 1.91-1.80 (m, 3H), 1.69-1.59 (m, 4H), 1.57 (s, 2H), 1.51-1.46 (m, 2H). Example 196: (S)-4-(2-(2-((3-(3'-Chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1- carboxylic acid (S)-4-(2-(2-((3-(3'-Chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid was prepared in a similar fashion to Example 195, replacing 3-bromo-2-chloroaniline with 3-bromo-2-methylaniline in(step (a). White solid, MS: m/z found 781 [M+H]+, retention time = 2.49 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 7.92 (d, 1H), 7.83 (d, 1H), 7.75 (d, 1H), 7.44 (d, 1H), 7.40 (t, 1H), 7.19 (d, 1H), 4.06 (s, 3H), 3.98 (s, 3H), 3.90-3.85 (m, 3H), 3.68 (s, 2H), 3.04 (t, 2H), 2.83 (t, 2H), 2.80-2.72 (m, 4H), 2.39-2.28 (m, 3H), 2.15 (s, 3H), 2.06-1.98 (m, 2H), 1.92-1.82 (m, 3H), 1.69-1.59 (m, 4H), 1.57 (s, 2H), 1.51-1.46 (m, 2H). Example 197: N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide N-(2-Chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide was prepared in a similar fashion to Example 110, replacing 2-iodoethan-1-ol with (1r,4r)-4-(bromomethyl)cyclohexan-1-ol in step (a). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.63 (d, 1H), 8.58 – 8.46 (m, 1H), 7.85 – 7.71 (m, 2H), 7.50 (dd, 1H), 7.43 (d, 1H), 7.22 (dd, 1H), 4.04 (s, 3H), 3.97 (s, 3H), 3.85 (d, 3H), 3.49 (s, 3H), 2.85 (t, 2H), 2.78 – 2.61 (m, 4H), 2.42 (d, 2H), 2.38 – 2.22 (m, 3H), 2.03 (s, 2H), 2.00 – 1.76 (m, 5H), 1.33 – 1.19 (m, 2H), 1.02 (t, 2H). MS: m/z found 747 [M+H]+, retention time = 2.48 min (Method A). Example 198: (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-((((1R,3R)-3- hydroxycyclopentyl)amino)methyl)-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-((((1R,3R)-3-hydroxycyclopentyl)amino)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid was prepared in a similar fashion to Example 191, replacing 1-(4-aminopiperidin-1-yl)ethan-1-one with (1R,3R)-3- aminocyclopentan-1-ol in step (d). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.65 (d, 1H), 8.59 – 8.49 (m, 2H), 7.91 (d, 1H), 7.77 (d, 1H), 7.55 – 7.46 (m, 2H), 7.21 (dd, 1H), 4.38 (dd, 1H), 4.14 (s, 2H), 4.09 (s, 3H), 3.81 – 3.64 (m, 1H), 3.59 – 3.45 (m, 2H), 3.01 – 2.83 (m, 2H), 2.77 (d, 2H), 2.45 (d, 2H), 2.35 – 2.25 (m, 1H), 2.26 – 2.05 (m, 1H), 1.94 (dd, 4H), 1.79 (ddd, 1H), 1.68 (dt, 2H), 1.44 (q, 2H), 0.99 (q, 2H). MS: m/z found 762 [M+H]+, retention time = 2.75 min (Method A). Example 199: (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-((((1S,3S)-3- hydroxycyclopentyl)amino)methyl)-6-methoxy-[2,4'-bipyridin]-2'- yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-((((1S,3S)-3- hydroxycyclopentyl)amino)methyl)-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1- methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid was prepared in a similar fashion to Example 191, replacing 1-(4-aminopiperidin-1- yl)ethan-1-one with (1S,3S)-3-aminocyclopentan-1-ol in step (d). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.60 – 8.45 (m, 2H), 7.90 (d, 1H), 7.77 (d, 1H), 7.55 – 7.43 (m, 2H), 7.21 (dd, 1H), 4.44 – 4.33 (m, 1H), 4.10 (s, 2H), 4.09 (s, 3H), 3.97 (s, 3H), 3.78 – 3.60 (m, 1H), 3.56 – 3.45 (m, 2H), 2.94 – 2.82 (m, 2H), 2.77 (d, 2H), 2.44 (d, 2H), 2.20 – 2.01 (m, 2H), 2.04 – 1.81 (m, 4H), 1.85 – 1.71 (m, 1H), 1.67 (d, 4H), 1.44 (d, 2H), 1.00 (t, 2H). MS: m/z found 762 [M+H]+, retention time = 2.76 min (Method A). Example 200: (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1- yl)methyl)-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid was prepared in a similar fashion to Example 191, replacing 1-(4-aminopiperidin-1-yl)ethan-1-one with (R)- pyrrolidin-3-ol in step (d). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.66 (d, 1H), 8.55 (dd, 1H), 7.96 (d, 1H), 7.78 (d, 1H), 7.56 – 7.44 (m, 2H), 7.22 (dd, 1H), 4.53 (t, 1H), 4.37 – 4.25 (m, 2H), 4.09 (s, 3H), 3.98 (s, 3H), 3.65 (s, 2H), 3.53 – 3.39 (m, 1H), 3.20 – 3.08 (m, 1H), 3.01 (s, 2H), 2.83 (d, 2H), 2.57 (d, 2H), 2.34 – 2.15 (m, 1H), 2.03 (s, 6H), 1.93 (dd, 5H), 1.69 (s, 1H), 1.45 (q, 2H), 1.04 (t, 1H). MS: m/z found 748 [M+H]+, retention time = 2.71 min (Method A). Example 201: (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1- yl)methyl)-6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid was prepared in a similar fashion to Example 191, replacing 1-(4-aminopiperidin-1-yl)ethan-1-one with (S)-pyrrolidin- 3-ol in step (d). White fluffy solid, 1H NMR (400 MHz, Methanol-d4) δ 8.66 (d, 1H), 8.55 (dd, 1H), 7.96 (d, 1H), 7.78 (d, 1H), 7.62 – 7.43 (m, 2H), 7.22 (dd, 1H), 4.54 (d, 1H), 4.31 (d, 2H), 4.09 (s, 3H), 3.98 (s, 3H), 3.65 (s, 2H), 3.44 (dd, 1H), 3.21 – 3.07 (m, 1H), 3.01 (s, 2H), 2.82 (t, 2H), 2.57 (d, 2H), 2.41 – 2.10 (m, 1H), 2.03 (s, 2H), 2.00 (d, 4H), 1.93 (d, 1H), 1.51 – 1.37 (m, 2H), 1.04 (t, 1H). MS: m/z found 748 [M+H]+, retention time = 2.69 min (Method A). Example 202: (S)-4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) Methyl 3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate 5-(tert-Butyl) 2-methyl 3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5- dicarboxylate (350 mg, 1.19 mmol) was stirred in a mixture of 1:1 v/v trifluoroacetic acid / dichloromethane, concentrated, to give methyl 3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine-2-carboxylate as the trifluoroacetate salt which was converted to the free base. MS: m/z found 196.1 [M+H]+, retention time = 0.38 min (Method B). (b) Methyl 5-(2-(4-(methoxycarbonyl)bicyclo[2.2.1]heptan-1-yl)ethyl)-3-methyl- 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate A mixture of methyl 3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2- carboxylate (132 mg, 0.68 mmol), methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, step (c)) (133 mg, 0.68 mmol) and acetic acid (39 uL, 41 mg, 0.68 mmol) in methanol / dichloromethane (1:1 v/v) was stirred for 1 hour at room temperature and then sodium cyanoborohydride (85 mg, 1.35 mmol) was added. The mixture was stirred for an additional 30 min, quenched with water, and extracted into dichloromethane three times. The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and concentrated to give methyl 5-(2-(4- (methoxycarbonyl)bicyclo[2.2.1]heptan-1-yl)ethyl)-3-methyl-4,5,6,7-tetrahydro-3H- imidazo[4,5-c]pyridine-2-carboxylate that was used in the next step without further purification. MS: m/z found 376.2 [M+H]+, retention time = 0.60 min (Method B). (c) Methyl (S)-4-(2-(2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate Methyl (S)-4-(2-(2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate was prepared in a similar fashion to Example 194, step (a), replacing methyl 5-(((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)methyl)-3- methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate with methyl 5-(2-(4- (methoxycarbonyl)bicyclo[2.2.1]heptan-1-yl)ethyl)-3-methyl-4,5,6,7-tetrahydro-3H- imidazo[4,5-c]pyridine-2-carboxylate. MS: m/z found 914.4 [M+H]+, retention time = 0.90 min (Method B). (d) (S)-4-(2-(2-((3-(2-(4-(((tert-Butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid A mixture of methyl (S)-4-(2-(2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (150 mg, 0.16 mmol) and lithium hydroxide monohydrate (21 mg, 0.49 mmol) in THF/water (3:1 v/v) was stirred at room temperature for 1 hour. Upon completion, the mixture was concentrated and acidified with 1.0 M HCl (aq.) to give the desired product as precipitate. Purification by preparative HPLC gave (S)-4-(2-(2- ((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid. MS: m/z found 900.4 [M+H]+, retention time = 0.85 min (Method B). (e) ((S)-4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of (S)-4-(2-(2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (100 mg, 0.11 mmol) in 1,4-dioxane (1 mL) was added HCl in dioxane (4.0 M, 2 mL) and the mixture was stirred at room temperature for 30 min. The formed precipitate was filtered off, washed three times with diethyl ether and dried to give (S)-4-(2-(2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid as a dihydrochloride salt. MS: m/z found 800.3 [M+H]+, retention time = 2.95 min (Method A). 1H NMR (400 MHz, Methanol-d4): δ 8.74 (d, 1H), 8.51 (dd, 1H), 7.62 – 7.57 (m, 2H), 7.54 (dd, 1H), 7.46 (d, 1H), 7.40 (dd, 1H), 7.22 (dd, 1H), 4.78 (d, 1H), 4.44 – 4.33 (m, 3H), 4.12 – 3.98 (m, 7H), 3.96 – 3.88 (m, 1H), 3.58 – 3.52 (m, 1H), 3.47 – 3.39 (m, 2H), 3.28 – 3.18 (m, 2H), 3.16 – 3.05 (m, 1H), 3.05 – 2.94 (m, 1H), 2.49 – 2.32 (m, 3H), 2.21 – 1.99 (m, 4H), 1.98 – 1.87 (m, 1H), 1.76 – 1.65 (m, 4H), 1.64 (s, 2H), 1.60 – 1.48 (m, 2H). Example 203: (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid (1r,4r)-4-((2-((2-Chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid was prepared in a similar fashion to Example 191, replacing 1-(4-aminopiperidin-1-yl)ethan-1-one with 2-aminoethan-1-ol in step (d). White fluffy solid, 1H NMR (400 MHz, Methanol-d4): δ 8.84 – 8.63 (m, 1H), 8.59 – 8.49 (m, 1H), 7.98 (d, 1H), 7.88 (d, 1H), 7.63 – 7.50 (m, 2H), 7.33 – 7.24 (m, 1H), 4.55 (d, 2H), 4.34 (s, 2H), 4.30 – 4.15 (m, 3H), 4.12 (d, 3H), 4.04 (d, 4H), 3.88 – 3.82 (m, 2H), 3.74 (ddd, 2H), 3.69 – 3.63 (m, 4H), 3.60 – 3.55 (m, 2H), 3.22 (t, 6H), 3.18 – 3.08 (m, 3H), 2.37 – 2.22 (m, 1H), 2.07 (d, 3H), 1.95 (t, 5H), 1.55 (dd, 3H), 1.16 (q, 3H). MS: m/z found 722 [M+H]+, retention time = 2.58 min (Method A). Example 204: (S)-4-(2-(2-((2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (a) Methyl (S)-4-(2-(2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate Methyl (S)-4-(2-(2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate was prepared in a similar fashion to Example 202, step (c), replacing tert-butyl (S)-(4-(4-(3-amino-2-chlorophenyl)-3-chloropyridin-2-yl)- 2-methoxybenzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate with tert-butyl (S)-((2'-(3-amino- 2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2- yl)methyl)carbamate (Example 187, step (b)). MS: m/z found 915.4 [M+H]+, retention time = 0.90 min (Method B). (b) (S)-4-(2-(2-((3-(5-(((tert-Butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (S)-4-(2-(2-((3-(5-(((tert-Butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid was prepared in a similar fashion to Example 202, step (d), replacing methyl (S)-4-(2-(2-((3-(2-(4-(((tert-butoxycarbonyl)((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate with methyl (S)-4-(2-(2-((3-(5-(((tert- butoxycarbonyl)((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate. MS: m/z found 901.4 [M+H]+, retention time = 0.85 min (Method B). (c) (S)-4-(2-(2-((2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid To a mixture of (S)-4-(2-(2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (50 mg, 0.06 mmol) in 1,4-dioxane (1 mL) was added HCl in 1,4-dioxane (4.0 M, 1 mL) at room temperature and the mixture was stirred at room temperature for 30 min. The formed precipitate was filtered off, washed three times with diethyl ether and dried to give (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl- 3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid as a dihydrochloride salt. MS: m/z found 801.3 [M+H]+, retention time = 2.85 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.69 (d, 1H), 8.54 (dd, 1H), 8.00 (d, 1H), 7.80 (d, 1H), 7.57 – 7.48 (m, 2H), 7.26 (dd, 1H), 4.76 (d, 1H), 4.44 – 4.31 (m, 3H), 4.13 (s, 3H), 4.11 – 4.04 (m, 1H), 4.04 (s, 3H), 3.97 – 3.84 (m, 1H), 3.61 – 3.49 (m, 1H), 3.48 – 3.38 (m, 2H), 3.30 – 3.22 (m, 2H), 3.17 – 2.93 (m, 2H), 2.48 – 2.32 (m, 3H), 2.20 – 1.98 (m, 4H), 1.98 – 1.85 (m, 1H), 1.75 – 1.59 (m, 6H), 1.61 – 1.44 (m, 2H). Example 205: (S)-3-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid (a) Methyl 5-((3-(methoxycarbonyl)cyclobutyl)methyl)-3-methyl-4,5,6,7-tetrahydro- 3H-imidazo[4,5-c]pyridine-2-carboxylate Methyl 5-((3-(methoxycarbonyl)cyclobutyl)methyl)-3-methyl-4,5,6,7-tetrahydro-3H- imidazo[4,5-c]pyridine-2-carboxylate was prepared in a similar fashion to Example 202, step (b), replacing methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate with methyl 3- formylcyclobutane-1-carboxylate. MS: m/z found 322.2 [M+H]+, retention time = 0.49 min (Method B). (b) Methyl (S)-3-((2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylate Methyl (S)-3-((2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylate was prepared in a similar fashion to Example 202, step (c), replacing methyl 5-(2-(4-(methoxycarbonyl)bicyclo[2.2.1]heptan-1-yl)ethyl)-3-methyl- 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate with methyl 5-((3- (methoxycarbonyl)cyclobutyl)methyl)-3-methyl-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine-2-carboxylate. MS: m/z found 860.3 [M+H]+, retention time = 0.85 min (Method B). (c) (S)-3-((2-((3-(2-(4-(((tert-Butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylic acid (S)-3-((2-((3-(2-(4-(((tert-Butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylic acid was prepared in a similar fashion to Example 202, step (d), replacing methyl (S)-4-(2-(2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate with methyl (S)-3-((2-((3-(2-(4-(((tert- butoxycarbonyl)((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate. MS: m/z found 846.3 [M+H]+, retention time = 0.82 min (Method B). (d) (S)-3-((2-((2-Chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid To a solution of (S)-3-((2-((3-(2-(4-(((tert-Butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylic acid (100 mg, 0.11 mmol) in 1,4-dioxane (1 mL) was added HCl in dioxane (4.0 M, 1.5 mL) at room temperature and the mixture was stirred at room temperature for 30 min. The formed precipitate was filtered off, washed three times with diethyl ether and subjected to preparative HPLC to give (S)-3-((2-((2-chloro-3-(3- chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4- yl)phenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylic acid as formic acid salt. MS: m/z found 746.3 [M+H]+, retention time = 2.57 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.65 (dd, 1H), 8.51 (dd, 1H), 8.49 (d, 1H), 7.52 – 7.45 (m, 2H), 7.44 (dd, 1H), 7.35 (d, 1H), 7.32 (dd, 1H), 7.16 (dd, 1H), 4.15 – 4.05 (m, 2H), 4.00 – 3.89 (m, 7H), 3.67 (s, 2H), 3.10 – 2.53 (m, 10H), 2.37 (dt, 5H), 2.12 – 1.93 (m, 2H), 1.90 – 1.79 (m, 1H). Example 206: (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (a) 2-(Isoxazol-4-yl)ethyl methanesulfonate To a solution of 2-(isoxazol-4-yl)ethan-1-ol (0.75 g, 6.63 mmol) in dichloromethane (10 mL) was added triethylamine (2.77 mL, 19.9 mmol) followed by methanesulfonyl chloride (3.64 mL, 47.0 mmol) at 0 °C, and the mixture stirred at room temperature for 2 hours under N2. Water (30 mL) and saturated aqueous brine solution (50 mL) were added, and the mixture was extracted with dichloromethane (2 x 50 mL). The combined organic phases were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by normal phase SiO2 chromatography (0-50% ethyl acetate / petroleum ether) to afford 2-(isoxazol-4-yl)ethyl methanesulfonate (1.2 g, 94% yield) as a yellow oil.1H NMR (400 MHz, DMSO-d6): δ 8.82 (s, 1H), 8.57 (s, 1H), 4.39 (t, 1H), 3.19 (s, 3H), 2.90 (t, 1H). (b) Methyl 5-(2-(isoxazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate A mixture of 2-(isoxazol-4-yl)ethyl methanesulfonate (50 mg, 0.26 mmol), methyl 1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate trifluoroacetate salt (323 mg, 1.05 mmol) and potassium carbonate (217 mg, 1.57 mmol) in acetonitrile (5 mL) was stirred at 90 °C for 12 hours under N2. The mixture was combined with another five batches at 50 mg scale and filtered. The filtrate was concentrated and purified by reverse phase HPLC to afford methyl 5-(2-(isoxazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxylate (90 mg) as a colorless oil. MS: m/z found 291 [M+H]+. (c) tert-Butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(2-(isoxazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'- bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate To a solution of tert-butyl (S)-((2'-(3-amino-2-chlorophenyl)-3'-chloro-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (Example 187, step (b)) (180 mg, 0.314 mmol) in THF (3 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 0.63 mL, 0.63 mmol) at 0 °C, and the mixture stirred at 0 °C for 0.5 hours under N2. A solution of methyl 5-(2-(isoxazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxylate (90 mg, 0.314 mmol) in THF (3 mL) was then added and the mixture was stirred at 0 °C for 0.5 hours under N2. Water (20 mL) was then added, and the mixture was extracted with ethyl acetate (2 x 30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO2, ethyl acetate : methanol = 10:1 v/v) to afford tert-butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(2-(isoxazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (35 mg) as a yellow solid. MS: m/z found 830 [M+H]+. (d) (S)-N-(2-Chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide To a solution of tert-butyl (S)-((3'-chloro-2'-(2-chloro-3-(5-(2-(isoxazol-4-yl)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy- [2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2-yl)methyl)carbamate (30 mg, 0.034 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2 mL, 26.9 mmol). The mixture was stirred at room temperature for 0.5 hours under N2, concentrated and purified by reverse phase HPLC to afford (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide (17.3 mg, 60% yield) as a yellow solid. MS: m/z found 730 [M+H]+, retention time = 2.43 min (Method A).1H NMR (400 MHz, Methanol-d4): δ 8.69 (d, 1H), 8.68 (s, 1H), 8.56 (dd, 1H), 8.47 (s, 1H), 7.99 (d, 1H), 7.79 (d, 1H), 7.56-7.52 (m, 2H), 7.27 (dd, 1H), 4.42-4.35 (m, 1H), 4.14 (s, 3H), 4.10- 4.05 (m, 4H), 3.74-3.71 (m, 2H), 3.56-3.54 (m, 2H), 3.32-3.27 (m, 2H), 3.13-3.09 (m, 4H), 2.49-2.38 (m, 3H), 1.95-1.92 (m, 1H). Example 207: Methyl (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3- methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1- carboxylate To a solution of methyl (S)-3-((2-((3-(2-(4-(((tert-butoxycarbonyl)((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylate (Example 205, step (b)) (50 mg, 0.06 mmol) in 1,4- dioxane (1 mL) was added HCl in 1,4-dioxane (4.0 M, 1 mL) at room temperature and the mixture was stirred at room temperature for 30 min. The formed precipitate was filtered off, washed three times with diethyl ether and subjected to preparative HPLC to give methyl (S)- 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate as formic acid salt. MS: m/z found 760.3 [M+H]+, retention time = 1.75 min (Method D).1H NMR (400 MHz, Methanol-d4): δ 8.67 – 8.62 (m, 1H), 8.53 – 8.49 (m, 1H), 8.49 (s, 1H), 7.53 – 7.45 (m, 2H), 7.45 – 7.41 (m, 1H), 7.34 (d, 1H), 7.31 (dd, 1H), 7.16 (dd, 1H), 4.13 – 4.03 (m, 2H), 4.00 – 3.95 (m, 6H), 3.95 – 3.89 (m, 1H), 3.72 – 3.64 (m, 3H), 3.62 (s, 2H), 3.20 – 3.05 (m, 1H), 2.98 – 2.89 (m, 2H), 2.89 – 2.83 (m, 2H), 2.78 (s, 1H), 2.75 – 2.58 (m, 4H), 2.49 – 2.29 (m, 5H), 2.14 – 2.04 (m, 1H), 2.04 – 1.95 (m, 1H), 1.91 – 1.77 (m, 1H). Example 208: Methyl (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate (a) Methyl (S)-3-((2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylate Methyl (S)-3-((2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylate was prepared in a similar fashion to Example 205, step (b), replacing tert-butyl (S)-(4-(4-(3-amino-2-chlorophenyl)-3-chloropyridin-2-yl)-2- methoxybenzyl)((5-oxopyrrolidin-2-yl)methyl)carbamate with tert-butyl (S)-((2'-(3-amino-2- chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)((5-oxopyrrolidin-2- yl)methyl)carbamate (Example 187, step (b)). MS: m/z found 861.3 [M+H]+, retention time = 0.85 min (Method B). (b) Methyl (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate To a solution of methyl (S)-3-((2-((3-(5-(((tert-butoxycarbonyl)((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'-yl)-2- chlorophenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylate (50 mg, 0.06 mmol) in 1,4-dioxane (1 mL) was added HCl in 1,4-dioxane (4.0 M, 1 mL) at room temperature and the mixture was stirred at room temperature for 30 min. The formed precipitate was filtered off, washed three times with diethyl ether and subjected to preparative HPLC to give methyl (S)-3-((2-((2-chloro-3-(3'- chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'- yl)phenyl)carbamoyl)-3-methyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclobutane-1-carboxylate as formic acid salt. MS: m/z found 761.3 [M+H]+, retention time = 0.65 min (Method B).1H NMR (400 MHz, Methanol-d4): δ 8.65 (dd, 1H), 8.54 (dt, 1H), 8.37 (s, 1H), 7.92 – 7.82 (m, 1H), 7.78 (dd, 1H), 7.51 (ddd, 1H), 7.47 (dd, 1H), 7.23 (dt, 1H), 4.07 (s, 3H), 4.06 – 4.01 (m, 2H), 3.97 (s, 3H), 3.95 – 3.88 (m, 1H), 3.73 – 3.64 (m, 5H), 3.17 – 3.05 (m, 1H), 2.97 – 2.87 (m, 4H), 2.85 – 2.77 (m, 2H), 2.74 (t, 2H), 2.66 (p, 1H), 2.47 – 2.28 (m, 5H), 2.06 – 1.94 (m, 2H), 1.93 – 1.79 (m, 1H). Example 209: In vitro activity in a T cell activation luciferase reporter cell culture system (T Cell Activation Assay) PD-1/PD-L1 binding has the net effect of inhibiting T cell receptor signaling. A test compound that is capable of binding to and inhibiting PD-L1 will disrupt PD-1/PD-L1 binding and thus cause an increase in T cell receptor signaling. Disruption and/or inhibition of the PD-1/PD-L1 interaction represents a validated target for the treatment of many advanced cancers. Compounds capable of disrupting and/or inhibiting the PD-1/PD-L1 interaction, either directly or indirectly, can be considered effective for the treatment of diseases which can be characterized by immunodeficiency and/or overexpression of PD-L1, including but not limited to cancer and hepatitis B and/or hepatitis D. In one aspect, this assay measures the ability of a test compound to bind to and/or inhibit activity of PD-L1 (i.e., PD-L1/PD-1 binding). The ability of compounds to mediate T cell activation in a T cell activation luciferase reporter cell culture system was assessed as described previously (Park et al., Nat Commun 12, 1222 (2021)). CHO-K1 cells stably expressing human PD-L1 and a cell surface protein designed to activate cognate T cell receptor in an antigen-independent manner (PD-L1 aAPC/CHO-K1, Promega) were incubated with PD-1 effector Jurkat T cells stably expressing human PD-1 and NFAT- transcription factor-induced luciferase in the absence or presence of small molecules or anti- PD-L1 blocking antibody at indicated concentration range according to the manufacturer’s instruction (Promega). Bio-Glo™ Reagent was added and luminescence quantified as a signal for Jurkat T cell activation. In the absence of PD-L1 inhibition, the PD-1/PD-L1 interaction in this co-culture system results in inhibition of T cell receptor signalling and inhibition of NFAT-mediated luciferase activity. Disruption of PD-1/PD-L1 interaction with compound or antibody treatment results in luciferase activity. Table 2. T Cell Activation EC50 Values in Luciferase Reporter Assay
Figure imgf000441_0001
Figure imgf000442_0001
Example 210: In vitro PD-L1 internalization assay As described elsewhere herein, PD-1/PD-L1 binding has the net effect of inhibiting T cell receptor signaling, and accordingly, disruption and/or inhibition of the PD-1/PD-L1 interaction represents a validated target for the treatment of many advanced cancers. Compounds capable of disrupting and/or inhibiting the PD-1/PD-L1 interaction, either directly or indirectly, can be considered effective for the treatment of diseases which can be characterized by immunodeficiency and/or overexpression of PD-L1, including but not limited to cancer and hepatitis B and/or hepatitis D. As described in the literature (Park et al., Nat Commun 12, 1222 (2021)), disruption of the PD-L1/PD-1 interaction may comprise small-molecule induced PD-L1 dimerization and internalization. Thus, in one aspect, internalization of PD-L1 induced by a compound can be a measure of PD-L1/PD-1 disruption. This assay measures the PD-L1 protein levels on the surface of Chinese hamster ovary cells overexpressing PD-L1 (CHO-K1-PD-L1). Internalization of PD-L1 can be measured by comparing the mean fluorescence intensity levels of PD-L1 in cells incubated with and without PD-L1 small molecule inhibitors. PD-L1 small molecule inhibitors were serially diluted using DMEM/Ham’s F12, 50/50 media and added to a 96-well V-bottom polystyrene plate. Designated control wells had media only. Chinese hamster ovary cells (CHO-K1) overexpressing PD-L1 were then added to the plate at 80,000-100,000 cells per well. The plates were then incubated at 37°C/5%CO2 for 40 minutes. After incubation, the plates were centrifuged at 1,500 rpm for 5 minutes and the supernatant discarded. After vortexing the plates briefly, antibody staining cocktail containing LIVE/DEAD fixable dead cell stain and anti-PD-L1 PE antibody in phosphate buffered saline + 2% fetal bovine serum were added to the wells. Mouse IgG1 kappa isotype PE was used as a staining control. The plates were then incubated in the dark at room temperature while gently shaking (35 rpm) for 20 minutes. The wells were subsequently washed with FACS buffer, centrifuged at 1,500 rpm for 5 minutes and the supernatant was discarded. The plates were vortexed briefly and the cells were fixed by addition of 2% paraformaldehyde in PBS. Plates were read using a BD LSRFortessa and the data analyzed using GraphPad Prism 8 software. Table 3. Internalization IC50 Values in PD-L1 Internalization Assay
Figure imgf000443_0001
Figure imgf000444_0001
Example 211: In vivo anti-tumor efficacy in humanized PD-L1 and PD-1 expressing MC38 tumor mouse model In one aspect, this assay measures the ability of a PD-L1 inhibitor to reduce the size of MC38 (a murine colon adenocarcinoma cell line) tumors in mice, as an indication of the PD-L1 inhibitor’s ability to help treat, ameliorate, and/or prevent cancer in the subject. In vivo anti-tumor efficacy of compounds was evaluated in mice expressing humanized PD-1 and PD-L1, in which the extracellular domains of murine PD-1 and PD-L1 were genetically replaced with the human extracellular domain counterparts (Huang et al., Scientific Reports, 2017;7:42687). Humanized PD-1/PD-L1 (hPD-1/hPD-L1) mice were subcutaneously implanted with the colorectal cancer cell line MC38 expressing human PD- L1 and compound treatment initiated when tumor volumes reached approximately 100 mm3. Compound was administered via oral gavage once daily at 3, 10 and 30 mg/kg for 28 days. The anti-PD-L1 monoclonal antibody atezolizumab was included as a positive reference control and administered via intraperitoneal injection at 5 mg/kg thrice weekly between study days 1 and 15. Tumor lengths and widths were measured by digital caliper and tumor volumes were calculated by the formula: Volume = ½ (Length × Width)2. Table 4. Tumor volumes (group mean, mm3) of MC38-tumor-bearing hPD-1/hPD-L1 mice treated with a compound of the present disclosure
Figure imgf000445_0001
Enumerated Embodiments The following enumerated embodiments are provided, the numbering of which is not to be construed as designating levels of importance. Embodiment 1 provides the compound of formula (I), or a salt, solvate, geometric isomer, isotopologue, stereoisomer, or tautomer thereof: (I), wherein: X1 is selected from the group consisting of CR2a and N; X2 is selected from the group consisting of CR2b and N; X3 is selected from the group consisting of CR2c and N; X4 is selected from the group consisting of CR2d and N; X5 is selected from the group consisting of CR2e and N; X6 is selected from the group consisting of CR2f and N; wherein one to four selected from the group consisting of X1, X2, X3, X4, X5, and X6 are N; R1a and R1b are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R1c is ; R1d is ; R2a, R2b, R2c, R2d, R2e, and R2f, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R3a, R3b, R3c, and R3d, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R4a and R4b are each independently selected from the group consisting of H and optionally substituted C1-C6 alkyl, wherein one of R4a and R4b may combine with one of R3b or R3c to form a optionally substituted C5-C8 cycloalkyl, optionally substituted C4-C8 heterocyclyl, or optionally substituted C6-C10 aryl; R5 is selected from the group consisting of H and optionally substituted C1-C6 alkyl, wherein R5 may combine with one of R3b or R3c to form an optionally substituted C4-C8 heterocycloalkyl; R6 is selected from the group consisting of H, -(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -(CH2)0-3(optionally substituted C3-C8 cycloalkyl), optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C1-C6 hydroxyalkyl, wherein R5 and R6 may optionally combine with the nitrogen atom to which they are bound to form an optionally substituted C2-C8 heterocyclyl, wherein each optional substituent in R6, or the C2-C8 heterocyclyl of R5 and R6, is independently selected from the group consisting of halogen, benzyl, phenyl, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O), C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2, and wherein two optional substituents in R6, or in the C2-C8 heterocyclyl of R5 and R6, may combine with the atoms to which they are bound to form a C3-C8 cycloalkyl or C2-C8 heterocycloalkyl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, C(=O), and C(=O)Ra; R7 is selected from the group consisting of H and optionally substituted C1-C6 alkyl; R8 is selected from the group consisting of , , , , , , , and ; R9a, R9b, R9c, R9d, R9e, and R9f, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R10 is selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted benzyl, and optionally substituted phenyl; R11 is selected from the group consisting of H, -(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -C(=O)(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -(CH2)0-3(optionally substituted C3-C8 cycloalkyl), -C(=O)(CH2)0-3(optionally substituted C3-C8 cycloalkyl), optionally substituted C1-C6 alkyl, C(=O)(optionally substituted C1-C6 alkyl), optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C1-C6 hydroxyalkyl, and -(CH2)0-3(optionally substituted phenyl), wherein each optional substituent in R11 is independently selected from the group consisting of halogen, benzyl, phenyl C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O), C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2, and wherein two optional substituents in R11 may combine with the atoms to which they are bound to form a C3-C8 cycloalkyl or C2-C8 heterocycloalkyl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, C(=O), and C(=O)Ra; L is selected from the group consisting of a bond and optionally substituted C1-C2 alkylenyl; T1 is selected from the group consisting of CR3a and N; Y is selected from the group consisting of NR10, O, and S; and Ra, Rb, and Rc are each independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted benzyl, and optionally substituted phenyl, wherein each optional substituent in Ra, Rb, and Rc is independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy, OH, CN, and NO2. Embodiment 2 provides the compound of Embodiment 1, wherein each occurrence of optionally substituted alkyl, optionaly substituted alkylenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aminoalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted phenyl, and optionally substituted benzyl is independently optionally substituted with at least one substituent selected from the group consisting of halogen, benzyl, phenyl, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2. Embodiment 3 provides the compound of Embodiment 1 or 2, which is selected from the group consisting of: (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), and (Ih). Embodiment 4 provides the compound of any one of Embodiments 1-3, wherein at least one of the following applies: (a) each of R2b, R2c, R2d, R2e, and R2f are H; (b) each of R2a, R2c, R2d, R2e, and R2f are H; (c) each of R2a, R2b, R2d, R2e, and R2f are H; (d) each of R2a, R2b, R2c, R2e, and R2f are H; (e) each of R2a, R2b, R2c, R2d, and R2f are H; (f) each of R2a, R2b, R2c, R2d, and R2e are H; Embodiment 5 provides the compound of any one of Embodiments 1-4, wherein R1a is selected from the group consisting of Cl and Me. Embodiment 6 provides the compound of any one of Embodiments 1-5, wherein R1b is selected from the group consisting of Cl and Me. Embodiment 7 provides the compound of any one of Embodiments 1-6, wherein R1c is selected from the group consisting of: , , , and . Embodiment 8 provides the compound of any one of Embodiments 1-7, wherein R5 is selected from the group consisting of H and Me. Embodiment 9 provides the compound of any one of Embodiments 1-8, wherein R6 is selected from the group consisting of (CH2)1-3CH2F, (CH2)1-3OH, (CH2)1-3OCH3, (CH2)0- 2CH(OH)(CH2)0-2CH3, (CH2)1-3C(CH3)2OH, (CH2)1-3C(=O)OH, (CH2)0-2CH(OH)(CH2)0- 2C(=O)OH, (CH2)0-2CH(CH3)(CH2)0-2C(=O)OH, (CH2)0-2(optionally substituted cyclopropylenyl), (CH2)0-2(optionally substituted bicyclo[1.1.1]pentanyl), (CH2)0-2(optionally substituted pentanyl) (CH2)0-3(optionally substituted 4-piperidinyl), (CH2)0-3(optionally substituted 5-oxopyrrolidin-2-yl), and (CH2)0-3(optionally substituted tetrahydropyran-4-yl). Embodiment 10 provides the compound of any one of Embodiments 1-9, wherein R6 is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , and . Embodiment 11 provides the compound of any one of Embodiments 1-7, wherein R5 and R6 combine with the nitrogen atom to which they are bound to form one selected from the group consisting of: , , , , , , , , , , and . Embodiment 12 provides the compound of any one of Embodiments 1-11, wherein R1c is selected from the group consisting of:
Figure imgf000451_0001
, , , , , , , , , , , , , , , , , , , , , , , , , , , , and , wherein each occurrence of R12 is independently selected from the group consisting of H, C(=O)(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, benzyl, and phenyl. Embodiment 13 provides the compound of any one of Embodiments 1-12, wherein at least one of the following applies: (a) R3b is selected from the group consisting of OMe, OCF2H, F, and Cl; (b) R3c is selected from the group consisting of OMe, OCF2H, F, and Cl; and (c) R12 is selected from the group consisting of H, Me, and C(=O)Me. Embodiment 14 provides the compound of any one of Embodiments 1-13, wherein R1c is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and . Embodiment 15 provides the compound of any one of Embodiments 1-14, wherein R7 is H. Embodiment 16 provides the compound of any one of Embodiments 1-15, wherein L is a bond. Embodiment 17 provides the compound of any one of Embodiments 1-16, wherein at least one of the following applies: (a) at least one selected from R9a, R9b, R9c, R9d, R9e, and R9f is H; (b) at least two selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; (c) at least three selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; (d) at least four selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; (e) at least five selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; and (f) each of R9a, R9b, R9c, R9d, R9e, and R9f are H. Embodiment 18 provides the compound of any one of Embodiments 1-17, wherein R10 is selected from the group consisting of H and Me. Embodiment 19 provides the compound of any one of Embodiments 1-18, wherein R11 is selected from the group consisting of H, (CH2)0-2(optionally substituted 5- oxopyrrolidin-2-yl), (CH2)0-3(optionally substituted piperidinyl), (CH2)0-3(optionally substituted cyclopropyl), (CH2)0-3(optionally substituted cyclohexyl), (CH2)0-3(optionally substituted bicyclo[2.2.1]heptanyl), (CH2)0-3(optionally substituted oxetanyl), (CH2)0- 3(optionally substituted bicyclo[1.1.1]pentanyl), (CH2)0-3(optionally substituted thiazolyl), (CH2)0-3(optionally substituted oxazolyl), (CH2)0-3(optionally substituted imidazolyl), (CH2)0- 3(optionally substituted 7,8-dihydroimidazo[1,2-a]pyrimidinyl), (CH2)0-3(optionally substituted imidazo[1,2-a]pyrimidinyl), (CH2)0-3(optionally substituted benzo[d]isoxazolyl), (CH2)0-3(optionally substituted tetrahydro-2H-pyranyl), (CH2)0-3(optionally substituted phenyl), (CH2)1-2CH(OH)CF3, (CH2)0-5CH2F, (CH2)0-5CF3, (CH2)1-5CH2OH, (CH2)1- 5CH2O(C1-C6 alkyl), and (CH2)1-5CH2O(C3-C6 cycloalkyl). Embodiment 20 provides the compound of any one of Embodiments 1-19, wherein R11 is selected from the group consisting of H, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and . Embodiment 21 provides the compound of any one of Embodiments 1-20, wherein R8 is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
, , , , , , , , , , , , , , , , , , , , , , , , , , , , 41 4 1 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and . Embodiment 22 provides the compound of any one of Embodiments 1-21, wherein R1d is selected from the group consisting of:
Figure imgf000461_0001
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Figure imgf000464_0001
, , , , , , , , , , , , , , , , , , , and . Embodiment 23 provides the compound of any one of Embodiments 1-22, which is selected from the group consisting of: N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-(difluoromethoxy)phenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3-methoxyphenyl)pyridin- 4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)- 3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((R)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((R)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-6-methoxy-5-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-[2,4’- bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-6-methoxy-5-(((2-methoxyethyl)amino)methyl)-[2,4’- bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3’-chloro-4-fluoro-6-methoxy-[2,4’- bipyridin]-2’-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((2- methoxyethyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)(methyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2-hydroxy-2- methylpropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3-hydroxypyrrolidin- 1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; ((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)glycine; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)propanoic acid; 4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (S)-4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (R)-4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 2-(1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)propanoic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; (S)-3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; (R)-3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)bicyclo[1.1.1]pentane-1-carboxylic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; 1-(2-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)ethyl)cyclopropane-1-carboxylic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-4-carboxylic acid; 4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; 5-(1-acetylpiperidin-4-yl)-N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (S)-4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (R)-4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)glycine; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)propanoic acid; 1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (S)-1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (R)-1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; 2-(1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid; 4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (S)-4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (R)-4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; methyl 2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; methyl (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; methyl (R)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; 2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; (R)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylprolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3-hydroxypyrrolidin-1-yl)acetyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((S)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((S)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-prolyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(L-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(D-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(L-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((D)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(R-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((D)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; methyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; methyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; 5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(pyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; methyl (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; methyl (R)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; 4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; (R)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(pyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol- 1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol- 1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; isopropyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; isopropyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; isopropyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; 5-(1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4-carbonyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2-hydroxypropyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)propanoyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2-a]pyrimidin-2-yl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-3-carbonyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpyrrolidine-3-carbonyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2-ylmethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methylprolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol-4-yl)ethyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylprolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3-oxopropyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((oxetan-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((oxetan-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 3-(((4-(4-(3-(5-((3-carboxybicyclo[1.1.1]pentan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2- yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 3-(((4-(4-(3-(5-((4-carboxybicyclo[2.2.1]heptan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2- yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (S)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (R)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3-yl)methyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1s,4s)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1s,4s)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3'-chloro-5-(((3-hydroxycyclopentyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-((((1R,3R)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-((((1R,3R)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-((((1S,3S)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-((((1S,3S)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-((3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl 3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; and methyl (R)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; or a salt, solvate, geometric isomer, isotopologue, or tautomer thereof. Embodiment 24 provides a pharmaceutical composition comprising at least one compound of any one of Embodiments 1-23 and at least one pharmaceutically acceptable carrier. Embodiment 25 provides the pharmaceutical composition of Embodiment 24, further comprising at least one additional agent that treats, ameliorates, and/or prevents hepatitis virus infection. Embodiment 26 provides the pharmaceutical composition of Embodiment 25, wherein the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitor; capsid inhibitor; cccDNA formation inhibitor; RNA destabilizer; oligomeric nucleotide targeted against the HBV genome; immunostimulator; GalNAc-siRNA conjugate targeted against an HBV gene transcript; and therapeutic vaccine. Embodiment 27 provides the pharmaceutical composition of Embodiment 26, wherein the immunostimulator is a checkpoint inhibitor. Embodiment 28 provides the pharmaceutical composition of Embodiment 27, wherein the checkpoint inhibitor is a PD-L1 inhibitor. Embodiment 29 provides the pharmaceutical composition of any one of Embodiments 24-28, wherein the hepatitis virus is at least one selected from the group consisting of hepatitis B virus (HBV) and hepatitis D virus (HDV). Embodiment 30 provides a method of treating, ameliorating, and/or preventing hepatitis virus infection in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of the compound of any one of Embodiments 1-23 and/or the pharmaceutical composition of any one of Embodiments 24-29, or a salt, solvate, prodrug, stereoisomer, isotopologue, tautomer, or any mixtures thereof. Embodiment 31 provides the method of Embodiment 30, wherein the subject is infected with hepatitis B virus (HBV). Embodiment 32 provides the method of any one of Embodiments 30-31, wherein the subject is further infected with hepatitis D virus (HDV). Embodiment 33 provides the method of any one of Embodiments 30-32, wherein the subject is infected with HBV and HDV. Embodiment 34 provides the method of any one of Embodiments 30-33, wherein the subject is further administered at least one additional agent useful for treating the hepatitis virus infection. Embodiment 35 provides the method of Embodiment 34, wherein the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitor; capsid inhibitor; cccDNA formation inhibitor; RNA destabilizer; oligomeric nucleotide targeted against the HBV genome; immunostimulator; GalNAc-siRNA conjugate targeted against an HBV gene transcript; and therapeutic vaccine. Embodiment 36 provides the method of Embodiment 35, wherein the immunostimulator is a checkpoint inhibitor. Embodiment 37 provides the method of Embodiment 36, wherein the checkpoint inhibitor is a PD-L1 inhibitor. Embodiment 38 provides the method of any one of Embodiments 34-37, wherein the subject is co-administered the at least one compound and the at least one additional agent. Embodiment 39 provides the method of any one of Embodiments 34-38, wherein the at least one compound and the at least one additional agent are coformulated. Embodiment 40 provides the method of any one of Embodiments 30-39, wherein the subject is a mammal. Embodiment 41 provides the method of Embodiment 40, wherein the mammal is a human. Embodiment 42 provides a method of treating, ameliorating, and/or preventing cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of the compound of any one of Embodiments 1-23 and/or the pharmaceutical composition of any one of Embodiments 24-29, or a salt, solvate, prodrug, stereoisomer, isotopologue, tautomer, or any mixtures thereof. Embodiment 43 provides the method of Embodiment 42, wherein the compound or composition is the only anticancer agent administered to the subject. Embodiment 44 provides the method of any one of Embodiments 42-43, wherein the compound is administered to the subject in a pharmaceutically acceptable composition. Embodiment 45 provides the method of any one of Embodiments 42-44, wherein the subject is further administered at least one additional agent or therapy useful for treating, ameliorating, and/or preventing the cancer. Embodiment 46 provides the method of Embodiment 45, wherein the additional anticancer agent or therapy comprises nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, and/or resection therapy. Embodiment 47 provides the method of Embodiment 45, wherein the additional anticancer agent or therapy comprises Rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and/or ipilimumab. Embodiment 48 provides the method of any one of Embodiments 42 and 44-47, wherein the compound or composition is coformulated and/or co-administered with the at least one additional agent. Embodiment 49 provides the method of any one of Embodiments 42-48, wherein the cancer is amenable to treatment by inhibiting PD-1, PD-L1, or the PD-1/PD-L1 interaction. Embodiment 50 provides the method of any one of Embodiments 42-49, wherein the cancer is at least one of pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer, or colon cancer. Embodiment 51 provides the method of any one of Embodiments 42-49, wherein the cancer is at least one of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL). Embodiment 52 provides the method of any one of Embodiments 42-51, wherein the subject is a mammal. Embodiment 53 provides the method of Embodiment 52, wherein the mammal is a human. The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this disclosure has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this disclosure may be devised by others skilled in the art without departing from the true spirit and scope of the disclosure. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

Claims

CLAIMS What is claimed is: 1. A compound of formula (I), or a salt, solvate, geometric isomer, isotopologue, stereoisomer, or tautomer thereof: (I), wherein: X1 is selected from the group consisting of CR2a and N; X2 is selected from the group consisting of CR2b and N; X3 is selected from the group consisting of CR2c and N; X4 is selected from the group consisting of CR2d and N; X5 is selected from the group consisting of CR2e and N; X6 is selected from the group consisting of CR2f and N; wherein one to four selected from the group consisting of X1, X2, X3, X4, X5, and X6 are N; R1a and R1b are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R1c is ; R1d is ; R2a, R2b, R2c, R2d, R2e, and R2f, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R3a, R3b, R3c, and R3d, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R4a and R4b are each independently selected from the group consisting of H and optionally substituted C1-C6 alkyl, wherein one of R4a and R4b may combine with one of R3b or R3c to form a optionally substituted C5-C8 cycloalkyl, optionally substituted C4-C8 heterocyclyl, or optionally substituted C6-C10 aryl; R5 is selected from the group consisting of H and optionally substituted C1-C6 alkyl, wherein R5 may combine with one of R3b or R3c to form an optionally substituted C4-C8 heterocycloalkyl; R6 is selected from the group consisting of H, -(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -(CH2)0-3(optionally substituted C3-C8 cycloalkyl), optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C1-C6 hydroxyalkyl, wherein R5 and R6 may optionally combine with the nitrogen atom to which they are bound to form an optionally substituted C2-C8 heterocyclyl, wherein each optional substituent in R6, or the C2-C8 heterocyclyl of R5 and R6, is independently selected from the group consisting of halogen, benzyl, phenyl, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O), C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2, and wherein two optional substituents in R6, or in the C2-C8 heterocyclyl of R5 and R6, may combine with the atoms to which they are bound to form a C3-C8 cycloalkyl or C2-C8 heterocycloalkyl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, C(=O), and C(=O)Ra; R7 is selected from the group consisting of H and optionally substituted C1-C6 alkyl; R8 is selected from the group consisting of , , , , , , , and ; R9a, R9b, R9c, R9d, R9e, and R9f, if present, are each independently selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 alkoxy, CN, NO2, ORa, N(Ra)(Rb), optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy; R10 is selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted benzyl, and optionally substituted phenyl; R11 is selected from the group consisting of H, -(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -C(=O)(CH2)0-3(optionally substituted C2-C8 heterocyclyl), -(CH2)0-3(optionally substituted C3-C8 cycloalkyl), -C(=O)(CH2)0-3(optionally substituted C3-C8 cycloalkyl), optionally substituted C1-C6 alkyl, C(=O)(optionally substituted C1-C6 alkyl), optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C1-C6 hydroxyalkyl, and -(CH2)0-3(optionally substituted phenyl), wherein each optional substituent in R11 is independently selected from the group consisting of halogen, benzyl, phenyl C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O), C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2, and wherein two optional substituents in R11 may combine with the atoms to which they are bound to form a C3-C8 cycloalkyl or C2-C8 heterocycloalkyl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, halogen, C(=O), and C(=O)Ra; L is selected from the group consisting of a bond and optionally substituted C1-C2 alkylenyl; T1 is selected from the group consisting of CR3a and N; Y is selected from the group consisting of NR10, O, and S; and Ra, Rb, and Rc are each independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted benzyl, and optionally substituted phenyl, wherein each optional substituent in Ra, Rb, and Rc is independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy, OH, CN, and NO2.
2. The compound of claim 1, wherein each occurrence of optionally substituted alkyl, optionaly substituted alkylenyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, optionally substituted hydroxyalkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aminoalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted phenyl, and optionally substituted benzyl is independently optionally substituted with at least one substituent selected from the group consisting of halogen, benzyl, phenyl, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, C(=O)ORa, C(=O)N(Ra)(Rb), C(=NRa)N(Rb)(Rc), C(=O)Ra, OC(=O)Ra, ORa, N(Ra)(Rb), N(Ra)C(=O)Rb, S(=O)2Ra, S(=O)2N(Ra)(Rb), N(Ra)S(=O)2Rb, CN, and NO2.
3. The compound of claim 1 or 2, which is selected from the group consisting of: (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), and (Ih).
4. The compound of any one of claims 1-3, wherein at least one of the following applies: (a) each of R2b, R2c, R2d, R2e, and R2f are H; (b) each of R2a, R2c, R2d, R2e, and R2f are H; (c) each of R2a, R2b, R2d, R2e, and R2f are H; (d) each of R2a, R2b, R2c, R2e, and R2f are H; (e) each of R2a, R2b, R2c, R2d, and R2f are H; (f) each of R2a, R2b, R2c, R2d, and R2e are H;
5. The compound of any one of claims 1-4, wherein R1a is selected from the group consisting of Cl and Me.
6. The compound of any one of claims 1-5, wherein R1b is selected from the group consisting of Cl and Me.
7. The compound of any one of claims 1-6, wherein R1c is selected from the group consisting of: , , , and .
8. The compound of any one of claims 1-7, wherein R5 is selected from the group consisting of H and Me.
9. The compound of any one of claims 1-8, wherein R6 is selected from the group consisting of (CH2)1-3CH2F, (CH2)1-3OH, (CH2)1-3OCH3, (CH2)0-2CH(OH)(CH2)0-2CH3, (CH2)1-3C(CH3)2OH, (CH2)1-3C(=O)OH, (CH2)0-2CH(OH)(CH2)0-2C(=O)OH, (CH2)0- 2CH(CH3)(CH2)0-2C(=O)OH, (CH2)0-2(optionally substituted cyclopropylenyl), (CH2)0- 2(optionally substituted bicyclo[1.1.1]pentanyl), (CH2)0-2(optionally substituted pentanyl) (CH2)0-3(optionally substituted 4-piperidinyl), (CH2)0-3(optionally substituted 5- oxopyrrolidin-2-yl), and (CH2)0-3(optionally substituted tetrahydropyran-4-yl).
10. The compound of any one of claims 1-9, wherein R6 is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , and .
11. The compound of any one of claims 1-7, wherein R5 and R6 combine with the nitrogen atom to which they are bound to form one selected from the group consisting of: , , , , , , , , , , and .
12. The compound of any one of claims 1-11, wherein R1c is selected from the group consisting of:
Figure imgf000524_0001
, , , , , , , , , , , , , , , , , , , , , , and , wherein each occurrence of R12 is independently selected from the group consisting of H, C(=O)(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, benzyl, and phenyl.
13. The compound of any one of claims 1-12, wherein at least one of the following applies: (a) R3b is selected from the group consisting of OMe, OCF2H, F, and Cl; (b) R3c is selected from the group consisting of OMe, OCF2H, F, and Cl; and (c) R12 is selected from the group consisting of H, Me, and C(=O)Me.
14. The compound of any one of claims 1-13, wherein R1c is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .
15. The compound of any one of claims 1-14, wherein R7 is H.
16. The compound of any one of claims 1-15, wherein L is a bond.
17. The compound of any one of claims 1-16, wherein at least one of the following applies: (a) at least one selected from R9a, R9b, R9c, R9d, R9e, and R9f is H; (b) at least two selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; (c) at least three selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; (d) at least four selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; (e) at least five selected from R9a, R9b, R9c, R9d, R9e, and R9f are H; and (f) each of R9a, R9b, R9c, R9d, R9e, and R9f are H.
18. The compound of any one of claims 1-17, wherein R10 is selected from the group consisting of H and Me.
19. The compound of any one of claims 1-18, wherein R11 is selected from the group consisting of H, (CH2)0-2(optionally substituted 5-oxopyrrolidin-2-yl), (CH2)0-3(optionally substituted piperidinyl), (CH2)0-3(optionally substituted cyclopropyl), (CH2)0-3(optionally substituted cyclohexyl), (CH2)0-3(optionally substituted bicyclo[2.2.1]heptanyl), (CH2)0- 3(optionally substituted oxetanyl), (CH2)0-3(optionally substituted bicyclo[1.1.1]pentanyl), (CH2)0-3(optionally substituted thiazolyl), (CH2)0-3(optionally substituted oxazolyl), (CH2)0- 3(optionally substituted imidazolyl), (CH2)0-3(optionally substituted 7,8-dihydroimidazo[1,2- a]pyrimidinyl), (CH2)0-3(optionally substituted imidazo[1,2-a]pyrimidinyl), (CH2)0- 3(optionally substituted benzo[d]isoxazolyl), (CH2)0-3(optionally substituted tetrahydro-2H- pyranyl), (CH2)0-3(optionally substituted phenyl), (CH2)1-2CH(OH)CF3, (CH2)0-5CH2F, (CH2)0-5CF3, (CH2)1-5CH2OH, (CH2)1-5CH2O(C1-C6 alkyl), and (CH2)1-5CH2O(C3-C6 cycloalkyl).
20. The compound of any one of claims 1-19, wherein R11 is selected from the group consisting of H, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .
21. The compound of any one of claims 1-20, wherein R8 is selected from the group consisting of: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .
22. The compound of any one of claims 1-21, wherein R1d is selected from the group consisting of:
Figure imgf000534_0001
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Figure imgf000537_0001
, , , , , , , , , , , , , , , , , , , , , and .
23. The compound of any one of claims 1-22, which is selected from the group consisting of: N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-(2-(2-((3-(2-(4-((6-acetyl-2,6-diazaspiro[3.3]heptan-2-yl)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-(difluoromethoxy)phenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3- methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)-3-methoxyphenyl)pyridin- 4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2-yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(4-(((3-fluoropropyl)amino)methyl)- 3-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((tetrahydro-2H-pyran-4- yl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((S)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((R)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(((R)-5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((5-oxopyrrolidin-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’,4-dichloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-chlorophenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-4-fluoro-6-methoxy-5-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)-[2,4’-bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-6-methoxy-5-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-[2,4’- bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3’-chloro-6-methoxy-5-(((2-methoxyethyl)amino)methyl)-[2,4’- bipyridin]-2’-yl)phenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3’-chloro-4-fluoro-6-methoxy-[2,4’- bipyridin]-2’-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridine-4-yl)phenyl)-1-methyl-5-(4,4,4-trifluorobutyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-5-methoxy-4-(((2- methoxyethyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxyethyl)(methyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2- hydroxypropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-(((2-hydroxy-2- methylpropyl)amino)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3-hydroxypyrrolidin- 1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3-chloro-2-(3-fluoro-4-((3- hydroxypyrrolidin-1-yl)methyl)-5-methoxyphenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3- (difluoromethoxy)phenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-fluoro-5-methoxy-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5- methoxyphenyl)-3-chloropyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-fluoro-5-methoxyphenyl)-3- chloropyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidin-4-yl)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3-chloro-2-(3-(difluoromethoxy)-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; ((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)glycine; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)propanoic acid; 4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (S)-4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (R)-4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorobenzyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(4-fluorophenethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(cyclohexyloxy)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(5,5,5-trifluoropentyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-4-fluoro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)-2-methylphenyl)-5-(3-fluoropropyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 2-(1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3,3,3-trifluoropropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(5-fluoropentyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)propanoic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-3-carboxylic acid; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; (S)-3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; (R)-3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; 3-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)bicyclo[1.1.1]pentane-1-carboxylic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; (S)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; (R)-1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5-yl)methyl)-3- methylpyrrolidine-3-carboxylic acid; 1-(2-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)ethyl)cyclopropane-1-carboxylic acid; 1-((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)piperidine-4-carboxylic acid; 4-(((3'-chloro-2'-(2-chloro-3-(5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)butanoic acid; 5-(1-acetylpiperidin-4-yl)-N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6- methoxy-[2,4'-bipyridin]-2'-yl)-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-cyclopropoxyethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (S)-4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (R)-4-((4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)amino)-3-hydroxybutanoic acid; (4-(3-chloro-4-(2-chloro-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamido)phenyl)pyridin-2-yl)-2-methoxybenzyl)glycine; 5-(1-acetylpiperidin-4-yl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((7-oxo-2,6- diazaspiro[3.4]octan-2-yl)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-acetyl-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-glycyl-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-methoxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-hydroxyacetyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)propanoic acid; 1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (S)-1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; (R)-1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)pyrrolidine-3-carboxylic acid; 2-(1-((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)azetidin-3-yl)acetic acid; 4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (S)-4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; (R)-4-(((2'-(3-(5-(1-acetylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamido)-2-chlorophenyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-5- yl)methyl)amino)-3-hydroxybutanoic acid; methyl 2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; methyl (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; methyl (R)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetate; 2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; (S)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; (R)-2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)acetic acid; 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-2,2-dimethylpropanoic acid; 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(pyrrolidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(5-((7-acetyl-2,7-diazaspiro[4.4]nonan-2-yl)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)-5-(3-fluoropropyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(1-(2-hydroxyethyl)piperidine-4- carbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(4-acetylpiperazin-1-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylprolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)-5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3-hydroxypyrrolidin-1-yl)acetyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((S)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((S)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-((R)-3-hydroxypyrrolidin-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-prolyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(L-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(D-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(L-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((D)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(R-prolyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((D)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(piperidin-1-yl)acetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-(piperidin-1- yl)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-morpholinoacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-tetrazol-5-yl)acetyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; methyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; methyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; tert-butyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; 5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-amino-2-methylpropanoyl)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1- yl)acetyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(5-methyl-1,2,4- oxadiazol-3-yl)acetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(pyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; methyl (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; methyl (R)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoate; 4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; (S)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; (R)-4-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butanoic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(cyclopropylmethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(pyrrolidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-pyrrolidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-3-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-piperidine-3- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethyloxazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((1,5-dimethyl-1H-imidazol-4- yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-azetidine-2-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(piperidine-4-carbonyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(azetidin-3-yl)acetyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(1-acetylpiperidine-4-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol- 1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-1,2,4-triazol- 1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; isopropyl 3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; isopropyl (S)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; isopropyl (R)-3-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoate; 5-(1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpyrrolidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4-carbonyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-4- carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-1,2,4-triazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2-hydroxypropyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-3,3,3-trifluoro-2- hydroxypropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)propanoyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3- (methylamino)propanoyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(azetidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((2,4-dimethylthiazol-5-yl)methyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(thiazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxazol-2-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2-a]pyrimidin-2-yl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((7,8-dihydroimidazo[1,2- a]pyrimidin-2-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpiperidine-3-carbonyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpiperidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(1-methylpyrrolidine-3-carbonyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((S)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((R)-1-methylpyrrolidine- 3-carbonyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2-ylmethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((S)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-((R)-1-acetylpiperidine-3-carbonyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7-tetrahydro-3H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-pyrazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-5-(3-fluoropropyl)-3-methyl-4,5,6,7- tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-5-(2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(4H-1,2,4-triazol-4-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(benzo[d]isoxazol-3-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(oxetan-3-ylmethyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methylprolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(3-(2-(4-(((1-acetylpiperidin-4-yl)amino)methyl)-3-methoxyphenyl)-3-chloropyridin-4- yl)-2-chlorophenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol-4-yl)ethyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(1-methyl-1H-pyrazol- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'-bipyridin]-2'- yl)-2-chlorophenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylprolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-L-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methyl-D-prolyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(methylglycyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(1H-pyrazol-1-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(3-amino-3-oxopropyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; 5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-amino-2-oxoethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)propanoyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3-oxopropyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-(methylamino)-3- oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((oxetan-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(3-(dimethylamino)-3-oxopropyl)- 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((oxetan-2-yl)methyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((S)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(((R)-oxetan-2- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(3-sulfamoylpropyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran- 4-yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-(2-(tetrahydro-2H-pyran-4- yl)ethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 3-(((4-(4-(3-(5-((3-carboxybicyclo[1.1.1]pentan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2- yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 3-(((4-(4-(3-(5-((4-carboxybicyclo[2.2.1]heptan-1-yl)methyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chlorophenyl)-3-chloropyridin-2- yl)-2-methoxybenzyl)amino)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin- 2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-5-(2-(2H-tetrazol-5-yl)ethyl)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5- oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4-yl)methyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((tetrahydro-2H-pyran-4- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (S)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; (R)-3-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propanoic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4-yl)ethyl)-1-methyl-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(1-isopropyl-1H-pyrazol-4- yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3-yl)methyl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-1-methyl-5-((3-methyloxetan-3- yl)methyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((3-(5-(((1-acetylpiperidin-4-yl)amino)methyl)-3'-chloro-6-methoxy-[2,4'- bipyridin]-2'-yl)-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[2,4'- bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1s,4s)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1r,4r)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(((1s,4s)-4- hydroxycyclohexyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2- carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((S)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; N-(2-chloro-3-(3'-chloro-6-methoxy-5-(((((R)-5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-((4-hydroxycyclohexyl)methyl)-1- methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; 4-((2-((2-chloro-3-(3'-chloro-5-(((3-hydroxycyclopentyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-((((1R,3R)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-((((1R,3R)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-((((1S,3S)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-((((1S,3S)-3-hydroxycyclopentyl)amino)methyl)- 6-methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-((3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6- methoxy-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1r,4r)-4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy-[2,4'- bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methyl)cyclohexane-1-carboxylic acid; (1s,4s)-4-((2-((2-chloro-3-(3'-chloro-5-(((2-hydroxyethyl)amino)methyl)-6-methoxy- [2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methyl)cyclohexane-1-carboxylic acid; 4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (S)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; (R)-4-(2-(2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylic acid; N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)- [2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine-2-carboxamide; (S)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; (R)-N-(2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)-5-(2-(isoxazol-4-yl)ethyl)-1-methyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide; methyl 3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (S)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (R)-3-((2-((2-chloro-3-(3-chloro-2-(3-methoxy-4-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)phenyl)pyridin-4-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl 3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; methyl (S)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; and methyl (R)-3-((2-((2-chloro-3-(3'-chloro-6-methoxy-5-((((5-oxopyrrolidin-2- yl)methyl)amino)methyl)-[2,4'-bipyridin]-2'-yl)phenyl)carbamoyl)-3-methyl-3,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)cyclobutane-1-carboxylate; or a salt, solvate, geometric isomer, isotopologue, or tautomer thereof.
24. A pharmaceutical composition comprising at least one compound of any one of claims 1-23 and at least one pharmaceutically acceptable carrier.
25. The pharmaceutical composition of claim 24, further comprising at least one additional agent that treats, ameliorates, and/or prevents hepatitis virus infection.
26. The pharmaceutical composition of claim 25, wherein the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitor; capsid inhibitor; cccDNA formation inhibitor; RNA destabilizer; oligomeric nucleotide targeted against the HBV genome; immunostimulator; GalNAc-siRNA conjugate targeted against an HBV gene transcript; and therapeutic vaccine.
27. The pharmaceutical composition of claim 26, wherein the immunostimulator is a checkpoint inhibitor.
28. The pharmaceutical composition of claim 27, wherein the checkpoint inhibitor is a PD-L1 inhibitor.
29. The pharmaceutical composition of any one of claims 24-28, wherein the hepatitis virus is at least one selected from the group consisting of hepatitis B virus (HBV) and hepatitis D virus (HDV).
30. A method of treating, ameliorating, and/or preventing hepatitis virus infection in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of the compound of any one of claims 1-23 and/or the pharmaceutical composition of any one of claims 24-29, or a salt, solvate, prodrug, stereoisomer, isotopologue, tautomer, or any mixtures thereof.
31. The method of claim 30, wherein the subject is infected with hepatitis B virus (HBV).
32. The method of any one of claims 30-31, wherein the subject is further infected with hepatitis D virus (HDV).
33. The method of any one of claims 30-32, wherein the subject is infected with HBV and HDV.
34. The method of any one of claims 30-33, wherein the subject is further administered at least one additional agent useful for treating the hepatitis virus infection.
35. The method of claim 34, wherein the at least one additional agent comprises at least one selected from the group consisting of reverse transcriptase inhibitor; capsid inhibitor; cccDNA formation inhibitor; RNA destabilizer; oligomeric nucleotide targeted against the HBV genome; immunostimulator; GalNAc-siRNA conjugate targeted against an HBV gene transcript; and therapeutic vaccine.
36. The method of claim 35, wherein the immunostimulator is a checkpoint inhibitor.
37. The method of claim 36, wherein the checkpoint inhibitor is a PD-L1 inhibitor.
38. The method of any one of claims 34-37, wherein the subject is co-administered the at least one compound and the at least one additional agent.
39. The method of any one of claims 34-38, wherein the at least one compound and the at least one additional agent are coformulated.
40. The method of any one of claims 30-39, wherein the subject is a mammal.
41. The method of claim 40, wherein the mammal is a human.
42. A method of treating, ameliorating, and/or preventing cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of the compound of any one of claims 1-23 and/or the pharmaceutical composition of any one of claims 24-29, or a salt, solvate, prodrug, stereoisomer, isotopologue, tautomer, or any mixtures thereof.
43. The method of claim 42, wherein the compound or composition is the only anticancer agent administered to the subject.
44. The method of any one of claims 42-43, wherein the compound is administered to the subject in a pharmaceutically acceptable composition.
45. The method of any one of claims 42-44, wherein the subject is further administered at least one additional agent or therapy useful for treating, ameliorating, and/or preventing the cancer.
46. The method of claim 45, wherein the additional anticancer agent or therapy comprises nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, and/or resection therapy.
47. The method of claim 45, wherein the additional anticancer agent or therapy comprises Rituxan, doxorubicin, gemcitabine, nivolumab, pembrolizumab, and/or ipilimumab.
48. The method of any one of claims 42 and 44-47, wherein the compound or composition is coformulated and/or co-administered with the at least one additional agent.
49. The method of any one of claims 42-48, wherein the cancer is amenable to treatment by inhibiting PD-1, PD-L1, or the PD-1/PD-L1 interaction.
50. The method of any one of claims 42-49, wherein the cancer is at least one of pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer, or colon cancer.
51. The method of any one of claims 42-49, wherein the cancer is at least one of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL).
52. The method of any one of claims 42-51, wherein the subject is a mammal.
53. The method of claim 52, wherein the mammal is a human.
PCT/IB2023/057373 2022-07-21 2023-07-19 Substituted imidazoamide compounds, and methods using same WO2024018403A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263390989P 2022-07-21 2022-07-21
US63/390,989 2022-07-21

Publications (1)

Publication Number Publication Date
WO2024018403A1 true WO2024018403A1 (en) 2024-01-25

Family

ID=89617292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/057373 WO2024018403A1 (en) 2022-07-21 2023-07-19 Substituted imidazoamide compounds, and methods using same

Country Status (1)

Country Link
WO (1) WO2024018403A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232256A1 (en) * 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
CA3152690A1 (en) * 2019-09-30 2021-04-08 Lingyun Wu Compound as small molecule inhibitor pd-1/pd-l1 and application thereof
WO2021158481A1 (en) * 2020-02-03 2021-08-12 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds and methods using same
CN115232125A (en) * 2021-05-14 2022-10-25 杭州和正医药有限公司 Multi-substituted benzene immunomodulatory compounds, compositions and uses thereof
CN115536657A (en) * 2021-06-29 2022-12-30 上海翰森生物医药科技有限公司 Salt of biphenyl derivative inhibitor, crystal form and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232256A1 (en) * 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
CA3152690A1 (en) * 2019-09-30 2021-04-08 Lingyun Wu Compound as small molecule inhibitor pd-1/pd-l1 and application thereof
WO2021158481A1 (en) * 2020-02-03 2021-08-12 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds and methods using same
CN115232125A (en) * 2021-05-14 2022-10-25 杭州和正医药有限公司 Multi-substituted benzene immunomodulatory compounds, compositions and uses thereof
CN115536657A (en) * 2021-06-29 2022-12-30 上海翰森生物医药科技有限公司 Salt of biphenyl derivative inhibitor, crystal form and preparation method thereof

Similar Documents

Publication Publication Date Title
US11013726B2 (en) Substituted pyridinone-containing trycyclic compounds, and methods using same
KR102376248B1 (en) Tricyclic spiro compound
AU2019397481B2 (en) Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
US11566002B2 (en) Substituted tetrahydrocyclopenta[C]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same
TWI815887B (en) Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
US20230108906A1 (en) Substituted bicyclic and tricyclic ureas and amides, analogues thereof, and methods using same
AU2022325137A1 (en) Cyanopyridine and cyanopyrimidine bcl6 degraders
WO2024018403A1 (en) Substituted imidazoamide compounds, and methods using same
WO2021097075A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
JP2023532027A (en) Novel compound and pharmaceutical composition for prevention or treatment of resistant cancer containing the same
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
WO2021025976A1 (en) Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
WO2024069448A1 (en) Substituted 1-arylaminocarbonyl-1'-heteroaryl compounds, substituted 1-heteroarylaminocarbonyl-1'-heteroaryl compounds and methods using same
TWI810547B (en) Pd-l1 antagonist compound
TW202409054A (en) Substituted imidazoamide compounds, and methods using same
US20230312481A1 (en) Substituted (phthalazin-1-ylmethyl)ureas, substituted n-(phthalazin-1-ylmethyl)amides, and analogues thereof
TW202400578A (en) Novel compound and its use for inhibiting checkpoint kinase 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23842543

Country of ref document: EP

Kind code of ref document: A1